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Abstract 
The role of community pharmacy (CP) in health promotion has developed over the 
last decade and a half following the introduction of the new National Health Service 
(NHS) plan in 2000. CPs have been turned into healthy living centres where 
individuals can access a variety of services designed to prevent disease and 
promote health. In 2005, three types of pharmacy service were introduced; 
essential, advanced and enhanced (currently known as locally commissioned). 
Enhanced pharmacy services were provided by Primary Care Trusts (PCTs) (until 
2010) based on local needs identified by PCTs. In 2010, the Government decided 
to abolish the PCTs by 1st April 2013; hence, PCTs entered a transition phase 
between 2010 and April 2013. By February 2011, each PCT was required to publish 
Pharmaceutical Needs Assessment (PNA) report regarding the provision and need 
for pharmacy services. The national commissioned vascular and sexual health 
enhanced pharmacy services in England are Stop Smoking Service (SSS), NHS 
health check, Emergency Hormonal Contraception (EHC) and chlamydia screening 
and treatment services. In 2012, the Healthy Living Pharmacy (HLP) scheme, which 
was piloted in Portsmouth PCT, was expanded to 30 PCTs known as HLP 
pathfinder PCTs. 
The aim of this research was to identify the correlation between needs, provision 
and uptake of vascular and sexual health pharmacy services at a PCT and CP 
level. It also aimed to investigate whether the provision of those services was cost 
effective. Finally, it aimed to determine the impact of the introduction of the HLP 
scheme on the provision and uptake of those services. 
At a PCT level, the PNA reports were used to identify the CP provision of SSS, 
EHC service and chlamydia screening service for the financial year 2009/2010. The 
local need for SSS (prevalence of smoking adults) and EHC services (rates of 
teenage pregnancy) were obtained from Health Profiles for each PCT. The need for 
chlamydia screening service (prevalence of positive chlamydia infection) was 
obtained from the National Chlamydia Service Programme (NCSP). Uptake and 
cost attributed to provision of those services for the financial year 2009/2010 were 
obtained from a short questionnaire targeted the public health leads for the related 
services in PCTs where the provision of services and the needs were identified. 
Simple cost-effectiveness analyses were performed on CP SSS and CP EHC 
provision, based on identified uptake and cost. At a CP level, a cross-sectional 
survey was conducted on 1 249 CPs in 28 PCTs across England in 2013. PCTs 
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were chosen based on provision of SSS, EHC and chlamydia screening service 
identified in the PNA reports. 7 PCTs out of 28 PCTs were HLP pathfinder PCTs. 
CPs were allocated to one of five groups based on deprivation. 
The response rates for SSS, EHC and chlamydia screening surveys were 30% 
(42/138), 30% (42/139) and 19% (21/111) respectively. Data analysis identified that 
the need for SSS and EHC services were highly correlated with deprivation, with 
Spearman's rank correlation coefficients (rho) of 0.76 and 0.83 respectively (both P 
< 0.001). The correlation between deprivation and the need for a chlamydia service 
was weak (rho = 0.25, P = 0.009). Higher number of CPs per 25 000 population 
were observed in more deprived PCTs (rho = 0.63, P < 0.001). CP provision 
(percentage of CPs offering a service out of total CPs in a PCT) of SSS, EHC and 
chlamydia service did not correlate with needs. The uptake of SSS, EHC and the 
chlamydia screening service did not correlate with increasing need or deprivation. 
However, pharmacists in areas of higher need dealt with a greater number of clients 
in relation to SSS and EHC services to meet their local needs, with rho of 0.4 and P 
of 0.01 in case of SSS and Pearson's correlation coefficient (R) of 0.36 and P of 
0.02 in case of EHC. A cost-effective analysis of CP SSS provision found it to be 
cost effective when compared to no intervention based on NHS perceptive and the 
incremental cost per Quality Adjusted Life Year (QALY) gained was £1 511. 
Similarly, the CP EHC service was also found to be cost effective with an NHS 
saving of £689 per unintended pregnancy prevented. 
The response rate for the CP survey was 19.3% (241/1 249). No significant 
differences were identified in terms of provision or uptake of SSS, EHC, chlamydia 
screening and NHS health check services between CPs with different deprivation 
neighbourhoods. 18.5% (31/168) of the respondent community pharmacists were 
working in HLPs. The uptake of SSS through HLPs (median = 6) was higher than 
that through non-HLPs (median = 4; P = 0.02). Playing a more active role in health 
promotion was cited as the main driver for pharmacists to adopt an HLP scheme. 
Respondent pharmacists indicated that the introduction of an HLP scheme had 
improved public awareness of vascular and sexual health services available in CPs 
and they suggested the use of social media websites to further improve public 
awareness. Lack of time and the provision of similar services via other providers 
were considered the main barriers.  
Local Authorities should increase the provision of vascular and sexual health 
pharmacy services to meet the needs of their localities. They should use the latest 
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technology to improve public awareness regarding availability of those services in 
CPs. 
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Chapter One: General introduction 
1.1 Historical developments in community pharmacy practice that led to the 
current pharmacy practice roles 
The modern history of pharmacists in Great Britain can be attributed to the 
foundation of the Pharmaceutical Society of Great Britain (PSGB) in 1841. In 1843 
Queen Victoria granted the Society Royal Charter and in 1988, Queen Elizabeth II 
granted the Society its Royal Title (Hudson et al., 2013). Prior to the creation of the 
PSGB, the pharmacy profession was closer to an apprentice than to a profession, 
when anyone could work in a pharmacy and could dispense medicines (they used 
to be called as apothecaries, chemists or druggists) (Anderson, 2005). Unlike 
chemists and druggists, apothecaries had to take qualifications to become an 
apothecary and pass oral exams which included the recognition of ingredients and 
preparing medicines (Hudson and Boylan, 2013). Between 1815 and 1834, most of 
the new apothecaries acted as general practitioners rather than expert in 
medicines, while chemists and druggists became apprentices for a pharmacist 
(Hudson and Boylan., 2013). The PSGB was the professional and regulatory body 
that used to control and supervise pharmacists in England, Wales and Scotland 
(Taylor and Harding, 2003). At its beginning, the PSGB intended to define clear 
boundaries between pharmacists and other healthcare professionals (doctors). In 
England and Wales, doctors were allowed to prescribe and dispense medicines, 
while in Scotland, their role was restricted to prescribing medicines (Anderson, 
2005). The role of dispensing by English and Welsh doctors was reflected on 
pharmacists who made their profits by selling over the counter products rather than 
dispensing prescribed medicines (Anderson, 2005).  
Two Pharmacy Acts were the milestones that controlled the pharmacy profession; 
the Pharmacy Act 1852 which restricted titles related to pharmacist for those who 
passed the Society's examination but it lacked legal definition for those who could 
practice the pharmacy profession, and the Pharmacy Act 1868 which empowered 
the Society and provided it with rights to examine and register all chemists and 
druggists (Anderson, 2005). Pharmacists were considered as doctors for poor 
people, who could not afford to pay (Whalley et al., 2008). In May 1911, the 
National Insurance Bill was introduced; the bill provided free medical help for those 
who were insured. However, the bill was restricted only to working persons who 
earned less than £160 per annum and up to 70 years old (Anderson, 2005). In 
1948, the creation of the National Health Service (NHS) in England, brought the 
hope for people, as the provision of health care services became free at the point of 
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access (Whalley et al., 2008). Community Pharmacists became independent 
contractors to the NHS with the capacity to dispense only NHS prescriptions 
(Richardson and Pollock, 2010). The role that community pharmacists used to play 
in health promotion and advice giving diminished and the workload increased. It 
was said that “Pharmacists effectively became invisible” (Anderson, 2007). The 
number of doctor’s prescriptions dispensed from Community Pharmacies (CPs)  
jumped from 65 million in 1937 to 250 million in 1950. Several Attempts have been 
made to retrieve the pharmacist traditional role in health promotion between 1948 
and 2000 (Anderson, 2007). In July 1999, the Government introduced the white 
paper “saving lives: our healthier nation” (Department of Health (DH), 1999). The 
white paper set a 10 years plan to improve health in general for everyone with focus 
on those who were in worst health situation. Given consideration to the main 
causes of death by that time (cancer, Coronary Heart Disease (CHD) and stroke, 
accidents and mental health), the Government set its plan to reduce the rate of 
each event by investment of more money, tackling smoking, improving health and 
setting high health standard (DH, 1999). In 2000, the Government introduced its 
plan for the new NHS in the new century, and considered the need for the 
expansion of community pharmacist's role to meet the new challenges of the new 
century (DH, 2000b). The NHS plan 2000 was followed by the Government white 
paper “pharmacy in the future-implementing the NHS plan” (DH, 2000a). The latter 
paper intended to explain the pharmacists’ role according to the NHS new plan and 
it set the challenges that pharmacy has to face in the upcoming years. These 
challenges were concerned with meeting patients’ needs. These needs are met by 
ensuring people are getting their medicines or pharmaceutical advice easily and 
conveniently, and by providing them with more support in using their medicines. 
Improving patients' confidence upon consultation by their pharmacist is also a key 
priority. The document also discussed the environmental changes for pharmacies 
with a vision for a more competitive retail environment for CP where arrangements 
for securing and paying for generic medicines are considered and electronic 
ordering and home delivery are achievable. Finally, the document outlined how 
professional standards should be maintained through better dealing with mistakes, 
professional education and training and making sure that pharmacists are keeping 
their skills up to date (DH, 2000a). 
In 2003, the document  “A vision for pharmacy in the NHS” was released; the 
document came to assess the success that happened as a result to the NHS plan 
2000 and how pharmacy needs to move in the future (DH, 2003a). The document 
listed the top ten key roles for pharmacists which have been identified by the chief 
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pharmaceutical officer for England, Dr Jim Smith (the roles are summarised in 
Table1.1). The document stated that as pharmacies are in the heart of the 
community, where the public can have easy access, the pharmacists have an 
important contribution in improving public health and broadening promotion of 
health such as smoking cessation, sexual health, reducing obesity and minimising 
health inequalities (DH, 2003a). The role of pharmacists in prescribing was re-
emphasised in this document with pharmacists to begin supplementary prescribing 
by the end of 2003 while independent prescribing to begin later in 2006 (DH, 2003a, 
Cooper et al., 2008a). An early experience of supplementary prescriber pharmacist 
showed benefit both to patients in terms of their medical management and to 
pharmacists in terms of job satisfaction and self-confidence, but the challenges 
identified included lack of funding, IT support and awareness by others (Cooper et 
al., 2008a).   
 
Table 1.1: Summarises the key role for pharmacists set be chief 
pharmaceutical officer 
CHIEF PHARMACEUTICAL OFFICER’S 10 KEY ROLES FOR PHARMACY 
To provide convenient access to prescription and other medicines 
To advise patients and other health professionals on the safe and effective use of medicines 
To be a point of first contact with healthcare services for people in the community 
To provide medicines management services, especially for people with enduring illness 
To promote patient safety by preventing, detecting and reporting adverse drug reactions and 
medication errors 
To contribute to seamless and safe medicines management throughout the patient journey 
To support patients as partners in medicines taking 
To prescribe medicines and to monitor clinical outcomes 
To be a public health resource and provide health promotion, health improvement and harm 
reduction services 
To promote value for money in the use of medicines and to reduce wastage 
 
In January 2003, the Office of Fair Trading (OFT) recommended the abolition of the 
control of entry regulations for CPs which were introduced in 1987 (Hassel, 2003). It 
emphasised that due to these regulations, the prices of Over the Counter (OTC) 
medicines are becoming higher, the innovation is lower (as the roles of pharmacists 
and providers in delivering new enhanced services were limited) and the quality of 
service is poorer (Hassel, 2003). In July 2003, the decision of DH was to reject the 
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recommendations made by the OFT report and to continue with the current 
regulations (DH, 2003b).      
In 2005, four categories of CPs were exempted from the control of entry test; a 
pharmacy established in a large retail area (15 000 m2 or more), a pharmacy with 
intention to open more than 100 hours per week, an internet based pharmacy and a 
pharmacy established within a one stop primary care centre (DH, 2005).  
A new era for the community pharmacist started in 2005, following the introduction 
of the new pharmacy contract. Three categories of pharmacy services were 
introduced; essential, advanced and enhanced. All CPs which are in contract with 
the NHS have to provide essential services. Essential services are the services that 
maintain the daily work of pharmacy through dispensing medicines, repeat 
dispensing, waste management, sign posting,.., etc. Advanced services need 
accreditation of pharmacist and premises. They include the services that assure the 
safe and good use of medicines and appliances such as; medicines use review, 
appliances use review and new medicine service. The last category (enhanced 
services) is provided based on needs identified by Primary Care Trusts (PCTs) for 
these services within each area. It includes stop smoking, chlamydia screening and 
treatment, Emergency Hormonal Contraception (EHC), NHS health check, needle 
and syringe exchange, and minor ailments (PSNC, 2014).  
In 2008, the document “pharmacy in England building on strengths – delivering the 
future”  was released (DH, 2008a). The document emphasised that services 
providing prevention rather than cure must be the NHS priority in the future as well 
as services that help people take care of themselves (DH, 2008a). In order to 
promote good health and prevent ill health, the pharmacy’s contribution must be 
enhanced through initiatives such as; stopping smoking, reducing teenage 
pregnancy rates through access to EHC and sexual health advice. It should also 
provide fast and effective treating for minor ailments and chlamydia screening and 
treatment. In general, CPs should be seen as community-based healthy living 
centres, which offer easily accessible and informal yet wholly professional advice 
and support, including support for self-care.  
There was a hierarchy of organisations that led the health services; the PCTs were 
the organisations that are in direct touch with CPs (Figure 1.1). The DH supervised 
Strategic Health Authorities (SHAs), which in turn supervised PCTs. In 2000, 28 
SHAs were created but they were merged into 10 in July 2006. On the other hand, 
303 PCTs were created in 2002, but they were merged into 152 PCTs in October 
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2006 (Whalley et al., 2008). In April 2010, the number of PCTs in England 
decreased from 152 to 151, as East and North Hertfordshire PCT merged with 
West Hertfordshire PCT (DH, 2011b).  
Figure 1.1: Summary of NHS structure prior to April 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 Changes following the election of the new Government in May 2010  
In July 2010, a white paper “equity and excellence: liberating the NHS” was 
released. One of the aims of the document was that PCTs should enter a transition 
period by which the commissions and roles of PCTs will be transferred to other 
suppliers and by April 2013, the PCTs will be phased out (DH, 2010). In September 
2010, the RPSGB was no longer the regulatory body for pharmacists and pharmacy 
Department of Health 
10 Strategic Health Authorities 
151 Primary Care Trusts 
Community pharmacies 
Commission and supervise 
provision of enhanced pharmacy 
services 
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technicians and its regulatory role was moved into the new formed regulatory body 
the General Pharmaceutical Council (GPhC). RPSGB sustained its leadership role 
and its name was changed to the Royal Pharmaceutical Society (RPS) (RPS, 
2014). The commissioning of enhanced services changed on 1st April 2013. 
Services related to public health such as SSS, screening services (such as 
chlamydia and NHS health check), EHC service, needle and syringe exchange 
service and supervised administration service were transferred to Local Authorities 
(LAs). Services such as minor ailment service, anticoagulation service and 
independent prescribing service were transferred to the NHS Commissioning Board 
(known also as NHS England) (Primary Care Commissioning, 2013).  
1.3 Trends in pharmacists and pharmacy type 
The last 50 years did not only witness changes in the role of pharmacist, but it also 
experienced a significant trend in the pharmacists’ gender. More than half of 
pharmacists who registered with the RPSGB in 2008 were females (Seston et al., 
2009), compared to less than 20% being females in 1964 (Hassell, 2003). 
Furthermore, in 2008, 30% of pharmacists who were registered belonged to non-
white ethnicity (Seston et al., 2009). 
In the UK, CPs can be owned by a pharmacist or a company that employs a 
designated superintendent pharmacist (there is no limit on how many pharmacies a 
company can own) (Bush et al., 2009).  In 1999, independent pharmacies used to 
represent more than 55% of all CPs within England and Wales. This rate has 
greatly changed with less than 40% being independents in 2009. This was 
attributed to the market competition where many CPs were taken over by big 
companies (OFT, 2010). 
1.4 Remuneration of CPs 
Three legal classes of medicines can be provided at CPs; Prescription Only 
Medicines (POMs), pharmacy medicines and general sale list ones. The POM 
category requires prescription from a qualified prescriber. The pharmacy category 
requires pharmacist's supervision and it can be sold only in pharmacies. The last 
category (general sale list) does not require neither prescription nor pharmacist's 
supervision and can be sold in pharmacies, supermarkets or even in gas stations 
(Medicines and Healthcare Products Regulatory Agency (MHRA), 2013a). 
The remuneration of CPs comes mainly from the NHS (Richardson and Pollock, 
2010). In CPs which depends mainly on prescribed medicines the NHS is 
responsible for 90% of their overall turnover. However, this share is lower in CPs 
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which has a health and beauty or supermarket business models. The NHS 
reimburses pharmacists for the dispensing of prescribed medicines and providing of  
advanced and enhanced services. In the case of prescribed medicines, the more 
the pharmacist dispenses, the more the turnover will be. Advanced services are 
paid for based on the number of services provided and the payment is fixed for all  
CPs in England. Enhanced services are paid for by the NHS, but the methods of 
payment and the amount differ between one PCT and another. Pharmacists are 
also able to earn more profit by selling pharmacy medicines, general sale 
medicines, goods and appliances (OFT, 2010).  
1.5 Vascular and sexual health enhanced pharmacy services 
Two types of enhanced services were the concern of this research; vascular and 
sexual health services. In England, in 2009/2010, the two nationally commissioned 
enhanced vascular health services were SSS and NHS health check service. 
Although alcohol screening and brief intervention and weight management services 
were commissioned in some PCTs, those services have not been yet nationally 
agreed. On the other hand, chlamydia screening and treatment services and EHC 
service were the services that were connected with sexual health (PSNC, 2014) 
1.5.1 Stop Smoking Service (SSS) 
Smoking is still the most preventable cause of death in developed countries, 
including England (Doll et al., 2004, Pirie et al., 2013). Smoking is strongly 
connected with socioeconomic status (SES), such as low educational attainment 
and unemployment.  In addition, smokers who live in lower SES areas are less 
likely to quit smoking than those who live in higher SES ones (Health and Social 
Care Information Centre (HSCIC), 2011b). The difference in smoking habits 
between lower and higher SES areas is the main factor in increasing health 
inequalities (Jha et al., 2006).  A key strategy to overcome health inequalities 
related to smoking habits is to increase smoking quit rates in lower SES areas and 
find the cost-effective avenues to achieve this goal. At the beginning of SSS, the 
plan was to target 26 areas known as Health Action Zones (HAZs). The HAZs were 
areas chosen by the Government, where deprivation status is common with the aim 
was to reduce health inequalities by helping smokers in those areas (McNeill et al., 
2005). The initial guidance sent to HAZs distinguished between two types of 
interventions (based on settings); opportunistic SSS interventions provided by 
health care professionals which resulted in maximum reach but minimum 
effectiveness. The second type was SSS through clinics which resulted in minimum 
reach and maximum effectiveness (McNeill et al., 2005). Currently, smokers can 
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get help to quit smoking from brief advice, to intermediate intervention and intensive 
intervention (DH, 2011a). A group-intervention is more effective than one-to one 
treatment (Bauld et al., 2009b, McEwen et al., 2006).        
1.5.1.1 Hazards of smoking and benefits of stop smoking 
Most smokers are aware of the hazards of smoking, but they try to convince 
themselves that smoking is not harmful if they smoke moderately (Heikkinen et al., 
2010).  In fact, smoking is responsible for causing several types of diseases; 
vascular, neoplastic and respiratory ones. It worsens the life condition of an 
individual and leads to an early death (Doll et al., 2004). For example, in England, in 
2010/2011, around 457 800 of hospital admissions, among adults aged 35 and 
over, were caused by smoking (HSCIS, 2011). The harm of smoking depends 
mainly on the heaviness of smoking and the age at the time the smoking started 
(Oza et al., 2011). The effects of smoking are cumulative and in order to reduce the 
harm of smoking, stop smoking should be achieved at an early age. For example, 
90% of the excess hazards attributed to smoking can be avoided if a smoker stops 
at 40 years of age and 97% could be avoided if he/she stops at 30 years of age 
(Doll et al., 2004).  Not all diseases will respond to stopping smoking in the same 
way, the ex-smoker will witness faster decline in heart disease and stroke risk than 
in lung cancer and chronic obstructive pulmonary disease (Oza et al., 2011). 
1.5.1.2 Smoking prevalence and other factors 
Smoking is responsible for 50% of the variations in death rates between adults who 
live in higher SES areas and those who live in lower ones (Jha et al., 2006, Hiscock 
et al., 2012a). Between 2001 and 2006 in England, the prevalence of smoking 
adults declined in general, but there was no decline among lower SES people (Jha 
et al., 2006). Despite that, smokers who were in lower SES received higher 
numbers of interventions than those who were in higher SES (Douglas and 
Szatkowski, 2013); the lower quit rates among lower SES decreased the chances 
of meething the goal of bridging the gap in health inequalities resulting from 
smoking (DH, 2011a). The stronger addiction to tobacco, insufficient social support 
and lower motivation to quit were the main suggested reasons for lower quit rates 
among lower SES (Hiscock et al., 2012b). Hiscock and co-workers (2012b) 
suggested raising the price of tobacco products, which will have a higher effect on 
low SES smokers and hence might help in reducing health inequalities.      
In terms of ethnicity, the prevalence of smoking is higher in Bangladeshi and Black 
Caribbean men when compared to White men (Karlsen et al., 2011). The variations 
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in smoking prevalence were explained by the variations in SES, where the two 
minor ethnicities lived in lower SES areas (Karlsen et al., 2011). The common 
barriers for successful quits among ethnic groups are language, religion and 
culture, lack of time and negative attitudes to services and doctors (White et al., 
2005, Fu et al., 2007).   
1.5.1.3 Types of pharmacological products provided for SSS 
Tobacco companies have tried to change the design of cigarettes by inclusion of 
filters, low-tar, and light variations. All those attempts have failed to reduce the 
disease risk. Contrary, they may have encouraged non-smokers to start smoking 
and thus slow down smoking cessation (Centers for Disease and Control 
Prevention (US), 2010). Cigarettes contain 93 harmful and potentially harmful 
compounds. They are carcinogenic, toxic to the respiratory and cardiovascular 
systems and contain reproductive or development toxic compounds (Food and 
Drug Administration (FDA), 2012). Only four compounds have addiction effect, 
which are acetaldehyde, anabasin, nornicotine and nicotine (the most important 
compound) (FDA, 2012). Smoking cigarettes causes quick absorption of nicotine 
through the lungs, which in turn, leads to a rapid increase in nicotine levels in the 
blood, hence making smoking the most powerful and dependence-produced form of 
nicotine administration (Hukkanen et al., 2005).      
Smoking cessation is accompanied with withdrawal symptoms which include 
irritability, urge/craving to smoke, depression, restlessness, increased heart rate, 
increased appetite and poor concentration (Hendricks et al., 2006). These 
symptoms reach their peak in the first week, and then decrease to preabsitence 
level within 1 to 4 weeks following the abstinence of smoking (Hendricks et al., 
2006). Three types of pharmacological products are available to help smokers quit 
smoking, Nicotine Replacement Therapy (NRT), bupropion and varenicline (DH, 
2011a). NRT reduces the withdrawal symptoms of nicotine, by stimulation of the 
nicotine receptors in the ventral tegmental area of the brain, which in turn leads to 
the release of dopamine in the nucleus accumbens. NRT mimics the mechanism of 
nicotine by smoking but in slower and lower levels than smoking cigarettes, thus it 
does not get rid of all the withdrawal symptoms (Molyneux, 2004). Various types of 
NRT are available in the UK; chewing gum, patches, tablets and lozenges, 
inhalators and nasal spray (MHRA, 2014). All types of NRT proved to increase the 
quit rate in comparison to placebo (Stead et al., 2012). The addition of rapid 
delivery of NRT with nicotine patch proved to be more effective than a single type of 
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NRT, such as nicotine gum (Stead et al., 2012). Bupropion, the second medication 
available to help quit smoking, eases withdrawal symptoms by mimicking nicotine 
effects on dopamine and noradrenaline. By its ability to antagonize nicotine 
receptors (it inhibits nicotine from binding to the nicotine receptors without inducing 
a biological response), it reduces the outcomes of nicotine uptake, which helps in 
preventing relapse (Warner et al., 2005). Bupropion is more effective than placebo 
(Aubin et al., 2004) and the addition of NRT to bupropion increases the efficacy of 
quitting smoking (Stead et al., 2012). Varenicline, the latest medication that became 
available to help in quit smoking, works as agonist and antagonist. It binds with 
nicotine acetylcholine receptors (nAChR) of the α4β2 subtype and increases the 
release of dopamine in relevant brain areas and hence minimizes the craving for 
nicotine and eases the symptoms of withdrawal (agonists effects). It also inhibits 
nicotine from binding with those receptors, which result in reduction of nicotine-
induced dopamine release (Fagerström and Hughes, 2008). The drug effect of 
pharmaceutical products against placebo varies from 2.27 (95% Confidence 
Interval (CI) 2.02, 2.55) for varenicline, 1.69 (95% CI, 1.53, 1.85) for bupropion and 
1.60 (95% CI, 1.53, 1.68) for any form of NRT (Aubin et al., 2013). Bupropion and 
varenicline require a prescription to be dispensed, while NRT can be sold as 
general sale list medicine (MHRA, 2014).  
1.5.2 NHS health checks service 
The NHS health check was introduced in 2009, following the publication of the 
white paper “putting prevention first- vascular checks: risk assessments and 
management”. The service aimed to provide risk assessment of diseases which 
affect the vascular system for everyone who is aged 40-74 years old. The risk is 
identified through physical assessment of the body, including blood samples. It also 
requires full details about family history with consideration of any lifestyle risk such 
as smoking (Figure 1.2). Those who are identified with low risk will receive advice 
and those who are at moderate risk will receive advice and assistance such as 
referring to SSS, obesity management and physical activity. Advice and intervention 
is required for those who are at high risk in addition to pharmacological intervention 
and intensive lifestyle programme for those with impaired glucose regulation (DH, 
2008b). The service aimed to identify those at risk such as; smokers, obese people, 
high alcohol drinkers and those with diabetes (PSNC, 2014). The economic model 
of NHS health check programme was estimated to cost no more than £ 3 000 per 
Quality Adjusted Life Year (QALY) gained (DH, 2008b). Initially, the programme 
aimed to target all eligible people over a period of 5-years with a minimum of 20% 
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of those eligible each year (DH, 2008b). However, the percentage of screened 
individuals varied in different Boroughs. For instance, in Ealing, in 2008/2009, 
44.8% of the patients who were invited attended the check (Dalton et al., 2011).In 
Hammersmith and Fulham, 32.7% of those who were invited in 2008/2009 attended 
compared to 20% in 2009/2010 (Artac et al., 2013a). Therefore, in 2011/2012, the 
DH asked PCTs to target 90% of their target, which is equivalent to 18% instead of 
20% per year (Artac et al., 2013b). The PCTs in total reached 8.2% of their target in 
2011/2012, with higher reach in more deprived PCTs compared to least deprived 
ones (Artac et al., 2013b). 
Figure 1.2: Summarises different actions based on results of health checks  
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1.5.2.1 Obesity prevalence 
The obesity is measured by the Body Mass Index (BMI) which is a measure of 
weight relative to height (Butland et al., 2007). In 2003/2004 the mean BMI for men 
and women in the UK was 27 kg/m2  which lay outside the healthy range (18-24.9 
kg/m2) but within the overweight range (25-29.9 kg/m2) (Butland et al., 2007). 
However, it is still lower than the obese range (30-40 kg/m2) and morbidity obese 
one (>40kg/m2) (Butland et al., 2007). There is a strong correlation between 
deprivation and obesity, especially among children where childhood obesity is more 
common in more deprived areas (Conrad and Capewell, 2012; Stafford et al., 
2010). Different explanations were suggested to explain this finding; the effect of 
fast food which is more common in more deprived areas (Fraser and Edwards, 
2010) and the lower level of physical activity in more deprived areas (Annear et al., 
2009) are the most accepted ones. 
1.5.2.2 Alcohol intake 
Alcohol intake over the allowed limit was seen among 42% of working men and 
39% of working women (HSCIC, 2011a). Furthermore, the level of drinking is higher 
among the employed (75% of men and 65% of women) than among the 
unemployed (59% of men and 62% of women) or economically inactive (54% of 
men and 45% of women) (HSCIC, 2011a). Drinking alcohol is associated with harm 
to the drinker, the people surrounding the drinker and to the society (World Health 
Organisation (WHO), 2014). Alcohol might be responsible for causing 
gastrointestinal disease, neuropsychiatric conditions, cancers, cardiovascular 
diseases and many other diseases (WHO, 2014).     
1.5.3 EHC service 
1.5.3.1 Risks of teenage age pregnancy 
The UK has the highest teenage pregnancy rates when compared to the other 
European countries (Social Exclusion Unit (SEU), 1999). The burden of the problem 
affects both affluent and deprived areas, with higher rates in more deprived areas 
(SEU, 1999). The rates of teenage pregnancy are associated with three main 
factors; dislike of school, pessimistic view of the future and poor circumstances and 
unhappy childhood (Harden et al., 2009). Kaplan and co-workers (2004) found that 
a female who gave a birth as a teenager, is more likely to have a lower income at 
the age of 30 and is likely to receive 34% to 39% more benefits than a female who 
does not. She is more likely to have a less well qualified partner who has a lower 
weekly wage. Such a female, is more likely to work lower hours per week, which in 
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turn will be reflected in less earning and more financial support from the 
Government. Furthermore, they found that she is less likely to complete post-
compulsory education by the age of 30 when compared to the ones who had not 
given birth when they were teenagers. Same findings were suggested by Goodman 
and co-workers (2004) and Ermisch and Pevalin (2004). According to Goodman 
and co-workers (2004) the family size is the main driver in determining the 
disadvantages related to the income, and the level of benefits claimed as the UK 
benefit system compensates the shortness in family income which is caused by 
less working hours per week. In addition to the financial disadvantages, teenage 
pregnancy is associated with higher risk of premature birth, low birth weight and 
neonatal mortality (Chen et al., 2007) and higher incidence of anaemia and 
pyelonephritis (renal inflammation) among pregnant teenagers (Gupta et al., 2008).        
1.5.3.2 Interventions to reduce teenage pregnancy 
In 1999, the UK Government suggested a national plan to halve the teenage 
pregnancy rates by 2010 (SEU, 1999). The plan suggested a national campaign to 
improve knowledge among teenagers about the risks of teenage pregnancy and 
how to achieve better prevention (SEU, 1999). Harden and co-workers (2009) 
found reliable evidence in their review, to support the effectiveness of interventions 
versus no intervention to improve knowledge among children and youths in 
preventing teenage pregnancies. This knowledge was reflected in 39% lower rates 
of teenage pregnancies among the intervention groups than those who did not 
receive any support with 0.61 as Relative Risk Ratio (RRR) and 95% confidence 
interval between 0.48 and 0.77 (Harden et al., 2009). In the UK, provision of 
contraception is free to all women and men through the NHS (NHS Choices, 2013). 
In the USA, Peipert and co-workers (2012) found that the provision of free 
contraceptive is significantly effective in preventing teenage pregnancy. However, a 
teenager can have unprotected sexual intercourse, which is defined by failure of 
using contraceptive methods (such as tearing of a condom or forgetting to take 
contraceptive pill) or using no protection at all. In this case, a teenager can ask for 
an emergency contraception. There are two methods of emergency contraception 
that can be obtained in the UK; emergency contraceptive pill and Intrauterine 
Device (IUD) (NHS Choices, 2013). There are two types of emergency 
contraceptive pill; EHC (levonorgestrel) which can be bought or obtained free from 
CPs under PGDs and does not require a prescription and can be bought as a 
pharmacy medicine under the supervision of a pharmacist. Ulipristal (the second 
type) requires a prescription from a qualified prescriber to be dispensed (NHS 
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Choices, 2013). Further details of the two types of emergency pills are presented in 
Chapter 3. The IUD is a small device which is T-shaped and requires a trained 
person to insert it into the uterine for up to 5 days following the unprotected 
intercourse to prevent the pregnancy (NHS Choices, 2013). 
1.5.3.3 Role of CPs in reducing teenage pregnancy 
Community pharmacists who agreed to provide EHC as an enhanced service, 
supply the EHC to clients under Patient Group Directions (PGDs), which are 
defined as a written instruction that allow the supply or administration of medicines 
to certain types of clients (MHRA, 2013b). The locally agreed PGDs will identify the 
age range for those who are eligible for the service (PSNC, 2014). The service aims 
mainly to target young people, and increase their knowledge about emergency 
contraception and other forms of contraception and hence increase access to the 
service in case of unprotected intercourse and reduce the rates of unintended 
pregnancies (PSNC, 2014). 
1.5.4 Chlamydia screening and treatment services 
1.5.4.1 Risks of Chlamydia 
Chlamydia trachomatis is a bacterium and its sexually transmitted strains D-K is 
responsible for causing genital tract infections in both women and men (Low et al., 
2007). The problem with chlamydia infections is that it can be asymptomatic and 
may cause severe complications if it is left untreated (Adams et al., 2004). 
Sonnenberg and co-workers (2013) found in their study on a sample of 15 162 
women and men in Britain between 2010 and 2012, that the chlamyida infection 
came second among the most sexually transmitted diseases, following human 
papillomarivus infection and followed by HIV and gonorrhoea.  
1.5.4.2 Interventions for Chlamydia screening 
In 2003, the National Chlamydia Screening Programme in England was introduced 
(Low et al., 2007). The programme was first piloted to target women in Portsmouth 
and Wirral. It was expanded later to 25% of PCTs by end of 2004 and by end of 
March 2007 the programme was nationally provided (Low et al., 2007). The 
programme aimed to target those who are sexually active and under 25 years old. 
The tests are available through GPs, CPs, community sexual and reproductive 
health and termination pregnancy services (Woodhall et al., 2012). Chlamydia 
infection can be treated with azithromycin (1 g single dose) or doxycycline (100 mg 
twice daily for 7 days) (Low et al., 2007). 
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1.5.4.3 Role of CPs in Chlamydia screening 
In 2008, azithromycin was reclassified from prescription only medicine into 
pharmacy medicine (MHRA, 2008). This allowed CPs to sell it to those aged 16 
years and above with confirmed asymptomatic chalmydia infection (MHRA, 2008). 
Chalmydia screening and treatment as an enhanced service through CPs was 
introduced in 2010 (PSNC, 2014). Pharmacists can participate in screening, 
treatment or screening and treatment. For those who deliver screening only, they 
supply the service user with chlamydia screening kit. Pharmacists should inform 
clients how to use the kit, how to return it to be tested and what will happen after 
that. The service user should complete the screening form and provide urine 
sample. Then, the service user has the choice to send it to the microbiology 
laboratory by themselves or to return it back to the pharmacist. In the later case,  
the pharmacist should ensure sending it to the laboratory. The service user will be 
informed of results by the post or via pharmacy. Those with positive results can get 
free treatment from sexual health clinics or from CPs, which offer chlamydia 
treatment services. A proof of positive results should be shown in both cases 
(PSNC, 2014, National Chlamydia Screening Programme (NCSP), 2010a). 
1.6 Healthy Living Pharmacy (HLP) 
In general, Portsmouth population have a health life worse than the England 
average based on their health profiles and there is a wide variation in life 
expectancy between those who live in most deprived areas and those who live in 
least deprived ones (NHS Portsmouth, 2009). In 2009, a model was developed by 
Portsmouth City PCT through which the CP will become a healthy living centre. The 
model was rolled out in 30 PCTs following the success of Portsmouth's model. In 
HLP model, pharmacists should deliver at least one service of EHC, chlamydia 
screening, alcohol service and weight management in addition to delivering SSS. 
HLP should have at least one Healthy Living Champion (HLC), who is member of 
the pharmacy team (not a pharmacist). In order to be a HLC, a member of 
pharmacy team has to attain certain course which can be attained by different 
providers (NHS networks, 2014). HLC plays as a contact point to attract individuals 
and answer their questions (Duggan et al., 2013). The candidate HLC has to study 
four modules in order to pass an exam of multiple choice question (MCQ) (National 
Pharmacy Association, 2014).The modules cover four topics; health and health 
inequalities, effective communication, promotion of health and wellbeing and impact 
of behaviour change in health and wellbeing (National Pharmacy Association, 
2014). The exam has to be taken under the supervision of the pharmacist within a 
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pharmacy within 45 minutes (National Pharmacy Association, 2014). In September 
2013, there were more than 700 CPs that adopted HLPs scheme and a number of 
2 100 were trained to be HLCs (Public Health England, 2014).    
1.7 Cost-effectiveness analysis of health interventions 
1.7.1 Cost-effectiveness definition 
Cost-effectiveness analysis is an analytical tool to compare the cost and health 
effect of an intervention with a purpose to prevent, diagnose and treat disease with 
an alternative strategy to achieve the same goal (Mandelblatt et al., 1997). It is 
important to distinguish between two types of cost-effectiveness analysis based on 
the relation between the intervention and the alternative strategy. The first type is 
called independent, where the costs and effects of one intervention are not affected 
by the introduction of the other intervention. The second type is called mutually 
exclusive, where implementation of one intervention restricts the implementation of 
the other, or where implementation of one intervention affects the cost and results 
of the other (Phillips, 2009). In addition to cost-effectiveness analysis, there are two 
types of health economic methodologies; cost-utility analysis and cost-benefit 
analysis (McCabe, 2009). The only difference between the three methodologies is 
the outcome measure, as the outcome measure in cost-utility analysis is the 
quantity and quality of life which can be expressed by QALYs and the outcome 
measure in cost-benefit analysis utilises monetary benefits (McCabe, 2009).     
1.7.2 Application of cost-effectiveness analysis 
The Incremental Cost- Effectiveness Ratio (ICER) is a measure to test the cost 
effectiveness. It is calculated based on difference in costs divided by difference in 
health effects as in Equation 1.1 (Phillips, 2009).   
 
       
                                               
                                                                 
                            (Equation 1.1) 
 
The National Institute for Health and Care Excellence (NICE) requires the use of 
cost-utility analysis which utilises the QALYs as an outcome measure and the ICER 
becomes ICER per QALY gained (Phillips, 2009). QALY is a measure of quality of 
life which utilises both quality and quantity of life. A QALY measures the years of 
life the individual will live in better health. A year of perfect health has the value of 1, 
a year of less than perfect health has the value less than 1 and death has the value 
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of 0 (Phillips and Thompson, 2009). The quality of life is measured by using the EQ-
5D measure (Phillips and Thompson, 2009). The EQ-5D involves 5 categories. The 
first category is the mobility which identifies whether the individual is able to move 
freely, has some difficulties in move or unable to get out of bed. The second 
category is the pain/discomfort which identifies whether the individual has no pain 
at all, moderate pain or severe pain. The third category is self-care which tests 
whether the individual is able to clean himself/herself, has some difficulties in 
cleaning himself or unable at all to clean himself/herself. The fourth category is the 
anxiety/depression which measures whether an individual is not depressed suffers 
from moderate depression or has severe depression. The last category is usual 
activities such as work, study, house work and leisure. The individual has no 
problem, moderate problem or severe problem in performing usual activities. Based 
on the three cases of each of the EQ-5D, there are 243 possible health states. 
When unconscious and death states were added the total, there will be 245 
possible health states (Phillips and Thompson, 2009). A recent study of economic 
model of the new medicine service from the NHS England perception found that the 
intervention will save the NHS £ 3 005 per QALY gained (Elliott et al., 2014). The 
NHS health check service was estimated to cost the NHS around £3 000 per QALY 
(DH, 2008b). NICE considered interventions of ICER of less than £20 000 per 
QALY gained to be cost effective (NICE, 2012). Furthermore, interventions with 
ICER between £20 000 and £ 30 000 per QALY gained could be considered as 
cost-effective if certain conditions are applied (NICE, 2012).  
 
1.7.3 Sensitivity analysis 
Cost-effectiveness analysis is highly connected with uncertainty in terms of used 
methods or the parameters that have been used to populate the model (Thaban et 
al., 2013). Hence, a sensitivity analysis is required to overcome this uncertainty, 
which can be conducted in one-way or multiway (Taylor, 2009). In case of the one-
way analysis the parameters should be varied according to the confidence interval 
of the data or they should be varied according to the whole range of values that 
have been reported in the literature (Taylor, 2009). In a multi-way analysis, more 
than one parameter is changed simultaneously (Taylor, 2009). For instance, there 
is uncertainty in both the cost of an intervention and its effectiveness. A one way 
sensitivity analysis would deal with either cost or effectiveness but not with both of 
them at the same time. Multi-way analysis will suggest different scenarios where 
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both the cost and effectiveness are increasing, decreasing or one is increasing and 
the other is decreasing.        
1.8 Literature review of vascular and sexual health pharmacy services 
A search of the literature on vascular and sexual health pharmacy services was 
performed to identify studies that were conducted to evaluate vascular and sexual 
health pharmacy services provision from CPs. Medline, Embase, Cinahl databases 
and Google scholars were used to conduct the search. The search was conducted 
in two stages; stage one (prior to proceeding with the identification of methods to be 
used and collection of data before end of 2011), stage two (during the time spent in 
data collection until the time of writing this thesis). The search included UK studies 
which were published between January 2000 and August 2014. The search 
strategy used the following key words; CP service, stop smoking/ smoking 
cessation, weight management, alcohol intervention, health check, cardio-vascular 
assessment, chlamydia screening, emergency contraception.  
1.8.1 Results of the search 
3652 articles were found through the search, 391 were UK studies. Only 44 studies 
were related to the CP vascular and sexual health services and hence they were 
included in the review (Tables 1.2 and 1.3).  
 
1.8.1.1 Method used in identified studies 
21 studies were related to vascular health pharmacy services and 23 studies were 
related to sexual health pharmacy services. Two Randomised Control Trials (RCTs) 
studies were identified (Maguire et al., 2001; Jolly et al., 2011). Twelve studies 
included interviews and focus groups (Fitzgerald et al., 2009; Dhital et al., 2010; 
Krska et al., 2010; Folkes et al., 2001; Seston et al., 2001; McAllister et al., 2002 
Bissell and Anderson, 2003; Bissell et al., 2006; Cooper et al., 2008b; Thomas et 
al., 2010b, Dabrera et al., 2011, McNaughton et al., 2011). Nine studies were 
survey questionnaire type studies (McCaig et al., 2011; Newlands et al., 2011; 
Killick and Irving, 2004; Cameron et al., 2007; Seston et al., 2007; Gale and 
Watson, 2011, Taylor et al., 2012, Weidmann et al., 2012, Cameron et al., 2012). 
Four studies used more than one method as its methodology (Baraitser et al., 2007, 
Dhital et al., 2013, Jhan et al., 2013, Krska and Mackridge, 2014). The remaining 
17 studies were observational studies (Tables 1.2 and 1.3). 
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1.8.1.2 Sample population and response rate 
The sample size was less than 50 community pharmacists in case of phone 
interviews, face-to-face interviews and focus groups based studies (Fitzgerald et 
al., 2009; Dhital et al., 2010; Krska et al., 2010; Seston, 2001; Bissell and 
Anderson, 2003; Bissell et al., 2006; Cooper et al., 2008b; Thomas et al., 2010b). 
The sample covered all eligible CPs in chosen areas in the case of the postal 
surveys conducted by McCaig and co-workers (2011) and Newlands and co-
workers (2011). The study by Killick and Irving (2004) targeted all community 
pharmacists of one large chain in the UK. It targeted 140 community pharmacists in 
the UK in the study by Cameron and co-workers (2007) and 128 community 
pharmacists in Scotland in the study by Gale and Watson (2011). The sample size 
was 6000 in case of targeting the public in the study conducted by Weidmann snd 
c-workers (2012) and 204 in the study conducted by Cameron and co-workers 
(2012). The observation studies dealt with a large number of service users (Boyd 
and Griggs, 2009; Horgan et al., 2009; Bauld et al., 2009b; Lloyd and Gale, 2005, 
Hunt et al., 2013, Morrison et al., 2013, Parsons et al., 2013) (Tables 1.2 and 1.3) 
The response rate of community pharmacist in the survey studies ranged from 
20.6% to 64.8% (Cameron et al., 2007; Gale and Wastson, 2011; McCaig et al., 
2011; Newlands et al., 2011, Weidmann, 2012, Dhital et al., 2013) (Tables 1.2 and 
1.3)  
 
1.8.1.3 Opportunities and success of vascular pharmacy services 
The services in general showed a good accessibility for the vascular health 
pharmacy services in terms of stop smoking service (Boyd and Griggs, 2009; Bauld 
et al., 2011), alcohol screening (Fitzgerald et al., 2008; Dhital et al., 2010, Dhital et 
al., 2013 krska et al., 2013, Krska and Mackridge, 2014), cardio-vascular 
assessment (Horgan et al., 2009, Taylor et al., 2012, Hunt et al., 2013) and weight 
management services (Jolly et al., 2011; Newlands et al., 2011; Krska et al., 2010, 
Weidmann et al., 2012, Morrison et al., 2013, Boardmann and Avery, 2014) (Table 
1.2). SSS was found to be effective (Maguire et al., 2001; Boyd et al., 2009; Bauld 
et al., 2009b). However, SSS was found to be more effective when it is provided 
through group based interventions compared to pharmacy intervention, as the time 
and frequency of meetings are higher (Bauld et al., 2009b). Similar findings were 
identified in case of the weight management service, where the intervention at 
shorter time (12 weeks) through CPs was effective and its effectiveness diminished 
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in a longer time (one year), unlike other interventions such as group based 
programmes which its effectiveness lasted for year (Jolly et al., 2011). Community 
pharmacists felt that lack of confidence when providing services such as alcohol 
screening and weight management can be overcome if additional training is 
provided ( McCaig et al., 2011; Fitzgerald et al., 2009; Newlands et al., 2011). 
Donyai and Berg (2009) found that the risk attributed to cardio-vascular disease 
was higher among people from deprived areas and Krska and co-workers (2010) 
found that the use of weight management service through CPs was higher in more 
deprived areas. Furthermore, Krska and Mackridge (2014) found that alcohol 
drinkers from more deprived areas are more willing to use alcohol screening service 
through CPs compared to those from less deprived ones. This suggests the 
importance of the role of CPs in reaching those who live in more deprived areas to 
tackle the gap related to vascular diseases that can be prevented by interventions 
through CPs (Table 1.2) 
 1.8.1.4 Opportunities and success of sexual health pharmacy services 
Community pharmacists showed positive views towards deregulation of EHC into a 
pharmacy status medicine (Folkes et al., 2001; Seston et al., 2001; McAllister et al., 
2002; Bissell and Anderson, 2003; Bissell et al., 2006; Baraitser et al., 2007). Early 
experience of deregulation raised concerns from community pharmacists about 
misuse of EHC and its impact on the use of regular contraceptive methods, which in 
turn might increase the chances of sexually transmitted infections (Folkes et al., 
2001; Seston et al., 2001; Bissell and Anderson, 2003; Cooper et al., 2008b). 
Pharmacists also showed a lack of knowledge regarding the mechanism of EHC 
and training programmes proved to be effective in filling this gap in knowledge 
(Seston et al., 2001; Bacon et al., 2003). Following couple of years after 
reclassification, pharmacists were found to be efficient and they showed a high 
standard in terms of EHC provision (Glasier et al., 2010). However, mistakes were 
seen through few numbers of pharmacists who supplied EHC in case of 
contraindication (Weiss et al., 2010). The accessibility of CPs was the factor that 
enabled clients to obtain EHC faster than other venues (family health clinics and 
General Practices (GPs)) and hence increased the number of obtaining EHC from 
CPs when compared to other providers (Killick and Irving, 2004; Lewington and 
Marshall, 2006; Black et al., 2008). In a recent study conducted by Cameron and 
co-workers (2012), it was found that the uptake of EHC was irrelevant to the 
knowledge of its free supply through CPs and women of less deprived areas are 
more willing to use EHC than women of more deprived ones (Table 1.3).  
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In case of chlamydia services, community pharmacists showed willingness to 
provide kits, to do the screening in house and to provide treatment (Cameron et al., 
2007; Dabrera et al., 2011). Anderson and Thronley (2011) found that public are 
accessing the services through CPs and Brabin and co-workers (2009) and 
Dabrera and co-workers (2011) suggested that the provision of kits to those who 
requested EHC can increase the accessibility of chlamydia screening (Table 1.3). 
1.8.2 Barriers towards provision of services 
The workload and inadequate training were found to be the most important barriers 
in terms of provision of vascular and sexual health services ( Fitzgerald et al., 2009; 
Dhital et al., 2010; McCaig et al., 2011; Newlands et al., 2011; Gale and Watson, 
2011) (Table 1.2 and 1.3). CP was not the first choice for the public to access 
services such as weight management services (Krska et al., 2011). A lack of 
reimbursement and additional staff were barriers towards provision of vascular and 
sexual health services (Newlands et al., 2011; Gale and Watson, 2011). Lack of 
privacy was reported as barrier in terms of provision of vascular health services 
(Taylor et al., 2012, Krsaka and Mackridge, 2014) (Tables 1.2 and 1.3). 
1.8.3 Methods to improve the uptake of vascular and sexual health services 
Posters in CPs or GPs were found to be the main method to inform individuals 
about availability of alcohol brief screening through CPs (Krska and Mackridge, 
2014). McNaughton and co-workers (2011) suggested overcoming IT barriers to 
improve uptake of health check service. Pharmacists were lacking a secure internet 
connection which enables them to transfer patients' data to the NHS server in a 
safe and secure way. In case of sexual health services, a combination of the two 
services (EHC service and chlamydia screening service) could improve the reach of 
chlamydia services, by enabling community pharmacists to offer young people who 
ask for an EHC a urine kit in order to be tested for chlamydia as it was 
recommended by Dabrera and co-workers (2011) (Tables 1.2 and 1.3).   
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Table 1.2: Published studies related to vascular health service through CPs 
Author (s) / Title  
( year) 
Aims/ Objectives Method  Setting, and 
number participating  
Key findings Comments 
Maguire et al. A 
randomized controlled 
trial of a smoking 
cessation intervention 
based in community 
pharmacies (2001). 
 
To evaluate whether 
a structured CP-
based smoking 
cessation programme 
(the 
PAS model) would 
give rise to a higher 
smoking cessation 
rate compared with 
ad hoc advice from 
pharmacists 
RCT 100 CPs in Northern 
Ireland and 24 CPs 
in London. 
484 smokers were 
recruited; n=265 for 
the intervention 
group and n=219 for 
the control group.  
Self-reported 
validation was used 
at 12 months  
The abstinence rate at 12 month 
follow up was 14.3% (38) for the 
intervention versus 2.7% (6) for the 
control group, with P < 0.001. 
The study covered only 
Northern Ireland and 
London, with more focus 
on Irish pharmacists and 
Irish smokers. Findings 
should be treated 
carefully upon 
generalisation. 
Boyd et al. Cost-
effectiveness of 
pharmacy and group 
behavioural 
support smoking 
cessation services in 
Glasgow (2009) 
Examine the cost-
effectiveness of NHS 
SSS group and 
pharmacy fresh 
programme. 
Observational 
study and 
information 
from the NHS 
Data for 1979 
smokers (1508 
through CPs and 
471 through group) 
who attended the 
service between 
March and May 
2007 in Glasgow 
was analysed. 
The incremental cost per QALY for 
lifetime quitter was £4 400 for 
pharmacy and £5 400 for group. 
The study was well 
conducted using direct 
measures to calculate 
costs and effectiveness 
(short-term) and literature 
(long-term effectiveness). 
It also used sensitivity 
analysis to overcome any 
uncertainty in 
effectiveness. 
Fitzgerald et al. 
Developing and 
evaluating training for 
community 
pharmacists 
to deliver interventions 
on alcohol issues 
(2009). 
To evaluate 
pharmacists' 
readiness to provide 
alcohol intervention 
and to develop a 
training based on 
findings to intervene 
hazards and harmful 
drinking.  
Phone 
interview with 
pharmacists, 
followed by 
two days 
training.  
8 CPs in Scotland.  Pharmacists felt that the provision 
of alcohol intervention is feasible. 
Training should focus on 
communication skills and alcohol 
related knowledge. The developed 
training course was positively 
evaluated and led to increase in 
knowledge, attitudinal scores and 
self-related competence 
The study had a low 
number of interested 
pharmacists who 
participated in interviews 
and training. The 
effectiveness of training 
was only measured on a 
short-term (after 2 days) 
with no further tests. 
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Continued - Table 1.2: Published studies related to vascular health service through CPs 
Author (s) / Title  
( year) 
Aims/ Objectives Method  Setting, and 
number participating  
Key findings Comments 
Horgan et al. 
Evaluation of a 
cardiovascular 
disease 
opportunistic risk 
assessment pilot 
(‘Heart MOT’ service) 
in community 
pharmacies 
(2009) 
To investigate the pilot 
of cardio vascular 
(CVD) assessment in 
CPs 
Observational 
study 
23 CPs in 
Birmingham, 
England.  
A number of 1141 
people used the 
service (1 June 
2007- 31 March 
2008) and data were 
available for 1130 
(99%). 
The service succeeded in 
reaching the targeted 
population as 70% of the 
people attended were 
referred to their GPs with 
25% being at CVD risk of 
20% or more. 
The study covered a 
reasonable number of people 
to be tested in a city with an 
identified poor health. 
However, it was 
underrepresented of women 
in the city. No follow up of the 
referred patients was 
conducted. 
Donyai and Berg. 
Coronary heart 
disease risk 
screening: the 
community 
pharmacy 
Healthy Heart 
Assessment Service 
(2009) 
Explore the 
characteristics  and 
CHD risk of people 
who accessed free 
healthy heart 
assessment (2004-
2006) 
Importing the 
data from the 
large chain where 
the services were 
conducted 
Large chain CPs in 
the UK. 8278 people 
data was checked 
64.89% were at low risk and 
35.12% were at moderate 
risk. 
Male had a higher moderate 
to higher risk than female, 
with RRR (1.72). Labour 
manual working and 
deprivation was associated 
with higher moderate risk. 
The study analysed data of 
8287 people. However, the 
study did not conduct any 
follow up for any of those who 
were at low risk.   
Bauld et al. A 
comparison of the 
effectiveness of 
group-based and 
pharmacy-led 
smoking cessation 
treatment in Glasgow 
(2009b) 
To compare the 
characteristics and 
outcomes of users 
accessing pharmacy 
and group-based 
smoking treatment. 
Observational 
study 
Glasgow, Scotland. 
Pharmacy fresh and 
group NHS SSS. 
Data for 1785 users 
between March and 
May 2007 was 
analysed  
Pharmacy co-validated quit 
rate at 4 weeks was 18.6% 
compared to 35.5% in the 
group-based service.   
The study was well conducted 
which clearly reported the 
benefit and costs of stop 
smoking cessation 
interventions. 
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Continued - Table 1.2: Published studies related to vascular health service through CPs 
Author (s) / Title  
( year) 
Aims/ Objectives Method  Setting, and 
number participating  
Key findings Comments 
Krska et al. 
Community 
pharmacy 
contribution to 
weight management: 
identifying 
opportunities (2010). 
To identify the public’s 
views on weight-
management 
services, including 
pharmacies as a 
potential venue, and 
the extent of current 
pharmacy 
involvement in weight 
management. 
Face- to-face 
interview 
Sefton PCT, 
England. 
177 public were 
interviewed. 
66 CPs were invited 
to be interviewed.   
75% of the public who were 
interviewed tried to lose weight. 
OTC medicines and weight-loss 
products were used more than 
prescribed medicines. Respondents 
felt that pharmacists and 
pharmacies are not the favourable 
to provide weight management 
services. 
The pharmacy response rate was 
75% (49).  
48 CPs dispended prescriptions for 
weight loss and 38 supplied OTC 
weight-loss products.  
Supply frequency increased with 
increasing deprivation of 
pharmacy's location.  
 
The study did not 
represent the whole 
population as almost 
70% of respondents 
were female. 
It was conducted in 
shopping centres during 
day time only and BMI 
of respondents was not 
measured by the 
researcher. 
Dhital et al. 
Community 
pharmacy service 
users’ views and 
perceptions of 
alcohol screening 
and brief 
intervention (2010) 
To investigate 
potential barriers and 
enablers of CP to 
deliver alcohol 
screening and brief 
intervention 
Semi-structured 
interviews with 
users of the 
service 
4 CPs within 
London. 237 
participants were 
approached 
43% agreed to be interviewed. 52% 
were identified as risky drinkers and 
it was higher among younger age 
group and professional. Higher 
qualification was least frequent 
visitors to CPs and they were seen 
in multiple rather than independent 
CPs. Public identified CPs as 
accessible and anonymous place, 
but lack of privacy and time as a 
barrier.  
The study was 
conducted in 
Westminster Borough, a 
Borough with an 
average deprivation 
score. The small 
sample size and 43% 
response rate limit the 
findings from 
generalisation. 
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Continued - Table 1.2: Published studies related to vascular health service through CPs 
Author (s) / Title  
( year) 
Aims/ 
Objectives 
Method  Setting, and number 
participating  
Key findings Comments 
Bauld et al.  
 One-Year Outcomes and a 
Cost-Effectiveness Analysis 
for Smokers Accessing Group-
Based and Pharmacy-Led 
Cessation Services (2011) 
To identify 
the 
proportion of 
NHS SSS 
recipients 
who reported 
prolonged 
abstinence 
for 52 weeks 
and 
confirmed by 
CO-validation  
Observatio
nal study 
NHS SSS Scotland.  Quit rate at 4 weeks was 22.5% 
which dropped to 3.6% at 52 
weeks. The group service 
achieved quit rate of 6.3% while 
the pharmacy 2.8%. 
The incremental cost per QALY 
gained was £4 800 for the 
group versus £2 600 for 
pharmacies. 
The study was well 
conducted and calculated 
both benefits and costs for 
one year follow up. It used 
sensitivity analysis to 
overcome uncertainty in 
calculations after one year. 
The only comment is that 
was conducted in Glasgow 
with significantly lower CO-
validated quit rate when 
compared to England. 
McCaig et al. Provision of 
advice on alcohol use in 
community pharmacy: 
a cross-sectional survey of 
pharmacists’ practice, 
knowledge, 
views and confidence (2011) 
To identify 
CPs' level of 
provision of 
advice to 
alcohol users 
in Scotland.  
A postal 
questionnai
re survey. 
All CPs in Scotland (n= 
1098). 
The response rate was 45% 
(497). Good level of knowledge 
(97% among male and 84% 
among female). Lower level of 
advice provision ( 5% did 
advice once or more per week 
and 29% no advice at all).  
Lack of confidence in screening 
and providing alcohol services 
The study targeted all CPs 
in Scotland and succeeded 
in achieving 45% response 
rate. The study depended 
mainly on perceptions and 
memory rather than 
recording data which might 
result in bias in answers. 
Jolly et al. Comparison of 
range of commercial or 
primary care 
led weight reduction 
programmes with minimal 
intervention control for weight 
loss in obesity: Lighten 
Up randomised controlled trial 
(2011). 
To assess 
the 
effectiveness 
of a range of 
weight 
management 
programmes 
in terms of 
weight loss. 
8-arm RCT Birmingham PCT. 740 
obese with comorbid 
disorder. The intervention 
includes a choice of one 
of six programmes  
counselling. The control 
group was provided with 
12 vouchers to use local 
leisure fitness free.  
Significant weight loss was 
seen through all interventions at 
the end of 12 weeks. At one 
year, all interventions had 
significant loss except GPs and 
CPs.  
The study was able to cover 
a various strata of society 
with focusing on mostly 
disadvantaged groups 
where the problem might be 
more serious. 
The self-report method in 
measuring effectiveness is 
still a short coming. 
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McNaughton et al. 
Making a success 
of providing NHS 
Health 
Checks in 
community 
pharmacies across 
the 
Tees Valley: a 
qualitative study 
(2011) 
To identify the 
challenges in delivering 
the Healthy Heart 
Checks through CPs 
and to make use of 
identified challenges to 
improve service 
through other settings. 
Interviews Tees Valley, England. Four challenges were 
identified; developing 
confident, establishing and 
maintaining pharmacy 
Healthy Heart Checks, 
overcoming IT barriers, 
competent staff and 
ensuring volume and 
through flow in pharmacy. 
The study was well 
conducted as it identified 
barriers based on 
pharmacists' perceptions 
and members of PCTs. It 
covered all possible 
barriers at the early stage 
of commissioning NHS 
health check service but 
not at long-term. 
Newlands et al. 
The provision of 
current and future 
Healthy Weight 
Management 
(HWM) services 
from community 
pharmacies: 
a survey of 
community 
pharmacists’ 
attitudes, practice 
and 
future possibilities 
(2011) 
To identify the 
community 
pharmacists' activities 
and attitudes towards 
the current and the 
future of healthy weight 
management services.  
A postal survey All 128 CPs in Grampian, 
Scotland. 
The response rate was 
64.8% (83). Supply of 
weight-loss medication 
was the most common 
activity 69 (84.1%), advice 
about its use (84%), 
dietary advice (72.8%), 
BMI calculation (68.3%) 
and physical activity 
advice (66.3%).67.5% CPs 
felt there is a need for 
those services and 57.9% 
a need to extend them.  
Barriers included 
workload, additional staff 
and inconvenient 
reimbursement. CPs felt 
there is a need for extra 
training   
The study targeted all CPs 
within one area of 
Scotland and achieved 
good response rate (%65). 
Most of the respondents 
(85.5%) studied in the 
same local university, 
which might cause a bias 
in responses. 
27 
 
Continued - Table 1.2: Published studies related to vascular health service through CPs 
Author (s) / Title  
( year) 
Aims/ Objectives Method  Setting, and number 
participating  
Key findings Comments 
Taylor et al. A 
community 
pharmacy-based 
cardiovascular 
screening 
service: views of 
service users and 
the public (2012) 
To identify whether 
pharmacy-based 
cardiovascular disease 
(CVD) 
screening reached the 
desired population and to 
investigate the local 
population’s awareness of 
pharmacy 
screening and the views of 
service users and the 
general public about CVD 
screening. 
Handed 
questionnaire 
by pharmacist 
and face-to-face 
questionnaire 
survey with 
public in 
participating 
pharmacies' 
neighbourhood. 
8 CPs in Sefton PCT, 
England 
259 individuals were screened, (97 
(37.4%)) completed the questionnaire. 
A significantly more service users 
(90.7%) agreed that pharmacy was a 
good place for screening comparing to 
non- users (77.4%; P < 0.005) and a 
significantly fewer service users (10.3%) 
compared to 25.3% of non-users felt that 
screening should be by doctors (P < 
0.005). 
Lack of privacy and confidently were the 
main barriers 
The study is 
limited to one 
PCT and had 
a low 
response rate 
which inhibits 
the findings 
from 
generalisation. 
Weidmann et al. 
Views of the 
Scottish general 
public on 
community 
pharmacy 
weight 
management 
services: 
international 
implications (2012) 
To investigate Scottish 
general public views on 
provision of weight 
management through CPs  
Cross-sectional 
postal 
questionnaire 
survey 
6000 member of 
Scottish general public 
aged 18 years and 
above. 
Response rate was 20.6%, 751 (60.1%) 
agreed or strongly agreed that they had 
easy access to pharmacy services, 438 
(35%) said that it was more convenient 
to obtain weight management advice 
from a pharmacist. 
Lack of awareness of the types of health 
services available was reported by 162 
(13.2%) and 320 (25%)  would 
not feel comfortable speaking to a 
pharmacist or medicines 
counter assistant about weight related 
issues. 
Privacy and perceived lack of 
pharmacists’ specialist knowledge were 
identified as barriers to service uptake. 
The study had 
a low 
response rate 
(20%). 
Most of the 
respondents 
were male and 
of age 60 
years or older, 
which incurred 
bias in 
representing 
the findings. 
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Dhital et al. The 
impact of training 
and delivering 
alcohol brief 
intervention on 
the knowledge 
and attitudes of 
community 
pharmacists: A 
before 
and after study 
(2013) 
To evaluate: 
pharmacists’ 
attitudes towards 
hazardous/harmf
ul drinkers and 
knowledge before 
training and after 
delivering brief 
intervention; and 
their experience 
of training 
Questionnaires 
survey, 
observational and 
focus group 
Community 
pharmacists of 62 
CPs in inner 
London, England.  
37 pharmacists expressed their 
willingness to participate, 2 were excluded 
due to lack of consultation room and 6 did 
not attend the training leaving 29 as final 
sample.  
139 alcohol interventions were delivered 
by 19 pharmacists over five months 
(recruiters).10 pharmacists completed no 
interventions (non-recruiters). Knowledge 
was improved and motivated pharmacists 
recruited more participants. 
The short-term training 
and the fast decrease in 
knowledge following the 
end of training did not 
reflect the real role the 
pharmacists can deliver 
in alcohol screening. 
Most of the surveyed 
pharmacists were 
already delivering a 
wide range of health 
services. 
Hunt et al. 
Evaluation of the 
Healthy Life 
Check 
programme: a 
vascular 
risk assessment 
service for 
community 
pharmacies in 
Leicester city, UK 
(2013) 
To evaluate the 
effectiveness of a 
pharmacy-led risk 
assessment 
service in 
Leicester City, 
UK. 
Observational study 39 CPs in Leicester 
City, England.  
2521 individuals were recruited  (1059 
(42%) males, 1696 (67%) South Asians 
and 199 (7.9%) individuals not registered 
with a GP. A total of 462 (18%) individuals 
were referred to primary care and 52.6% 
of a representative subset were 
subsequently recorded as having 
attended an appointment with their GP. 
The study was 
conducted in a city with 
a possible coronary 
heart disease due to 
deprivation and high 
percentage of minor 
ethnicities. It proved 
that pharmacists were 
able to reach a good 
number of people, 
especially those who 
were at high risk. 
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Khan et al. Alcohol 
brief intervention 
in community 
pharmacies: a 
feasibility 
study of outcomes 
and customer 
experiences (2013) 
To identify the uptake of 
the 
CP alcohol brief 
intervention service, to 
establish 
post-brief intervention 
changes in alcohol 
consumption for 
hazardous 
drinkers, to report the 
acceptability of the 
service to 
customers who 
received it and  to 
determine the cost 
effectiveness  of service 
through CPs 
Observational 
study, 
questionnaire 
and telephone 
interview  
26 CP in Lambeth, 
London, England. 
141 (21%) of eligible 
customers used the 
service, 75% were risky 
drinkers.  
The brief intervention was 
effective in significantly 
reducing a 7-day alcohol 
unit consumption and 
drinking days for 
hazards.10 (91%) of 
harmful drinkers who were 
contactable post-BI had 
accessed further alcohol 
related services. 
The provision of service 
was estimated to cost £134 
per customer. 
The study was well 
conducted and covered 
costs for providing alcohol 
BI, in addition to alcohol's 
impact on employment 
status. However, the study 
only estimated a short-term 
benefit (3-months) and did 
not investigate any further 
benefit upon reducing 
alcohol consumption. 
Morrison et al. A 
community 
pharmacy weight 
management 
programme: an 
evaluation of 
effectiveness 
(2013) 
To evaluate weight 
change among patients 
who used 
Counterweight 
management 
programme which 
delivered by community 
pharmacist. 
 
 
 
Observational 
study. 
16 CPs in Scotland.  
 
458 patients were enrolled 
(75% women, with mean 
age of 54 years and mean 
BMI of 36.1 kg/m
2.
.  
32 patients out of 77 who 
attended for a year had 
achieved the target weight 
loss of ≥5% with 4.1 kg as 
a mean weight loss. 
 
 No difference in weight 
loss was related to sex, 
baseline BMI or age. 
It targeted CPs in areas 
where overweight is a 
common problem and no 
offering of counterweight 
services. However, it has 
an over estimation of 
women in that areas. 
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Boardman and 
Avery. 
Effectiveness of 
a community 
pharmacy weight 
management 
Programme 
(2014) 
To evaluate the effectiveness of 
community pharmacists in 
helping patients to reduce their 
weights 
Observational 
study.  
CPs in four PCTs in 
England (Berkshire 
West, Cornwall and 
Isles of Scilly, 
Coventry and 
Plymouth) 
Data of 281 patients 
were analysed. 
77% were female,  with mean 
age 52.8 years and mean 
baseline weight 96.3 kg,  mean 
weight loss at 3 months was 
3.07 kg and mean  
waist circumference loss was 
3.87 cm,  with no difference in 
blood pressure. Mean weight 
loss at 6 months was 4.59 kg 
and mean  waist circumference 
loss was 4.79 cm, with reduction 
in systolic blood pressure of 9.5 
mmHg and diastolic of 4.7 
mmHg. 
Good evaluation of 
weight management 
programme was 
reported at two 
points; 3 and 6 
months. 
It had a higher 
percentage of women 
(77%). 
It did not compare the 
results based on 
social differences 
(e.g. employability 
and deprivation) and 
smoking status. 
Krska and  
Mackridge. 
Involving the 
public and other 
stakeholders 
in development 
and evaluation of 
a community 
pharmacy 
alcohol 
screening and 
brief advice 
service (2014) 
To determine the views of CP 
staff, the general public and 
other stakeholders towards 
alcohol screening and advice 
service.  
To design an acceptable and 
feasible pharmacy based 
alcohol screening and advice 
service based on stakeholder 
views. 
To evaluate a pilot service from 
the user perspective. 
Telephone 
interviews with 
stakeholders, 
street survey with 
public, work 
group with 
stakeholders and 
telephone 
interviews with 
service users.  
Sefton PCT, 
England 
All stakeholder groups viewed 
pharmacy-based alcohol 
screening services as 
acceptable and feasible with the 
potential for integration and/or 
combination with existing public 
health services.  
Privacy was the main barrier and 
drinkers of more deprived areas 
were more willing to use the 
service.  
Posters were considered as the 
main venue to inform users.  
The study was well-
conducted using 
triangulation 
(interviews and 
survey). 
It identified views of 
stakeholders and 
public. 
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Folkes et al. A qualitative 
study of the views of women 
aged 18-29 on over the 
counter availability of 
hormonal emergency 
contraception (2001) 
To investigate the 
women's perceptions 
regarding deregulation 
of EHC prior to its 
deregulation on 
January 1st 2001. 
Qualitative study 
using face to 
face and semi-
structured 
interviews. 
A NHS family 
planning clinic and 
a general practice 
in South West of 
England. 
27 women aged 
between 18 and 29 
were interviewed 
Women showed positive views 
regarding deregulation as it 
would bring a fast, convenient 
and anonymous delivery. 
Concerns were raised regarding 
misuse and costs. 
CP was their preferred choice 
obtaining EHC 
The study was well 
conducted. However, 
there was no 
justification for 
approaching only 
women without male 
partners. 
Seston et al. Emergency 
hormonal contraception: The 
community pharmacy 
Perspective (2001) 
To explore the CPs' 
views regarding the 
deregulation of EHC 
into pharmacy 
medicine. 
Two focus 
groups 
14 CPs in North 
West England.  
There was a lack of knowledge 
about how the EHC works 
among number of CPs.  
CPs felt that the new method of 
supply has some risks and 
might be abused. 
The study was 
amongst the first 
studies to identify 
pharmacists' views 
towards deregulation 
of EHC. 
However, it was 
limited to one region 
of the UK. 
McAllister et al. Evaluation 
of a young person’s sexual 
health service in a 
commercial setting (2002) 
To investigate how 
young people are 
accepting are 
accessing sexual 
health service in a city 
centre pharmacy. 
A qualitative 
survey and 
semi-structured 
interviews 
One community 
pharmacy in 
Scotland 
98 attended the service and 53 
out of them attended the 
service for EHC, 26 for 
hormonal contraception.  
A 93% of clients were satisfied/ 
very satisfied with the opening 
times and all with pharmacy 
location. 
Despite that the study 
reached only 98 
persons, the majority 
were sexually active 
and came from 
different areas of the 
city, which could be 
representative to the 
rest of population. 
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Bacon et al. Training 
and supporting 
pharmacists to supply 
progestogen-only 
emergency 
contraception (2003) 
To describe and 
evaluate the 
training received 
by CPs to 
provide EHC 
under PGD in 
Lambeth, 
Lewisham and 
Southwark, 
London. 
A systematic 
analysis of 
written and oral 
data from 
pharmacists pre, 
post and during 
training , followed 
by  
analysis of training 
Lambeth, 
Lewisham and 
Southwark, 
London. 
20/22 CPs in 
the training 
cohort and 6/23 
who applied but 
were not 
accepted. 
The training course was effective in 
informing pharmacist about how to deal 
with EHC.  
The study tested the 
community pharmacists' 
knowledge for a short 
and long term.  
However, it only covered 
pharmacists in socially 
deprived cities.   
Bissell and Anderson. 
Supplying emergency 
contraception via 
community 
pharmacies in the UK: 
reflections on the 
experiences 
of users and 
providers (2003) 
To explore the 
pharmacists and 
the users 
regarding 
supplying of 
EHC. 
Interviews with 
pharmacists. Focus 
group with service 
users  
North- West 
England. 
Interviews with 
24 
pharmacists. 
540 were 
invited to 
participate. 
 
47 (8.7%) users participated. Two focus 
groups were conducted; 5 women (group 
1) ,6 women (group 2)  
Positive views were seen from pharmacists 
and users. The benefits included enhanced 
free access to EHC when it is mostly 
needed, absence of judgmental attitudes 
and improve profession.  
The concerns included misuse, changes in 
contraceptive behaviour and fear of STIs.  
The study covered both 
pharmacists and users 
perceptions. However, 
75% of interviewed 
pharmacists were 
female. 
Killick and Irving. A 
national study 
examining the effect 
of making emergency 
hormonal 
contraception 
available without 
prescription (2004). 
To identify 
women's views 
regarding the 
access and 
uptake of EHC  
Self-completed 
questionnaire to 
women requesting 
EHC 
CPs of one 
large chain in 
the UK. 
419 women returned the questionnaire.  
A greater proportion of women reported 
that they were able to obtain EHC within 
24 hours through pharmacies versus than 
through prescriptions from doctors (64% 
versus 46%; P= 0.029). 
Women preferred obtaining EHC through 
pharmacies but reported its cost as an 
issue.  
The study could not 
identify the response 
rate. The study identified 
the post codes of users; 
however, it did not make 
any use of this to 
compare the use of 
service through different 
localities. 
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Lloyd and Gale. 
Provision of emergency 
hormonal contraception 
through 
community pharmacies 
in a rural area (2005). 
To assess how the 
EHC service 
success in reaching 
the target group and 
why the people use 
it and how it was 
accessed.  
Descriptive 
study 
Hambleton and 
Richmondshire 
PCT, UK. 
 
 
1412 pharmacy consultations for EHC 
were conducted between 1 January 
2000 and 31 December 2003. 
A shift in venues to obtain EHC, by 
December 2003, CPs was the first 
place to provide.  
Pharmacy posters and 
word of mouth were 
amongst the most source 
of information for knowing 
about the EHC through 
PGDs. 
Lewington and 
Marshall. Access to 
emergency hormonal 
contraception from 
community pharmacies 
and family planning 
clinics (2006) 
 
To evaluate 
differences in the 
time taken to 
access EHC by 
young women from 
family planning or 
CP settings.  
An 
observational 
study of 
women 
requesting 
EHC. 
South-West Kent 
PCT, England. 
203 women who 
accessed EHC from 
family planning and 
CPs.  
Women who were able to obtain EHC 
from CP was significantly faster than 
from family planning  clinics (16 h 
versus 41 h, P < 0.001). 
Older teenagers tended to seek EHC 
more quickly and were more likely to 
have had a contraceptive failure 
rather than have used no 
contraception at all 
The study did not identify 
any difference between 
the two groups in terms of 
surrounding CPs with 
EHC service, walking 
distance to CPs and 
family clinics and 
occupation of the users.  
Bissell et al. A 
qualitative study of 
pharmacists’ 
perspectives on the 
supply of 
emergency hormonal 
contraception via 
patient group direction 
in the UK (2006) 
To investigate 
pharmacists’ views 
and experiences of 
supplying (EHC) via 
a group prescribing 
protocol in CPs 
Qualitative 
study using 
depth 
interviews. 
44 CPs in health 
action zones across 
the UK. 
Positive views were reported. The 
confidential nature was advantage as 
well as the scope for referral to other 
service providers. Improvement in 
profession was an advantage. 
Concerns raised about  the extent of 
repeated use of EHC, the possible 
impact on contraceptive behaviours 
and STIs and its impact on male 
coercive 
The study covered 
pharmacist from different 
cities across England. 
However, all the cities 
were considered as 
deprived cities. 
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Baraitser et al. Chlamydia 
testing in community 
pharmacies: evaluation of a 
feasibility pilot in south east 
London (2007) 
To investigate 
the feasibility 
and acceptability 
to users 
and pharmacists 
of chlamydia 
testing service 
Survey of users. 
Indepth semi-
structure 
interviews with 
pharmacists and 
users.  
Structured 
evaluation 
reports 
completed by 
professional 
patients paid to 
visit CPs. 
3 CPs in 
Lambeth and 
Southwark, 
London, 
England. 
83 tests were conducted, 8 out of them 
(9.5%) tested positive infection. 
The majority were women 73 (95%) and 
from ethnic minorities 56 (71%). 80 users 
completed the survey questionnaire and 
24 were interviewed. 
Pharmacists were the main venue to 
inform users about the service.  
Users reported the speed, the 
convenience and the non-judgmental of 
pharmacist as advantages. 
71% of those tested 
were from ethnic 
minorities (reflection of 
the population in 
Lambeth and 
Southwark). 
The study mentioned 
that those who were 
tested know about the 
service through 
pharmacist, but did 
identify any other 
source of information. 
Cameron et al. Willingness 
of gynaecologists, doctors 
in family 
planning, GPs, practice 
nurses and pharmacists to 
adopt novel interventions for 
treating sexual 
partners of women with 
chlamydia (2007). 
To determine 
willingness of 
health 
professionals to 
adopt new 
interventions for 
treating sexual 
partners of 
women 
with chlamydia. 
Self-
administrated 
questionnaire. 
UK clinical 
meetings and 
CPs in 
Lothian, 
Scotland.  
308 
questionnaires 
to doctors, 94 
to nurses and 
140 to CPs.  
Response rate was 69% (211), 78% (73) 
and 36% (50) for the doctors, nurses and 
CPs, respectively.  
The most popular choice among doctors 
(30%) and nurses (23%) was to combine 
posting test kit with a provision of 
medication to partner.  
Most pharmacists were willing to provide 
free test kit (98%), offering testing (75%) 
and treatment (100%) and 80%  to 
partner 
It tested different 
healthcare 
professionals and had 
a good response rate 
in terms of doctors 
(69%) and nurses 
(75%), but not in terms 
of pharmacists (36%). 
Seston et al. Women’s 
preferences for the provision 
of emergency hormonal 
contraception services 
(2007) 
To determine 
the women's 
preferences in 
obtaining EHC 
Self-completed 
questionnaire of 
women who 
attended sexual 
health services 
269 women 
who attended 
sexual health 
clinics in North 
West England 
Opening hours, medical staff seen, cost, 
wait to be seen, privacy of consultation 
and attitude of staff were the factors that 
significantly influence the preferences of 
women choice to obtain EHC  
The study only 
investigated those who 
pay for the service not 
those who could get it 
free under PGDs.  
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Black et al. Provision of 
emergency contraception: a 
pilot study comparing access 
through pharmacies and 
clinical settings (2008). 
To compare 
the provision 
of EHC 
through CPs 
versus 
clinical 
services 
A pilot 
observational 
study. 
133 women in 
South London 
were recruited 
(50 women 
accessed EHC 
service through 
CPs and 83 
through clinical 
services) 
Faster provision of EHC through CPs 
(70%  versus 43.9% through clinical 
services; P= 0.004). 
More comfortable, better informed about 
EHC and future contraceptive through 
clinics than through pharmacies, with P 
= 0.007, 0.015 and < 0.001, 
respectively.  
The researcher met with 
service users after 4 
months of obtaining the 
EHC, which could have 
influenced the accuracy of 
answers. 
Cooper et al. Ethical, religious 
and factual beliefs about the 
supply of 
emergency hormonal 
contraception by UK 
community 
pharmacists (2008b) 
To explore 
pharmacists' 
views and 
their ethical 
concern 
regarding the 
sale of EHC 
through CP 
Semi-
structured 
qualitative 
interviews 
With 23 CPs in 
the UK. 
Three types of pharmacists were 
identified; those who sold EHC 
welcomed the idea but concerned with 
the consequences of limit stock. 
Contingently ones who felt that GP 
should be the first choice. Not-selling 
ones who considered EHC as an 
abortion method and had ethical issues 
with selling. 
The study did not identify 
any training the 
pharmacists received for 
selling EHC and did not 
test any difference in 
terms of gender and 
experience of 
pharmacists. 
Brabin et al. Delivery of 
chlamydia screening to young 
women requesting 
emergency hormonal 
contraception at pharmacies 
in Manchester, 
UK: a prospective study (2009) 
To assess 
the uptake of 
free postal 
chlamydia 
screening by 
women under 
25 years who 
requested 
EHC at CPs 
Audit data on 
EHC 
coverage 
was obtained 
from PCTs to 
assess the 
eligibility for 
screening 
and to verify 
the uptake. 
33 CPs within 
Manchester, UK. 
24.8% (675/2718) of women who 
received EHC were also offered 
chlamydia screening, representing 
46.4% (1348/2904) of total who were 
offered a kit. 17.6% (264) of those who 
accepted the kit returned a sample, with 
whom 9.1% were chlamydia positive. 
Chlamydia positivity increased  with 
age.  
The study had a low 
percentage of those who 
returned the kits (17.6%) 
and no information about 
whether the rest of those 
who received kits were 
tested somewhere else. 
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Glasier et al. 
Community 
pharmacists providing 
emergency 
contraception give 
little 
advice about future 
contraceptive use: a 
mystery shopper study 
(2010) 
To investigate the 
quality of EHC provision 
in CPs and to identify 
what advice related to 
contraception after EHC 
use. 
 
 
Mystery shopper study.  8 CPs were 
visited in the 
pilot study 
and 40 CPs 
in the main 
study. 
All CPs 
were in 
contract with 
the NHS 
and located 
in Lothian, 
Scotland.  
The EHC was unavailable in 5 
(12.5%), was refused to be given 
in 7 (17.5%) because of 
contraindication, and was 
provided in 28 (70%). No 
provision of EHC after 72 h of 
sexual intercourse was seen and 
EHC was provided when the 
date of last menstrual period was 
uncertain. Advice about future 
contraception was given through 
32.5% of all CPs and 43% of 
those issuing EHC. 
The study focused on 
CPs of the most 
deprived areas. 
There was no 
information about the 
time of each visit 
(especially weekends 
and evenings) and 
whether it had an effect 
on obtaining EHC. 
Thomas et al. A 
qualitative study of 
pharmacists’ views 
on offering chlamydia 
screening to women 
requesting emergency 
hormonal 
contraception (2010b). 
To explore pharmacists’ 
views on chlamydia 
screening, its perceived 
relevance to clients and 
whether these 
perceptions had affected 
their willingness to offer 
chlamydia screening. 
A qualitative study, exit 
interviews followed by 
semi-structured depth 
interviews. 
26 CPs in 
Manchester, 
England. 
26 completed the exit interview 
and 12 agreed to do the depth 
interview. Pharmacist feared to 
provide chalmydia screening to 
married or long-relationship 
women. The criteria for choosing 
women were based on age, 
education and ethnicity.  
 
Weiss et al. Use of 
simulated patients to 
assess the clinical and 
communication 
skills of community 
pharmacists (2010) 
To investigate the 
quality and 
appropriateness 
of  (EHC) 
supply from CPs 
Two mystery shoppers 
scenarios to each 
participant CPs; 
scenario 1 (appropriate 
supply) and scenario 2 
(inappropriate) 
 Focus groups evaluated 
the findings. 
CPs in 
South West 
of England 
40 CP visits were completed: 21 
scenarios 1 and 19 for scenario 
2, with 18 were visited twice. 
Five pharmacists supplied EHC 
in case of scenario 2 where EHC 
was a contraindication. 
Communication skills of 
pharmacists were rated highly.  
The study was limited to 
CPs in one city and 
findings cannot be 
generated. Both 
scenarios were 
represented by students 
who lack the potential to 
be convenient. 
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Continued- Table 1.3: Published studies related to sexual health services through CPs 
Author (s)/ Title  
( year) 
Aims/ Objectives Method  Setting, and 
number 
participating  
Key findings Comments 
Anderson  and 
Thornley. A 
pharmacy-based 
private chlamydia 
screening 
programme: 
results from the first 
2 years of screening 
and treatment 
(2011). 
To analyse the data 
from private provider of 
chlamydia services. To 
identify the correlation 
between positivity 
results and users 
characteristics. 
To identify the 
feasibility of reaching 
unreached public 
through other settings   
Cross-
sectional 
study. Data 
was collected 
from the 
private 
provider 
database. 
CPs in the UK A total of 14,378  screening tests were 
performed 
in CPs over 2 year period. Positivity 
was higher in male than female (9.8% 
versus 6.8%) and in 15-24 years old 
than in 25 and above. 47% of those 
who tested positive paid for treatment 
and 25% of their partners accessed 
the treatment.  
The study was well-
conducted covering data 
for the first two years of 
launching chlamydia 
services. 
Dabrera et al. 
Chlamydia 
screening by 
community 
pharmacists: 
a qualitative study 
(2011) 
To identify 
pharmacists' 
perceptions towards 
the provision of 
chlamydia screening 
through CPs. 
Semi-
structured 
interviews 
10 community 
pharmacists in 
London and 
Greenwich, 
England.  
Pharmacists had a good knowledge 
about importance of chlamyida 
infection and need for screening. 
Concerns  were raised about how to 
approach young people and those 
who attends the CP for non-sexual 
health services. Opportunities were 
seen in case of offering screening for 
those who attend for EHC. 
The study was limited to 
10 CPs in one city of 
London and findings 
cannot be generated. 
Gale and Watson. 
The provision of 
current and future 
sexual health 
services 
from community 
pharmacies in 
Grampian, Scotland 
(2011) 
To identify CPs’ 
activities and attitudes 
towards the provision 
of sexual health 
services  
A cross-
sectional 
questionnaire 
survey. 
128 CPs in 
Scotland. 
37% as a response rate. The average 
number of services provided per CP 
per month was 6. Respondents 
welcomed current and future provision 
of service but they identified 
inadequate training. Barriers included 
workload, lack of training and need of 
payment for additional services.  
The study had a good 
response rate (74%) and 
covered pharmacists from 
different types of CPs and 
only 1% of respondents 
were locum pharmacist. 
The study was limited to 
one city and the findings 
cannot be generated. 
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Continued- Table 1.3 Published studies related to sexual health services through CPs 
Author (s)/ Title  
( year) 
Aims/ 
Objectives 
Method  Setting, and number 
participating  
Key findings Comments 
Cameron et al. The 
effect on use of 
making emergency 
contraception 
available free of 
charge (2012) 
To evaluate the 
women 
knowledge 
about  
availability of 
free EC from 
pharmacies, 
and its use to 
prevent the 
index 
pregnancy 
A questionnaire 
survey.  
204 women attending 
clinics for abortion in 
Edinburgh, Scotland. 
143/204 respondents knew that EC was 
available free from CPs and only 22 (11%) 
had used it in the cycle in which 
conception occurred.  
Knowledge of EHC availability free of 
charge did not affect use of it.  
Women from affluent areas were 
significantly more likely to have used EC 
to try to prevent the pregnancy than 
compared to women from less affluent 
areas (p=.041). 
The study focused on 
those who came for 
induced abortion. 
However, it did not 
compare the findings 
with those who used 
EHC and actually 
worked with them. 
Parsons et al. 
Evaluation of a 
community 
pharmacy 
delivered oral 
contraception 
service (2013) 
To evaluate the 
oral 
contraceptive 
service 
delivered by 
CPs 
Observational 
study 
5 CPs in Southwark and 
Lambeth, London, 
England 
741 consultations occurring following 
supply of EHC. The mean consultation 
time was 19 minutes. Combined 
OC was most commonly supplied with 
nearly half (46.1%) of initial supplies to 
first-time pill users. Most consultations 
(92.2%) were with women aged under 30 
years, with 22.5% aged under 20. Most 
consultations were with black or black 
British clients. Of the 99 women 
who completed the satisfaction 
questionnaires, 
most clients were very satisfied or 
satisfied with 
the service and felt comfortable talking to 
the 
pharmacist about contraception 
The study focused on 
two boroughs in 
London; however, the 
respondents were 
overrepresented for 
Black and Black 
Caribbean women 
and underrepresented 
for white and Irish 
women. 
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1.9 Vascular and sexual health pharmacy services in developed countries 
A similar literature search was conducted to identify the experience and outcome of 
vascular and sexual health services offered in other developed countries. An 
overview of these studies is presented below. Bock and co-workers (2010) found 
that using a tailored software system was helpful in increasing delivery of smoking 
cessation, quit attempts and quit rates through American community pharmacists. 
The software is located in a small room, where patients who are waiting for their 
prescriptions can use (Bock et al., 2010). The software can test patients' conditions 
through entering data and provides printed results of four pages that can identify 
barriers and opportunities for smoker to help quit smoking (Bock et al., 2010). Dent 
and co-workers (2009) found in their RCT that participants who received 3-sessions 
of face to face programme with pharmacists were more likely to quit smoking than 
participants who received 5-10 minutes standard care from pharmacists over the 
telephone (with free medication in both cases), 28% and 11.8% quit rate at 6 
months follow up, respectively. In another study, Corelli and co-workers (2013) 
found a solution to utilize USA pharmacists in delivering smoking cessation service, 
by referring patients to the quit line service. In another study which was conducted 
in Canada, Costello and co-workers (2011) identified that increasing the frequency 
of face-to-face meeting with smokers from 1-session to 3-sessions will improve the 
quit rate from 18% to 27.7%. Horsfield and co-workers (2014) found that 25.4% of 
respondent pharmacists in New Zealand were offering quit smoking consultation 
service. In Australia, community pharmacists are extending their role to meet their 
local needs (Berbatis et al., 2007). The type of services offered seems to be similar 
to that in the UK. These include smoking cessation, weight management, diabetes 
care and hypertension care (Berbatis et al., 2007). However, for smoking cessation, 
diabetes care and hypertension care there was a decrease in percentages of CPs 
offering the service between 2002 and 2006, while the only increase was in case of 
weight management (Wibowo et al., 2010). A pharmacist might charge a fee upon 
provision of those services or offer them free of charge, and in case of weight 
management 23.3% of respondent pharmacists charged a fee in 2006 (Wibowo et 
al., 2010). Australian pharmacists were satisfied that they can offer weight 
management service, but they suggested co-ordination with other healthcare 
professionals. In addition, they considered low remuneration and lack of demand as 
barriers towards provision of weight management (Um et al., 2010). Furthermore, 
previous users of weight management service through CPs were willing to pay in 
the future to get help and support from pharmacist in weight management, while  
respondents (previous users and those who have not used a service) raised 
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concerns about pharmacist's experience and available time (Um et al., 2012). 
Pharmacists can offer more than just medication to help in weight management as 
it was found by Ahrens and co-workers (2003). They can offer advice on meal 
replacement or conventional reduced-calorie diet and both of these programmes 
were found to be effective in decreasing waist circumference and lowering systolic 
and diastolic blood pressure and triglyceride levels (Ahrens et al., 2003). USA 
pharmacists identified three barriers in terms of provision of weight management 
through CPs; lack of time, lack of demand and lack of remuneration (O'Donnell et 
al., 2006).    
In terms of sexual health services, Gudka and co-workers (2013) found that 
chlamydia screening uptake in Australian CPs can be improved if kits are offered to 
individuals who ask for EHC.  
1.10 Vascular and sexual health pharmacy services in developing countries 
Similarly, studies outlining the provision of vascular and sexual health services from 
CPs in developing countries were investigated. The situation in developing 
countries differs between one country and another, however some of the vascular 
health services offered in a number of developing countries. Services such as brief 
intervention for smoking cessation and weight management were identified in the 
United Arab Emirates (Hasan et al., 2012). Obesity management was also seen 
through CPs in Kuwait (Awad and Waheedi, 2012). In Iran, Sarayani and co-
workers (2012) implemented the effectiveness of continues education of 
pharmacists to deliver weight management service through a basic lecture, a 
lecture with case studies and a lecture with small group training. The three methods 
of teaching helped in improving pharmacists’ knowledge and self-confidence to 
deliver weight management services. In Nigeria, the pharmaceutical care 
intervention was effective in reducing blood pressure (Smith, 2009).  
1.11 Rational of the study 
 As the new plan for NHS was introduced following the new Government in 2010, 
with an intention to abolish the PCTs and create a new system for delivering 
enhanced pharmacy services. It was necessary to conduct this research to identify 
how the enhanced pharmacy services were contributing to bridge the gaps in health 
inequalities on a national level. The Pharmaceutical Needs Assessment (PNA) 
reports that each PCT was required to publish by February 2011 were the pivot on 
which the research was based to determine the provision of vascular and sexual 
health pharmacy service through all PCTs in England. However, the uptake of 
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services in detail was not provided in the PNA reports and it was required to survey 
the PCTs to obtain data regarding uptake and cost attributed to the provision of 
services to identify the cost-effectiveness of those services on a national level. A 
primary investigation of the PNA reports regarding the provision of NHS health 
check service found that only 42 PCTs started providing NHS health check service 
in 2009/2010 through CPs out of total 151, representing 27.82%. Furthermore, the 
provision was in its pilot phase and only 389 CPs provided the service out of total 
10 845 CPs in England, representing 3.59%. The PNA reports also indicated lack of 
uptake of NHS health check service through CPs. Therefore, the study focused only 
on evaluating the provision and uptake of SSS as a vascular health service. It also 
investigated the provision and uptake of EHC and chlamydia screening as sexual 
health services. Later in (2012) when the HLP scheme was rolled out, it was 
necessary to identify how the new scheme changed the provision and uptake of 
those services. The literature review conducted has shown that none of the 
previous studies compared the provision and uptake of vascular and sexual health 
services between different PCTs. 
Therefore, the aim of this project is to identify the provision and success of vascular 
and sexual health pharmacy services and how the uptake and success matched 
with the local needs and deprivation. The research investigated this on two levels; 
PCT level and CP level. The project also aimed to investigate the cost-effectiveness 
of SSS and EHC services through CPs. It also aimed to identify how the services 
changed following the introduction of the HLP scheme and how the services can be 
improved. Finally, it aimed to identify pharmacists' perceptions about how to 
improve the uptake and success of vascular and sexual health services using SSS 
as a model case.  
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Chapter Two:  Needs, provision and uptake of stop smoking service 
2.1 Introduction 
In 1999, England established its unprecedented network for Stop Smoking Service 
(SSS), following the introduction of the white paper “smoking kills”. The white paper 
set a target to reduce prevalence of adult smoking from 28% to 24% or less by 
2010 and to reduce the gap in smoking prevalence between different 
socioeconomic status (SES) groups (DH,1998). In 2000, an update to the smoking 
cessation guidelines was published. It summarised the roles of each health care 
professional to help a smoker to quit smoking. It highlighted that General 
Practitioners (GPs) should give advice and prescribes effective medication to a 
smoker during routine consultation. It also emphasised the role of behavioural 
support for a smoker (in groups or individually). It encouraged other health care 
professionals (such as pharmacists, dentists, health visitors and nurses) to give 
advice to a smoker whether he was seeking help with stopping or not (West et al., 
2000). In 2005, the prevalence of smoking adults fell to 26% (HSCIC, 2007) and in 
2010, to 20% (HSCIC, 2012b) which overrode the targets set in 1998 by the white 
paper “smoking kills” (DH, 1998). The SSS guidance published in 2011 
recommended that PCTs and SHAs should aim to treat at least 5% of their 
estimated local population who smoke or use any form of tobacco each year (DH, 
2011a). It also recommended a success rate of at least 35% at 4 weeks, validated 
by carbon monoxide (CO) monitoring (DH, 2011a). The geographical distribution of 
SSS was not intended to be equal and priority should be given to areas with lower 
SES and higher percentages of Black and Minority Ethnicities (BME) (DH, 2011a). 
Although the NHS SSS was aimed to target areas with lower SES (DH, 2011a), a 
recently published report showed that, in fact, there is a link between deprivation 
and smoking (Wise, 2014). An overview of how deprivation is measured gives an 
idea of why deprivation is connected with smoking. The deprivation is measured 
based on seven domains. These are income; employment; health deprivation and 
disability; education, skills and training; barriers to housing and services; crime and 
living environment (Department for Communities and Local Government, 2011). 
The association between smoking prevalence and the first domain (income) in 
developed countries is arguable. While one study found a strong association 
between low income and smoking prevalence in men and women (Fukuda et al., 
2005), another study found that it was only associated with smoking prevalence in 
men (Huisman et al., 2005).  Another study found no significant association at all 
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(Wilkins et al., 2007). The lack of a significant association observed can be 
attributed to the increased tax prices for cigarettes as a venue to reduce the 
smoking prevalence, which seemed to have a slight effect on smoking prevalence 
(Callinson and Kaestner, 2014). In contrast, the high income had a negative effect 
on smoking prevalence among teenagers (Ben Lakhdar, 2012). The employment 
situation (the second domain in deprivation) seemed to be more associated with 
smoking prevalence, as those who were unemployed were more likely to smoke 
than those who were employed (De Vogli and Santinello, 2005, Schunk and Rogge 
, 2012). The intensity in smoking among unemployed was arguable, while Schunk 
and Rogge, 2012 found no association with unemployment, Bolton and Rodrigues, 
(2009) found a slight increase in intensity among the unemployed who did not 
receive any compensation. The effect of psychological factors such as the inability 
to control one's life and emotional isolation might be a predictor to the association 
between unemployment and smoking (De Vogli and Santinello, 2005). For the third 
domain (health deprivation), smoking habits were responsible to cause several 
types of health problems such as cardiovascular disease, lung cancer and asthma 
(Jha et al., 2013), which result in health deprivation. The fifth domain (education, 
training and skills) is one of the most important measures for smoking prevalence. 
Educated people were found to be less likely to smoke than uneducated ones 
(Huisman et al., 2005, Gilman et al., 2008). This is one of the reasons to establish 
more than one setting to reach smokers and provide them with missing or 
unrecognised information about hazards of smoking and benefits of quitting. The 
introduction of housing improvement to deprived areas encouraged smokers to 
think about quit smoking, but failed to reduce smoking prevalence (Bond et al., 
2012).  
Although, the additional expenses caused by smoking can act as a motivator to quit 
smoking among lower SES smokers (Pisinger et al., 2010), smokers who live in 
lower SES areas are less likely to quit smoking than those who live in higher SES 
areas (Giskes et al., 2006). In fact when looking at the short term quit smoking at 4 
weeks, SES was significantly associated with quit smoking relapse in direct and 
indirect association (Businelle et al., 2010). The main reasons among lower SES 
groups to relapse could be attributed to stress, depression and lack of social 
support (Busineel et al., 2010 and Pisinger et al., 2010). However, when looking at 
the longer time of quit beyond one year, no direct association between SES status 
and relapse was identified. The real association was with nicotine dependence, 
craving, withdrawal symptoms and lack of smoking cessation aids (Zhou et al., 
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2009). Sindelar and O`Malley (2014) suggested that the focus on the financial 
benefit of quit smoking might provide better results than the focus on health 
benefits.   
In 2009/2010, after 10 years of the NHS SSS establishment, SSS was available 
through primary care (GPs and other health care professionals such as; practice 
nurses, midwives and health visitors), dental practice, pharmacy, hospital wards, 
and military bases. The smokers could go through different types of interventions 
such as; closed groups, telephone support, couple/family, open group, one-to-one 
support and drop in sessions (HSCIC, 2010).  
CPs are well placed in the heart of the community to provide services that promote 
health and help in reducing health inequalities (DH, 2003a, DH, 2008a). A recent 
study by Todd and co-workers (2014) found that 89.2% of England population can 
access CPs within 20 minutes walk (98.3% in urban areas, 79.9% in town and 
fringe and 18.9% in rural areas). However, the access is better in most deprived 
areas (99.8% of population have access in 20 minutes) when compared to the least 
deprived ones (90.2%) (Todd et al., 2014). The provision of SSS through CPs was 
considered to be effective (Maguire et al., 2001 and Sinclair et al., 2004) and cost-
effective (Bauld et al., 2009b). For an intervention to be considered as cost-
effective, ICER per QALY gained should be less than £20 000 (National Institute for 
Health and Care Excellence (NICE), 2012). In 2009/2010, more than half of English 
CPs did provide SSS. In addition, almost 140 000 smokers set a quit date through 
pharmacies which represented 18% of all smokers who set a quit date through all 
providers (HSCIC, 2010).  
The aim of SSS though CPs is to improve access and widen choices for a smoker 
who wishes to quit. However, to be eligible to provide SSS, pharmacists and other 
staff should be trained to ensure proper and safe use of the service. The service 
includes initial assessment, through which the CP can test the smoker's readiness 
and willingness to quit smoking. At this initial consultation, a thorough description of 
the risks of smoking, benefits of quit smoking, available medications to help quit 
smoking and withdrawal symptoms should be explained. Having decided to quit 
smoking, the NRT will be provided and a 4-week follow up will be done to test the 
results of using the SSS (PSNC, 2014). At 4-week follow up, the smoker is 
considered as quitter, if he/she never smoked from two weeks after the agreed set 
date for quit smoking (HSCIC, 2010). However, the self assessment for quitting 
smoking should be validated by CO validation method which should be lower than 
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10 part per million (ppm) (DH, 2011a). Each PCT has its criteria for supplying NRT 
and follow up. In most cases, an initial supply of NRT to cover two weeks is done, 
followed by two weeks supply when the smoker shows commitment and willingness 
to quit smoking to cut the drug waste followed by a further supply of NRT for up to 
12 weeks ((Kent PCT, Mid Essex PCT, Devon PCT, Kirklees PCT and 
Peterborough PCT  (Appendix 1). In summary, the supply of NRT will be at 2 
weeks, 2 weeks (to guarantee his commitment to quit smoking), 4 weeks and 4 
weeks for a smoker who succeeded in quit smoking at 4-week and still needed 
help. The prescription charges also differ between the PCTs. For those who are not 
exempted from prescription charges, they have to pay the prescription charges 
every 5 weeks in case of Peterborough PCT and every 4 weeks in case of Devon 
PCT and per every item dispensed (to cover one week) in case of Kirklees PCT, 
Cumbria PCT, Mid Essex PCT and Kent PCT. In order for pharmacy to be 
reimbursed for the dispensed NRT, a form should be filled and submitted to the 
PCT. 
2.2 Aims and objectives 
This research aimed to determine how the provision and uptake of SSS matched 
the prevalence of smoking adults (needs) at PCT level and whether it reduced 
health inequalities between different PCTs with different needs. It also aimed to 
investigate if the provision of SSS through CPs (based on uptake and costs 
attributed) was cost effective or not based on NICE cost-effectiveness threshold 
(£20 000).  
The specific objectives of this phase of the project were: 
1. To assess how the prevalence of smoking adults (needs) differ across 
different PCTs in England and which of the PCTs' demographic 
characteristics (deprivation, gender and ethnicity) is correlated with higher 
needs. 
2. To determine the PCTs' success in meeting NICE guidelines; treat at least 
5% of their estimated number of smokers and achieve a quit rate at 4-weeks 
of 35% or more as validated by CO measurement. 
3. To identify the factors that are associated with higher uptake of SSS through 
all providers. 
4. To assess the role of CPs in delivering SSS and whether it meets the needs 
of the local population and helps reduce health inequalities. 
46 
 
5. To identify the costs attributed to the provision of SSS and investigate 
whether the provision of SSS through CPs is cost-effective. 
2.3 Method 
To meet the above described aims, published data was used to compare the needs 
and uptake of SSS through all providers. In case of CPs, the provision of SSS was 
identified through PNA reports. The uptake and cost attributed for SSS were 
identified through a cross-sectional survey of PCTs. Prior to their demolition, PCTs 
were required to prepare and publish reports about pharmaceutical needs in their 
areas and to publish those reports called PNA reports) by 1st February 2011 under 
the Health Act (2009) regulations (Legislation.gov.uk, 2009). The PNA reports were 
the main resource to obtain data regarding the provision of pharmaceutical services 
from CPs. Those reports provided data related to the financial year 2009/2010 
(starting on 01/04/2009 and ending on 31/03/2010). Consequently, the focus was 
on data related to the financial year 2009/2010 only. 
2.3.1 Measures and definitions 
The measures are divided into outcome measures which are tested against 
explanatory measures.  
 
2.3.1.1 The outcome measures 
 Total reach out of needs: is the percentage of NHS SSS setters out of total 
number of smokers within a PCT. 
  Total success out of needs: is the percentage of NHS SSS quitters (at 4-
weeks follow up, self-reported and CO validated) out of total number of 
smokers within a PCT.  
 Quit rate: is the percentage of NHS SSS quitters at 4 weeks follow up out of 
NHS SSS setters. 
 Pharmacy reach out of needs: is the percentage of NHS SSS setters 
through CPs only out of total number of smokers within a PCT. 
 Pharmacy success out of needs: is the percentage NHS SSS quitters (at 4-
weeks follow up, self-reported and CO validated) through CPs only out of 
total number of smokers within a PCT.  
 Pharmacy quit rate: is the percentage of NHS SSS quitters through CPs 
only at 4 weeks follow up out of NHS SSS setters through CPs. 
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  Pharmacy share in reach: is the percentage of NHS SSS setters through 
CPs out of total NHS SSS setters through all providers. 
  Pharmacy share in success: : is the percentage of NHS SSS quitters 
through CPs out of total NHS SSS quitters through all providers. 
 Setters per pharmacy per year: is the number of smokers who set a quit 
date per pharmacy during the financial year 2009/2010. 
  Quitters per pharmacy per year: is the number of smokers who set a quit 
date at CPs and proved to be non-smokers at 4 weeks follow up during the 
financial year 2009/2010. 
 
2.3.1.2 The explanatory variables 
 
A- Demographic variables: 
 PCT deprivation (Index of Multiple Deprivation (IMD) score) (2010): is a 
population weighted average of the combined scores for the Lower Layer 
Super Output Areas (LSOAs) in a PCT. LSOAs are homogenous small 
areas with small population size (around 1 500 people) of which there are 
32 482 in England and the LSOA with the rank 32 482 is the most deprived. 
The LSOA deprivation represents seven main domains, which were 
described in Section 2.1.  
  Ethnicity minority proportion: is the percentage of minor ethnicities (Asians, 
Blacks and Chinese and other ethnicity) out of total adults in a PCT. 
  Adult male proportion: is the percentage of adult males out of total number 
of adults in a PCT. 
 
B- Pharmacy provision variables: 
 Weighted number of CPs: is the number of CPs per 25 000 people within a 
PCT. 
 Weighted pharmacy provision of SSS against population: is the number of   
CPs providing SSS per 25 000 people within a PCT. 
 Weighted pharmacy provision of SSS against number of CPs: is the 
percentage of CPs providing SSS out of total CPs within a PCT. 
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2.3.2 Data Collection 
The study used published data from several resources which were used previously 
in other studies. The resources used included the Health and Social Care 
Information Centre (HSCIC), which was used by West and co-workers (2013) in an 
evaluation of the performance of NHS SSS over ten years. The Office for National 
Statistics (ONS) used for demographic characteristics and was used by Artac and 
co-workers (2013b) for evaluation of NHS health check service. To assess the 
uptake and cost effectiveness of SSS, the study used a postal questionnaire, which 
was found by Bowling (2005) to provide high coverage of sampling, if the addresses 
and details of the proposed sample were up to date. 
2.3.2.1 Published resources 
The prevalence of smoking adults (which reflects the needs) in each PCT was 
obtained from the health profiles for each PCT (Public Health England, 2010). In 
few cases the health profile for the PCT was not available. As a result, health 
profiles for each locality within that PCT were considered. A population-weighted 
value was calculated to represent the whole PCT as in the case of Mid Essex PCT, 
where the calculated percentage of smoking adults was 19.77% as shown in Table 
2.1. 
Table 2.1: An example of calculation of weighted values for localities against 
population to represent the whole PCT 
Mid Essex PCT 
(localities) 
1 
Population 
Mid-year 
Percentages of 
smoking adults
 
Total adult 
smokers 
2 
Weighted 
value (%) 
3 
Braintree 142 100 22.10 31 404  
Maldon 63 100 17.64 11 131  
Chelsford 167 100 18.59 31 064  
Total 372 300  73 601 19.77 
1- Mid Essex PCT consists of three localities; Braintree, Maldon and Chelsford. 
2- Total adult smokers: equals to (population (column 2) × percentages of smoking adults 
(column three). 
3- Weighted value (%): equals to (total adult smokers (73 601) / total population (372 300) × 
100) . 
 
The number of smokers in each PCT was calculated by multiplying the prevalence 
of smoking adults with the number of estimated adult population mid-year 2009 as 
imported from the Office for National Statistics (ONS) (ONS, 2011). The number of 
smokers who set a quit date through all providers and the number of smokers who 
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proved to be non-smokers at 4 weeks follow up were obtained from the Health and 
Social Care Information Centre website (HSCIC, 2011b).  
The ONS website was used to collect data regarding each PCT demographics 
(population, proportion of adult males and proportion of BME) (ONS, 2011). The 
PNA reports were investigated to assess the number of CPs in each PCT, the 
number of CPs which were providing SSS and any data regarding the number of 
smokers who set a quit date or quit smoking after 4 weeks follow up through CPs. 
2.3.2.2 Survey 
As mentioned above, a cross-sectional survey of PCTs was required to obtain the 
data regarding the uptake of SSS through CPs and the costs attributed to the 
provision of SSS through CPs. 
2.3.2.2a Questionnaire design 
Questionnaire design took into account the specified aims of this Chapter. Part A of 
the questionnaire was concerned with the uptake and costs of SSS for the financial 
year 2009/2010. Question 1 asked about the year the service was initially 
commissioned in a PCT. Question 2 asked about CP's payment for provision of 
SSS. Question 3 asked about overhead costs (training, advertising and equipment). 
Question 4 asked about number of setters and question 5 asked about number of 
quitters at 4 weeks follow up for the financial year 2009/2010 and question 6 asked 
about the method used to validate the quit smoking. Part B asked about the 
provision of SSS in 2012 and how the uptake and the payment changed since 
2009/2010. The final questionnaire and the invitation letter are available in 
Appendix 2. 
 2.3.2.2b Ethical approval 
The questionnaire was submitted to the Science, Engineering and Computing 
Ethics Committee at Kingston University in June 2012 to obtain ethical approval to 
conduct the survey. The Ethics Committee approved the study in July 2012.   
2.3.2.2c Sample population  
The questionnaire was posted to the public health leads of SSS in each PCT. The 
questionnaire asked direct information about costs and provision of SSS and did 
not ask for perceptions. Therefore, it was not required to validate the questionnaire.  
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2.3.3 Data analysis 
The collected data from the survey and the PNA reports were coded and carefully 
entered into SPSS version 17 for data management and analysis. Appropriate 
statistical tests were applied to meet the set objectives, as described below. 
2.3.3.1 Data analysis for all PCTs 
Descriptive statistical measures were done to the explanatory variables and 
outcome measures, such as median, lower quartile, upper quartile and range. The 
normality of distribution was tested using Shapiro-Wilk test. Univariable correlation 
between two variables was tested using Spearman's correlation coefficient in case 
of non-normal distribution and Pearson's correlation coefficient in case of normal 
distribution at 95% confidence level. A significant correlation between two variables 
was identified where the P-value was less than 0.05. The strength of significant 
correlation was identified by the value of correlation coefficient (R) in case of 
Pearson's test and Spearman's rank correlation coefficient (rho) in case of 
Spearman's test. A value of (R) or (rho) between 0.1 and 0.3 indicates a weak 
correlation. A value of (R) or (rho) between 0.4 and 0.6 indicates a moderate 
correlation. A value between 0.7 and 0.9 indicates that there is a strong correlation 
and the correlation is perfect when the value of (R) or (rho) is 1 (Dancey and Reidy, 
2011).      
2.3.3.2 Data analysis for the sample 
In order to see if the responding sample of PCTs is representative to the rest of 
PCTs, the above mentioned outcome measures (Section 2.3.1.1) and the 
explanatory variables (Section 2.3.1.2) were compared between the sample and the 
rest of PCTs. The normal distribution of each variable in each group (the sample 
and the rest of PCTs) was initially tested using Shapiro-Wilk test. Mann-Whitney U 
test was used in case of non-normal distribution and T-test of two independent 
samples was used in case of normal distribution.  
2.3.3.3 Cost effective analysis for SSS through CPs 
2.3.3.3a Data analysis 
Descriptive statistical measures were done to the sample outcome measures, such 
as median, lower quartile, upper quartile and range. To perform the analysis the 
percentage of quitters who were CO-validated was necessary. In case of using both 
methods for validation and there was no definition of the percentages of smokers 
who used each method, the relevant percentages of smokers who were CO-
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validated through all providers together were used to estimate the number of CO-
validated through CPs.  
2.3.3.3b Calculating costs 
No costs were attributed to self-quit as the study was undertaken from the NHS 
perspective. Three types of costs were attributed to the provision of SSS through 
CPs; the overhead costs, the NRT reimbursement, and the payments to 
pharmacist. The overhead costs include costs of training, equipment, materials and 
advertising. They were assessed through direct questions to PCTs. The average 
overhead cost from responses was used as overhead cost for the rest of PCTs. For 
the cost of NRT, this was determined in two ways. If the smoker is exempted from 
paying the prescription charges the total cost of NRT is considered. If the smoker is 
not exempted from paying the prescription charges, the prescription  fee (£7.20 for 
the financial year 2009/2010) was used to estimate the costs of NRT. In 2009/2010, 
50.3% (of total setters) were eligible for free prescription and 49.7% were not 
eligible. In addition, 48% (of total quitters) were eligible for free prescription and 
52% were not eligible (HSCIC, 2010). The average cost of  different forms of NRT 
per week was estimated at £9.98 (British National Formulary 2009). The 
reimbursed costs for NRT were estimated as shown in Table 2.2. Each PCT has its 
criteria to supply NRT. They all agree with an initial supply of NRT to cover two 
weeks, then a supply of an extra two weeks only if the smoker shows commitment 
and willingness to quit smoking, as described in Section 2.1. An additional supply of 
NRT to cover 4 weeks will be provided and a final 4 weeks supply if the smoker still 
needs help. Three outcomes could be identified at 4 weeks follow up; firstly, the 
smoker quit smoking, secondly, the smoker failed to quit but the CP was able to 
follow him, and finally, the smoker's situation is unknown or lost to follow up. Table 
2.2 summarises the assumptions that have been made to calculate the costs 
attributed to the supply of NRT.  
Table 2.2: Explanation of the method used to calculate costs for NRT 
reimbursement 
Eligibility 
for 
exemption 
NRT reimbursement 
cost £ 
(Unknown or lost to 
follow up) 
NRT reimbursement 
cost £ 
(Fails to quit but was 
able to be followed) 
NRT reimbursement 
cost £ 
(Succeeds in quit) 
Eligible
 
2 × 9.98 4 × 9.98  12 × 9.98 
Not-eligible
 
 2 × (9.98-7.20) 4 × (9.98-7.20) 12 × (9.98- 7.20) 
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If the smoker's situation at 4 weeks was unknown or he was lost to follow up (48% 
of total non-quitters were unknown or lost to follow up in 2009/2010, (HSCIC, 
2010)), it is assumed that they set a quit date and obtained an initial NRT supply to 
cover two weeks, then they were lost to follow up. As a result, the NHS will incur the 
costs of two weeks supply of NRT as in column one (Table 2.2). If the smoker failed 
to quit at 4 weeks follow up, it is assumed that they received a 4 weeks supply of 
NRT (one per first two weeks and the later per second two weeks), as in column 
two (Table 2.2). If the smoker at 4 weeks follow up was found to be abstinent from 
smoking from 2 weeks following the quit data and so on, it is assumed that they will 
need up to 12 weeks of NRT as in column 3 (Table 2.2). To predict the percentages 
of eligible and non-eligible for free prescription among non-quitters at 4 weeks 
follow up and those who were unknown or lost to follow up, the percentages of 
setters who were eligible (50.3%) and who were not eligible (49.7%) were used 
(HSCIC, 2010). 
Two types of pharmacy payment were identified; fixed (irrelevant to the uptake or 
results), and non-fixed based on either uptake, success or both. For the fixed type, 
the payments to pharmacy were calculated based on the annual fee per pharmacy 
divided by the number of smokers who set a quit date. For the non-fixed type, the 
payments to pharmacy equals to (the payment for recruitment of smoker plus (the 
payment for success in quit smoking × quit rate). Therefore, the total cost per client 
was calculated as in Equation 2.1. 
                                                                                       (Equation 2.1) 
Cost 1 is the payments to pharmacy, cost 2 is the overhead costs per client and 
cost 3 is the costs of NRT reimbursement. 
 
2.3.3.3c Calculating incremental cost per quitter and Quality Adjusted Life 
Years (QALYs) 
To calculate the incremental cost per quitter and QALYs, the method used by Boyd 
and co-workers (2009) was adopted. The method used a simple model to compare 
the quit smoking through CPs with self-quitting (no-additional help). An assumption 
of 10% self-quit CO-validated was assumed at 4 weeks. The incremental cost per 
quitter was calculated using Equation 2.2 
Incremental cost per quitter = 
                                                    
                                                 
                (Equation 2.2) 
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At the beginning, the incremental cost per quitter was calculated based on a 4-week 
period. Then an assumption of 75% relapse rate was applied between 4-weeks and 
52 weeks for both intervened quit and self-quit (Ferguson et al., 2005, Stapleton, 
1998). Bauld and co-workers (2012) found that the relapse rate between 4 weeks 
and 52 weeks was 78.2%, but in their study the majority (68%) lived in deprived 
areas. Furthermore, Bauld and co-workers (2009a) in their systematic review of 
effectiveness of NHS SSS, found a relapse rate of 72% between 4-weeks and 52-
weeks for CO-validated quitters. This resulted in a self-quit rate of 2.5% at 52 
weeks, this value agreed with previous studies (Cornuz et al., 2006 and Maguire et 
al., 2001).  An additional 35% relapse rate was applied between 52 weeks and 
lifetime (Stapleton et al., 1998, Woolacott, 2002). Previous studies reported the 
value of discounted QALYs per lifetime quitter as 1.98 (Fiscella and Franks, 1996) 
and as 1.98 for female and 1.97 for male (Cromwell et al., 1997). The two values for 
females and males were weighted against proportion of adult males (52.5%) and 
proportion of adult females (47.5%) in the 138 PCTs, the resulted value was 1.975.  
As a result, the 1.98 was applied in this research. The costs per QALY gained for 
lifetime quitter was calculated as shown in Equation 2.3. 
 
The costs per QALY gained  
                                     
                                        
                            (Equation 2.3) 
2.3.3.3d Sensitivity analysis 
The above mentioned analysis which was used to calculate the costs per QALY 
gained was based on assumptions. To test the uncertainty made through this 
analysis, it was necessary to conduct sensitivity analysis. For each of the outcome 
measures where assumptions have been made, a lower value and upper value 
were applied to test the uncertainty. Five different scenarios were tested to test 
uncertainty. The first two scenarios dealt with the CO-validated quit rate, where in 
the first scenario, it was assumed that it went down from 10% to 5%, while in the 
second scenario; it was assumed that it went up to 15%. The third scenario dealt 
with the self-reported validation results, which was ignored in the main analysis. 
The fourth scenario assumed a supply of NRT for 8 weeks for smoker who 
succeeded in quit smoking after 4-weeks follow up, as in case of Cumbria PCT 
(Appendix 1). The fifth scenario assumed the 4 weeks supply of NRT for a smoker 
who was lost to follow up.  2.4. Results  
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2.4.1 All PCTs 
Out of 151 PCTs (total PCTs in England in 2009/2010), 138 PCTs were included in 
this part of the study. The prevalence of smoking adults could not be identified for 5 
PCTs and the number of CPs which were providing SSS could not be identified for 
8 PCTs. The excluded PCTs are marked with red stars (Figure 2.1). 
 
Figure 2.1 PCTs excluded from the survey 
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2.4.1.1 Descriptive analysis of SSS uptake through all providers 
NICE guidelines require PCTs to treat 5% of their local smokers and to achieve at 
least 35% quit rate which is confirmed by CO-validation method (DH, 2011a). The 
prevalence of smoking adults varied across the different PCTs (Table 2.3). This 
means that in order for SSS in PCTs with higher needs to meet NICE guidelines, 
more efforts should be placed to reach higher number of smokers to help them quit 
smoking. In general, the median PCT's total reach out of needs was 7.9% (higher 
than 5%), ranging from 2.5% to 33.9% (Table 2.3 and Figure 2.3a). Three PCTs 
achieved total reach smaller than the lower quartile; those PCTs belonged to East 
Midlands North West and South West of England. They belonged to three different 
stratum of deprivation, one of the most deprived, one in the middle and the last was 
one of the most affluent PCTs. Thirty three PCTs achieved total reach higher than 
the higher quartile. Three outliers were identified (achieved total reach of 22.2% 
and above). These belonged to the most third affluent PCTs. When looking at the 
total success out of needs, the median was 3.9% (lower than 5% which was 
recommended by NICE guidelines), ranging from 1.2% to 17.1% (Table 2.3 and 
Figure 2.2b). Thirty four PCTs achieved total success out of needs smaller than the 
lower quartile (3.4%). Nothing was common among those PCTs; they belonged to 
different locations across England and had different deprivation scores. Twenty 
eight PCTs achieved total success out of needs higher than the higher quartile. 
Four outliers were identified (achieved total success of 10.1% and above). These 
belonged to the most affluent PCTs in England. The outliers in reach were the 
same as the outliers in success, with an addition to one outlier. The mean self-
reported quit rate was 49.9% (Table 2.3 and Figure 2.3a) and it decreased to 34.2% 
when it was validated by CO-validation method (Table 2.3 and Figure 2.3b). Sixty- 
one PCTs achieved lower than 35% CO-validated quit rate (Figure 2.3). No outliers 
were identified in case of quit rate. In addition to the wide variations in terms of 
uptake and success of SSS, there was wide variations in terms of PCTs' 
demographic factors such as, deprivation scores which ranged from 8.8 to 43.5 with 
a median of 23. Also, the pharmacy provision of SSS varied across the PCTs, while 
only 8% of CPs in one PCT offered SSS, all CPs were offering the SSS in another. 
The median pharmacy provision (as percentages out of all CPs) was 69.2% (Table 
2.3).  
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Table 2.3: SSS uptake and demographic and pharmacy factors 
Variable Median/Mean
7 
LQ
8 
UQ
9 
Min - Max 
Prevalence of smoking adults (%) 22.4 19.3 26.7 12 - 35 
SSS uptake     
Total reach out of needs (%)
1 
7.9 6.7 9.7 2.5 - 33.9 
Total success out of needs (%)
2 
3.9 3.4 4.8 1.2 - 17.1 
Self reported quit rate (%)
3 
49.9
* 
44.1 56.8 31.1 - 69.8 
CO-validated quit rate (%) 34.2
* 
28.2 40.8 2.7- 58.3 
Demographic factors     
Deprivation score (IMD)
4 
23.0 16.4 29.3 8.8 - 43.5 
Ethnicity minority proportion (%) 9.1 5.4 16.2 2 - 52.3 
Male proportion (%) 52.5 52.1 53.0 49.8 - 53.9 
CP factors     
Weighted provision of SSS (%)
5 
62.9 39.1 76.8 8 - 100 
Weighted provision of SSS (N)
6 
3.2 2.1 4.3 0 - 7 
1- Total reach out of needs (%): Percentages of smokers who set a quit date through all 
providers out of total smokers within a PCT. 
2- Total success out of needs (%): Percentages of smokers who quit smoking after 4-weeks 
follow up out of total smokers within a PCT. 
3- Total quit rate (%): Percentages of smokers who quit smoking after 4 weeks follow up out 
of total smokers who set a quit date. 
4- IMD stands for Index for Multiple Deprivation. 
5- Weighted provision of SSS (%): Percentages of CPs which were offering SSS out of total 
CPs within PCT. 
6- Weighted provision of SSS (N): Number of CPs which were offering SSS per 25 000 
population.  
7- Mean was used in case of self-reported and CO-validated quit rates, while median was 
used in other cases. 
8- LQ stands for Lower Quartile, 9- UQ stands for Upper Quartile. 
Figure 2.2: Total reach (%) and total success (%) histograms for the 138 PCTs 
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Figure 2.3: Quit rate self reported (%) and CO-validated quit rate (%) 
histograms 
 
 
 
 
 
 
 
2.4.1.2 Association between prevalence of smoking adults and PCTs’ 
demographic factors and CP SSS provision 
In terms of demographic factors, smoking prevalence did not correlate with either 
male proportion or ethnicity proportion, as the P-value for Spearman's coefficient 
test was bigger than 0.05 (Table 2.4). This agreed with the fact that the higher 
prevalence of smoking among men which was seen in 1980 (42% of men smoked 
and 36% of women) was diminished in 2010 as 20% of men smoked in comparison 
to 19% of women (HSCIC, 2012b). In 2004, the self-reported prevalence of 
smoking varied across different ethnicities, the highest prevalence among men was 
40% for Bangladeshi, followed by 29% for Pakistani, 25% for Black Caribbean, 21% 
for Black African and for Chinese and 20% for Indian, in comparison to 24% for  the 
general population (HSCIC, 2006). When adjustment has been made for age, the 
Bangladeshi men were more likely to smoke than the general population and the 
Indian men were less likely to smoke (HSCIC, 2006). The situation in women was 
different as the prevalence of smoking was higher in general population than 
among minor ethnicities apart from Black Caribbean which was higher (HSCIC, 
2006). This supports the findings that when minor ethnicities are combined (as in 
this research) a direct correlation between ethnicity and smoking prevalence could 
not be identified as smoking prevalence is only correlated with certain type of 
ethnicities and for specific gender. The most considerable correlation in relation to 
smoking prevalence was with deprivation. As higher prevalence of smoking adults 
was seen in higher deprivation score PCTs, Spearman's rank coefficient (rho = 
0.76) and (P-value < 0.001) (Table 2.4). This means that the gap in smoking 
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prevalence between areas with different SES which the NHS SSS aimed to bridge 
upon its introduction in 1999, is still there. Although CPs can offer convenient 
access to SSS, there was no correlation between prevalence of smoking and CPs 
SSS provision, as P-value was 0.67 and 0.22 in case of provision as percentages 
and provision as numbers, respectively (Table 2.4). This suggests that the higher 
needs in some PCTs were not met by higher provision of SSS through CPs. 
Table 2.4: Correlations between prevalence of smoking adults and 
demographic and CP factors 
 Prevalence of smoking adults (%) 
Rho (P-value) 
Demographic factors  
Deprivation score (IMD)
1 
0.76 (< 0.001) 
Ethnicity minority proportion (%) - 0.02 (0.8) 
Male proportion (%) - 0.07 (0.45) 
CP factors  
Weighted provision of SSS (%)
2 
- 0.04 (0.67) 
Weighted provision of SSS (N)
3 
- 0.02 (0.22) 
1- IMD stands for Index for Multiple Deprivation. 
2- Weighted provision of SSS (%): The percentages of CPs which were offering SSS out of 
total CPs within PCT. 
3- Weighted provision of SSS (N): The number of CPs which were offering SSS per 25 000 
population.  
4- Significant correlations are shown in bold. 
2.4.1.3 Association between pharmacy provision factors and population 
demographics 
Higher concentrations of CPs were seen in more deprived PCTs and in PCTs with 
higher prevalence of smoking adults, where rho was 0.63 and 0.34, respectively 
and P < 0.001 in both cases (Table 2.5). Slightly higher concentrations of CPs were 
more likely to be seen in PCTs with higher ethnic minority proportion with rho of 
0.18 and P of 0.034 and less likely to be seen in PCTs with higher male proportion 
with rho of -0.23 and P of 0.006 (Table 2.5). In comparison with CP SSS provision, 
there was no significant correlation between the needs (prevalence of smoking 
adults) and the provision in terms of numbers or percentages. However, due to 
higher concentrations of CPs in more deprived PCTs, there was a slightly higher 
number of CPs per 25 000 population which offered SSS with rho of 0.27 and P of 
0.001 (Table 2.5). Moreover, the CP SSS provision was higher in PCTs with a 
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higher ethnic minority proportion (rho = 0.36) in case of CP SSS provision as 
percentage and (rho =0.33) in case of provision per 25 000 population with P < 
0.001 in both cases (Table 2.5).  
Table 2.5: Correlations between pharmacy factor and other explanatory 
variables 
 CPs per 25 000 
rho (P-value)
3 
Weighted 
provision (1)
1 
rho (P-value) 
Weighted 
provision (2)
2 
rho (P-value) 
Prevalence of smoking adults (%) 0.34 (0.000) 0.06 (0.47) - 0.037 (0.69) 
Deprivation score  0.63 (0.000) 0.27 (0.001) 0.09 (0.3) 
Ethnic minority proportion (%) 0.18 (0.034) 0.36 (<0.001) 0.33 ( <0.001) 
Adult male proportion (%) - 0.23 (0.006) - 0.12 (0.15) - 0.07 ( 0.44) 
1- Weighted provision (1): The number of CPs which were offering SSS per 25 000 
population. 
2- Weighted provision (2): The percentage of CPs offering SSS out of total CPs. 
3- Significant correlations are shown in bold. 
 
2.4.1.4 Association between SSS uptake factors and demographic factors 
Table 2.6 presents the univariable correlations between SSS uptake (total reach out 
of needs, total success out of needs and total quit rate) and demographic and 
pharmacy factors. There was a significant positive correlation between total reach 
and deprivation ((rho) = 0.21, P = 0.013), which means that when moving from an 
affluent PCT into a deprived one, there is an increase in the percentage of smokers 
who set a quit date out of total smokers within a PCT. Unfortunately, no significant 
correlation was identified between deprivation and total success (P = 0.95). A 
negative significant correlation was identified between the total quit rate and 
deprivation ((rho) = - 0.4, P < 0.001). This suggests that for two PCTs; deprived and 
affluent, where the total success is equalled, the total reach and quit rate for the two 
PCTs follow Equation 2.4. The good results of the total reach in a deprived PCT are 
worsening by the lower quit rate and the bad results of the total reach in an affluent 
PCT are improved by the higher quit rate.  
The total success (deprived PCT)                                           (Equation 2.4) 
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According to the results, CP SSS provision factors did not correlate with total reach 
and total success. It must be noted that in 2010, only 18% of total setters were 
through CPs and 17% of total quitters were through CPs (HSCIC, 2010). However 
there was a weak negative correlation between the number of CPs which were 
offering SSS per 25 000 population and the total quit rate, with rho of - 0.19 and P 
of 0.028 (Table 2.6). This agreed with the fact that the total quit rate through all 
NHS SSS providers together was 49% including CPs and 50.4% excluding CPs 
and for CPs only was 45% (HSCIC, 2010).  
Table 2.6: Correlations between SSS uptake and demographic and pharmacy 
factors 
Predictor variables Total reach %
 
rho (P-value)
4 
Total success %
 
rho (P-value) 
Quit rate % 
rho (P-value) 
Demographic factors 
Deprivation score (IMD)
1 
0.21 (0.01) - 0.01 (0.95) - 0.4 (<0.000) 
Ethnic minority proportion % - 0.01 (0.89) - 0.15 (0.07) - 0.14 (0.1) 
Adult male proportion (%) - 0.03 (0.65) 0.03 (0.7) 0.14 (0.11) 
Pharmacy factors    
Weighted provision of SSS (%)
2 
0.15 (0.08) 0.11 (0.21) -0.08 (0.352) 
Weighted provision of SSS (N)
3 
0.13 (0.12) 0.03 (0.7) - 0.19 (0.028) 
1- IMD stands for Index for Multiple Deprivations. 
2- Weighted provision of SSS (%): The percentages of CPs which were offering SSS out of 
total CPs within PCT. 
3- Weighted provision of SSS (N): The number of CPs which were offering SSS per 25 000 
population.  
4- Significant correlations are shown in bold. 
2.4.2 Sample results 
2.4.2.1 Response rate 
Out of the 138 questionnaires sent to the public health leads of SSS within the 
PCTs in England, 29 responses were received. Following the reminders, extra 18 
responses were received, thus a total of 47 PCTs responded representing a 34% 
response rate. One response was with blank answers, 11 responses missed 
information about either the number of smokers who set a quit date or the number 
of smokers who quit or both, hence, and they were excluded from the analysis. Six 
responses provided information irrelevant to the financial year 2009/2010. One 
response came from two PCTs, where it was difficult to distinguish between data 
related to each PCT. The PNA reports were used to obtain data for an extra 14 
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PCTs. The final sample was thus 42 PCTs, which represented 30% of the target 
138 PCTs (Figure 2.4). 
Figure 2.4: Responses to the survey and the final sample  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     
 
 
 
 
 
Questionnaires were sent to 138 
PCTs 
29 responses in October 18 PCTs responses 
following reminders  
47 responses to the survey 
20 PCTs were excluded; 
- One blank response 
- 11 responses with incomplete 
information 
- 6 responses with irrelevant 
information 
- One response with data related to 
two PCTs 
PNA reports used to 
obtain data for 14 PCTs 
28 PCTs 
The final sample was 
42 PCTs 
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2.4.2.2 Sample PCTs versus non-respondent PCTs 
The results of normality distribution for each variable for the two groups (sample 
and non-respondent PCTs) showed that the prevalence of smoking adults, total quit 
rate and the weighted CP provision of SSS per 25 000 population were normally 
distributed. Hence, the two independent sample T-test was applied to test the 
difference between the two groups. The prevalence of smoking adults did not 
significantly differ between the two groups (mean = 23.26% for sample versus 
mean = 22.8% for the non-respondent PCTs, P= 0.6). The total quit rate did not 
significantly differ (mean = 49.3% for sample versus mean = 50.2% for the non-
respondent PCTs, P = 0.59). However, the CP provision of SSS per 25 000 
population was lower in case of the sample (mean = 2.7) compared to the non-
respondent PCTs (mean = 3.4)  (P = 0.005). Mann-Whitney test was applied to the 
rest of variables (not normally distributed).  The deprivation score did not 
significantly differ between the two groups (median = 23.2 for sample versus 
median = 22.5 for the non-respondent PCTs, P = 0.8). Similarly, no significant 
differences were identified in case of; total reach (median = 8.3% for sample versus 
median = 7.9% for the non-respondent PCTs, P = 0.37), total success (median = 
4.03% versus median = 3.8%, P = 0.29), ethnic minority proportion (median = 7.7% 
versus median = 10.3%, P = 0.1) and adult males (median = 52.5% for sample 
versus median = 52.5% for the non-respondent PCTs, P = 0.97). However, the CP 
provision of SSS as percentage was significantly lower in case of the sample 
(median = 55.1%) when compared to the non-respondent PCTs (median = 67.5%) 
(P = 0.049). As a result, the differences between the two groups were only related 
to the CP provision of SSS (per 25 000 population and as percentage). As a result, 
the sample was found to be representative of the non- respondent PCTs in terms of 
prevalence of smoking, deprivation, ethnic minority proportion, adult male 
proportion, total reach, and total success and quit rate. However, it was not a 
representative in terms of pharmacy provision of SSS (per 25 000 population and 
as percentages). This suggests that any finding from the sample analysis should 
consider this, as any outcome measure that is positively correlated with CP 
provision of SSS is expected to be higher in non-respondent PCTs than in the 
sample, and vice versa.  
2.4.2.3 Descriptive analysis of uptake of SSS for the sample 
The sample analysis showed wide variations in terms of pharmacy reach out of 
needs, pharmacy share in reach, pharmacy success out of needs and pharmacy 
share in success (Table 2.7 and Figures 2.5 & 2.6). The median pharmacy reach 
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was 1.3% with a range from 0.1 to 6.7% (Table 2.7 and Figure 2.5a). In 5 PCTs the 
pharmacy reach was 5% and above, those PCTs belonged to different location 
across England; East England, South East Coast, North West and North East. 
However, in two PCTs out of 5, 97% and above of CPs were offering SSS. While 
23%, 46% and 67% of CPs were offering SSS in the rest of PCTs. The median 
pharmacy share in reach was 12% with a range from 0.6 to 53.3% (Table 2.7 and 
Figure 2.5b). Between 40 to 45% of setters set quit date through CPs in three 
PCTs, between 45 to 50% in one PCT and between 50 to 55% in another PCT 
(Figure 2.5b). Those five PCTs had deprivation scores with a range from 14.98 to 
25.63, this means that none of those PCTs belonged to the most third deprived 
PCTs across England. The median pharmacy success out of needs was 0.4% with 
a range from 0.03 to 2.9% (Table 2.7 and Figure 2.6), while it was over than 2% in 
case of 4 PCTs (Figure 2.6).Two out of those PCTs belonged to the most deprived 
PCTs and the other two belonged to the most affluent PCTs. The median pharmacy 
share in success was 9.8% (Table 2.7, Figure 2.6). Ten PCTs share in success out 
of needs was less than lower quartile (3.4%) and ten PCTs share in success was 
higher than upper quartile (24.9%) (Table 2.7 and Figure 2.6). In terms of number of 
setters per each pharmacy per year, the median number was 15 setters with a 
range from  2 setters to 116 setters and the median of quitters was 6 with a range 
from 1 quitter to 42 quitters (Table 2.7 and Figure 2.7). The pharmacy quit rate was 
normally distributed (Figure 2.8) with mean of 44.5% (Table 2.7). This quit rate 
agreed with the total quit rate through CPs across the 151 PCTs in England which 
was 45% (HSCIC, 2010). In addition to the variations in SSS uptake, there were 
wide variations in terms of demographic and pharmacy factors (Table 2.7). 
 
Figure 2.5: Pharmacy reach out of needs and pharmacy share in reach 
histogram  
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Table 2.7: SSS uptake and demographic and pharmacy factors for the sample 
Variable Median/Mean LQ
10 
UQ
11 
Min- Max 
Prevalence of smoking adults (%) 22.7 19.3 26.9 14.9 - 35.2 
Demographic factors 
Deprivation score (IMD)
1 
23.3 15.3 28.8 8.8 - 43.5 
Ethnic minority proportion (%)          7.7 5 11 2- 38.6 
Adult male proportion (%) 52.5 52 53.1 49.8 - 53.5 
SSS uptake all providers 
Total reach out of needs(%)
2 
8.3 6.9 10.7 4 -16 
Total success out of needs (%)
3 
4.0 3.5 5 2 - 7 
Total Quit rates (%)
4 
49.2
* 
43.7 54.1 33.1 - 67 
SSS uptake CPs only 
Pharmacy reach out of needs (%)
5 
1.3 0.5 2.9 0.1 – 6.7 
Pharmacy share in reach (%)
5 
12 3.5 23.2 0.6 – 53.3 
Pharmacy success out of needs (%)
6 
0.4 0.2 1.4 0.03 – 2.9 
Pharmacy share in success (%)
6 
9.8 3.4 24.9 0.7 – 49.2 
Pharmacy quit rate (%) 44.5
* 
39.4 49.4 30.7 – 64.5 
Setters per pharmacy/ year (N)
 
15 8 43 2 – 116 
Quitters per pharmacy/ year (N)
 
6 3 18 1 – 42 
Pharmacy provision factors 
Weighted provision of SSS (%)
7 
55.1 35.4 70.6 14.8 - 100 
Weighted provision of SSS (N)
8 
2.7 1.8 3.4 1 - 5 
1- IMD stands for Index for Multiple Deprivation. 
2- Total reach out of needs (%): The percentage of setters through all providers out of total 
smokers in a PCT. 
3- Total success out of needs (%): The percentage of quitters through al providers out of 
total smokers in a PCT. 
4- Total quit rate (%): The percentage of quitters out of setters through all providers. 
5- Pharmacy reach out of needs: The percentage of setters through CPs out of total 
smokers in a PCT 
6- Pharmacy success out of needs: The percentage of quitters through CPs out of total 
smokers in a PCT. 
7- Weighted provision of SSS (%): The percentages of CPs which were offering SSS out of 
total CPs within PCT. 
8- Weighted provision of SSS (N): The number of CPs which were offering SSS per 25 000 
population. 
9- Mean was in case of total quit rate and pharmacy quit rate, while median was in all other 
cases. 
10- LQ stands for Lower Quartile, 11- UQ stands for Upper Quartile. 
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Figure 2.6: Pharmacy success out of needs and pharmacy share in success 
histograms 
 
 
 
 
 
 
 
 
Figure 2.7: Number of setters and quitters per pharmacy per year histogram 
 
 
 
 
 
 
 
Figure 2.8: Pharmacy self-reported quit rate histogram 
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2.4.2.4 Association between SSS pharmacy uptake outcomes and 
demographic and pharmacy factors 
The CP uptake outcomes (reach out of needs, share in reach, success out of 
needs, share in success, setters per pharmacy and quitters per pharmacy) were not 
normally distributed (Figures 2.5. 2.6 and 2.7). As a result, Spearman's rank 
correlation test was used to test correlations between SSS pharmacy uptake and 
other factors (Table 2.8). The CP uptake measures did not significantly correlate 
with the prevalence of smoking, the deprivation, the ethnicity or the gender factors. 
However, the prevalence of smoking adults was responsible for 40% of the number 
of setters per pharmacy per year and it was responsible for 31% of the number of 
quitters per pharmacy per year, with P of 0.01 and 0.046 respectively. This means 
that in PCTs with higher needs (higher prevalence of smoking adults), there is a 
higher numbers of smokers who set a quit date per pharmacy and higher numbers 
of smokers who quit smoking per pharmacy. On the other hand, the CP provision of 
SSS (per 25 000 population and as percentage) was responsible for 48% and 50% 
of reach respectively, with P = 0.01 in both cases. The CP provision was 
responsible for 47% and 51% of pharmacy success of quit smoking in case of 
provision per 25 000 population and percentage provision respectively, with P = 
0.01. The CP SSS provision was responsible for 53% of pharmacy share in reach 
and in success and for 48% of pharmacy share in reach and success in case of 
provision as percentage and per 25 000 population respectively, with P of 0.01 in all 
cases (Table 2.8). This means that any increase in CPs' provision of SSS will 
encounter an increase in uptake of SSS and this will be reflected in quit smoking 
success.  
In case of pharmacy quit rate, this was normally distributed (Figure 2.8 above), 
consequently, the association between pharmacy quit rate and demographic factors 
were assessed using Pearson’s (P) correlation coefficient. The higher the 
prevalence of smoking adults and the higher the deprivation scores, the lower the 
quit rate (R= - 0.61) and (R = -0.58) respectively, with P < 0.001 in both cases. On 
the other hand, no significant correlations were identified between the pharmacies 
quit rate and any other demographic factors. This suggests that the quit rate 
through CPs curve was similar to the total quit rate through all providers which was 
negatively correlated with deprivation (Section 2.4.1.4) and this indicates that to 
improve the SSS through either CPs or other providers, factors that force setters to 
resume smoking in more deprived PCTs should be identified and work should be 
done to overcome those factors. 
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Table 2.8: Correlations between uptake of SSS through CPs and demographic 
and pharmacy factors 
Predictor 
variables 
Reach
6 
Rho, P-
value 
Share 1
7 
Rho, P-
value 
Success
8
 
 
Rho, P-
value) 
Share 2
9 
Rho ( P-
value) 
Setters
10 
Rho 
( P-value) 
Quitters
11 
Rho (P-
value) 
Needs
1 
0.24, 0.13 0.14, 0.37 0.16, 0.31 0.11, 0.47 0.4, 0.01 0.31, 0.046 
Demographic factors 
Deprivation 0.16, 0.3 0.06, 0.7 0.08, 0.62 0.02, 0.88 0.29, 0.06 0.18, 0.25 
EMP (%)
2 
0.12, 0.43 0.23, 0.14 0.12, 0.44 0.21, 0.19 0.02, 0.9 0.05, 0.78 
Male (%)
3 
- 0.06, 0.71  - 0.02, 0.9 - 0.03, 0.85 - 0.03, 0.87 - 0.13, 0.4 - 0.09, 0.58 
Pharmacy factors 
Provision 1
4 
0.5, 0.01 0.53, 0.01 0.51, 0.01 0.53, 0.01 0.21, 0.19 0.24, 0.13 
Provision 2
5 
0.48, 0.01 0.48, 0.01 0.47, 0.01 0.48, 0.01 0.2, 0.21 0.20, 0.20 
1- Needs: The prevalence of smoking adults (%). 
2- EMP: stands for Ethnic Minority Proportion. 
3- Male (%): The percentage of adult males within PCT. 
4- Provision 1: (%): The percentage of CPs which were offering SSS out of total CPs within 
PCT. 
5- Provision 2: The number of CPs which were offering SSS per 25 000 population. 
6- Reach: The percentage of setters through CPs out of total smokers in a PCT. 
7- Share 1: CPs' share in total reach out of needs 
8- Success: The percentage of quitters through CPs out of total smokers in a PCT. 
9- Share 2: CPs' share in total success out of needs 
10- Setters:  The number of smokers who set a quit date per pharmacy per year. 
11- Quitters: The number of smokers who quit smoking after 4-weeks follow up per 
pharmacy per year. 
10- The significant P-value for Spearman's correlation coefficient was shown in bold. 
 
2.4.3 Cost effective analysis of SSS through CPs 
2.4.3.1 Sample description 
Two responses out of the 28 complete responses in Figure 2.3 did not provide 
information about payments to pharmacy for provision of SSS. As a result the final 
sample was 26 PCTs, 3 responses mentioned that they use only self-method to 
validate quit smoking. The results of those 3 responses were included only in case 
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of sensitivity analysis. As a result, the final sample was 23 responses (17% of the 
targeted PCTs).  
As PCTs had their own choice to allocate their funds between services as 
appropriate, the payments to CPs for providing SSS varied across the different 
PCTs (Table 2.9). Hence, the median cost per quitter excluding NRT 
reimbursement was £71.3 with a range from £23.8 to £602.5. Upon consideration of 
NRT reimbursement, the median cost per quitter was £116.7 with a range from 
£65.2 to £649.2. Five PCTs had a total cost per quitter including NRT 
reimbursement lower than lower quartile (£83.4), two PCTs out of them belonged to 
East England, two PCTs belonged to South East Coast and one to London. Five 
PCTs had a total cost per quitter higher than higher quartile (£188.8). Two belonged 
to South West England, two belonged to East England and one belonged to 
Yorkshire and the Humber. 
Table 2.9: Summary description of the SSS uptake, payments and costs 
Variable 
 
Median LQ
7 
UQ
8 
Min-Max 
Setters per PCT (N)
1 
532 180 984 31 - 5270 
Quitters per PCT (N)
2 
235 90 503 20 - 2573 
Quit rate % 47.9 39.9 53 34 - 76 
Payment for recruitment (£)
3 
17.50 6.4 26.3 0 - 57 
Payment for success (£)
4 
31.6 6 50.5 0 - 60 
Total cost per quitter  1 (£)
5 
71.3 37.9 143.8 23.8 - 602.5 
Total cost per quitter  2 (£)
6 
116.7 83.4 188.8 65.2 - 649.2 
1- Setters per PCT: is the number of smokers who set a quit date through CPs for the 
financial year 2009/2010. 
2- Quitters per PCT: is the number of quitters who achieved quit smoking through CPs 
following 4-weeks follow up. 
3- Payment for recruitment: Are the payments to CPs for recruitment of smokers who set up 
a quit date. 
4- Payment for success: is the payment to CPs who help smokers who set up a quit date in 
achievement of quit smoking after 4-weeks follow up. 
5- Total cost per quitter 1: is the cost for provision of SSS from CPs excluding NRT 
reimbursement. 
6- Total cost per quitter 2: is the cost for provision of SSS from CPs including NRT 
reimbursement. 
7- LQ stands for Lower Quartile, 8- UQ stands for Upper Quartile. 
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 2.4.3.2 Association between costs per quitter and demographic and 
pharmacy factors 
No significant correlation could be identified between costs per quitter and any of 
the demographic factors (deprivation, ethnicity and gender) or pharmacy factors 
(Appendix 3) 
2.4.3.3 Incremental cost per quitter 
The incremental cost per quitter at 4-weeks was calculated using Equation 2.1. As 
explained previously, two assumptions regarding self-quit were made; firstly, the 
CO-validated quit rate was assumed to be10% and secondly, no costs were 
attributed to the self-quit as it was taken from the NHS perspective. The median 
incremental cost per quitter at 4 weeks was £486.4 (Table 2.10) with a range from 
£220.2 to £2 517.5. One outlier was identified with an incremental cost of £2 517.5. 
This PCT had only 41% of those who reported self-quit being tested through CO-
validation method and this was the lowest percentage among the 22 PCTs. For 
calculations of incremental cost per quitter at 52 weeks, an assumption of 75% 
relapse rate was applied to the quitter through CPs and to the self-quit. The median 
incremental cost at 52 weeks was £1 945.4 (Table 2.10). For calculations of 
incremental cost per quitter at lifetime, an assumption of relapse rate of 35% 
beyond 52 weeks was applied. As a result, the median incremental cost at lifetime 
quit was £2 993. 
Table 2.10: Results of incremental costs per quitter at 4 weeks, 52 weeks and 
lifetime quit 
Incremental cost per 
quitter 
Median LQ UQ Min-Max 
At 4 weeks (£) 486.4 298.6 486.4 220.2 - 2517.5 
At 52 weeks (£) 1 945.4 1 835.4 5 173.5 889.7 - 9 189.1 
At lifetime (£) 2 993 1 193 3 362.7 1 355 - 15 492 
 
2.4.3.4 Sensitivity analysis 
As stated above, the baseline median incremental cost per quitter at 4 weeks was 
£486.4 (Table 2.10). In scenario 1 where the self-quit CO-validated rate at 4 weeks 
was reduced from 10% (original scenario) to 5%, the median incremental cost was 
decreased by 17% to £402.5. In contrast, when the self-quit CO-validated rate was 
increased to 15% in scenario 2, the median incremental cost per quitter was 
increased by 26% to £614.4 (Table 2.11). When the self-reported results were 
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considered (in original scenario only CO-validated quit rate was used) the 
incremental cost per quitter was reduced to £310 (scenario 3). The supply of NRT 
was assumed to be given at a maximum period of treatment (12 weeks in original 
scenario), when an assumption of supply of 8 weeks is made the incremental cost 
per quitter will decrease to, £433.6. The last scenario, it is assumed that the smoker 
who lost to follow at 4-weeks follow up will get NRT supply to cover 4 weeks, the 
incremental cost per quitter will thus increase to £499 (Table 2.11).   
Table 2.11: Results of use different scenarios to reduce uncertainty 
Scenarios Median incremental cost 
per quitter at 4-weeks 
(£) 
(Scenario 1) 5% self-quit 402.5 
(scenario 2) 15% self-quit 614.4 
(scenario 3) Self-reported validation considered 310 
(scenario 4) supply of NRT for 8 weeks 433.6 
(scenario 5) supply of NRT for 4 weeks for who lost to follow  499 
 
2.4.3.5 Costs of QALYs gained for lifetime quitter 
As explained earlier (Section 2.3.3.3c), the discounted QALYs gained for lifetime 
quitter, which equalled to 1.98, was used to calculate the cost per QALY gained, 
using the previously identified Equation 2.3: 
                     
                                     
                                        
 
The median cost per QALY gained for lifetime quitter was £1 511, which is less than 
£20 000 recommended by NICE to be cost effective (NICE, 2012), with a range 
from £684.3 to £7 824.3. Even with the maximum value the commission of service 
is still cost effective. 
2.5 Discussion 
2.5.1 Needs, provision and uptake of SSS through all providers 
The study is among the first to test the success of NHS SSS through all providers 
with focus on CPs provision. Despite the fact that there is high intention to quit 
smoking among UK smokers (77% among UK smokers intend to quit smoking 
(Lader, 2007)), NHS SSS was able to reach only 7.9% of the total smokers (Section 
2.4.1.1). This can be explained by the fact that more than half of UK smokers try to 
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quit smoking without using any treatment and only 6% out of those who tried to quit 
smoking used NHS SSS (Kotz and West, 2009). However, the study finds that the 
NHS SSS in total failed to help 5% or more of UK smokers to quit smoking. As the 
median success out of needs was only 3.9% (Section 2.4.1.1). Of those who set a 
quit date, 49.9% self-reported quit smoking and 68.5% out of them were tested 
through CO-validation method (34.2% out of total setters), which is lower than the 
35% CO-validated quit rate that was recommended by the Government (DH, 
2011a). When NHS SSS was first established in 1999/2000, it was piloted in hard to 
reach areas of deprivation (Health Action Zones (HAZs)) with intentions to reach 
more deprived smokers (Bauld et al., 2007). As the service was rolled out across 
the country in the following years, the NHS SSS uptake and success varied across 
the different PCTs and it seemed to correlate with PCTs' deprivation. In 2009/2010 
SSS reached more smokers in more deprived PCTs (Section 2.4.1.4). This was the 
case for NHS SSS over ten years between 2001/2002 and 2010/2011 (West et al., 
2013). This suggests that smokers of lower SES areas were more willing to try to 
quit smoking, which can be explained by tobacco expenses, which in turn push 
them to quit smoking (Lowey et al., 2003, Bauld et al., 2006, Pisinger et al., 2010). 
This finding contraindicated the old idea that smokers with lower SES were less 
willing to access SSS (Wiltshire et al., 2001) and proved that the lack of knowledge 
about NHS SSS among lower SES smokers suggested by Roddy and colleagues 
(2006) has improved. However, smokers with lower SES achieved lower quit rate 
than smokers with higher SES (Section 2.4.1.4), which agreed with the results from 
previous studies (Giskes et al., 2006 and Businelle et al., 2010). Low and co-
workers (2007) suggested four scenarios in relation to SSS. They assumed that quit 
rate among lower SES is lower than among higher SES, which agreed with the 
study's findings (quit rate was negatively associated with deprivation with rho of - 
0.4 and P < 0.001 (Section 2.4.1.4). The first scenario assumes that the proportion 
of smokers who set quit date for smoking through NHS SSS is higher among higher 
SES smokers than among lower ones. This will result in maximization of health 
improvement, as it is expected to have higher proportion of quitters in total (higher 
SES smokers are more likely to quit). The second scenario assumes same 
proportion of access for lower and higher SES smokers (equity of access). This 
scenario  will still widen the gap between the two groups (higher and lower SES).In 
their third scenario ”equity of outcome“, the proportion of smokers who set a quit 
date was higher among lower SES than among higher SES and the proportion of 
quitters were not different, which agreed with our findings that total reach out of 
needs was positively correlated with deprivation with rho of 0.21 and P of 0.01 and 
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total success out of needs did not significantly correlate with deprivation (Section 
2.4.1.4). Based on this scenario, the NHS SSS is not widening the gap in health 
inequalities or narrowing it, and its effect is neutral (Low et al., 2007). In the fourth 
scenario, the proportion of smokers who set a quit date is higher among lower SES 
smokers than among higher ones, and this difference is capable of making a 
change to reduce the gap in health between the two groups (Low et al., 2007). This 
scenario is the optimal scenario and is the one that the service commissioners 
should follow.  However, Bauld and co-workers (2006) found only a modest 
improvement in reducing health inequalities based on success of NHS SSS in case 
of Glasgow. 
2.5.2 Needs, provision and uptake of SSS through CPs 
CPs are in the heart of community, thus they are ideal to reach hard to reach 
patients. This was highlighted in the Government document “A vision for pharmacy 
in the new NHS” and “Pharmacy in England: building on strengths- delivering the 
future” (DH, 2003a and DH, 2008a). As mentioned previously, a recent study by 
Todd and co-workers (2014) found that the majority of English population are able 
to access CP within 20 minutes walk.  When SSS was firstly introduced, CPs 
identified a number of barriers for provision, such as lack of time, lack of training 
skills, premises barriers and financial concerns (Sinclair et al., 2004). Most of those 
barriers were overcome, as for a pharmacist to be able to provide SSS; they are 
required to attend local training (PSNC, 2014). Furthermore,  most CPs has 
counselling rooms and the service is funded by local providers. The importance of 
CPs in the community was translated into higher concentration of CPs per 25 000 
population in more deprived PCTs where smoking is more prevalent and higher 
concentration of CPs in PCTs with a higher ethnic minority proportion (Section 
2.4.1.3). Furthermore, it was translated into a higher provision of SSS through CPs 
in PCTs with higher ethnic minority proportion (Section 2.4.1.3). However, the 
prevalence of smoking is not significantly correlated with ethnic minority proportion 
(Section 2.4.1.2, Table 2.4), as it is higher among certain ethnicities (Bangladeshi 
men and Black Caribbean women) (HSCIC, 2006). To make the best use of this 
higher provision of SSS among PCTs with higher minor ethnicities, language 
barriers for many of those ethnicities should be overcome. Overall, CP SSS 
provision per 25 000 population correlated significantly with deprivation and ethnic 
minority proportion and it did not correlate with prevalence of smoking adults 
(needs) (Section 2.4.1.3; Table 2.5). Therefore, CPs in PCTs with higher needs had 
to deal with a higher number of smokers who set a quit date per year (rho = 0.4) 
73 
 
(Section 2.4.2.4). Although quit rate for smokers who set a quit date through CPs 
was negatively correlated with the needs, CPs in PCTs with a higher needs 
achieved higher number of quitters per pharmacy per year with rho of 0.31and P of 
0.046 (Section 2.4.2.4). Thus, an increase in pharmacy provision of SSS will result 
in higher reach of SSS and in higher success of SSS out of needs (Section 2.4.2.4, 
Table 2.8). This suggests that to improve the uptake of SSS and avoid the increase 
in workload related to SSS for CPs in PCTs with higher needs, an increase in SSS 
provision through CPs is necessary. Otherwise, if the workload related to SSS 
overrides certain limits which CPs cannot tolerate, this will result in increased stress 
and decreased job satisfaction (Gidman, 2011 and Lea et al., 2012). This in turn 
might reflect on pharmacist's routine work and affect patient safety (Gidman, 2011). 
When sample PCTs were compared to the non-respondent PCTs, it was found that 
the CP SSS provision was higher in case of non-respondent PCTs, with median of 
67.5% for the non-respondent and 55.1% for the sample (Section 2.4.2.2). An 
increase in 22.5% should result in higher SSS reach of 11.25% of their smokers in 
non-respondent PCTs when compared to the sample PCTs (50% of the SSS reach 
through CPs was attributed to CP SSS provision (Section 2.4.2.4). 
 2.5.3 Cost effective analysis of CP SSS 
The median cost per participant was £116.7 (Section 2.4.3.1,Table 2.9), which 
resulted in £486.4 as median incremental cost per quitter at 4 weeks (Table 2.10). 
A previous study which was done in Glasgow, reported a £53.31 as cost per 
participant and £772 as incremental cost per quitter at 4 weeks for the pharmacy 
intervention (costs calculated at 2007 prices) (Boyd and Briggs, 2009). Despite that 
the cost per participant was lower in case of Boyd's study. The CO-validated quit 
rate was almost twice in case of this study than the one which was identified in 
Boyd's study (Boyd and Briggs, 2009). Another study reported £300 as incremental 
cost per quitter when using an intensive pharmacy intervention rather than standard 
help (Sinclair et al., 1999). This study was taken from the social perspective and the 
quit rate was identified at 9 months following the quit date. A Scottish study 
reported £524.45 as cost per quitter and the self-reported quit rate at 4 weeks was 
44.6% (Cramp et al., 2007). The median incremental cost per quitter at 4 week in 
our study was £486.4 which is very close to Cramp and co-workers (2007) findings. 
When looking at the cost per QALYs gained, the median cost was £1539 with a 
range from £695 to £7 891. The costs per QALYs gained for intensive counselling 
and NRT was €4 900 (£3 062.5) based on 2000 prices and for 75 years (Feenestra 
et al., 2007).  Even in the PCTs with higher costs per QALYs (£7 824.3 (Section 
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2.4.3.5)), the intervention is still below £20 000 (reported by NICE to be cost 
effective), which means that the provision of SSS through CPs is cost effective. 
2.6 Limitations of the study 
The study had a low response rate of 34%. However, to overcome this low 
response rate the sample was weighted against the non-respondent PCTs as it was 
recommended by Brick and Kalton (Finchman, 2008). In case of the cost-effective 
analysis, several measures were not given by the respondent PCTs exactly. Thus a 
sensitivity analysis was conducted to overcome this problem.  
2.7 Conclusions  
After 10 years of introducing NHS SSS, smoking prevalence is still highly correlated 
with deprivation. However, the NHS SSS, based on the findings, is helping in not 
widening the gaps in terms of smoking prevalence between PCTs with different 
SES. The CP SSS provision (as percentage) did not match with the needs, despite 
the fact that there was a higher concentration of CPs in more deprived areas. CPs 
share is less than fifth of NHS SSS through all providers. If the CP SSS provision 
increases, the total reach and total success of SSS through CPs will increase. Even 
though CP SSS quit rate was lower than other providers, it is still cost-effective and 
it will provide smokers who wish to quit smoking with a convenient and accessible 
place to help them to quit smoking.    
2.8 Future of SSS 
Electronic cigarettes which became available recently in the market are to be 
regulated to quit smoking in the UK from 2016 (Torjesen, 2013). Electronic 
cigarettes have less hazards when compared to regular cigarettes (Henkler and 
Luch, 2014). However, there is a hazard from components which are used in 
electronic cigarettes such as solvent, flavour, additives and contaminants (Hutzler 
et al., 2014). Few clinical trials found that electronic cigarettes can help stop 
smoking as the speed that the nicotine reaches the central nervous system is 
comparable to that of some of the NRTs (Nowak et al., 2014). However, there is still 
no clear idea about the benefits and risks of electronic cigarettes in stop smoking 
and further clinical studies should be conducted to estimate the risks and benefits. 
As SSS was cost-effective based on the model used in 2009/2010, hence a 
payment by result method might encourage CPs to reach more smokers in their 
locality and improve the effectiveness of CPs. In April 2010, a new system for 
payment by results for SSS was introduced (Wyatt, 2012). However, West (2011) 
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suggested that providers might chase ‘cherry-pick easy cases’ and ignore the cases 
that are related to health inequalities. 
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Chapter Three: Needs, provision and uptake of sexual health pharmacy 
services 
3.1 Introduction 
3.1.1 EHC  
In 1999, the Government assessed the situation of teenage pregnancy in the UK. It 
analysed how other European countries which had similar teenage pregnancy rates 
to the UK in 1970, succeeded in reducing the rates while the UK failed (Social 
Exclusion Unit, 1999). Thus, it set out a plan to halve teenage pregnancy by 2010 
through improvements in teenage knowledge about sex, relationships and 
contraception and to improve the quality of life for young parents by supporting 
education, training and employment (Social Exclusion Unit, 1999). Despite the 
teenage pregnancy rate being reduced by 10% between 1999 and 2010, teenage 
pregnancy was found to be highly connected with deprivation (Conrad, 2012). This 
suggests that despite a reduction in the overall problem, health inequalities caused 
by teenage pregnancy have not been solved (Conrad, 2012).   
The probability of getting pregnant following unprotected sexual intercourse 
depends mainly on the day of intercourse in relation to the menstrual cycle (Wilcox 
et al., 2001). Wilcox and co-workers (2001) found that the mean probability of 
getting pregnant following one act of unprotected intercourse during any day of the 
cycle is 3.1%. One of the effective methods in preventing unintended pregnancy is 
EHC (Marciante et al., 2001). Prior to 2000, the EHC contained both estrogen and 
progestogen (Yuzpe®) and the side effects kept it as a POM (Anderson and 
Blenkinsopp, 2006). In 2000, a new progestogen-only EHC was introduced 
(Levonelle-2®; containing levonorgestrel), the new EHC was more effective and 
safer than the old one. Its success rate ranged from 95% if the dose is taken within 
the first 24 hours after intercourse to 58% if it is postponed to 48-72 hours (Killick 
and Irving, 2004). In 2003, the dose of levonelle was changed from taking two 
tablets each containing 750 µg 12-hours apart to a single dose of 1500 µg , as it 
was noticed that many women failed to take the second tablet (MHRA, 2003). The 
effectiveness of two doses of 750 µg and one single dose of 1500 µg was similar 
(Hertzen et al., 2002). Grimes and co-workers (1998) found that taking two doses of 
levonorgestrel 12 hours apart within 72 hours following a single act of unprotected 
sexual intercourse is effective in preventing 75% of unintended pregnancies. 
Creinin and co-workers (2006) found that taking two doses of levonorgestrel 750 µg 
within 72 hours following one act or more of sexual intercourse to be effective in 
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preventing 69% of unintended pregnancies. Glasier and co-workers (2010b) found 
that taking one dose of  levonorgestrel 1500 µg within 120 hours following one or 
more act of unprotected intercourse to be effective in preventing 52% of unintended 
pregnancies. Hertzen and co-workers (2002) found that the single dose is effective 
in preventing 84% of unintended pregnancies if it is taken within 72 hours following 
a single act of sexual intercourse and is effective in preventing 63% of pregnancies 
if it is taken between 72 and 120 hours following the intercourse. The mean age of 
women in each of the four studies was different with 23.6 years (Glasier et al., 
2010b), 24.3 (Creinin et al., 2006), 27.1 (Hertzen et al., 2002) and 27.3 (Grimes et 
al., 1998). Furthermore, there were differences in terms of BMI and ethnicity.  
 In 2001, EHC was deregulated from POM status into P status (MHRA, 2013a). 
This allowed women (aged 16 and above) to buy EHC from CPs at £19.99 cost in 
2001 (in 2009/2010, price was around £25, varied between sellers (Hinchliffe, 
2010)). In addition EHC can be obtained free through a prescription provided by 
GPs, family planning clinics and walk in centres (Harrison-Woolrych et al., 2001). 
The advantages and disadvantages of EHC deregulation were arguable. The direct 
link between improving access to EHC and total unintended pregnancy and 
abortion rates was unclearly defined. Glasier (2006, 2013) found that there is no 
direct link between the increase uptake of EHC and lower total unintended 
pregnancy rates and abortion rates. On the other hand, Oza (2009) found that the 
improved access to EHC in USA through pharmacies decreased the abortion rates 
among 15-29 years old by 37.2%. The situation in the UK was different, as the hope 
that increased access to EHC would lead to a decrease in unwanted pregnancies 
as suggested by Harrison-Woolrych and  workers (2001) did not occur, and there 
was no increase in use or changes in the patterns of use (Martson et al., 2005). 
However, there was a shift in venues where women obtained their EHC, as they 
tended to buy EHC from pharmacies in comparison to other venues (Martson et al., 
2005). The women from higher SES areas would use EHC more often than women 
in lower SES ones (Cameron et al., 2012). This contraindicated the aim to lower the 
gap in SES in terms of unintended pregnancies between higher and lower SES 
areas.  
Many researchers found no evidence  to support the suggestion that improving 
access to EHC might direct the women to abandon other methods for birth control 
and might increase the incidence of Sexually Transmitted Infections (STIs) (Camp 
et al., 2003; Jackson et al., 2003; Black et al., 2006). Only one study which 
investigated the effect of improving access of EHC through pharmacies on a large 
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sample size (n= 440 038), found that this improvement was responsible for 17.8% 
increase in STIs among 15-29 year old women (Oza, 2009).  
Pharmacists welcomed the EHC scheme, as they thought it would help women in 
obtaining EHC and it would improve their profession (Bissell et al., 2006). However, 
both pharmacists and users raised concerns about its misuse and its impact on 
changing contraceptive behaviour and increasing STIs (Seston et al., 2001; Bissell 
et al., 2006). As timing is very important for the effectiveness of EHC, the 
availability of EHC through CPs, gives a chance to get it within 24 hours following 
sexual intercourse, where it is most effective (Killick and Irving, 2004; Lewington 
and Marshall, 2006). Marciante and co-workers (2001) found that obtaining the 
EHC form pharmacists after unprotected sex was cost-saving from both payer and 
private perspective in comparison to health clinics. 
The enhanced service (currently known as local commissioned service) of EHC 
include the supply of EHC to women through specific written instructions which are 
called PGDs. The supply will be free of charge to women who met the PGD criteria 
(PSNC, 2014). Each PCT had its own criteria of inclusion in terms of age of client 
and most of them include only teenagers (under 16 years old). However some 
exceptions were seen in case of the service in Ashton, Leigh and Wigan PCT 
where the service was free to all ages (NHS Ashton, Leigh and Wigan, 2011) and in 
Berkshire West PCT, where it  was free to ages between 13 and 19 under PGD 
with those who are 20 years and over having to buy it over the counter (Berkshire 
Local Pharmaceutical Committee, 2011).   
3.1.2 Chlamydia screening  
The second sexual pharmacy health service examined in this Chapter deals with 
Chlamydia. Chlamydia trachomatis is the most common sexually-transmitted 
infection in the UK, affecting both men and women, even those that are less 
sexually active (National Chlamydia Screening Programme (NCSP), 2010a).  It is 
more common in young people aged under 25 years old than older ones (Adams et 
al., 2004). Chlamydia infections are largely asymptomatic and if untreated they can 
lead to severe complications to the woman’s reproductive system, which will result 
in infertility or ectopic pregnancy (Balfe et al., 2010). Fortunately, a urine test can 
detect chlamydia infection and a single dose of antibiotics can treat the infection 
(Peipert, 2003). In 2003, the DH established a network to offer free screening and 
treatment and partner notification to those under 25 years old. The target for 
2009/2010 was to test 25% of men and women aged 15-24 in healthcare settings 
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and non-healthcare settings; genitourinary medicine (GUM) activity apart. 
Community pharmacists can participate in offering kits only, offering screening in 
site, or providing treatment and partner notification for sexually active people under 
25 years old (NCSP, 2013). For those who offer only kits, they should inform the 
client about how to utilise the kit, how to return it for testing, the process following 
the completion of test and how they will be informed of the results. For those who 
offer chlamydia screening at site, they should inform the client about the benefits of 
chlamydia screening, specimen collection, procedures followed to manage the 
results and free treatment. In case of positive results, CPs will refer the client into 
other sexual health services to obtain treatment (if the CP is offering screening 
only). A record of the client details and a signed consent form should be prepared 
prior to screening. For those who offer treatment at site, they can provide antibiotic 
under PGDs (PSNC, 2014). CPs showed willingness to provide chlamydia services 
(kits, screening, treatment and partner notification) (Cameron et al., 2007).  Public 
perceptions towards using chlamydia screening through CPs were arguable. The 
public welcomed the service and stated how it was convenient and accessible in a 
study in South East London (Baraitser et al., 2007). On the other hand, the majority 
of young adults who were surveyed in Ireland stated that they would prefer to be 
screened by a doctor or nurse and the majority did not want to be screened by a 
pharmacist (Brugha et al., 2011). The results of the first two years of chlamydia 
screening through CPs indicated that the service was feasible and accessible as 
there was a number of people who accessed the service (Anderson and Thornley, 
2011). Providing chlamydia services alongside EHC service seemed to improve the 
number of clients who were screened through CPs (Brabin et al., 2009; Gudka et 
al., 2013; Gudka et al., 2014).  
3.2 Aims and objectives 
The aim of this Chapter is to identify the needs for both sexual health services 
across different PCTs and to assess whether the provision and uptake of services 
through CPs match with the needs. 
The specific objectives are: 
1. To identify the needs for EHC as an enhanced service (under PGD) and 
chlamydia service on PCT level for all PCTs in England and to identify what 
are the factors that are associated with higher needs. 
2. To investigate whether the provision of services through CPs matches with 
the needs. 
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3. To assess whether the uptake level of each service matches with the level 
of provision and in turn with the level of needs. 
4. To calculate the incremental cost-effectiveness ratio ICER for EHC 
intervention in comparison to no intervention at all. 
3.3 Method 
In order to meet the aims of this Chapter, the PNA reports were used to collect 
information regarding the CP provision of EHC and chlamydia screening service. A 
short survey was conducted to obtain the missing data regarding the uptake and 
costs of both services to perform the required analysis. All collected data were 
related to the financial year 2009/2010, which started in 01/04/2009 and ended in 
31/03/2010. 
3.3.1 Measures, definitions 
The measures and definitions are divided into; 
3.3.1.1 Measures and definitions that are related to EHC service 
 Need for EHC: the conception rate per 1000 females (15-17 year olds only), 
as the service aimed mainly to reduce teenage pregnancy and this is how 
the teenage pregnancy rates were presented in health profiles (Public and 
Health Observatories website, 2010).  
  Provision of EHC through CPs: the percentage of CPs providing EHC 
under PGD within a PCT. 
  Weighted provision of EHC: the number of CPs providing EHC per 10 000 
females under 60 years old, as two details of the population per PCT were 
available; under 16 years old and 16-59 years old.  
  Number of teenagers accessing  EHC per month during 2009/2010  
  Number of teenagers provided with EHC per pharmacy during 2009/2010.   
  Ethnic minority female percentage: percentage of women who are of an 
ethnic minority 
3.3.1.2 Measures and definitions that are related to chlamydia service 
 Need for chlamydia services: the percentage of 15-24 year-olds who tested 
positive chlamydia out of the total tested. 
  Reach of chlamydia services: the percentage of 15-24 year-olds tested for 
chlamydia infection out of all 15-24 year-olds. 
  CP provision of chlamydia screening: the number of CPs offering chlamydia 
screening services out of the total in a PCT.  
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 Weighted CP provision of chlamydia screening service: the number of CPs 
which offer the service per 10 000 15-24 year-olds. 
3.3.1.3 Measures and definitions that are related to both services 
 PCT deprivation (Index of Multiple Deprivation (IMD) score) (2010): (see 
section 2.3.1.2). 
3.3.2 Data collection 
3.3.2.1 The published resources 
Teenage pregnancy rates were imported from the health profiles (published 2010) 
for each PCT (Public Health England, 2010). As in Chapter 2, where the health 
profile was not available for a given PCT, a weighted mean (based on population 
size) was calculated using values from the localities within that PCT. The 
prevalence of chlamydia was imported from the national chlamydia screening 
website (2010b). The number of CPs within each PCT and number of CPs which 
were providing an EHC service, chlamydia service or both were obtained from the 
PNA reports. Demographic characteristics were imported from the office for national 
statistics (ONS, 2011). 
3.3.2.2 The survey 
3.3.2.2a Questionnaire design 
As in Chapter 2, a questionnaire was designed to collect the data regarding the 
uptake and the costs of EHC and chlamydia services. The final version is available 
in Appendix 3. The questionnaire had two sections; section one was related to the 
EHC service and section two was related to the chlamydia services. The 
questionnaire asked about the uptake of each service during the financial year 
2009/2010 and the costs attributed to the provision of each service; pharmacy 
payment, overhead costs and medication costs.  
3.3.2.2b Ethical approval 
The final draft was submitted to the Science, Engineering and Computing Ethics 
Committee at Kingston University to obtain ethical approval. The Committee met on 
21/06/2012, approved the questionnaire and recommended to use the term sexual 
health services rather than sexual services. The questionnaire was posted to the 
public health leads of sexual health services in each of the targeted PCTs in 
November 2012, followed by reminders in December 2012. 
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3.3.2.2c Validation of the questionnaire 
The questionnaire was chosen to ask direct questions about the uptake and costs 
of EHC service and chlamydia service (Appendix 3). However, to make sure that 
the questionnaire provide exact data, a comparison between the costs identified 
from responses was made with the costs found through the PCT investigation 2011 
that covered the financial year 2010/2011 (Chemist and Druggist, 2011). No 
differences were identified and hence the responses from the survey were 
validated. 
3.3.3 Data Analysis 
The collected data were coded and entered into SPSS version 17 for analysis. 
3.3.3.1 Data analysis for all PCTs 
Descriptive analysis was performed on all measures to identify the mean, median 
and range. Normality distribution was tested for all measures using Shapiro-Wilk 
test. Correlations between the needs and other factors were tested using 
Spearman's rank test in case of non-normal distribution and Pearson's coefficient 
test in case of normal distribution with 95% confidence level in all cases.  
3.3.3.2 Data analysis for the sample 
3.3.3.2a Comparison between respondent PCTs and non-respondent PCTs 
PCTs that responded to the questionnaire were separated from the non-
respondents (the rest of PCTs). A comparison between these two groups in terms 
of all measures identified above was performed using the Mann-Whitney test in 
case of non-normal distribution and a T-test between two independent samples 
where a normal distribution was seen (95% confidence level).   
3.3.3.2b Sample added measures 
This included the two services uptake measures; 
A- for the EHC service 
 Number of clients who accessed the EHC per month: the number of CP 
clients who asked for EHC under PGD per calendar month. 
  Number of clients who were issued with EHC medication per month: the 
number of CP clients who accessed CP EHC service and were provided 
with EHC. In case this number was absent for PCT, the average rate of 
supply for all PCTs was used. 
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  Number of clients who accessed the EHC per month per pharmacy: this 
was calculated by dividing the number of clients who accessed the EHC per 
month by the number of CPs which were providing EHC. 
 Number of clients who were issued with EHC per month per pharmacy: this 
was calculated by dividing the number of clients who received EHC per 
month by the number of CPs which were providing EHC. 
B- for chlamydia service 
 Pharmacy reach of chlamydia screening: the percentage of 15-24 years old 
in a given PCT who were screened through CPs out of the total population 
of 14-25 years old. 
  Pharmacy share in chlamydia screening: the percentage of 15-24 years old 
who were screened through CPs out of the total screened through all 
venues. 
 Chlamydia screen per pharmacy (2009/2010): the number of 15-24 years 
old who were screened per CP during the financial year 2009/2010. 
3.3.3.2c Applied statistical tests 
Descriptive analysis (mean, median, range... etc.) was performed on all measures 
of the sample PCTs as it was performed on all PCTs. In the case of EHC, 
Pearson's coefficient test was used to identify the correlation between needs and 
deprivation on one side, and uptake of EHC through CPs on the other. The uptake 
measures (the number of clients who accessed the EHC service and those who 
were issued with EHC medication) were log10 transformed to make them closer to 
normal distribution. Spearman's Rank test was used to investigate the association 
between uptake and demographic factors (age and ethnicity). In case of chlamydia 
service, log10 transformed values for chlamydia uptake through CPs were used and 
Pearson's coefficient test was used to compare the log transformed values with 
needs and provision. A 95% confidence level was used in all cases.   
3.3.3.2d Cost-effectiveness analysis of EHC intervention 
A simple cost-effective analysis model was used to compare EHC intervention with 
no intervention, as described in a Figure 3.1. The analysis was taken from the NHS 
perspective. The costs of intervention (EHC through CPs) included costs of 
consultation (payment to CPs), costs of medication and costs of unintended 
pregnancy. Both of consultation costs and medication costs were calculated based 
on answers from questionnaires sent to PCTs (Appendix 3). For any missing cost, 
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the median cost for the rest of PCTs within the sample was calculated and used as 
a replacement. No costs for medication and consultation were attributed to no-
intervention, as it was taken from the NHS perspective.  
 
Figure 3.1: Decision tree following unprotected sexual intercourse 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
To define the effectiveness of EHC, a meta-analysis of Randomised Control Trial 
(RCT) studies (which are described in Table 3.1) was conducted. The criteria for 
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choosing those studies was based on RCT studies that test the observed 
pregnancy rates for women who used levonorgestrel (one dose 1.5 mg or two 
doses 0.75 mg12-h apart) within 120 hours of the unprotected sexual intercourse. 
Creinin and co-workers (2006) calculated the expected pregnancy rates based on 
Wilcox's method (Wilcox et al., 2001). While the rest of the studies calculated the 
expected pregnancy rates based on Trussell's method. A meta-analysis of the four 
RCT studies found that the taking of levonorgestrel following unprotected 
intercourse one dose or two doses (12 hours apart) was resulted in 93/5 420 
(1.72%) as observed pregnancies versus 386/5 420 (7.1%) as expected 
pregnancies for no intervention (Figure 3.1). The costs of one case of unintended 
pregnancy (£ 1016) were obtained from Montouchet and Trussell (2013). The costs 
were related to the costs of unintended pregnancy in England to the NHS in 2010, 
which agreed with the period of time the collected data was related to (financial 
year 2009/2010). Thomas and co-workers (2010a) found that the cost of 
unintended pregnancy was £948 to the NHS in 2007-2008, as it was not related to 
the financial year 2009/2010, the value was not used. The total costs of an 
unintended pregnancy equalled to the costs of each event (child birth, induced 
abortion, ectopic pregnancy and spontaneous abortion) multiplied by its probability 
(Table 3.2) in the page below.  
Table 3.1: Summary of the four RCT which was used in meta-analysis 
Study Methods Location Time UI 
(frequency 
of  UI) 
Results (N. Pregnancies) 
 Intervention 
(Observed) 
No intervention 
(Expected) 
Glasier 
et 
al.,2010 
RCT. 
One dose 1.5 mg 
levonorgestrel  
UK, 
Ireland 
and USA 
Within 120-h 
(one or more) 
25/958 52/958 
Creinin 
et 
al.,2006 
RCT. 
Two doses of 
levonorgestrel 0.75 
mg 12 hours apart  
USA Within 72-h 
(one or more) 
13/774 42/774 
Hertzen 
et al., 
2002 
RCT. 
a- One dose 1.5 mg 
levonorgestre. 
b- Two doses of 
levonorgestrel 0.75 
mg, 12 hours apart 
10 
countries 
Within 120-h 
(one) 
20/1356 
 
 
 
24/1356 
111/1356 
 
 
 
106/1356 
Grimes 
et al., 
1998 
RCT. 
Two doses of 
levonorgestrel 0.75 
mg, 12 hours apart 
21 
countries 
Within 72-h 
(one) 
11/976 75/976 
UI: Unprotected intercourse. 
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Figure 3.2: Forest plot of observed pregnancies using levonorgestrel versus 
expected pregnancies with no intervention  
 
 
Table 3.2: Costs and probability of pregnancy outcomes 
Pregnancy outcome Probability
1 
Cost
2 
Probability x 
Cost
3 
Child birth 0.14 £1579 £221 
Induced abortion 0.83 £919 £763 
Spontaneous abortion  0.02 £375 £8 
Ectopic pregnancy 0.01 £2462 £24 
Unintended pregnancy
4 
1  £1016 
1- Probability of each event was obtained from (Montouchet and Trussell, 2013) for the 
unintended pregnancies for girls aged 15-24 years old n England for 2010. 
2- The costs of each event were derived from (Montouchet and Trussell, 2013). 
3- The fourth column is resulted from multiplying probability with cost of each event. 
4- Total cost of unintended pregnancy equals to the total costs. 
The incremental cost-effectiveness ratio (ICER) of using EHC intervention through 
CPs versus no intervention was calculated using (Equation 3.1).  
ICER  
               
                         
                                                                             (Equation 3.1) 
1- Costs 1: costs attributed to EHC intervention = (Costs of consultation per client + cost of 
medication per client) + (probability of unintended pregnancy (1.7%) × costs of unintended 
pregnancy (£1 016). 
2- Costs 2: costs attributed to no intervention = probability of unintended pregnancy (7.1%) 
× costs of unintended pregnancy (£1 016). 
3- Probability 1: the probability of not getting pregnant using EHC= 100- 1.7 (%) 
4- Probability 2: the probability of not getting pregnant with no intervention = 100-7.1 (%). 
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3.3.3.2e Sensitivity analysis 
In order to overcome uncertainty in calculating the incremental cost-effectiveness 
ratio, a sensitivity analysis was applied to the costs and benefits of EHC 
intervention in comparison to no intervention. As the costs of intervention 
(consultation and medication) varied across different PCTs, and the median was 
used to calculate the incremental cost, the lowest costs of intervention were used in 
the first scenario and the highest costs were used in the second scenario. The third 
and fourth scenario were related to the probability of getting pregnant using EHC 
versus no intervention. The third scenario used the results of Glasier and co-
workers (2010) which had the highest risk relative ratio (0.48) in Figure 3.2. The 
fourth scenario used the results of Grimes and co-workers (1998) which had the 
lowest risk relative ratio (0.15) in Figure 3.2.  
3.4 Results 
3.4.1 EHC 
Out of the 151 PCTs which were available in 2009/2010, teenage pregnancy rates 
could not be identified for 5 PCTs and provision of EHC through CPs could not be 
identified for 7 PCTs. As a result, 139 PCTs were included. 
3.4.1.1 Descriptive analysis for the 139 PCTs 
The PCTs displayed a wide variation in needs (Figure 3.3), demographic factors 
(Figure 3.4), and CP provision of EHC (Figure 3.5). The teenage pregnancy rates 
ranged from 22.1 to 74.8 per 1000 with a median of 43.2 (Table 3.3). Thirty four 
PCTs had teenage pregnancy rates lower than the lower quartile (34.1) and they 
belonged to the most affluent PCTs in England and thirty four PCTs had rates 
higher than the higher quartile (52.4) and they belonged to the most deprived PCTs 
in England. The deprivation scores also varied across the PCTs from 8.8 to 43.5 
with a median of 23.2 (Table 3.3 and Figure 3.3). Thirty three PCTs had a 
deprivation score lower than the lower quartile (16.4) and 26 out of them were in 
common with those of teenage pregnancy rates lower than the lower quartile. Thirty 
four PCTs had a deprivation score higher than the higher quartile (29.5) and 23 out 
of them were in common with those who had teenage pregnancy rates higher than 
the higher quartile. In terms of ethnicity, the median proportion of females aged 
under 60 years old of BME was 8.9% with a range from 1.8 to 53.8% (Table 3.3). 
The highest 5 PCTs of proportion of BME females (under 60 years old) belonged to 
London, two out of them belonged to the most affluent PCTs and three belonged to 
the most deprived PCTs. The CPs provision of EHC varied across the different 
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PCTs with a median of 52.3% and a range from 5.3 to 90% (Table 3.3 and Figure 
3.5).  Thirty three PCTs had a CP EHC provision higher than the upper quartile 
(65.1%), the highest four had a moderate (neither high nor low) teenage pregnancy 
rates. No outliers were identified in terms of needs, demographic factors or CP 
provision factors. 
Table 3.3: Description of the 139 PCTs 
Variable Median LQ UQ Min- Max 
Needs     
Teenage pregnancy rate1 43.2 34.1 52.4 22.1- 74.8 
Demographic factors     
Deprivation score (IMD)
2 
23.2 16.4 29.5 8.8- 43.5 
Female under 16 years (%)
3 
24.1 22.9 24.8 15.1- 29.2 
Female under 60 as BME (%)
4 
8.9 4.9 18.8 1.8- 53.8 
Female under 16 years as BME(%)
4 
7.8 4.2 18.6 1.4- 56 
Female (16-59) as BME %
4 
9 4.9 19.2 1.9- 52.9 
Pharmacy provision factors     
CPs  per 10 000 female under 60 5.5 4.9 6.2 3.7- 12.5 
CPs providing EHC per 10 000  2.8 1.9 3.5 0.3- 5.7 
CPs providing EHC (%) 52.3 34.5 65.1 5.3- 90 
1- Teenage pregnancy rate: The conception rate per 1000 females (15-17 year olds only). 
2- IMD: Index of Multiple deprivations. 
3- Female under 16 years (%): The percentage of females under 16 years old out of total 
females under 60 years old. 
4- BME (Black and Minority Ethnic) %: The percentage of Asians, Blacks and Chinese or 
other ethnicities out of total population.   
Figure 3.3: Teenage pregnancy rates histogram 
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Figure 3.4: Deprivation score histogram 
 
Figure 3.5: CPs providing EHC (%) histogram 
 
3.4.1.2 Association between teenage pregnancy rates (needs) and other 
factors 
Despite the progress that had been made between 1999 and 2009 in reducing 
teenage pregnancy rates, higher rates were still found to be strongly correlated with 
deprivation (rho = 0.83, P < 0.001). There was only a weak correlation between 
teenage pregnancy rate and the ethnic make-up of a PCT (rho = 0.2, P= 0.018). 
Although there was a greater concentration of CPs in PCTs with greater needs (rho 
= 0.4, P < 0.001), this did not translate into an improved provision of EHC through 
90 
 
CPs either as a percentage of CPs, or per 10 000 females and as no significant 
correlation could be identified (Table 3.4).  
Table 3.4: Association between needs and other factors 
 Rates of teenage pregnancy 
Rho (P-value) 
Demographic factors 
Deprivation score (IMD)
1 
0.83 (< 0.001)
 
Female under 16 years (%)
2 
- 0.145 (0.08) 
Female under 60 as BME (%)
3 
0.161 (0.06) 
Female under 16 years as BME(%)
3 
0.2 (0.02) 
Female (16-59) as BME %
3 
0.145 (0.09) 
Pharmacy provision factors 
CPs  per 10 000 female under 60 0.4 (< 0.001)
 
CPs providing EHC per 10 000  0.14 (0.1) 
CPs providing EHC (%) 0.002 (0.99) 
1- IMD: Index of Multiple deprivations. 
2- Female under 16 years (%): The percentage of females under 16 years old out of total 
females under 60 years old. 
3- BME (Black and Minority Ethnic) %: The percentage of Asians, Blacks and Chinese or 
other ethnicities out of total population. 
4- Significant correlations were shown in bold.   
 
3.4.1.3 Sample PCTs 
3.4.1.3a Response rate 
15 PCTs responded to the questionnaire which were sent in November 2012 a 
further 5 PCTs responded to the reminders which were sent in December 2012. 
The questionnaire asked for the uptake of EHC through CPs. One of the 
respondents did not provide uptake information so was excluded. As a result, the 
respondent sample consisted of 19 PCTs. An investigation through the PNA reports 
provided uptake results for a further 23 PCTs, where the uptake information was 
related to the financial year 2009/2010. The final sample was 42 PCTs out of 139 
PCTs (30% response rate; Figure 3.6). The majority of respondent PCTs belonged 
to North East, North West and South East of England (Figure 3.7) 
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Figure 3.6: Explains the process in getting the final sample 
 
 
 
 
 
 
Figure 3.7: Map of PCTs which responded to EHC survey
 
 
3.4.1.3b Comparison between respondent and non-respondent PCTs 
The results of Mann-Whitney tests between the sample and the rest of PCTs (Table 
3.5) showed that median teenage pregnancy rate and median deprivation score 
were higher in the sample than the rest of PCTs. The median rate of teenage 
pregnancy per 10 000 was 48.5 for the sample and 41.02 for the rest of the PCTs 
(P = 0.035). The median deprivation score was 26.00 for the sample and 20.54 for 
the rest of the PCTs (P = 0.002). However, there was no significant difference in 
any of the other variables. This indicates that even though there was a higher need 
Questionnaires were sent to 
139 PCTs in November 2012 
15 PCTs responded in 
November 2012 (one was 
excluded (missing data) 
Reminders were sent to 124 
PCTs in December 2012 
5 PCTs responded to the 
reminders in December 2012 
The PNA reports were 
investigated for any extra 
information 
Data were imported for 23 
PCTs 
The final 
sample was 42 
PCTs 
92 
 
for EHC service in the sample when compared to the rest of PCTs, there was no 
significant difference in terms of CPs EHC provision.  
Table 3.5: Comparison of variables between respondent PCTs (sample) and 
non-respondents 
Variable Sample 
Median
 
Rest of PCTs 
Median 
P-value 
Needs 
Teenage pregnancy rate
1
 48.5 41.02 0.035 
Demographic factors 
Deprivation (IMD)
2 
26.00 20.54 0.002 
Female under 16 years (%)
3 
24.18 24.03 0.66 
Female under 60 as BME (%)
4 
8.04 8.94 0.88 
Female under 16 years as BME(%)
4 
7.27 8.28 0.903 
Female (16-59) as BME %
4 
8.44 9.38 0.916 
Pharmacy provision factors 
CPs  per 10 000 female under 60 5.61 5.48 0.499 
CPs providing EHC per 10 000
5
  3.04
 
2.73 0.157 
CPs providing EHC (%)
5 
54.15 49.00 0.151 
1- Teenage pregnancy rate: The conception rate per 1000 females (15-17 year olds only). 
2- IMD: Index of Multiple deprivations. 
3- Female under 16 years (%): The percentage of females under 16 years old out of total 
females under 60 years old. 
4- BME (Black and Minority Ethnic) %: The percentage of Asians, Blacks and Chinese or 
other ethnicities out of total population.   
5- For CPs providing EHC per 10 000 female (<60) and the percentage of CPs providing 
EHC, the mean was used as they were normally distributed, while the median was used for 
the rest of variables as they were not normally distributed. 
 
3.4.1.3c Descriptive analysis of the sample 
Table 3.4 summarises the descriptive results for the sample. There was a wide 
variation in uptake of EHC through different PCTs. For instance, one PCT only had 
10 clients that accessed EHC via CPs per month, while in another PCT 833 
accessed the service with a median of 159 clients per month (Table 3.6). Fifteen of 
the respondent PCTs (36%) dealt with less than 100 clients per month (ten out of 
them were lower than the lower quartile (66)) and ten PCTs (24%) dealt with more 
than 300 clients per month (all of them were higher than the upper quartile (303) 
(Figure 3.8). When the uptake per month was divided by number of CPs within a 
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PCT, the median number of clients per month per CP was 5 clients with a range 
from 1 to 86 (Table 3.6 and Figure 3.9). Twenty two PCTs (52.4%) of the 
respondent PCTs dealt with less than 5 clients per month per CP (Figure 3.9). On 
the other hand, when the uptake per month was divided by number of females aged 
between 15 and 24 years old, the median number of clients was 9 with a range 
from 1 to 45 (Table 3.6 and Figure 3.10). Thirteen PCTs had a number of clients 
per month per female less than the lower quartile (4) and ten PCTs had a number 
higher than the upper quartile (14) and nothing was in common within each group.  
Figure 3.8: Number of clients who accessed EHC per month histogram 
 
Figure 3.9: Number of clients who accessed the EHC service during calendar 
month per CPs (3.9a) and per female aged 15-24 years old (3.9b) 
Figure 3.9a                                                              Figure 3.9b 
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Table 3.6: Description of sample measures 
Variable Median LQ
10 
UQ
11 
Min- Max 
Needs     
Teenage pregnancy rate
1 
48.5 38.5 53.9 25.4- 68.5 
Demographic factors     
Deprivation (IMD)
2 
26.0 21.1 33.9 11.3- 43.5 
Female under 16 years (%)
3 
24.2 23 24.8 19.4- 29.2 
Female under 60 as BME (%)
4 
8.0 4.5 23.3 2.5- 46.4 
Female under 16 years as BME(%)
4 
7.3 4.2 21.8 2.2- 55.3 
Female (16-59) as BME %
4 
8.4 4.5 23 2.4- 46.1 
CP provision factors     
Clients accessed EHC/M
5 
159 66 303 10- 833 
Clients issued with medication/M
6 
155 62 291 10- 803 
Clients accessed the EHC/M/CP
7 
5 3 8 1- 86 
Clients issued with EHC/M/CP
8 
5 3 7 1- 84 
Clients accessed EHC/M/F
9
  9 4 14 1-45 
1- Teenage pregnancy rate: The conception rate per 1000 females (15-17 year olds only). 
2- IMD: Index of Multiple deprivations. 
3- Female under 16 years (%): The percentage of females under 16 years old out of total 
females under 60 years old. 
4- BME (Black and Minority Ethnic) %: The percentage of Asians, Blacks and Chinese or 
other ethnicities out of total population.   
5- Clients accessed EHC/M: 
 
The number of clients who accessed EHC service during 
2009/2010 per calendar month, M stands for Month. 
6- Clients issued with medication/M: The number of clients who were issued with EHC 
medication during 2009/2010 per calendar month. 
7- Clients accessed the EHC/M/CP:  The number of clients who accessed the EHC/Month 
per CPs which were offering the EHC. 
8- Clients issued with EHC/M/CP:  The number of clients who were issued with EHC 
medication/Month per CPs which were offering the EHC. 
9- Clients accessed EHC/M/F: The number of clients who accessed EHC per calendar 
month per female aged 15-24 years old. 
10, 11- LQ stands for Lower Quartile, UQ stand for Upper Quartile. 
3.4.1.3d Association between uptake and other variables 
All the uptake variables were log10 transformed to make them closer to normal 
distribution. The uptake factors were measured on three levels; uptake per calendar 
month, uptake per calendar month per CP and uptake per calendar month per 
female aged 15-24 years old (it was not possible to get data regarding female 15-17 
years old). There was no significant correlation between needs (teenage pregnancy 
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rates) and uptake per calendar month (Table 3.7). This finding is not surprising as 
each PCT has different number of population (female under 16 years old). When 
the uptake was weighted against number of CPs which were offering EHC service, 
the needs were significantly correlated with the uptake with R of 0.36 and P of 0.02 
(Table 3.7). This suggests that CPs in PCTs with higher needs had to deal with 
higher number of clients per months to meet their local needs as the CPs EHC 
provision did not match the needs. When the uptake was weighted against number 
of females aged 15-24 years old, no significant correlation was identified between 
needs and uptake (Table 3.7). The deprivation did not correlate with any of the 
uptake factors (Table 3.7). An increase in CPs EHC provision should be 
accompanied with higher uptake. When this was tested against the uptake per 
calendar month, it was very close to significantly correlate with the uptake, as P 
was 0.05 (Table 3.7). However, when the uptake was weighted against the female 
population aged 15-25, a strong correlation was found with R of 0.51 and P of 0.001 
(Table 3.7)       
Table 3.7: Associations between uptake and needs and deprivation 
Uptake factors Teenage pregnancy 
rate
 
R (P-value) 
Deprivation 
(IMD)
 
R (P-value) 
CPs providing 
EHC (%) 
R (P-value) 
Clients accessed EHC/M
1 
0.05 (0.75) - 0.05 (0.76) 0.3 (0.05) 
Clients issued with medication/M
2 
0.06 (0.72) - 0.05 (0.76) 0.3 (0.05) 
Clients accessed the EHC/M/CP
3 
0.36 (0.02) 0.29 (0.06) -0.09 (0.58) 
Clients issued with EHC/M/CP
4 
0.36 (0.02) 0.29 (0.06) - 0.09 (0.59) 
Clients accessed EHC/M/F
5
 0.21 (0.18) 0.17 (0.29) 0.51 (0.001) 
1- Clients accessed EHC/M
: 
 The number of clients who accessed EHC service during 
2009/2010 per calendar month. 
2- Clients issued with medication/M:  The number of clients who were issued with EHC 
medication during 2009/2010 per calendar month. 
3- Clients accessed the EHC/M/CP:  The number of clients who accessed the EHC/Month 
per CPs which were offering the EHC 
4- Clients issued with EHC/M/CP: The number of clients who were issued with EHC 
medication/Month per CPs which were offering the EHC. 
5- Clients accessed EHC/M/F: The number of clients who accessed EHC per calendar 
month per female aged 15-24 years old. 
As both of the uptake and age and ethnicity factors were non-normally distributed, 
Spearman's rank coefficient was used to test the correlations between the uptake 
and other factors.  No significant correlation was identified between uptake and 
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ethnicity factors (Table 3.8). The EHC service under PGD was designated to female 
16 years old and under, which means that the higher percentages of female 16 
years old and under in a PCT, the higher the uptake will be. However, as the age 
percentages here was for under 16 years old (16 years old not included), no exact 
conclusion can be withdrawn, as the uptake of EHC was negatively associated with 
the percentages of females under 16 years old (rho = - 0.38, P = 0.01) in case of 
clients who accessed EHC per calendar month.  
Table 3.8: Association between EHC uptake and age and ethnicity 
 Access/M
3 
Rho (P-
value) 
Treated/M
4 
Rho (P-
value) 
Access/M/CP
5 
Rho (P-value)
 
Treated/M/CP
6 
Rho (P-value) 
Female under 16 years (%)
1 
- 0.38, 0.01 - 0.37, 0.02 -0.46, 0.002 - 0.47, 0.002 
Female under 60  BME (%)
2 
0.08, 0.61 0.07, 0.64 0.17, 0.28 0.16, 0.32 
Female under 16 BME(%)
2 
0.06, 0.69 0.06, 0.73 0.15, 0.34 0.14, 0.38 
Female (16-59)  BME %
2 
0.08, 0.63 0.07, 0.67 0.17, 0.29 0.16, 0.32 
1- Female under 16 years (%):  The percentage of females under 16 years old out of total 
females under 60 years old. 
2- BME (Black and Minority Ethnic) %: The percentage of Asians, Blacks and Chinese or 
other ethnicities out of total population. 
3- Access/M:
 
 The number of clients who accessed EHC service during 2009/2010 per 
calendar month. 
4- Treated/M:  The number of clients who were issued with EHC medication during 
2009/2010 per calendar month. 
5- Access/M/CP:  The number of clients who accessed the EHC/Month per CPs which were 
offering the EHC. 
6- Treated/M/CP:  The number of clients who were issued with EHC medication/Month per 
CPs which were offering the EHC. 
7- Significant correlations are shown in bold. 
 
3.4.1.3e Cost effective analysis  
Cost-effective analysis was performed on the sample set of 42 PCTs (Section 
3.4.1.3a). The responses from the questionnaire were used to obtain the cost of 
consultation and the cost of medication. The cost of consultation was available for 
15 PCTs and ranged from £10 to £15.5 with a median of £12.50. The cost of 
medication ranged from £5.2 to £6 with a median of £5.37. The median cost of 
consultation and the median cost of medication were used in case of missing 
values (blank answer from PCT). 
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The total cost of providing EHC in each PCT includes the total cost of consultations 
and total cost of medications, where; 
                                                                            (Equation 3.2) 
                                                                           (Equation 3.3) 
                     
                                                  
                                         
                           (Equation 3.4) 
The median cost per client was £17.68 ranging from £15.78 to £20.57. The ICER 
for EHC intervention in comparison to no intervention had a negative value of 
688.7. This means that the provision of EHC is cost effective. 
Table 3.9: Explains how the ICER was calculated 
 EHC 
intervention 
No 
intervention 
Costs of consultation and medication £17.68 No costs 
Costs of unintended pregnancy
1 
£17.27 £72.14 
Total costs
2 
£34.95 £72.14 
Difference in pregnancy rate
3 
5.4% 
ICER
4 
- 688.7 
1- Cost of unintended pregnancy is probability of getting pregnant × cost of unintended 
pregnancy (£1016) (mentioned in (Montouchet and Trussell, 2013), (1.7% × 1 016) in case 
of EHC intervention and (7.1% × 1 016) in case of no intervention. 
2- Total costs equal to costs of consultation and medication + costs of unintended 
pregnancy. 
3- Difference in pregnancy rate equals to probability of not-getting pregnant using EHC 
(100- 1.7= 98.3%) minus probability of not-getting pregnant with no intervention (100-7.1= 
92.9%). 
4- ICER: Incremental cost-effectiveness ratio of EHC in comparison to no intervention. 
 
3.4.1.3f Sensitivity analysis 
Table 3.10 presents the results of the conducted sensitivity analysis. In first 
scenario, when the minimum cost of EHC intervention was used instead of the 
median, the EHC intervention found to be more cost effective. In the second 
scenario, when the maximum cost of intervention was used instead of median cost, 
the EHC intervention was still cost effective. This means that the provision of EHC 
across all the respondent PCTs was cost effective. The third scenario used an 
alteration in the probability of getting pregnant with EHC intervention (2.6% rather 
than 1.7 %) versus the base probability of becoming pregnant (5.4% rather than 
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7.1%; Glasier et al., 2010). The fourth scenario used an alteration in the probability 
of getting pregnant with EHC intervention (1.13% rather than 1.7 %) versus the 
base probability of becoming pregnant (7.68% rather than 7.1%; Hertzen et al., 
1998). In all the scenarios, provision of EHC through CPs as an enhanced service 
was cost effective and it would save at least £384.29 to the NHS. 
  
 
Table 3.10: Summary of the results of different scenarios used in sensitivity 
analysis 
Scenarios EHC 
intervention 
No 
intervention 
Difference
6
  ICER 
First scenario
1 
Costs of intervention
3 
£15.78 No costs   
Costs of unintended pregnancy
 
£17.27 £72.14 5.4% - 723.89 
Total costs
 
£33.05 £72.14   
Second scenario
2 
Costs of intervention
3 
£20.57 No costs   
Costs of unintended pregnancy
 
£17.27 £72.14 5.4% - 635.19 
Total costs
 
£37.84 £72.14   
Third scenario
4 
    
Costs of intervention
 
17.68 No costs   
Costs of unintended pregnancy
 
26.42 54.86 2.8% -384.29 
Total costs
 
44.1 54.86   
Fourth scenario
5 
    
Costs of intervention
 
17.68 No costs   
Costs of unintended pregnancy
 
11.48 78.03 6.55% -746.11 
Total costs
 
29.16 78.03   
1- First scenario: Costs of intervention was £15.78. 
2- Second scenario: Costs of intervention was £20.57 
3- Costs of intervention equal to cost of consultation in addition to cost of medication. 
4- The probability of getting pregnant using EHC in third scenario is 2.6% versus 5.4% for 
no intervention. 
5- The probability of getting pregnant using EHC in fourth scenario is 1.13% versus 7.68% 
for no intervention. 
6- Difference: is the difference in pregnancy rates between intervention and no intervention. 
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3.4.2 Chlamydia services 
Based on the PNA reports, there were 111 PCTs out of 151 PCTs providing a 
chlamydia screening service in the financial year 2009/2010. As a result, this 
analysis is concerned with those 111 PCTs. 
3.4.2.1 Description of the 111 PCTs 
The need for chlamydia services (prevalence of 15-24 year-olds testing positive for 
chlamydia), varied widely across the different PCTs from 2.37% to 13.2% with a 
median of 6% (Table 3.11 and Figure 3.10). Twenty nine PCTs had a prevalence 
lower than the lower quartile (4.9), the lowest 12 out of them belonged to London 
and twenty seven PCTs had a prevalence higher than the upper quartile (7) with 
one outlier identified with a prevalence of 13.2 (Table 3.11 and Figure 3.10). CPs 
chlamydia provision as percentage had a mean of 42.4% with a range from 1.1 to 
100% (Table 3.11 and Figure 3.11a). When CPs chlamydia provision was weighted 
against population aged 15-24 years old, the median provision was 6.4 with a range 
from 0.2 to 19.3 (Table 3.11 and Figure 3.11b). Four out of the highest PCTs in 
terms of CPs chalmydia provision (as percentage or per 10 000 populations) had a 
prevalence of chlamydia higher than the upper quartile (7). The total chlamydia 
service reach also varied across the 111 PCTs with a range from 10.1% to 40.8% 
and a median of 22.6% (Table 3.11 and Figure 3.12). Seven PCTs which had the 
highest reach 30% and above belonged to London, 3 out of them had lower needs, 
two in the middle and 2 had the highest needs among the 111 PCTs  
Table 3.11: Description of the chlamydia variables across different PCTs 
Variable  Median LQ
 
UQ
 
Min- Max 
Prevalence of chlamydia
1 
6.0 4.9 7.0 2.4- 13.2 
Deprivation score (IMD) 21.8 16.4 27.8 8.8- 43.5 
CP provision % 
2 
42.4 20.4 62.2 1.1- 100 
Weighted CP provision
3 
6.4 3.4 9.9 0.2- 19.3 
Total chlamydia reach %
4 
22.6 19.8 26.3 10.1- 40.8 
1- Prevalence of chlamydia: The percentage of 15-24 year-olds tested for chlamydia that 
tested positive. 
2- Pharmacy provision: The percentage of CPs in a PCT offering chlamydia screening. 
3- Weighted pharmacy provision: The number of CPs offering chlamydia screening per 10 
000 people aged 15-24 year-olds 
4- Total chlamydia reach: The percentage of 15-24 year-olds in a PCT that were tested for 
chlamydia. 
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Figure 3.10: Chlamydia prevalence among the 111 PCTs 
 
 
 
 
 
 
 
 
Figure 3.11: CPs chlamydia service provision (3.11a) as percentage and 
(3.11b) as per 10 000 population 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Chlamydia service reach out of population aged 15-24 years old 
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3.4.2.2 Association between need and other factors 
The needs for chlamydia service seemed to be slightly correlated with deprivation 
with rho of 0.25 and P of 0.009. Unlike needs for SSS which had rho of 0.76 
(Section 2.4.1.2) and for EHC service which had rho of 0.83 (Section 3.4.1.2). 
However, the total reach of chlamydia service was significantly correlated with 
needs with rho of 0.3 and P of 0.001 (Table 3.12). The CP provision of chlamydia 
services did not correlate with need as either an absolute percentage (P= 0.56), or 
for weighted pharmacy provision (P = 0.58; Table 3.12). 
Table 3.12: Association between needs and other factors  
 Prevalence of chlamydia 
Rho (P-value) 
 IMD 0.25 (0.009) 
Total reach % 0.3 (0.001) 
Pharmacy provision factors 
Pharmacy provision %
1 
0.06 (0.51) 
Weighted pharmacy provision
2 
0.06 (0.58) 
1- Pharmacy provision %: The percentage of CPs which were offering chlamydia screen 
services out of total CPs within a PCT. 
2- Weighted pharmacy provision: The number of CPs which are offering chlamydia 
screening service to 10 000 people aged 15-24 years old. 
3.4.2.3 Sample PCTs 
3.4.2.3a Response rate 
Questionnaires (Section 3.3.2.2) were sent to 111 PCTs. 12 PCTs responded to the 
main survey or to a reminder. Data provided was incomplete for 2 PCTs, 
consequently they were excluded. The PNA reports were used to obtain data for a 
further 11 PCTs. The final sample was 21 PCTs which represents19% of the total. 
3.4.2.3b Comparison between respondent PCTs and non-respondent PCTs 
Either a Mann-Whitney test (non-normally distribution) (all variables apart from total 
reach) or a T-test (normally distribution) (total reach only) was used to compare 
between the variables for the respondent PCTs and the non-respondents. No 
significant differences were found between the two groups (Table 3.13). As a result, 
the sample of respondent PCTs can be used as a representative to the rest of non-
respondent PCTs. 
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Table 3.13: Comparison between respondent PCTs and non-respondent ones 
Variable Sample 
Median/Mean
1 
Rest of PCTs 
Median/Mean
1 
P-value 
Prevalence of chlamydia 5.58 6.11 0.087 
IMD 24.98 21.64 0.324 
Total reach (%)
1 
22.61 22.67 0.96 
Pharmacy provision factors 
Pharmacy provision (%)
2 
45.92 40.8 0.5 
Weighted pharmacy provision
3 
7.05 6.34 0.378 
1- Total reach (%): The percentage of 15-24 year-olds who were tested for chlamydia. 
2- Pharmacy provision %: The percentage of CPs which were offering chlamydia screen 
services out of total CPs within a PCT. 
3- Weighted pharmacy provision: The number of CPs which are offering chlamydia 
screening service to 10 000 people aged 15-24 years old. 
3.4.2.3c Sample description 
Unlike the CP SSS which could reach 6.7% out of total smokers in one PCT 
(Section 2.4.2.3), CP chlamydia service could not reach more than 0.9% of 15-24 
year-olds in any of sample PCTs  with a median reach of 0.3% (Table 3.14 and 
Figure 3.13). CP chlamydia service had a median share in total reach of 1.2% with 
a range from 0.2 to 6.3% (Table 3.14 and Figure 3.14), while CP SSS had a median 
reach of 12% with a range from 0.6 to 53.3% (Section 2.4.2.3). The uptake per CP 
was poor, as in its best result, CPs had not to deal with more than 21 persons per 
year (Table 3.14). Two PCTs had a number of clients screened per CP lower than 
the lower quartile (2) and they belonged to the North West of England and four 
PCTs screened a number of clients higher than the upper quartile (8) and they 
belonged to London, Yorkshire and the Humber, West Midlands and South East 
Cost of England (Table 3.14). 
Figure 3.13: Pharmacy reach of young people across different PCTs 
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Figure 3.14: Pharmacy share in reach of their young people across different 
PCTs 
 
Table 3.14: Description of sample needs, provision and uptake  
Variable Median LQ
6 
UQ
7 
Min- Max 
Prevalence of chlamydia 5.6 4.3 6.5 3.2- 7.0 
Deprivation score (IMD) 25 16.5 34.0 8.8- 41.0 
Total reach % 23.7 21.6 26 10.1- 29.5 
Pharmacy provision%
1 
45.9 31.8 31.9 5.3- 95.4 
Weighted pharmacy provision
2 
7.1 5.3 10.2 0.6- 19.4 
Pharmacy reach%
3 
0.3 0.1 0.4 0.1- 0.9 
Pharmacy share%
4 
1.2 0.8 1.7 0.2- 6.3 
Screen per pharmacy
5 
4 2 8 0.4- 21.3 
1- Pharmacy provision: percentage of CPs in a PCT offering chlamydia screening. 
2- Weighted pharmacy provision: number of CPs offering chlamydia screening per 10 000 
15-24 year-olds 
3- Pharmacy reach: percentage of 15-24 year-olds screened through CPs. 
4- Pharmacy share: percentage of 15-24 year-olds screened through CPs out of all venues. 
5- Screen per pharmacy: average number of young people in a PCT screened per CP. 
6- LQ: stands for Lower Quartile. 
7- UQ: stands for Upper Quartile. 
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3.4.2.3d Association between need, provision and uptake 
The pharmacy uptake variables were log (10) transformed to approach normal 
distribution. The uptake through pharmacies did not match with needs or 
deprivation, as no significant correlation could be identified. Unlike SSS and EHC 
services, where the increase in pharmacy provision resulted in higher uptake 
(Sections 2.4.2.4 and 3.4.1.3d), the increase in CP chlamydia service provision did 
not improve the uptake (Table 3.15). Contrary, the increase in provision resulted in 
lower screen per pharmacy (R= - 0.59, P = 0.005) in case of pharmacy provision as 
percentage and (R= - 0.57, P = 0.007) in case of pharmacy provision per 10000 
population (Table 3.15). 
Table 3.15: Association between needs, provision and uptake 
 Pharmacy 
reach
3
  
R (P-value) 
Pharmacy 
share
4 
R (P-value) 
Screen per 
pharmacy
5 
 (P-value) 
Prevalence of chlamydia -0.11 (0.65) -0.1 (0.68) - 0.11 (0.64) 
Deprivation score (IMD) - 0.05 (0.83) - 0.23 (0.32) 0.23 (0.32) 
Pharmacy provision 
Pharmacy provision (%)
1 
0.14 (0.54) 0.11(0.63) - 0.59 (0.005) 
Weighted pharmacy provision
2 
0.24 (0.31) 0.20 (0.38) - 0.57 (0.007) 
1- Pharmacy provision: percentage of CPs in a PCT offering chlamydia screening. 
2- Weighted pharmacy provision: number of CPs offering chlamydia screening per 10 000 
15-24 year-olds 
3- Pharmacy reach: percentage of 15-24 year-olds screened through CPs. 
4- Pharmacy share: percentage of 15-24 year-olds screened through CPs out of all venues. 
5- Screen per pharmacy: average number of young people in a PCT screened per CP. 
 
3.5 Discussion 
3.5.1 Needs, provision and uptake of EHC 
Despite all the progress that has been made in reducing teenage pregnancy rates 
in England, following the Government plan which was set in 1999, rates of teenage 
pregnancies are still highly associated with deprivation at PCT level, which agrees 
with Conrad's findings (2012). In 1998, prior to the deregulation of EHC, women 
said that they did not use EHC because it was hard to get (Galsier and Baird, 
1998). However, the deregulation and hence the availability through CPs provided 
more rapid access when compared to sexual health clinics (Black et al., 2008; 
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Anderson and Blenkinsopp, 2006). The role of CPs in delivering EHC service is 
underutilised. Despite the fact that there is a higher concentration of CPs in PCTs 
with higher rates of teenage pregnancies, this was not translated into a higher 
number of CPs which were offering EHC service under PGDs (Section 3.4.1.2). 
This contradicts the action plan which was set by the Government in its white paper 
“pharmacy in England- building on strengths- delivering the future” to improve 
access to contraceptive services through CPs (DH, 2008a). As there was no 
increase in provision of EHC (as percentages), pharmacists in PCTs with higher 
rates of teenage pregnancies had to deal with higher number of teenagers when 
compared to PCTs with lower rates with R of 0.36 and P of 0.02 (Section 3.4.1.3d). 
Unfortunately, even this high uptake per CP of EHC in PCTs with higher needs did 
not reach a level to make the total uptake of EHC through all CPs in deprived PCTs 
significantly high. In other words, as the provision of EHC did not match the needs, 
whereas the overall uptake of EHC is correlated with the provision (R=0.51), this 
meant that the uptake is not correlated with needs despite the efforts of 
pharmacists. The effect of this uncorrelated needs and uptake is arguable, as many 
studies found that improving accessibility of EHC led to a higher uptake and earlier 
use (Black et al., 2008; Oza, 2009), but the direct link between uptake of EHC and 
public unintended pregnancy rates and abortion rates is still undefined (Glasier, 
2013; Gross et al., 2014) as unintended pregnancy rates is connected with different 
social, economic and cultural factors (Glasier, 2013).  
3.5.2 Needs, provision and uptake of chlamydia 
Chlamyida prevalence was not highly connected with deprivation as in case of 
smoking prevalence (Section 2.4.1.2) and teenage pregnancy rates (Section 
3.4.1.2). Consequently, the provision of chlamydia services should mainly match 
with needs (chlamydia prevalence) and partially with deprivation. Despite chlamydia 
services in general (through all providers) being able to reach more young people in 
PCTs with higher needs with rho of 0.3 and P of 0.001, this significant increase is 
still weak and need to be improved (Section 3.4.2.2). The role of CPs in delivering 
chlamydia services was still restricted, as the study did not identify a correlation 
between the needs and the provision of chlamydia services through CPs (Section 
3.4.2.2). Furthermore, the increase in provision of chlamyida services through CPs 
was not associated with higher uptake (Section 3.4.2.3d). This agreed somehow 
with previous studies which found that despite the service being feasible and 
accessible (Anderson and Thornley, 2011) and that a good percentage use CPs for 
picking up testing kits and giving a specimen, the number of tests that were 
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conducted through CPs were limited (Saunders et al., 2012) and CPs were among 
the last choice for performing the tests (Brugha et al., 2011). Targeting the clients 
who accessed EHC for chlamydia screening through CPs was an effective option to 
increasing the uptake of chlamydia services (Brabin et al., 2009; Gudka et al., 2013; 
Gudka et al., 2014). However, an improvement in CPs premises might improve the 
uptake, especially the toilets facilities that are necessary to provide the screening in 
CPs and hence guarantee that the kits provided will be used and the specimen will 
be given to be tested. Training of other members of the pharmacy team to provide 
the chlamydia services in addition to the pharmacist can free the pharmacist's time 
and increase the uptake (Duggan et al., 2013). 
 3.5.3 Cost-effectiveness of CP EHC service provision 
The findings from the cost-effectiveness analysis showed that the EHC service was 
cost-effective when compared to no intervention based on using median costs of 
intervention and mean of meta-analysis of effectiveness of EHC versus no 
intervention (Section 3.4.1.3e). Furthermore, the sensitivity analysis showed that 
the EHC service was still cost effective, even if the higher cost of intervention which 
was found through PCTs' responses was used (Section 3.4.1.3f). The service is still 
cost effective when the difference in probability in getting pregnant following 
unprotected sexual intercourse of EHC versus no intervention (2.6% versus 5.4% 
for no intervention; Glasier et al., 2010) was used (Section 3.4.1.3f).The 
incremental cost per QALYs gained could not been identified as unintended 
pregnancy is accompanied with life and life had a value of 1 and death has a value 
of 0 in terms of QALYs .Marciante and co-workers (2001) found that the ICER for 
obtaining EHC from pharmacies over other venues was $48 (£33) from public payer 
perspective and $158 (£109) from private payer perspective over a period of 9 
months. On the other hand, Trussell and co-workers (2009) found that the ICER of 
levenorgestrel intrauterine system is $930 when compared to no method. The study 
identified that the ICER per one prevented unintended pregnancy is £688.7 
(Section 3.4.1.3e).  
3.6 Limitation of the study 
The study had a low response rate (30%) in case of EHC service and (19%) in case 
of chlamydia service. The costs for providing EHC service were not identified for 
some PCTs. The needs for teenage pregnancies were identified based on rates of 
teenage pregnancies per 1000 female aged between 15-17 years old. The service 
is mainly aimed to target 16 years and younger females. As it was not possible to 
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obtain data regarding the 16 years and younger female, this suggests that results 
should be interpreted with caution.  
3.7 Conclusions 
The analysis through all targeted PCTs (139) in case of EHC service and (111) in 
case of chlamydia service, identified that there is a strong correlation between 
needs and deprivation in case of EHC service and a weak correlation in case of 
chlamydia service. The provision of each service through CPs did not match with 
the needs. However, The higher concentration of CPs in case of higher needs for 
EHC service might compensate this shortness. Chlamydia service uptake through 
all providers (including CPs which did not participate in more than 1.2% of total 
uptake) was able to meet the needs. An increase in CP EHC provision would result 
in higher uptake of the service. Contrary, the increase in CP chlamydia provision 
may not necessary result in an increase in uptake of the service. Finally, the CP 
EHC provision was cost-effective from the NHS perspective. 
3.8 Future of EHC 
Ulipristal the second pill which requires a prescription to be dispensed in case of 
unprotected sexual intercourse could be the future of EHC (NHS Choices, 2013). 
Ulipristal is more effective than levonorgestrel (EHC), with 1.8% as failure 
probability for ulipristal versus 2.6% for levonorgestrel (Galsier et al., 2010). 
Thomas and co-workers (2010a) found that using ulipristal rather than 
levenorgestrel within 120 hours following unprotected intercourse would save the 
NHS £311 in terms of preventing one intended pregnancy.  Bayer and co-workers 
(2013) found that using ulipristal versus levonorgestrel could save $116.3 million 
annually in USA from a societal perspective.  
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Chapter Four: Vascular and sexual health pharmacy services and 
Healthy Living Pharmacies (HLPs) 
4.1 Introduction  
The role of CPs as centres to promote healthy living was emphasised during the 
introduction of the new NHS in 2000 and through two published white paper 
documents (DH, 2000a; DH, 2003a). In April 2008, the DH in England published its 
document “Putting prevention first- Vascular checks: risk assessment and 
management” (DH, 2008b). The document provided a plan for a vascular risk 
assessment programme for people aged between 40 and 74 years old. Few days 
after this publication the DH published its white paper “Pharmacy in England- 
building on strengths, delivering the future” (DH, 2008a). The white paper 
implemented how pharmacist should participate in delivering vascular risk 
assessment programme (called as NHS health check) alongside other services that 
promote healthy living such as SSS, EHC and chalmydia services (DH, 2008a). 
There was good evidence to support the effectiveness of commissioning those 
services through CPs, especially the case of SSS and NHS health check (defined in 
Section 1.5.2) (Brown et al., 2012). Eades and co-workers (2011) found in their 
review that pharmacists considered public health services as important and part of 
their role, in addition to their roles in medicines management. The barriers identified 
in their review included lack of time, lack of counselling room, low demand and lack 
of training. However, in England most CPs has a consultation room to conduct a 
private consultation with the patient (Merks et al., 2014). With regards to training, 
pharmacists had to take special training to provide vascular and sexual health 
pharmacy services (Noyce, 2007). Pharmacists seemed to be able to provide 
health services that are comparable to that provided by doctors in terms of health 
care (Tinelli et al., 2013). In 2009, Portsmouth City PCT developed a model to turn 
a pharmacy into a healthy living centre. In this model, pharmacist should promote 
health and wellbeing by consistent delivering of pharmacy services. The services 
include delivering targeted respiratory medicines use reviews and delivering 
enhanced services including at least one of EHC, chlamydia screening, alcohol 
service and weight management in addition to SSS. The DH supported this model 
and commissioned Portsmouth City PCT (on behalf of South Central SHA) to 
develop a national framework for HLPs, based on Portsmouth model (Duggan et 
al., 2013). The HLP framework is a tiered framework aimed to deliver health 
services that meet local needs, promote the health and wellbeing of local population 
and help reduce health inequalities, through achievement of consistent delivery of 
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those services (Duggan et al., 2013). An HLP requires special development in 
terms of the workforce team, premises and relationship with the local community 
and other health care professionals (especially GPs). In case of the workforce 
team, the pharmacy should have a HLC (a special trained person in the pharmacy 
team, not a pharmacist, who shows an interest in the HLP scheme and is ready to 
be the main contact point to deliver HLP services, answer clients' enquiries and be 
a role model for other staff. The premises should have facilities that are appropriate 
to provide the HLP services. The HLP should achieve and maintain high quality 
delivery of HLP services (Duggan et al., 2013). Findings from the Portsmouth case 
showed a significant increase in the uptake of vascular and sexual health services 
in HLPs; especially SSS and respiratory medicine review, while the uptake of EHC 
was comparable (Brown et al., 2014). The HLP scheme was expanded to 30 PCTs 
(known as HLP pathfinders).The results of HLP pathfinders, showed an increase in 
the number of smokers who set a quit date in 7 PCTs out of 9, an increase in 
number of smokers who quit smoking in 7 PCTs out of 9 and an increase in quit 
rates in 4 PCTs out of 9. In case of EHC, 3 PCTs out of 6 showed an increase in 
the number of consultations (Duggan et al., 2013). Pharmacists were the focal 
points in delivering EHC and chlamydia, while the pharmacy team other than 
pharmacist were the focal points in more than half of SSS provision in an HLP 
(Duggan et al., 2013). Lack of time was a major barrier in regards to provision of 
SSS (Kissiwaa et al., 2012; Thomas et al., 2013).This suggests that if the pharmacy 
team participated in delivering SSS, the uptake of SSS might increase (Duggan et 
al., 2013). 
4.2 Aims and objectives 
The aim of this Chapter is to assess the provision and uptake of vascular and 
sexual health pharmacy services through CPs on CP level and how this changed 
following the introduction of HLP scheme. It also aimed to delineate the perception 
of pharmacists regarding the commissioning and provision of these services.  
The aim is translated into the following objectives: 
A. To identify the type of vascular and sexual health pharmacy services that 
are being provided. 
B. To determine the current level of provision of each service from current 
providers and the future willingness from non-providers. 
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C. To consider the perception of pharmacists with regards to the importance of 
vascular and sexual health pharmacy services, pharmacists’ motivation to 
provide such services and the barriers to provision. 
D. To determine, based on pharmacists' opinion, whether the introduction of 
the HLP scheme altered public awareness/perception, and hence the 
uptake of services.   
E. To assess the pharmacist perceptions regarding reasons for relapse in quit 
smoking and how to reduce rates of relapse. 
4.3 Method 
4.3.1 Questionnaire development 
A questionnaire for pharmacists was developed utilising some of the questions 
asked by PCTs in their PNA reports (Wolverhampton city, Milton Keynes, and 
Barking and Dagenham PCTs) (Appendix 4). The final version (Appendix 5) was 10 
pages long and consisted of 20 closed questions distributed into five sections, and 
two open questions. All questions were directed to community pharmacists to 
gauge their perceptions and obtain quantitative data regarding services. Section 
one had four questions on the provision, importance, motivation for provision and 
uptake of vascular and sexual health services. Section two had two questions to 
identify barriers related to the provision of enhanced services. Section three had six 
questions on the current implementation of HLPs and the effect that HLPs have had 
on the awareness and uptake of enhanced services. Section four had four 
questions about public awareness of pharmacy services and how to improve 
success of SSS through CPs. Section five had four questions on general 
information about the pharmacist and the pharmacy. 
At the end of section four there was an open ended question for any comment or 
extra information the pharmacist wanted to add. 
 4.3.2 Ethical approval 
The research was conducted in accordance with Kingston University ethical policy 
(as it involved approaching pharmacists). An ethical approval (RE4) form (Appendix 
5) was filled out prior to commencing the research. This was reviewed and 
approved by the Ethics Committee of the Science, Engineering and Computing 
Faculty at Kingston University.  
The project information was made available through the covering letter which was 
attached to the questionnaire (a copy of this letter is available in Appendix 5). 
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Anonymity of respondents was guaranteed by the research student at all stages of 
the research.  
4.3.3 Pilot study and questionnaire validation 
The questionnaire was designed based on PNA reports. The questionnaire was 
then reviewed by the supervisory team. Then, the questionnaire was given to 5 
community pharmacists in Kingston to ascertain its content and face validity. 
Pharmacists were asked to test the physical appearance of the questions, the flow 
of the questionnaire, any difficulty in understanding or answering the questionnaire 
and the time needed to fill in the questionnaire. The responses from the 
pharmacists showed an overall satisfaction with all aspects of the questionnaires. 
Hence, a pilot study was conducted to validate the questionnaire. 
4.3.3.1 Pilot sample 
At the time the research was conducted (2011/2012), there were 11 236 CPs within 
England (HSCIC, 2012a). The pilot sample size suggested by previous researchers 
ranged between 24 and 50 CPs (Lancaster et al., 2004; Hertzog, 2008). Five PCTs 
were chosen for the pilot (Kingston, Sutton and Merton, Wandsworth, Richmond 
and Lambeth). Two factors influenced the choice of those PCTs; the first four were 
chosen based on their location (South West London) where the researcher can 
hand the questionnaire. Lambeth PCT was chosen because it was one of the 30 
HLP pathfinders (Duggan et al., 2013). The number of CPs in the four PCTs was 
identified through their PNA reports and the sample size was calculated with 95% 
confidence level and 5 as interval level using an electronic sample size calculator 
(http://www.surveysystem.com/sscalc.htm). As a result, 188 CPs was chosen to be 
surveyed from the four PCTs (28, 65, 54, 41) in Kingston, Sutton and Merton, 
Wandsworth and Richmond, respectively. In case of Lambeth PCT, the full details 
of the 21 HLPs in the PCT were provided by Lambeth PCT. Hence, the final pilot 
sample was 188+21= 209.  
4.3.3.2 Questionnaire distribution 
The questionnaire was handed to CPs in Kingston and Richmond PCTs and was 
posted to the CPs in the other 3 PCTs in February 2013 along with a stamped, 
addressed envelope. A code for each pharmacy was written inside the envelope to 
identify non-respondents. 
4.3.3.3 Pilot results 
Out of 209 CPs surveyed 52 responded (25%). The responses showed overall 
satisfaction with the questionnaire in terms of ease to answer the questions. In 
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order to test the reliability of the questionnaire, the internal consistency of the Likert 
scale (a scale used to measure the level of agreement with 6 points, from strongly 
disagree (point 1) to strongly agree (point 6) was tested, as it was recommended by 
Gliem and Gliem (2003). The Likert scale of 6 items that measured pharmacists' 
perceptions towards the current and future of enhanced pharmacy service upon 
introduction of HLP scheme had a Chronbach’s alpha value (α) of 0.77 for internal 
consistency, which is higher than the 0.7 as the value suggested by Nunnaly for an 
acceptable reliability of questionnaire (Santos, 1999). Consequently, the version 
used for the pilot survey was used for the main survey. 
4.3.4 Main sample 
The main sample was n=1 249 CPs (including the 209 CPs in pilot study). The 
sample was distributed between 28 PCTs across England from North to South and 
from East to West (Table 4.1 and Figure 4.1). The main sample size was calculated 
based on the total number of CPs within each PCT, then calculating the sample 
size based on 95% confidence level and 5% confidence interval using an electronic 
sample size calculator (http://www.surveysystem.com/sscalc.htm).The criteria for 
choosing those PCTs were based initially on the PNA reports, where provision of 
vascular and sexual health pharmacy services was identified. PCTs with higher CP 
provision (%) of vascular and sexual health services and PCTs with lower CP 
provision of those services were chosen to be surveyed (Table 4.1). For instance, 
Stockport and Bedfordshire PCTs had a low level of provision of vascular and 
sexual health services, while Knowsley, Isle of Wight and Wandsworth PCTs had a 
high level of provision (Table 4.1). Seven of the chosen PCTs (Blackburn with 
Darwen, Brighton and Hove City, Dudley, Hastings and Rother, Isle of Wight, 
Lambeth and Portsmouth) were HLP pathfinder PCTs. Furthermore, the feasibility 
of those PCTs to represent the rest of PCTs in England was tested in terms of 
demographic characteristics, needs for vascular and sexual health services and 
pharmacy provision (Section 4.3.4.1).  
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Table 4.1 Chosen PCTs to be surveyed based on average provision of 
services 
PCT Location Average provision of 
services
3 
Knowsley North West 78.43 
Isle of Wight
*
 South Central 71.11 
Greenwich Teaching London 69.14 
Southwark London 67.21 
Portsmouth City
* 
South Central 66.67 
Wandsworth London 66.67 
Croydon London 65.28 
Richmond & Twickenham London 63.04 
Lambeth
* 
London 60.10 
Blackburn with Darwen
* 
North West 59.69 
Middlesbrough North East 55.95 
Haringey Teaching London 51.46 
Dudley
* 
West Midlands 48.99 
Warwickshire West Midlands 48.98 
Medway SEC
1 
48.00 
Sutton and Merton London 45.30 
Doncaster Y&H
2 
43.98 
Kingston London 37.78 
North Somerset South West 37.50 
Brighton and Hove City
* 
SEC
1 
37.29 
Bexley London 35.56 
Blackpool North West 33.33 
Hastings and Rother
* 
South East 32.43 
Bristol South West 32.20 
Lewisham London 28.4 
Leeds Y&H
2 
25.05 
Bedfordshire East England 18.41 
Stockport North West 8.33 
1- SEC: stands for South East Coast. 
2- Y&H: stands for Yorkshire and the Humber. 
3- Average provision of services is the mean of percentages of CPs in each PCT which 
offered SSS, EHC and chlamydia screening service in 2009/2010. 
* HLP finder PCTs. 
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Figure 4.1 Map of surveyed PCTs
 
 
4.3.4.1 Sample selection 
Normality distribution of each category (i.e. demographic characteristics, needs and 
provision) was initially tested using Shapiro-Wilk test. To investigate the difference 
between the chosen PCTs to be surveyed and the rest of PCTs in England, T-test 
of two independent sample was applied in case of normal distribution and Mann-
Whitney test was applied in case of non-normality distribution for any of the above 
mentioned categories (i.e. demographic characteristics, needs, ..., etc).  A 95% 
value was applied as confidence level. T-test was applied in all cases apart from 
case of BME%, where Mann-Winey test was applied (Table 4.2). The P-value in all 
cases apart from chlamydia screening provision through CPs was higher than 0.05, 
which meant that there was no significance difference between the sample and the 
rest of PCTs in terms of demographic characteristics, needs and pharmacy 
provision of vascular and sexual health pharmacy services. As a result, the sample 
of chosen PCTs to be surveyed was considered as a representative of the rest of 
PCTs in England.  
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Table 4.2: Tests between the main sample and the rest of PCTs 
Variable Sample 
Mean/Median 
Rest of PCTs 
Mean/Median 
P-value 
Demographic characteristic 
Deprivation score  24.92 22.92 0.26 
Male (%) 
52.26 52.53 0.1 
BME (%)
1 
11
 
12.58 0.21 
Needs for services 
Prevalence of smoking adults 23.31 22.85 0.65 
Teenage pregnancy rates 
47.31 43.23 0.12 
Chlamydia prevalence (%) 
6.55 6.91 0.84 
Pharmacy provision factors 
SSS provision (%) 55.18 59.39 0.39 
EHC provision (%) 
49.91 50.70 0.86 
Chlamydia screening provision (%) 
43.55 30.81 
0.04 
1- BME (%): percentages of Asian, Black, Chinese or other ethnicities out of total ethnicities. 
2- Significant difference was shown in bold. 
4.3.4.2 Questionnaire distribution 
The questionnaires were posted to the randomly chosen CPs in May 2013 along 
with a covering letter (Appendix 5) and a stamped, self-addressed envelope. 
Respondents were given a period of three weeks to respond to the questionnaire. 
Envelopes had the codes to identify which pharmacies had responded. Non-
respondents were contacted by telephone follow up in June 2013, to investigate 
their interest in filling out the questionnaire in order to send them another copy of 
the questionnaire.  
4.3.5 Data analysis 
Data from the respondents were coded and carefully entered into SPSS® version 
17 for data analysis, including descriptive analysis of the sample distribution. The 
socioeconomic status of a pharmacy's user was predicted from the postcode. 
Townsend Deprivation Index (TDI) was used in this research, where the 34 753 
LSOAs (identified in Section 2.3.1.2) in England were divided into five equal groups; 
group 1 includes 20% of most deprived LSOAs in England and group 5 includes 
20% of least deprived LSOAs in England. CPs were allocated to the appropriate 
group based on the postcode. Differences in provision and willingness to provide 
services were tested using Chi-squared test (as the answers to those questions 
were yes or no). Differences in the uptake of each service were tested using Mann-
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Whiney test in case of two categories only such as case of gender (male, female) 
and case of HLP status (HLP or non-HLP) and were tested using Kruskal-Wallis 
test in case of more than two categories (deprivation status, years of experience 
and type of CP) .  
4.4 Results 
4.4.1 Response rate and sample demographics 
The response rate was 19.3% (241 pharmacists responded out of the 1 249 who 
were surveyed). The majority of responses came from CPs of PCTs with higher 
level of provision of SSS, EHC and chlamydia screening services. Of the 241 
pharmacists who responded 118 were females (49%) and 117 were males (48%) 
and 6 were unknown (blank answers) (3%). A further investigation into the role of 
pharmacists who responded to the survey showed that the highest respondents 
were managers (97/241), followed by employee pharmacists (61/241) and owners 
(58/241). Few respondents were locum pharmacists (18/241) and 7 respondents 
chose not to declare their role (Figure 4.2).  
Figure 4.2: Roles of CPs who responded to the survey 
 
The highest percentage of respondent pharmacists 38% (92/241) had more than 10 
years’ experience and only 5% (13/241) had an experience of less than one year 
(Figure 4.3). The remaining respondents had the following experience; 1-2 years 
(15%) 35/241, 3-4 years (8%) 20/241, 5-6 years (11%) 26/241, 7-8 years (9%) 
22/241 and (5%) 11/241 chose not to declare their experience. This shows that the 
answers of the questionnaire are coming mainly from experienced pharmacists. 
25% 
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Figure 4.3: Experience of CPs who responded to the survey
 
The highest percentage of respondent pharmacists came from small chain (40%) 
97/241, followed by large chain (30%) 73/241, independent pharmacy (19%) 46/241 
and multiple (10%) 24/241 (Figure 4.4).  
Figure 4.4: Type of CPs which responses came from 
 
4.4.2 Enhanced services 
4.4.2.1 Provision of enhanced services 
The EHC service was the most common service provided among the respondent 
pharmacists, where 189 (78%) were current providers, followed by SSS where 178 
(75%) were current providers, then chlamydia screening service which was 
provided by 109 (48%) and NHS health check which was provided by 77 (33%) 
(Figure 4.5). Non-providers were very enthusiastic towards future provision of 
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services, as 103 (45%) of pharmacists were willing to provide chlamydia services 
and only 17 (8%) were unwilling. The willingness to provide NHS health check was 
11 fold higher than unwillingness, as 145 (60%) were willing and only 13 (5%) were 
unwilling. The percentage of respondent pharmacists who were willing to provide 
EHC and SSS was higher than those who were unwilling to provide, where 38 
(16%) expressed their willingness to provide and 14(6%) expressed their 
unwillingness to provide EHC. Furthermore, 53 (22%) expressed their willingness to 
provide SSS and 8 (3%) expressed their unwillingness to provide SSS (Figure 4.5).   
Figure 4.5 Current and future provisional status of enhanced services 
 
4.4.2.2 Factors associated with provisional status of enhanced services  
In case of chlamydia service, there was no significant difference in terms of 
provision, willingness to provide or unwillingness to provide between male and 
female respondent pharmacists (Table 4.3). Furthermore, there was no significant 
difference in provision, willingness to provide or unwillingness between respondent 
pharmacists in case of years of experience or in case of type of CP (Table 4.3). 
Chlamydia prevalence was weakly correlated with deprivation (Section 3.4.2.2). 
This was not translated into any significant difference in terms of provision or 
willingness to provide chlamydia service between pharmacists with different 
deprivation neighbourhood (Table 4.3). In case of EHC provision, willingness and 
unwillingness to provide were not significantly different between male and female 
respondent pharmacists (Table 4.4). Moreover, no significant difference was 
identified in terms of EHC provision status between respondents with different 
experience and from different types of CPs. A significant difference (P= 0.04) was 
seen in terms of EHC service provision with percentage of provision of 87% 
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amongst the respondent CPs who belonged to the most deprived LSOAs, 81.3%, 
82.6% and 70.6% for CPs of the next group 2, 3 and 4 of deprivation 
neighbourhood compared to only 44.4% of the respondents with lowest deprivation 
neighbourhood (Table 4.4). An exclusion of the least deprived group resulted in no 
difference (P= 0.48) between the first four groups based on deprivation, hence the 
provision was lower only in CPs in the least deprived areas when compared to any 
of the other four group areas. 
Table 4.3: Comparison between respondents’ characteristics and provision 
status of chlamydia 
Characteristics Chlamydia current 
provider 
Number (%) 
P-value 
Chlamydia 
willing to 
provide 
Number (%) 
P-value 
Chlamydia 
unwilling 
to provide 
Number 
(%) 
P-value 
Gender 
Female (70) 36 (51.4%) 27(38.6%) 3 (4.3%) 
Male (83) 35 (42.2%) 35 (42.7)% 9 (10.8%) 
P-value 0.25 0.61 0.13 
Years of experience 
Less than 1 year (20) 9 (45%) 7 (35%) 2 (10%) 
1-2 years (15) 4 (26.7%) 7 (46.7%) 3 (20%) 
3-4 years (12) 6 (50%) 4 (33.3%) 1 (8.3%) 
5-6 years (6) 2 (33.3%) 4 (66.7%) 0 (0%) 
7-8 years (4) 1 (25%) 2 (50%) 0 (0%) 
9-10 years (7) 2 (28.6%) 5 (71.4%) 0 (0%) 
> 10 years (82) 47 (57.3%) 25 (30.9%) 7 (8.5%) 
P-value 0.23 0.23 0.68 
Type of pharmacy 
Independent (59) 29 (49.2%) 20 (34.5%) 8 (13.6%) 
Small chain (17) 12 (70.6%) 4 (23.5%) 0 (0%) 
Large chain (13) 9 (39.1%) 10 (43.5%) 2 (8.7%) 
Multiple (48) 20 (41.7%) 22 (45.8%) 2 (4.2%) 
P-value 0.17 0.34 0.18 
Deprivation of pharmacy location 
First 20% (most deprived) (54) 23 (42.6%) 22 (40.7%) 5 (9.3%) 
Next 20% (48) 26 (54.2%) 16 (33.3%) 3 (6.3%) 
Next 20% (23) 9 (39.1%) 12 (52.2%) 0 (0%) 
Next 20% (17) 11 (64.7%) 6 (35.3%) 1 (5.9%) 
Last 20% (least deprived) (9) 3 (33.3%) 5 (55.6%) 1 (11.1%) 
P-value 0.31 0.5 0.63 
Chi-squared test applied 
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Table 4.4: Comparison between respondents’ characteristics and provision 
status of EHC 
Characteristics 
 
  
EHC current 
provider 
Number (%) 
P-value 
EHC willing to 
provide 
Number (%) 
P-value 
EHC 
unwilling to 
provide 
Number 
(%) 
P-value 
Gender  
Female (70) 55 (78.6%) 10 (14.3%) 3 (4.3%) 
Male (83) 65 (78.3%) 17 (20.5)% 3 (3.6%) 
P-value 0.97 0.32 0.83 
Years of experience 
Less than 1 year (20) 18 (90%) 2 (10%) 0 (0%) 
1-2 years (15) 8 (53.3%) 4 (26.7%) 2 (13.3%) 
3-4 years (12) 9 (75%) 2 (16.7%) 0 (0%) 
5-6 years (6) 5 (83.3%) 1(16.7%) 0 (0%) 
7-8 years (4) 4 (100%) 0 (0%) 0 (0%) 
9-10 years (7) 6 (85.7%) 1 (14.3%) 0 (0%) 
> 10 years (82) 64 (78%) 17 (20.7%) 3 (3.7%) 
P-value 0.2 0.82 0.4 
Type of CPs 
Independent (59) 48 (81.4%) 27 (18.4%) 1 (1.7%) 
Small chain (17) 13 (76.5%) 2 (11.8%) 2 (11.8%) 
Large chain (13) 17 (73.9%) 6 (26.1%) 1 (4.3%) 
Multiple (48) 38 (79.2%) 8 (16.7%) 0 (0%) 
P-value 0.89 0.68 0.07 
Deprivation of pharmacy location 
First 20% (most deprived) (54) 47 (87%) 7 (13%) 0 (0%) 
Next 20% (48) 39 (81.3%) 8 (16.7%) 1 (2.1%) 
Next 20% (23) 19 (82.6%) 4 (17.4%) 0 (0%) 
Next 20% (17) 12 (70.6%) 3 (17.6%) 2 (11.8%) 
Last 20% (least deprived) (9) 4 (44.4%) 3 (33.3%) 2 (22.2%) 
P-value 0.04 0.7 0.002 
-Chi-squared test applied 
- Significant differences are shown in bold. 
In case of SSS, no significant difference was identified in terms of provision status 
between male and female pharmacists, between pharmacists with different 
experience or between pharmacists from different type of CPs (Table 4.5). On a 
PCT level, there was a significant correlation between deprivation and provision of 
SSS per 25 000 population, however this was due to higher concentration of CPs in 
more deprived PCTs (Section 2.4.1.3). This was not evident on CP level, as there 
was no significant difference in terms of SSS provision between areas with different 
deprivation status (Table 4.5). In case of NHS health check service, the service was 
more provided by male pharmacists than by female with P of 0.02 (Table 4.6). The 
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NHS health check was significantly provided more by respondents from small chain 
pharmacy than by respondents from other types of pharmacy with P of 0.046 (Table 
4.6). No significant difference was identified in terms of NHS health check current 
provision, willingness to provide or unwillingness to provide between pharmacists 
with different years of experience. 
Table 4.5: Comparison between respondents’ characteristics and provision 
status of SSS 
Characteristics SSS current 
provider 
Number (%) 
P-value 
SSS willing to 
provide 
Number (%) 
P-value 
SSS 
unwilling to 
provide 
Number (%) 
P-value 
Gender  
Female (70) 50 (71.4%) 14 (20%) 3 (4.3%) 
Male (83) 57(68.7%) 23 (27.7)% 3 (3.6%) 
P-value 0.71 0.27 0.83 
Years of experience 
Less than 1 year (20) 15 (75%) 3 (15%) 2 (10%) 
1-2 years (15) 12 (80%) 2 (13.3%) 0(0%) 
3-4 years (12) 5 (41.7%) 5 (41.7%) 1 (8.3%) 
5-6 years (6) 2 (33.3%) 4 (66.7%) 0 (0%) 
7-8 years (4) 3 (75%) 0 (0%) 0 (0%) 
9-10 years (7) 4 (57.1%) 3 (42.9%) 0 (0%) 
> 10 years (82) 60 (73.2%) 19 (23.2%) 3 (3.7%) 
P-value 0.12 0.56 0.72 
Type of CPs 
Independent (59) 46 (78%) 10 (16.9%) 3 (5.1%) 
Small chain (17) 11 (64.7%) 5 (29.4%) 1 (5.9%) 
Large chain (13) 15 (65.2%) 6 (26.1%) 1 (2.1%) 
Multiple (48) 29 (60.4%) 16 (33.3%) 1 (5.1%) 
P-value 0.25 0.26 0.85 
Deprivation of pharmacy location 
First 20% (most deprived) (54) 40 (74.1%) 10 (18.5%) 1 (1.9%) 
Next 20% (48) 35 (72.9%) 10 (20.8%) 3 (6.3%) 
Next 20% (23) 13 (56.5%) 9 (39.1%) 1 (4.3%) 
Next 20% (17) 13 (76.5%) 3 (17.6%) 1 (5.9%) 
Last 20% (least deprived) (9) 6 (66.7%) 3 (33.3%) 0 (0%) 
P-value 0.6 0.3 0.77 
- Chi-squared test applied. 
- Significant differences are shown in bold. 
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Table 4.6: Comparison between respondents’ characteristics and provision 
status of NHS health check 
Characteristics NHS health 
check current 
provider  
Number (%)  
 P-value 
NHS health 
check willing 
to provide  
Number (%)  
 P-value 
NHS health 
check 
unwilling to 
provide  
Number (%)  
 P-value 
Gender  
Female (70) 12 (17.1%) 50 (71.4%) 3 (4.3%) 
Male (83) 28 (33.7%) 47 (56.6)% 5 (6%) 
P-value 0.02 0.06 0.63 
Years of experience 
Less than 1 year (20) 6 (30%) 12(60%) 3 (15%) 
1-2 years (15) 4 (26.7%) 9 (60%) 1(6.7%) 
3-4 years (12) 4 (33.3%) 7 (58.3%) 1 (8.3%) 
5-6 years (6) 0 (0%) 6 (100%) 0 (0%) 
7-8 years (4) 0 (0%) 3 (75%) 0 (0%) 
9-10 years (7) 2(28.6%) 5 (71.4%) 0 (0%) 
> 10 years (82) 22 (26.8%) 52 (63.4%) 9 (6.2%) 
P-value 0.67 0.65 0.66 
Type of CP 
Independent (59) 15 (25.4%) 40 (67.8%) 2 (3.4%) 
Small chain (17) 9 (52.9%) 7 (41.2%) 3 (17.6%) 
Large chain (13) 5 (21.7%) 14 (60.9%) 1 (4.3%) 
Multiple (48) 9 (18.8%) 34 (70.8%) 3 (6.3%) 
P-value 0.046 0.15 0.19 
Deprivation of pharmacies locality 
First 20% (most deprived) (54) 15 (27.8%) 31 (57.4%) 1 (5.6%) 
Next 20% (48) 13 (27.1%) 36 (75%) 2 (4.2%) 
Next 20% (23) 6 (26.1%) 15 (65.2%) 1 (4.3%) 
Next 20% (17) 4 (23.5%) 11 (64.7%) 2 (11.8%) 
Last 20% (least deprived) (9) 5 (55.6%) 3 (33.3%) 0 (0%) 
P-value 0.47 0.13 0.72 
- Chi-squared test applied. 
- Significant differences are shown in bold. 
4.4.2.3 Uptake of enhanced services 
4.4.2.3a Sexual health services uptake  
Figures 4.6 and 4.7 show the distribution of uptake of sexual health services 
through CPs which were providing the service. The median uptake of chlamydia 
service was 1 per month with a range from 0 to 40, the lower quartile = 0 and the 
upper quartile = 3 with two outliers (one at 18 and one at 40). Both of the outliers 
belonged to PCTs with moderate needs for chlamydia screening services. One of 
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the outlier (at 18) was an HLP. The median uptake of EHC equalled to 4 times per 
month prior to the survey (Figure 4.7) with a range from 0 to 60 with the lower 
quartile being 1 and the upper quartile being 10. Four outliers were identified at (40, 
42, 56 and 60 times per month). Three out of the outliers came from female 
pharmacists (40, 42, and 60) and one was missing data (60). Only one of the 
outliers was an HLP (42) (Figure 4.7). Furthermore, the two outliers (56 and 60) 
came from one PCT (Wandsworth), where the teenage pregnancy rate was 56.6, 
while the median teenage pregnancy rate was 48.5 (Section 3.4.1.1). 
Figure 4.6: Number of clients who accessed chlamydia service in month prior 
to survey 
 
Figure 4.7: Number of clients who accessed the EHC service in month prior to 
survey 
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4.4.2.3b vascular health services uptake 
A median number of  4 people set a quit date in the month prior to the survey, with 
a range from 0 to 50 (Figure 4.8). Twenty nine CPs dealt with number of smokers 
smaller than the lower quartile (2) and twenty CPs dealt with number of smokers 
higher than the upper quartile (10) (Figures 4.8).Ten CPs showed uptake of 20 or 
more times per month; 6 CPs at 20, one at 24, two at 40 and one at 50. The last 
three 40, 40 and 50 were outliers. The three outliers came from three PCTs (Bristol, 
Knowsley and Blackburn) with prevalence of smoking adults of 25.64%, 27.87% 
and 30.1% respectively and the median prevalence of smoking adults was 30.4% 
(Section 2.4.1.1). Half of the ten CPs (4 at 20 and one at 50) were HLPs. The 
median uptake of NHS health check service was 2 clients per month, with a range 
from 0 to 40 (Figure 4.9). Twelve CPs dealt with number of clients higher than the 
upper quartile (5 per month) (Figure 4.9). One outlier was identified (at 40 per 
month) and it was an HLP. 
Figure 4.8: Number of clients who set a quit date through CPs in month prior 
to survey 
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Figure 4.9: NHS of clients who accessed the health check in month prior to 
survey 
 
4.4.2.3c Comparison between uptake of services 
Both  EHC and SSS service had the highest median at 4 clients per month prior to 
the survey, followed by NHS health check at 2 and chlamydia service at 1 (Figure 
4.10). CPs were able to reach 22 clients per month in case of EHC compared to 20 
clients per month in case of SSS (Figure 4.10).  
Figure 4.10: Comparison between uptakes of services in month prior to 
survey 
 
4.4.2.3d Factors associated with differences in uptake of services 
When the uptake of services was compared between HLPs (18%) and non-HLPs, 
the only significant difference was in case of SSS, with a median uptake of 4 in non-
HLPs and 6 in HLPs (P of 0.02) (Table 4.7). No significant differences were 
identified in terms of uptake of any of the four services between male and female 
respondent pharmacists (Table 4.7). The level of experience of the respondents did 
not affect significantly the rate of uptake (Table 4.7). A lower uptake in case of 
chlamydia service was seen in case of small chains when compared to the other 
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types of CPs with P of 0.005 (Table 4.7). Whilst the aim of these services is to 
bridge gaps in health inequalities, deprivation did not impact the uptake of any of 
the four services (Table 4.7). For the EHC service this is probably because more 
CPs were offering an EHC service in more deprived areas (Section 4.4.2.2). 
However, for the other services we hypothesise a greater concentration of CPs in 
areas of greater deprivation sharing the workload (Section 2.4.1.3). 
Table 4.7: Comparison between uptake of enhanced services in terms of 
differences in responded pharmacists and pharmacy 
Characteristic Chlamydia 
uptake 
(median) 
EHC 
uptake 
(median) 
SSS 
uptake 
(median) 
NHS health 
check uptake 
(median) 
HLP status 
HLP 2 3 6 2 
Non-HLP 1 5 4 2 
P-value 0.96 0.68 0.02 0.38 
Gender     
Female (70) 2 5 4 3 
Male (83) 1 3 5 2 
P-value 0.49 0.29 0.79 0.37 
Years of experience 
Less than 1 year (20) 2 8 4 0 
1-2 years (15) 3 4 4 2 
3-4 years (12) 1 6 5 8 
5-6 years (6) 4 2 4 NA 
7-8 years (4) 4 3 1 NA 
9-10 years (7) 3 2 2 4 
> 10 years (82) 1 3 5 3 
P-value 0.27 0.31 0.67 0.31 
Type of CPs 
Independent (59) 2 3 4 2 
Small chain (17) 0 2 5 0 
Large chain (13) 2 4 3 4 
Multiple (48) 2 5 6 3 
P-value 0.005 0.44 0.06 0.31 
Deprivation of pharmacy's location 
First 20% (most deprived) (54) 1 3 6 2 
Next 20% (48) 2 5 4 1 
Next 20% (23) 1 5 6 3 
Next 20% (17) 1 2 3 8 
Last 20% (least deprived) (9) 0 3 3 2 
P-value
 
0.95 0.74 0.26 0.57 
1- Mann-Whitney test was used in case of gender and HLP status 
2- Kruskal-Wallis test was used in all other case. 
3- Significant differences are shown in bold. 
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4.4.2.4 Importance of enhanced services based on pharmacists' perceptions 
When 210 pharmacist were asked to rank the services in order of importance, only   
13 (6%) considered chlamydia screening to be the most important, 33 (16%) chose 
the NHS health check, 72 (34%) chose SSS, and EHC was considered to be the 
most important by almost half 92 (44%) (Figure 4.11). 
 
Figure 4.11: Percentage of pharmacists who considered each service as the 
most important 
 
 
4.4.2.5 Motivational drivers and barriers towards provision of enhanced 
services 
While pharmacists felt that they could improve their role in health promotion for their 
local clients, they felt that competition with other health care professionals was a 
barrier to taking up new roles (Figures 4.12 and 4.13). Pharmacists felt that the 
provision of enhanced services helped to meet the needs of their local population; 
however lack of time and a lack of public awareness were major barriers (Figures 
4.12 and 4.13). 
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Figure 4.12: Motivational drivers to provide enhanced services 
 
 
Figure 4.13: Barriers to provide enhanced services 
 
 
4.4.2.6 Other services provided by pharmacies 
In addition to the four services, pharmacists reported provision of other services. 
The most common service was medicine use review service with 214 (89%), 
followed by blood pressure monitoring with 145 (60%) (Figure 4.14). The alcohol 
screening service provision was very low with only 36 (15%) respondents providing 
it. This is expected as the alcohol screening service had only been recently 
introduced.  
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Figure 4.14: Percentage of CPs who provide services  
 
 
4.4.3 Healthy living pharmacies 
Only 18.5% (31/168) of respondent CPs worked at an HLP compared to 81.5% 
(137/168) worked at premises that were not HLPs. However, 4.4% (6/137) of non-
HLPs were in the process of becoming HLPs and 23.4% (32/137) were willing to 
provide HLP scheme in the future. The two main barriers among non-HLPs were 
limited training for the staff to provide the service and inadequate facilities and 
resources (Figure 4.15). The main two drivers for current HLPs or those in the 
process to become HLPs were to play a more active role in health promotion and to 
meet the local needs of the population (Figure 4.16). 
Figure 4.15: Barriers to becoming a HLP 
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Figure 4.16: Drivers to become HLPs 
 
 
4.4.3.1 Changes in enhanced services following the introduction of the HLP 
scheme 
Respondent pharmacists who were current HLPs were asked how the services 
changed following the introduction of the HLP scheme in terms of public awareness 
and uptake. Half of them answered that public awareness increased in case of 
SSS, followed by 34% in case of EHC, 25% in case of chlamydia service and 18% 
in case of NHS health check (Figure 4.17 a-d). The improvement in public 
awareness has been reflected on the uptake of services. Five HLPs reported an 
increase in uptake of chlamydia service, two had no uptake at all prior to being 
HLP, one reported an increase of 2.5 fold, one at 2.7 and one at 3.7. Four HLPs out 
of thirty one reported an increase in uptake of EHC service of 1.3, 1.5, 1.7 and 2.5 
fold of the uptake prior to being HLPs. Seven HLPs out of thirty one reported an 
increase in uptake of SSS, two out of them had no uptake at all prior to becoming 
HLPs, two reported an increase of 1.3 fold, one at 1.7 and two at 2.5. Three HLPs 
reported an increase in uptake of NHS health check, two had no uptake at all prior 
to being HLPs, and one had a two fold increase. 
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Figure 4.17: Perceived changes in public awareness of the availability of 
enhanced services related to HLP status 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3.2 Pharmacists' perceptions of the current and future of enhanced 
services upon the introduction of the HLP scheme 
Pharmacists indicated their level of agreement with six statements regarding the 
HLP scheme (Table 4.8). A percentage of 35.7 (51/143) of the respondent 
pharmacists agreed or strongly agreed with the statement that the HLP scheme will 
be the future for all enhanced pharmacy services, whilst 12.6% (18/143) disagreed 
or strongly disagreed (Table 4.8). Respondent pharmacists saw that the HLP 
scheme provide an opportunity to improve their role in the community as 36.4% 
(52/143) agreed or strongly agreed with the related statement and 16.1% (27/143) 
disagreed or strongly disagreed. However, pharmacists felt that there was more 
efforts can be done to market and promote the HLP scheme, as 39.9% (57/143) 
disagreed or strongly disagreed with the related statement and only 11.2% (16/143) 
agreed or strongly agreed (Table 4.8). Respondent pharmacists felt that pharmacy 
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students should be trained for the HLP scheme, as 33.6% (53/143) agreed or 
strongly agreed with the related statement and only 21% (25/143) disagreed or 
strongly disagreed. Pharmacists did not think that the failure of the HLP scheme 
would impact the future of commissioning services, as 33.6% (48/143) disagreed or 
strongly disagreed with this statement and only 21% (30/143) agreed or strongly 
agreed (Table 4.8). Finally, pharmacist agreed or strongly agreed 42.7% (61/143) 
that the introduction of the HLP enhanced the public awareness about the 
enhanced services (Table 4.8)  
Table 4.8: Responses (%) to statements regarding HLPs (n= 143) 
Statement Strongly 
Disagree 
    Strongly 
Agree 
NA 
HLP scheme will be the future 
for all enhanced pharmacy 
services 
4.2 8.4 27.3 14 18.2 17.5 10.5 
HLP has enhanced the role of 
the pharmacist in the 
community 
6.3 12.6 15.4 18.2 21.7 14.7 11.2 
The marketing and promotion 
of HLP scheme was effective 
18.2 21.7 24.5 11.9 4.9 6.3 11.9 
Training for HLP scheme 
should be provided at 
undergraduate level of study 
8.4 9.1 18.2 15.4 16.1 21 11.2 
If HLP scheme fails to achieve 
the desired results, enhanced 
pharmacy services will be 
decommissioned 
15.4 18.2 21 12.6 13.3 7.7 11.2 
HLP is a way to improve 
awareness of the public 
regarding enhanced services. 
8.4 2.8 14 20.3 18.2 24.5 11.2 
- Highest level of agreement or disagreement was indicated with bold. 
Further analysis was conducted for the neutral statements (neither agree nor 
disagree, where the results were broken into two groups (HLPs and non-HLPs) 
(Table 4.9). The HLPs category included pharmacists who were already HLPs, in 
the process to be HLPs or would like to be HLPs, and non-HLPs included those 
who were not willing to be HLPs in the future. Differences were identified in 
statement related to the effectiveness of marketing and promotion of HLP scheme, 
where higher percentages of non-HLPs indicated disagreement with this statement 
in comparison to HLPs (P= 0.009). This reflects that non-HLPs felt more ignorant 
regarding the marketing and promotion of HLP scheme than those who belonged to 
the HLP category.  
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Table 4.9: Breakdown of level of agreements between HLPs and non-HLPs 
Statement Strongly 
disagree/disagree 
Unsure Strongly agree/ 
agree 
 HLP
1 
Non-HLP HLP
1 
Non-HLP HLP
1 
Non-HLP 
HLP scheme will 
be the future for 
all enhanced 
pharmacy 
services 
8.7% 14.7% 39.1% 47.4% 52.2% 37.9% 
P-value
2 
0.31 0.36 0.11 
The marketing 
and promotion 
of HLP scheme 
was effective 
28.3% 51.6% 58.7% 36.6% 13% 1.8% 
P-value
2 
0.009 0.013 0.84 
If HLP scheme 
fails to achieve 
the desired 
results, 
enhanced 
pharmacy 
services will be 
decommissioned 
30.4% 43.6% 52.2% 29.8% 17.4% 26.6% 
P-value
2 
0.13 0.01 0.23 
1- HLP that includes current HLPs, in the process to be HLP or willing to be in the future. 
2- Chi-squared test was used to compare the two groups. 
4.4.4 Public awareness of enhanced services 
In order to consider how public awareness of the availability of enhanced services 
through CPs might be improved, pharmacists were asked how they felt members of 
the public had been made aware of the enhanced services and how public 
awareness could be improved. Pharmacists considered media advertisements to be 
the main route to inform the public about enhanced services, followed by a 
recommendation from a friend or family member (Figure 4.18). They did not 
consider leaflets, posters or advice from pharmacists to be as effective as media 
campaigns in increasing public awareness (Figure 4.18). Moreover, pharmacists 
thought that by using social websites and organising health campaigns public 
awareness might be improved (Figure 4.19). 
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Figure 4.18: Pharmacists' perceptions of the venues by which members of the 
public were made aware of enhanced services 
  
Figure 4.19: Methods to improve public awareness of enhanced services 
based on CPs' perceptions. 
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reduce the rates of relapse (Figure 4.21). Involvement of relatives and friends 
(47%) (Figure 4.21) and making it a social experiment by sharing the experience 
with other smokers who are wishing to quit (38%) (Figure 4.21), could also help in 
reducing the rate of relapse. 
Figure 4.20: Reasons smokers relapse based on CPs' perceptions 
 
 
 
Figure 4.21: Methods to reduce the rate at which smokers relapse based on 
CPs' perceptions 
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4.5 Discussion 
4.5.1 Comparison between respondent pharmacists and the pharmacists 
across England  
In 2008, 55.9% of all registered pharmacists in England were females and 44.1% 
were males (Seston, 2009). Whilst in the respondent sample, the percentage of 
females and males was 49% and 48%, respectively (Section 4.4.1). This indicates 
that the respondent pharmacists came from a sample of overestimated male 
pharmacists when compared to the actual proportion among pharmacists in 
England. In 2013, the percentage of independent and small chain CPs was 39% 
and 61% for large and multiple chain, respectively (HSCIC, 2013). However, 59% of 
the responses came from independent and small chain and 41% from multiple and 
large chain (Section 4.4.1). The highest response (38%) came from pharmacists 
with an experience of 10 years and more (Section 4.4.1) and this percentage was 
comparable to the finding that the largest proportion of the pharmacists (51%) who 
registered with RPSGB in 2008 were aged 40 years and above (Seston, 2009). The 
two most common services among respondent pharmacists were EHC service 
(78%) and SSS (75%) and the two least were chalmydia service (48%) and NHS 
health check (33%) (Section 4.4.2.1). This agrees with the finding from PNA reports 
that the most common services are SSS with 63.9% of CPs offering the service 
(Section 2.4.1.1) and 52.3% of CPs offering EHC (Section 3.4.1.1).  The majority 
81.5% (137/168) of responses came from pharmacists who worked in a non-HLP 
compared to 18.5% (31/168) who worked in HLPs. In September 2013, 700 out of 
11 236 CPs in England succeeded in becoming HLPs, representing 6.3% (Public 
Health England, 2014).  
4.5.2 Differences in provision and uptake of enhanced services based on 
differences in respondent pharmacists 
The study did not identify any difference in terms of provision or uptake of sexual 
health services and SSS between male and female pharmacists (Sections 4.4.2.2 
and 4.4.2.3). This agrees with the finding that gender of respondent pharmacists 
was found to be irrelevant to the success of vascular health services (Maguire et 
al., 2001). Furthermore, the effect of gender difference in terms of provision was not 
identified through other studies (Meshack et al., 2009; Verma et al., 2012; 
Weidmann et al., 2012; Laliberte et al., 2012). The only difference was in case of 
NHS health check provision, as the study found that NHS health check provision 
was higher among male respondents than among female respondents (Section 
4.4.2.1). A recent study by Saba and co-workers (2014) found that male 
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pharmacists had a better clinical experience than female ones when dealing with 
pregnant smokers.  
In terms of sexual health services, several studies did not identify differences in 
uptake of EHC service through male or female pharmacists (Downing et al., 
2011;Bissell et al., 2006; Baraitser et al., 2007). However, one study found that 
female pharmacists feel uncomfortable in offering sexual health services for young 
people behind their parents, which was a barrier to providing EHC (Gale and 
Watson, 2011). In terms of chlamydia, Irish women did not prefer to be screened 
where their identity might be known (Bafle et al., 2010). Furthermore, 65% of the 
respondent young females in another study liked to be screened for chlamydia by 
female health care professionals (Brugha et al., 2011). The last two studies were 
related to the Irish community, which is known to be more sexually conservative 
when compared to the English community (Daguerre and Nativel, 2006).  
The years of experience of respondent pharmacists were not reflected on provision 
or uptake of any of the four services (Section 4.4.2.2 and 4.4.2.3d). In general, the 
experience of pharmacists increases with age. Hence, it is possible to correlate the 
age with the experience. The age of pharmacists in relation to the vascular and 
sexual health services was arguable. One study found that younger pharmacists 
are more successful in obtaining medical history of smokers who wish to quit (Saba 
et al., 2014). Another study found that pharmacists with experience of 20 years and 
more were more likely to read the NICE guidelines regarding their role in smoking 
cessation for patients with chronic obstructive pulmonary disease (Verma et al., 
2012). The findings from the two studies suggest that experienced pharmacists are 
more likely to read the guidelines and hence provide a safe and optimal service, 
while young pharmacists have the youth spirit which can be reflected on 
approaching individuals and informing them about available services within 
pharmacy. In this study, most of the respondents were pharmacists with 10 years or 
more experience (Section 4.4.1), which in turn guarantee the safe and optimal 
provision of vascular and sexual health services.     
 
Pharmacists who worked in small chain type of CPs provided more NHS health 
check services and had a lower uptake of chlamyida service when compared to 
those working in other types of CPs (Sections 4.4.2.2 and 4.4.2.3d). This study did 
not identify any difference in terms of provision or uptake of SSS based on the 
responses from pharmacists who worked in different types of CPs (Sections 4.4.2.2 
and 4.4.2.3d).This agrees with findings from the study by Maguire and co-workers 
(2001), who found that the  success of SSS from pharmacists who worked in 
138 
 
different types of CPs was comparable and findings from the study by Saba and co-
workers (2014), who found that the performance in dealing with pregnant smokers 
of pharmacists who worked in different types of CPs was also comparable (Saba et 
al., 2014). However, the recent evaluation of the new medicine service concluded 
that large pharmacy chains are more capable to roll out and support the programme 
(Elliott et al., 2014). This might make pharmacists working in independent and small 
chain CPs feel insecure, as the services other than essential service might not be 
commissioned in their CPs and restricted to large chain CPs. The study findings 
contraindicate this plan and suggest that independent CPs and small chain CPs 
can perform in a comparable fashion to large chain CPs and even better as in case 
of uptake of NHS health check which was higher among respondents from CPs of 
small chain type when compared to the respondents of other types of CPs (Section 
4.4.2.2 and 4.4.2.3d).   
 
As previously emphasised, the aim of vascular and sexual health pharmacy 
services is to bridge the gap in health inequalities as was recommended by the 
white paper “pharmacy in England: building on strengths- delivering the future” (DH, 
2008a). The provision of chlamydia, SSS and NHS health check services did not 
vary across CPs which belonged to areas with different deprivation (Section 
4.4.2.2). The only significance difference was in case of EHC provision as the 
provision was lower in CPs which belonged to the least deprived areas when 
compared to most deprived and moderate ones (Section 4.4.2.2). This suggests 
that the higher needs (which is highly correlated with deprivation in case of SSS 
and slightly correlated with deprivation in case of chlamydia) were not met by the 
current provision of those services through CPs. This agreed with findings from 
Chapters 2 and 3 based on PCT level, where the provision (as percentage) of 
services did not match with either the needs or deprivation (Sections 2.4.1.2, 
3.4.1.2 and 3.4.2.2). The initial aim of the NHS health check programme was to 
reach 20% of those aged 40-74 years old each year every year for a period of 5 
years (DH, 2008b). However, the programme through all providers failed to reach 
its target in 2011/2012 (Artac et al., 2013b). However, the reach was higher in more 
deprived PCTs when compared to least deprived ones (Artac et al., 2013b). CPs 
can play an important role in reaching individuals in more deprived areas as 
outlined by Murray and co-workers (2009). They found  that the  important role of 
CPs in delivering the SSS to a wide variety of smokers, is due to smokers being 
able to access a service provided by trained health professionals without a 
prebooked appointment. Only 33% of the respondent pharmacists provided NHS 
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health check (Section 4.4.2.1). In order to improve the reach especially for those 
who live in deprived areas, extra provision of CP NHS health check service should 
be implemented.  
4.5.3 Barriers and motivators towards provision of enhanced services 
Pharmacists felt that the provision of enhanced services allow them to play a more 
active role in health promotion. This was expected, as pharmacists by their 
connection with health and sick people can participate in promoting health 
(Anderson, 2000). Although the provision of enhanced services is an extra resource 
to earn more money, pharmacists did not feel that remuneration was amongst their 
driver or barrier towards provision of services (Section 4.4.2.5). In contrast to the 
study findings, Newlands and co-workers (2011) and Gale and Watson (2011) 
identified inconvenient remuneration as barrier towards provision of weight 
management service and sexual health services. Both of those studies were related 
to Scottish CPs. Scottish demographic is different from that in England and 
Scotland has its own system in providing pharmacy services. For instance, in terms 
of sexual health services, Scottish pharmacists received higher payment for 
provision of EHC service (£25) (The Scottish Government, 2011) compared to 
different payments in different PCTs in England with average of £17.68 per each 
EHC service (Section 3.4.1.3e). 
The main barrier for the provision of services was their availability through other 
health care professionals and lack of time (Section 4.4.2.5). Tremblay and co-
workers (2009) found that trained pharmacists had an experience of counselling 
regarding smoking cessation that is comparable to doctors and better than other 
health care professionals such as; dentists and nurses. Hence, the access of CP 
within 20 minutes walk which was identified by Todd and co-workers (2014) and the 
opening times should have the advantage to attract individuals to use CPs rather 
than other health care providers. The preference of other health care providers 
especially, GPs, can be attributed to the lack of privacy in CPs which was identified 
in terms of weight management service in the study by Weidmann and co-workers 
(2012), in terms of heart check in the study by Taylor and co-workers (2012) and in 
terms of alcohol screening in the study by Krska and Mackridge (2014). Eades and 
co-workers (2011) found in their review, that lack of time and lack of demand are 
the main barriers to provision of public health services through CPs. Pfleger and co-
workers (2008) found that lack of time, lack of training and inappropriate premises 
were the main barriers to utilise pharmacists' experience and knowledge in 
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improving and promoting health for patients. Lack of time is an important issue, and 
pharmacists should consider that spending more time in relation to providing those 
services, might increase their workload, and that will affect both pharmacists and 
patients (Jacobs et al., 2013; Hassell et al., 2011). 
4.5.4 Healthy living pharmacies 
The introduction of the HLP scheme was a new scheme to revive the vascular and 
sexual health pharmacy services. Respondent from HLPs reported an increase in 
public awareness for all the services, especially in case of SSS (Section 4.4.3.1). 
Thus, the initiative overcame the barrier that was suggested by respondent 
pharmacists (lack of public awareness for enhanced services provision) (Section 
4.4.2.5). The involvement of member of pharmacy team to deliver the services, as 
per the HLP scheme, will free some of the pharmacists' time and increase the 
uptake of services (Duggan et al., 2013). This was seen in case of SSS, as the 
number of smokers who set a quit date through HLPs was significantly higher than 
through non-HLPs (Section 4.4.2.3d). In addition, lack of time was not amongst the 
major two barriers to be HLP (Section 4.4.3). HLPs stated that the main reason for 
being an HLP was to play a more active role in health promotion and to meet the 
local needs of their local population (Section 4.4.3). The health promotion role was 
also seen through pharmacists’ answers to the statement “HLP has enhanced the 
role of the pharmacist in the community”.  Lack of training for pharmacy staff was 
suggested to be the main barrier to be HLP. In September 2013, 2 100 HLCs were 
trained to work in HLPs (Public Health England, 2014), hence potentially 
overcoming this barrier. Pharmacists who did not wish to be HLPs were pessimistic 
about the effectiveness of marketing and promotion of the HLP scheme (Section 
4.4.3.2).This suggests that there is need to review this finding and improve the 
promotion and marketing of the HLP scheme, especially among non-HLPs. 
4.5.5 Public awareness of pharmacy services 
Pharmacists suggested that the public become aware of health services through 
the media or through a friend or family. Media advertising was proved to be 
effective in increasing public awareness of health services (Schillo et al., 2011; 
Wilson et al., 2005; Momen et al., 2014). Furthermore, Atusingwize and co-workers 
(2014) found that media campaigns for stop smoking can be effective and provide 
good value for money. The use of latest resources such as internet was proved to 
be effective in case of stop smoking (Momen et al., 2014). Posters through CPs or 
through GPs were found to be effective in informing individuals about alcohol 
screening in CPs (Krska and Mackridge, 2014). Thus, an adoption of simple 
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methods such as posters and social websites could inform the public and it will be 
better than large health campaigns which require big proportion of the NHS budget.  
4.5.6 Smoking cessation relapse 
Pharmacists felt that the most important reason for smokers who set a quit date to 
relapse were the loss of stress relief and lack of follow up (Section 4.4.5). Zhou and 
co-workers (2009) and Allen and co-workers (2008) found that smoking cessation 
relapse is mainly dependant on nicotine dependence, craving and withdrawal 
symptoms. Anxiety, depression and stress are found to be more common among 
smokers than non-smokers (Park et al., 2009) and smokers think that by smoking 
they are overcoming those symptoms (Jarvis, 2004). Pharmacists felt that 
increasing the frequency of follow up, and involving a friend or family should 
encourage the smoker to overcome withdrawal symptoms, thus a smoker might 
have a better chance to success in quit smoking and relapse rates might decrease 
(Section 4.4.5).    
4.6 Limitations of the study 
The study had a low response rate of 19.3% (Section 4.4.1) which is lower than the 
lowest response rate (20.6%) of studies related to vascular and sexual health 
services identified in Section 1.8.1.2. The low response rate restricts the   
generalisation of the findings and thus the results should be treated with caution. 
4.7 Conclusions  
The provision of vascular and sexual health pharmacy services on CP level did not 
match with deprivation, which is correlated with needs. The main driver for 
pharmacists to provide services is to play a more active role in health promotion. 
The main identified barriers were lack of time and provision of services through 
other providers. The introduction of the HLP scheme based on pharmacists' 
perceptions improved the awareness about the availability of vascular and sexual 
health services in CPs. The median uptake of SSS was higher among HLPs (6) 
when compared to non-HLPs (4) with P = 0.02. HLCs are the main point in 
delivering services through HLPs. Thus the focus should be on increasing the 
number of trained HLCs. Utilising new techniques such as social websites can also 
help in improving public awareness about the availability of those services through 
CPs. Finally, to improve the commitment and success of smokers who set a quit 
date through CPs, increasing the follow up frequency and involving a member of 
their family or a close friend can help.      
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4.8 Future of vascular and sexual health pharmacy services 
The future of vascular and sexual health pharmacy services seems to be still 
unclear. Since the Local Authorities took the responsibility of commissioning those 
services, it seems that the same services are still being commissioned with a move 
to a payment by result model. The HLP scheme might be the future of those 
services, however, the uptake and implementation of this scheme is still limited. 
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Chapter Five: General conclusion and recommendations 
5.1 General Conclusions 
5.1.1 Review of the study 
CPs are well placed in the heart of the community to offer services that promote 
public health. The dramatic changes in community pharmacists' role since the 
reform of the NHS in 2000 were presented in Section 1.1 and 1.2. The recognition 
of the role that community pharmacists can play to meet the public health needs 
was explained through the Government papers presented in Sections 1.1 and 1.2. 
The major shift in pharmacist role was in 2005, following the pharmacy contract, 
where three categories of services were introduced. Essential services that CPs 
have to offer as part of their contract with the NHS. These include daily routine 
services, such as; dispensing medicines repeat dispensing, waste management 
and signposting. The second category of pharmacy services is called advanced 
services. Those require accreditation of the pharmacist and the premises. This 
category currently includes; medicine use review, appliance use review, stoma 
appliance customisation and new medicine review services 
Payments for essential and advanced services are set through the drug tariff. The 
last category of pharmacy services was used to be called enhanced services 
(currently known as locally commissioned services). The provision of those services 
has changed following the implementation of the new NHS structure which was 
introduced in 2010. This category of services, before 1st April 2013, was 
commissioned by PCTs based on identification of public needs for those services. 
From April 2013, the commissioning of those services was transferred to Local 
Authorities, Clinical Commissioning Groups and NHS England's area teams. The 
nationally commissioned enhanced (or locally commissioned) services include 
services such as, SSS, NHS vascular check, EHC service, chlamydia screening 
and treatment services, supplementary prescribing and needle and syringe 
exchange. The literature review identified opportunities for vascular and sexual 
health pharmacy services. However, all the studies were related to limited number 
of PCTs and none of the studies looked at the difference between provision and 
uptake of services on national level.      
5.1.2 Aims of the study 
The project aimed to identify whether the provision and uptake of vascular and 
sexual health pharmacy services matched the needs at PCT level for the financial 
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year 2009/2010 (started on 01/04/2009 and ended on 31/03/2010) and on CP level 
for the year 2013. It also aimed to investigate whether the provision of SSS and 
EHC services through CPs was cost-effective. Finally, it aimed to determine the 
changes in uptake of vascular and sexual health services following the introduction 
of the HLP scheme and how to improve the uptake of services using SSS as a 
special case.  
5.1.3 Methods used in the study 
To achieve the aims of the project, three categories of data were required to be 
collected; needs for each service, CPs provision of each service and uptake of each 
service. With regards to SSS (Chapter Two), the needs were identified based on 
percentage of smoking adults which was obtained from Health Profile for each PCT 
in England. The CP SSS provision was identified from the PNA report published in 
February 2011. The uptake and the costs attributed to the SSS were identified 
through a short survey questionnaire which was posted to the public health leads of 
SSS in PCTs. With regards to EHC service (Chapter Three), the needs were 
identified based on rates of teenage pregnancies which was obtained from the 
Health Profile for each PCT in England. The EHC service provision was identified 
from the PNA reports. The uptake and cost of EHC service were identified through 
survey questionnaire which was posted to the public health leads of sexual health 
services in PCTs. In terms of chlamydia screening service (Chapter Three), the 
needs were identified based on prevalence of chlamydia and the provision was 
identified from the PNA reports. A survey questionnaire was posted to the public 
health leads of sexual health service in PCTs to gauge the uptake of chlamydia 
screening service through CPs.  
To identify the provision and uptake of vascular and sexual health services at CP 
level, a survey questionnaire was posted to CPs within 28 PCTs. The questionnaire 
aimed to gauge the pharmacists' perceptions towards vascular and sexual health 
services and how the introduction of HLP scheme affected those services. 
5.1.4 Key findings of the study 
The PCT response rate to the questionnaire regarding the uptake of services was 
30% (42/138), 30% (42/139) and 19% (21/111) for SSS, EHC and chlamydia 
screening services, respectively (Sections 2.4.2.1, 3.4.1.3a and 3.4.2.3a). However, 
to overcome this low response rate, demographic characteristics and CP provision 
of services were tested for respondent PCTs versus non-respondent ones as was 
recommended by Brick and Kalton (Finchman, 2008). The provision of SSS through 
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CPs was lower in respondent PCTs when compared to the non-respondent ones 
(Section 2.4.2.2). The needs for EHC and deprivation were higher in respondent 
PCT when compared to the non-respondent ones (Section 3.4.1.3b). The 
demographic characteristics and chlamydia screening provision were comparable 
for the respondent and non-respondent PCTs (Section 3.4.2.3b).  
Needs for SSS and EHC service were significantly correlated with deprivation with 
rho of 0.76 and 0.83, respectively and P< 0.001 in both cases (Sections 2.4.1.2 and 
3.4.1.2). The correlation between needs for chlamydia screening service and 
deprivation was weak with rho of 0.25 and P = 0.009 (Section 3.4.2.2). The 
importance of CPs in providing public health services becomes evident based on 
the finding that CPs were found to be more concentrated in more deprived PCTs 
(Section 2.4.1.3). This agrees with the findings of Todd and co-workers (2014), that 
ease of access of CPs is better in more deprived areas (99.8% can access CPs 
within 20 minutes) than in least deprived ones (90.2% can access CPs within 20 
minutes walk). Despite that, there was no significant correlation between needs or 
deprivation and CP provision (as percentage out of all CPs in a PCT) for SSS, EHC 
and chlamydia screening services. The higher concentration of CPs in higher need 
PCTs was responsible for a weak correlation with needs in case of SSS, however 
this correlation was not evident in case of EHC or chlamydia services (Sections 
2.4.1.3, 3.4.1.2 and 3.4.2.2). The findings from the CP survey in 2013 indicated that 
there was no significant correlation between provision of SSS, NHS health check, 
EHC or chlamydia screening services with deprivation and hence with needs 
(Section 4.4.2.2).  
CPs were responsible for 12% of overall uptake of SSS (through all providers) in 
2009/2010 (Section 2.4.2.3) and for 1.2% of overall uptake of chlamydia screening 
(through all providers) (Section 3.4.2.3c). No data was identified for share in EHC 
service. However, a previous study by Martson and co-workers (2005) found a shift 
towards CPs to obtain EHC. This emphasises the importance of CPs in delivering 
vascular and sexual health services. Provision of any of the services through other 
providers should not be considered as barrier as respondent pharmacists 
expressed (Section 4.4.2.5). On the contrary, it should act as an incentive for 
competition with other providers to attract more clients and achieve better results, 
especially for working people, as time is an obstacle to access such services.  
Although the uptake of SSS (through all providers) was significantly higher in more 
deprived PCTs, the smoking quit rates at 4-weeks follow up was significantly lower 
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in more deprived PCTs (Sections 2.4.1.4 and 2.4.2.4). This suggests that the SSS 
through all providers (including CPs) is not widening the gap in health inequality 
which is related to smoking between PCTs. Nevertheless, the NHS is enduring 
higher costs due to the negative correlation between quit rate and deprivation.    
The uptake of services at PCT level did not match with needs or deprivation in case 
of SSS (Section 2.4.2.4), EHC service (Section 3.4.1.3d) or chlamydia screening 
service (Section 3.4.2.3d). However, when the uptake was weighted per CP, a 
significant correlation was identified for SSS (Section 2.4.2.4) and for EHC service 
(Section 3.4.1.3d) with needs. This suggests the importance of time, which 
respondent pharmacists considered as the second main barrier towards provision 
of vascular and sexual health pharmacy services (Section 4.4.2.5). In PCTs with 
higher needs, pharmacists have to deal with higher number of clients in regards to 
vascular and sexual health services. Hence if the workload related to vascular and 
sexual health services, in CPs of PCTs with higher needs, exceeds enduring limits, 
this could be reflected on pharmacist's routine roles and would affect both patients 
and pharmacist.  
The introduction of the HLP scheme seems to improve the delivery of vascular and 
sexual health pharmacy services. Firstly, pharmacists felt that this scheme 
improved public awareness of pharmacy services, which was found to be a barrier 
for the NHS health check by Taylor and co-workers (2012). Secondly, the HLP 
scheme introduced the concept of the HLC, who should be trained to help in 
attracting more clients and delivering services. This can free the time of the 
pharmacist with one condition, that he/she should supervise and maintain safe and 
efficient delivery of services. The uptake of SSS was better among HLP 
pharmacists when compared to non HLPs (Section 4.4.2.3d). This agreed with the 
findings from HLP pathfinder PCTs (Duggan et al., 2013). 
The economic evaluation of SSS and EHC service identified that both services are 
cost-effective from the NHS perceptive. CP SSS was able to save £1 511 per QALY 
gained (Section 2.4.3.5). The economic model was taken from the NHS England 
perceptive. CP EHC service provision was also cost effective and could save 
£688.7 for the NHS (Section 3.4.1.3e). 
Pharmacists felt that public awareness about pharmacy services could be improved 
by use of social websites (Section 4.4.4). To achieve better success of SSS, 
increasing the follow up meetings was the most intervention recommended by the 
respondent pharmacists (Section 4.4.5).    
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In summary, the needs for vascular and sexual health pharmacy services are not 
met by the provision of those services through CPs. Pharmacists of PCTs of more 
needs are doing more efforts to meet the needs of their localities. CP SSS is cost 
effective and could save the NHS £1 511 per QALY gained per individual. EHC 
service is cost effective and could save the NHS £688.7 per one prevention of 
unintended pregnancy. Pharmacists felt that the introduction of the HLP scheme 
improved the public awareness of vascular and sexual health pharmacy services, 
which was reflected on higher uptake of those services. Using social websites and 
increasing follow up of service users will help in achieving better success results.    
5.1.4 Limitations 
The low response rate was a limitation in both cases of PCT and CP surveys. 
However, for PCT survey, it was overcome by testing differences between 
respondent and non-respondent PCTs. For the CP survey, the low response rate is 
still a limitation and findings should be treated with caution. In case of EHC service, 
the provision of services was weighted against women aged 60 years old and 
under, as there was no exact data for women who have the ability to conceive. The 
limitation in collection of exact figures in relation to the cost effectiveness analysis in 
both SSS and EHC was overcome by conducting sensitivity analysis. 
5.2 Recommendations 
5.2.1 Recommendations to the commissioner 
Findings from the study identified shortness in CP provision of vascular and sexual 
health services in PCTs with higher needs. Hence, the Local Authorities (the current 
commissioner of vascular and sexual health services) should increase the number 
of CPs which offer those services or to implement the HLP scheme on a national 
level. The pharmacy team need to be trained to offer those services in order to 
meet the local needs of their population. The public awareness about the availability 
of vascular and sexual health services should be improved. Based on the literature 
review conducted in Chapter 1, posters in the CPs were the most important method 
in informing public about services within CPs in case of alcohol services and EHC 
services (Krska and Makridge, 2014, Lloyd and Gale, 2005). However, pharmacists 
in this study recommended the role of social websites in informing public. This can 
be translated by considering that websites should be utilised to improve the 
awareness (both of services offered and success stories) by designing pages and 
blogs to attract individuals with maintaining current methods in improving the public 
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awareness such as posters in CPs. Improving CPs' premises to include 
consultation rooms with toilet facilities, so individuals who visit CPs for chlamydia 
services can have privacy to conduct the test, will increase the uptake of this 
service.  
5.2.2 Recommendations to the community pharmacist 
The pharmacists and the pharmacy team should try to attract more individuals to 
use vascular and sexual health pharmacy services, especially those in more 
deprived areas. They should also try to share  the load that some community 
pharmacists take in some areas to meet their local needs. They should compete 
with other providers to prove to the commissioners that they are able to perform 
and achieve success that is comparable to other health care providers. Pharmacists 
should try to achieve the HLP status if it is nationally commissioned and to train the 
pharmacy team to offer help in delivering vascular and sexual health services.  
Furthermore, they should increase the follow up of service users to achieve better 
results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
References 
1. Adams, E.J, Charlett, A, Edmunds, W.J. Hughes, G. Chlamydia trachomatis in 
the United Kingdom: a systematic review and analysis of prevalence studies. Sex 
Transm Infect (2004); 80: 354–362. doi:10.1136/sti.2003.005454. 
2. Allen, S.S, Bade, T, Hatuskami, D. Craving, withdrawal, and smoking urges on 
days immediately prior to smoking relapse. Nicotine & Tobacco Research 
(2008);10: 35- 45. doi: 10.1080/14622200701705076. 
3. Anderson, C, Blenkinsopp, B. Community pharmacy supply of emergency 
hormonal contraception: a structured literature review of international evidence. 
Human Reproduction (2006); 21: 272–284. doi: 10.1093/humrep/dei287. 
4. Anderson C. Health promotion in community pharmacy: the UK situation. Patient 
Educ and Couns (2000); 29: 285– 291. doi: 10.1016/S0738-3991(99)00025-7. 
5. Anderson, C, Thornley, T. A pharmacy-based private chlamydia screening 
programme: results from the first 2 years of screening and treatment. Int J Clin 
Pharm (2011); 33: 88–91. doi: 10.1007/s11096-010-9460-3. 
6. Anderson, S. Community pharmacy and public health in Great Britain, 1936 to 
2006: how a phoenix rose from the ashes. J Epidemiol Community Health (2007); 
61: 844–848. doi:10.1136/jech.2006.055442. 
7. Anderson S. Making medicines: a brief history of pharmacy and pharmaceuticals: 
Pharmaceutical Press; (2005). p. 77-92. 
8. Annear, M.J, Cushman, G, Gidlow, B. Leisure time physical activity differences 
among older adults from diverse socioeconomic neighborhoods. Health Place 
(2009); 15: 482–490. doi: 10.1016/j.healthplace.2008.09.005. 
9. Arhens, R. A, Hower, M, Best, Al. M. Effects of Weight Reduction Interventions 
by Community Pharmacists. J Am Pharm Assoc (2003); 43(5): 583- 589. 
10. Artac, M, Dalton, A.R.H, Majeed, A, Car,J. Uptake of the NHS Health Check 
programme in an urban setting. Family Practice (2013a); 30: 426– 435. doi: 
10.1093/fampra/cmt002. 
11. Artac, M, Dalton, A.R.H, Bates, H.B, Majeed, A. Primary care and population 
factors associated with NHS Health Check coverage: a national cross-sectional 
study. Journal of Public Health (2013b); 35: 431– 439. doi: 10.1093/pubmed/fdt069.  
12. Atusingwize, E, Lewis, S, Langley, T. Economic evaluations of tobacco control 
mass media campaigns: a systematic review. Tob Control (2014); 0: 1– 8. 
doi:10.1136/tobaccocontrol-2014-051579. 
13. Aubin, H. J, Lebargy, F, Berlin, I, Bidauat-Mazel, C, Chemali-Hudary, J, Largue, 
G. Efficacy of bupropion and predictors of successful outcome in a sample of 
French smokers: a randomized placebo-controlled trial. Addiction (2004); 99: 1206–
1218. doi: 10.1111/j.1360-0443.2004.00814.x 
150 
 
14. Aubin, H. J, Luquiens, A, Berlin, I. Pharmacotherapy for smoking cessation: 
pharmacological principles and clinical practice. British Journal of Clinical 
Pharmacology (2013); 77: 324- 336. doi: 10.1111/bcp.12116. 
15. Awad, A, Waheedi, M. Community Pharmacists role in obesity treatment in 
Kuwait: a cross-sectional study. BMC Public Health (2012); 12: 863- 871. doi: 
10.1186/1471-2458-12-863. 
16. Bacon, L, Savage, I, Cook, S, Taylor, B. Training and supporting pharmacists to 
supply progestogen-only emergency contraception. Journal of Family Planning and 
Reproductive Health (Care 2003); 29(2): 17– 22. doi: 
10.1783/147118903101197476. 
17. Balfe, M, Brugha, R, O’Connell, E, McGee, H, O’Donovan, D. Where do young 
Irish women want Chlamydia-screening services to be set up? A qualitative study 
employing Coffman's impression management framework. Health & Place (2010); 
16: 16– 24. doi: 10.1016/j.healthplace.2009.07.003. 
18. Baraitser, P, Pearce, V, Holmes, J, Horne, H. Chlamydia testing in community 
pharmacies: evaluation of a feasibility pilot in south east London. Qual Saf Health 
Care (2007);16:303–307. doi: 10.1136/qshc.2006.020883 
19. Bauld, L, Bell, K, McCullough, L, Richardson, L, Greaves, L. The effectiveness 
of NHS smoking cessation services: a systematic review. Journal of Public Health 
(2009a); 32: 71- 82. doi:10.1093/pubmed/fdp074. 
20. Bauld, L, Boyd, KA, Briggs, AH, Chesterman, J. One-year outcomes and cost-
effectiveness analysis for smokers accessing group-based and pharmacy-led 
cessation services. Nicotine & Tobacco Research (2011); 12: 135- 145. doi: 
10.1093/ntr/ntq222. 
21. Bauld, L, Chesterman, J, Ferguson, J, Judge, K. A comparison of the 
effectiveness of group-based and pharmacy-led smoking cessation treatment in 
Glasgow. Addiction (2009b); 104(2): 308- 316. doi: 10.1111/j.1360-
0443.2008.02446.x 
22. Bauld, L, Ferguson, J, McEwen, A, Hiscock, R. Evaluation of a drop-in rolling-
group model of support to stop smoking. Addiction (2012); 107: 1687–1695. doi: 
10.1111/j.1360-0443.2012.03861.x. 
23. Bauld L, Ferguson J, Lawson L, Chesterman J, Judge K. Tackling smoking in 
Glasgow: final report. Glasgow: Glasgow Centre for Population Health (2006). doi: 
10.1111/j.1360-0443.2009.02875.x. 
24. Bauld L, Judge K, Platt S. Assessing the impact of smoking cessation services 
on reducing health inequalities in England: observational study. Tob Control. 
(2007); 16: 400–404. doi:10.1136/tc.2007.021626. 
 
151 
 
25. Bayer, L.L, Edelman, A.B, Caughey, A.B, Rodriguez, M.I. The price of 
emergency contraception in the United States: what is the cost-effectiveness of 
ulipristal acetate versus single-dose levonorgestrel? Contraception (2013); 87: 385–
390. doi: 10.1016/j.contraception.2012.08.034.  
26. Ben Lakdar, C, Cauchie, G, Vaillant, N. G. The role of family incomes in 
cigarette smoking: Evidence from French students. Social Science & Medicine 
(2012); 74: 1864- 1873. doi: 10.1016/j.socscimed.2012.02.036. 
27. Berbatis, C. G, Sundeland, V. B, Joyce, A, Bulsara, M. Enhanced pharmacy 
services, barriers and facilitators in Australia’s community pharmacies: Australia’s 
National Pharmacy Database Project. International Journal of Pharmaceutical 
Science (2007); 15: 185- 191. doi: 10.1211/ijpp.15.3.0005. 
28. Berkshire Local Pharmaceutical Committee. Pharmaceutical Needs 
Assessment West. [Published February 2011; cited 1st April 2011]. Available from:   
http://archive.communitypharmacyhumber.org.uk/ERHLPC/www.lpc-
online.org.uk/berkshire_lpc/pharmaceutical_needs_assessment_west.html 
29. Bissell, P, Anderson, C. Supplying emergency contraception via community 
pharmacies in the UK: reflections on the experiences of users and providers. Social 
Science & Medicine (2003); 57(12): 2367- 2378. doi: 10.1016/S0277-
9536(03)00129-1. 
30. Bissell, P, Savage, I, Anderson, C. A qualitative study of pharmacists’ 
perspectives on the supply of emergency hormonal contraception via patient group 
direction in the UK. Contraception (2006); 73: 265 – 270. doi: 
10.1016/j.contraception.2005.07.017. 
31. Black, K. I, Catherine, H. M, Johnson, A.M, Wellings, K. Sociodemographic and 
sexual health profile of users of emergency hormonal contraception: data from a 
British probability sample survey. Contraception (2006); 74:  309–  312. doi: 
10.1016/j.contraception.2006.05.067 
32. Black, K.I, Mercer, C.H, Kubba, A, Wellings, K. Provision of emergency 
contraception: a pilot study comparing access through pharmacies and clinical 
settings. Contraception (2008); 77:  181–185. doi: 
10.1016/j.contraception.2007.12.001. 
33. Boardman, H, Avery, A. J. Effectiveness of a community pharmacy weight 
management programme. Int J Clin Pharm  (2014) 36:800–806. doi: 
10.1007/s11096-014-9964-3 
34. Bock, B. C, Hudmon, K.S, Christian, J, Graham, A. L. A tailored intervention to 
support pharmacy-based counseling for smoking cessation. Nicotine & Tobacco 
Research (2010); 12: 217–225. doi: 10.1093/ntr/ntp197 
35. Bolton, K.L, Rodriguez, E. Smoking, drinking and body weight after re-
employment: does unemployment experience and compensation make a 
difference? BMC Public Health (2009); 9: 77- 89. doi: 10.1186/1471-2458-9-77 
152 
 
36. Bond, L, Egan, M, Kearns, A. Smoking and intention to quit in deprived areas of 
Glasgow: is it related to housing improvements and neighbourhood regeneration 
because of improved mental health? J Epidemiol Community Health (2012); 0: 1– 
6. doi:10.1136/jech-2012-201828. 
37. Bowling A. Mode of questionnaire administration can have serious effects on 
data quality. Journal of Public Health (2005); 27: 281- 291. 
doi: 10.1093/pubmed/fdi031. 
38. Boyd, K. A, Briggs, A.H. Cost-effectiveness of pharmacy and group behavioural 
support smoking cessation services in Glasgow. Addiction (2009); 104: 317- 325. 
doi: 10.1111/j.1360-0443.2008.02449.x. 
39. Brabin, L, Thomas, G, Hopkins, M, O'Brien, K, Roberts, S. Delivery of 
chlamydia screening to young women requesting emergency hormonal 
contraception at pharmacies in Manchester, UK: a prospective study. BMC 
Women's Health (2009), 9: 1- 7. doi: 10.1186/1472-6874-9-7. 
40. British Medical Association/ Royal Pharmaceutical Society of Great Britain. 
British National Formulary No 58. London (2009). 
41. Brown, D, Portlock, J, Rutter, P. Review of services provided by pharmacies 
that promote healthy living. Int J Clin Pharm (2012); 34: 399– 409. doi: 
10.1007/s11096-012-9634-2. 
42. Brown, D, Portlock, J, Rutter, P, Nazar, Z. From community pharmacy to 
healthy living pharmacy: positive early experiences from Portsmouth, England. 
Research in Social and Administrative Pharmacy (2014); 10(1): 72- 87. doi: 
10.1016/j.sapharm.2013.04.014.  
43. Brugha, R, Balfe, M, Jeffares, Conroy, R, Clarke, E. Where do young adults 
want opportunistic chlamydia screening services to be located? Journal of Public 
Health (2011); 33(4): 571– 578. doi: 10.1093/pubmed/fdr028.  
44. Bush, J, Langley, C. A, Wilson, K. A. The corporatization of community 
pharmacy: Implications for service provision, the public health function, and 
pharmacy’s claims to professional status in the United Kingdom. Research in Social 
and Administrative Pharmacy (2009); 5(4): 305-318.  doi: 
10.1016/j.sapharm.2009.01.003 
45. Businellea,M. S, Kendzora, D.E, Reitzela, L.R.  Mechanisms linking 
socioeconomic status to smoking cessation: A structural equation modeling 
approach. Health Psychol (2010); 29(3): 262– 273. doi: 10.1037/a0019285. 
46. Butland, B, Jebb, S, Kopelman, P, McPherson, K, Thomas, S. Foresight. 
Tackling obesities: future choices—project report. Government Office for Science, 
London. [Published 2007, cited 11th May 2014]. Available from:  
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/2879
37/07-1184x-tackling-obesities-future-choices-report.pdf. 
153 
 
47. Callison, K, Kaestner, R. Do higher tobacco taxes reduce adult smoking? new 
evidence of the effect of recent cigarette tax increases on adult smoking. Economic 
Inquiry (2014); 52: 155- 172. doi: 10.3386/w18326.   
48. Cameron, S. T, Gordon, R, Glasier, A. The effect on use of making emergency 
contraception available free of charge. Contraception (2012); 86: 366– 369. 
doi:10.1016/j.contraception.2012.02.018. 
49. Cameron, S. T, Melvin, L, Glasier, A, Scott, G. Willingness of gynaecologists, 
doctors in family planning, GPs, practice nurses and pharmacists to adopt novel 
interventions for treating sexual partners of women with chlamydia. An International 
Journal of Obstetrics & Gynaecology (2007); 114(12): 1516- 1521. doi: 
10.1111/j.1471-0528.2007.01506.x. 
50. Camp, S. L, Wilkerson, D. S, Raine, T. R. The benefits and risks of over-the-
counter availability of levonorgestrel emergency contraception. Contraception 
(2003); 68:  309– 317. doi: 10.1016/j.contraception.2003.08.011. 
51. Centers for Disease Control and Prevention (US); National Center for Chronic 
Disease Prevention and Health Promotion (US); Office on Smoking and Health 
(US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for 
Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): 
Centers for Disease Control and Prevention (US); 2010. 3, Chemistry and 
Toxicology of Cigarette Smoke and Biomarkers of Exposure and Harm. Available 
from: http://www.ncbi.nlm.nih.gov/books/NBK53014/  
52. Chen, X, Wen, S.W, Fleming, N, Demissie, K. Teenage pregnancy and adverse 
birth outcomes: a large population based retrospective cohort study. International 
Journal of Epidemiology (2007);36: 368–373. doi: 10.1093/ije/dyl284. 
53. Chemist and Druggist. PCT investigation 2011. [Published  2011, cited 8th 
October 2013]. Available from: http://www.chemistanddruggist.co.uk/pct-home# 
54. Conrad, D. Deprivation-based inequalities in under-18 conception rates and the 
proportion of under-18conceptions leading to abortion in England, 1998–2010. 
Journal of Public Health (2012); 3: 609–614. doi: 10.1093/pubmed/fds031. 
55. Conrad, D, Capewell, S. Associations between deprivation and rates of 
childhood overweight and obesity in England, 2007e2010: an ecological study. BMJ 
open (2012); 2: 1-6. doi: 10.1136/bmjopen-2011-000463. 
56. Cooper R.J, Anderson C, Avery T, Bissel P. Nurse and pharmacist 
supplementary prescribing in the UK – A thematic review of the literature. Health 
Policy (2008a); 85: 277- 292. doi: 10.1016/j.healthpol.2007.07.016. 
57. Cooper, R. J, Bissell, P, Wingfield, J. Ethical, religious and factual beliefs about 
the supply of emergency hormonal contraception by UK community pharmacists. J 
Fam Plann Reprod Health Care (2008b); 34(1): 47–50. doi: 
10.1783/147118908783332122. 
154 
 
58. Corelli, R. L, Zillich, A.J, Moor, C. Recruitment of community pharmacies in a 
randomized trial to generate patient referrals to the tobacco quitline. Research in 
Social and Administrative Pharmacy (2013); 9: 396– 404. 
59. Cornuz, J, Gilbert, A, Pinget. C, Mcdonald, P, Salma, K. Cost-effectiveness of 
pharmacotherapies for nicotine dependence in primary care settings: a 
multinational comparison. Tobacco Control (2006);15: 152- 159. doi: 
10.1136/tc.2005.011551. 
60. Costello, M. J, Sproule, B, Victor, J. C. Effectiveness of pharmacist counseling 
combined with nicotine replacement therapy: a pragmatic randomized trial with 
6,987 smokers. Cancer Causes Control (2011); 22: 167– 180. doi:  
10.1007/s10552-010-9672-9 
61. Cramp, G.J, Mitchell, C, Steer, C, Pfleger, S. An evaluation of a rural 
community pharmacy-based smoking-cessation counseling and nicotine 
replacement therapy initiative. International Journal of Pharmacy Practice (2007); 
15: 113- 121. doi: 10.1211/ijpp.15.2.0006. 
62. Creinin, M. D, Schlaff, W, Archer, D. F, Wan, L. Progesterone receptor 
modulator for emergency contraception: a randomized controlled trial. Obstet 
Gynecol (2006); 108(5): 1089- 1097. doi: 10.1097/01.AOG.0000239440.02284.45 
63. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness 
of the clinical practice recommendations in the AHCPR guideline for smoking 
cessation. JAMA 1997; 278(21): 1759– 1766. 
doi:10.1001/jama.1997.03550210057039. 
64. Dabrera, G, Pinson, D, Whiteman, S. Chlamydia screening by community 
pharmacists: a qualitative study. J Fam Plann Reprod Health Care  (2011); 37: 17- 
21.  doi:10.1136/jfprhc.2010.0003. 
65. Daguerre, A, Nativel, C. When children become parents: welfare state 
responses to teenage pregnancy. Bristol, Policy Press, 2006.   
66. Dancey, C, P, Reidy J. Statistics without Maths for Psychology. Pearson 
Education  [e- book]. Pearson Education;  2011. p. 168- 210. [cited 23rd February  
2014]. Avialable from: https://www.dawsonera.com/readonline/9780273726036. 
67. De Vogli, R, Santinello, M. Unemployment and smoking: does psychosocial 
stress matter? Tobacco Control (2005); 14: 389– 395. doi:10.1136/tc.2004.010611. 
68. Dent, L. A, Harris, K. J, Noonan, C. W. Randomized Trial Assessing the 
Effectiveness of a Pharmacist- Delivered Program for Smoking Cessation. The 
Annals of Pharmacotherapy  (2009); 43: 194- 201.  
69. Department for Communities and Local Government. The English Indices of 
Deprivation 2010. [Published March 2011, cited 6th September 2013]. Available 
from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/6871/
1871208.pdf. 
155 
 
70. Department of Health. A Vision for Pharmacy in the new NHS. [Published 
October 2003a; cited 20th August 2010]. Available from: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAn
dGuidance/DH_4070097 
71. Department of Health. Equity and excellence: Liberating the NHS. [Published 
July 2010; cited 23rd August 2013]. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/2138
23/dh_117794.pdf 
72. Department of Health. Guidance for providing and monitoring stop smoking 
services, 2011 to 2012. [Published March 2011a, cited 6th June 2013]. Available 
from: https://www.gov.uk/government/publications/guidance-for-providing-and-
monitoring-stop-smoking-services-2011-to-2012 
73. Department of Health. NHS (England) summarised accounts 2010-2011- 
summarised accounts of the strategic health authorities, primary care trusts and 
NHS trusts for the year ended 31 March 2011. [Published October 2011b; cited 10th 
October 2013]. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/2291
34/1297.pdf. 
74. Department of Health. Pharmacy in England: building on strengths – delivering 
the future. [Published April 2008a; cited 20th August 2010]. Available from: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAn
dGuidance/DH_083815 
75. Department of Health. Pharmacy in the future: implementing the NHS Plan. 
[Published September 2000a; cited 24th August 2013]. Available from: 
http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/e
n/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_40059
17. 
76. Department of Health. Putting prevention first- vascular checks: risk 
assessment and management. [Published April 2008b; cited 7th January 2014]. 
Available from: 
http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/publicationsandstati
stics/Publications/PublicationsPolicyAndGuidance/DH_083822. 
77. Department of Health. Response to the health select committee 5th report of 
the session 2002-03 on the control of entry regulations and retail pharmacy 
services in the UK. [Published July 2003b; cited 2nd  February 2014]. Available 
from: 
http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/pr
od_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4068
205.pdf 
 
156 
 
78. Department of Health. Saving our lives: Our Healthier Nation. [Published July 
1999; cited 24th September 2013]. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/2655
76/4386.pdf. 
79. Department of Health. Smoking Kills: a White paper on tobacco. [Published 
January 1998, cited 13th September 2013]. Available from: 
http://www.archive.official-documents.co.uk/document/cm41/4177/4177.htm 
80. Department of Health. The NHS Plan: a plan for investment, a plan for reform. 
[Published July 2000b; cited 25th September 2013]. Available from: 
http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/pr
od_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh
_118522.pdf. 
81. Department of Health. The NHS (Pharmaceutical Services) Regulations 2005- 
Information for Primary Care Trusts. [Published 2005; cited 2nd September 2014]. 
Available from: http://www.gpcwm.org.uk/wp-
content/uploads/file/PHARMACEUTICAL%20SERVICES/NHS_pharmaceutical_ser
vices_regs_2005_info_for_pcts.pdf 
82. Dhital, R, Norman, I, Whittlesea, C, McCambridge, J. Effectiveness of alcohol 
brief intervention delivered by community pharmacists: study protocol of a two-arm 
randomised controlled trial. BMC Public Health (2013); 13: 152- 159. 
doi:10.1186/1471-2458-13-152. 
83. Dhital, R, Whittlesea, C. M, Norman, I. J, Milligan, P.  Community pharmacy 
service users’ views and perceptions of alcohol screening and brief intervention. 
Drug and Alcohol Review (2010); 29(6): 596- 602. doi: 10.1111/j.1465-
3362.2010.00234.x. 
84. Doll R, Peto R, Boreham J, Sutherland, I. Mortality in relation to smoking: 50 
years’ observations on male British doctors. BMJ (2004); 10: 1136- 1145.  doi: 
http://dx.doi.org/10.1136/bmj.38142.554479.AE. 
85. Donyai, P, Berg, M. V. D. Coronary heart disease risk screening: the community 
pharmacy Healthy Heart Assessment Service. Pharm World Sci (2009); 31: 643–
647. doi: 10.1007/s11096-009-9338-4.  
86. Douglas, L, Szatkowski, L. Socioeconomic variations in access to smoking 
cessation interventions in UK primary care: insights using the Mosaic classification 
in a large dataset of primary care records. BMC Public Health (2013); 13: 546- 553. 
doi: 10.1186/1471-2458-13-546. 
87. Downing, S.G, Payze, C. Doyle-adams, S. Gorton, C. Emergency contraception 
over-the-counter: Practices and attitudes of pharmacists and pharmacy assistants 
in far North Queensland. Australian and New Zealand Journal of Obstetrics and 
Gynaecology (2011); 51: 527–531. doi: 10.1111/j.1479-828X.2011.01347.x. 
 
157 
 
88. Duggan, C, Evans, D, Holden, M, Kennington, E, Leach, R. 
Evaluation  of  the  Healthy  Living Pharmacy  work  programme  2011- 2012  
[Published April 2013, cited 5tof November 2013] available from: 
http://psnc.org.uk/wp-content/uploads/2013/08/HLP-evaluation.pdf. 
89. Eades, C.E, Ferguson, J.S, O'Carroll, R.E. Public health in community 
pharmacy: A systematic review of pharmacist and consumer views. BMC Public 
Health (2011); 11: 582. doi:10.1186/1471-2458-11-582. 
90. Elliott, R. A, Boyd, M. J, Waring, J, Barber, N, Mehta, R. Department of Health 
Policy Research Programme Project ‘Understanding and Appraising the New 
Medicines Service in the NHS in England (029/0124). [Published August 2014; 
cited 5th September  2014]. Available from: 
http://www.nottingham.ac.uk/~pazmjb/nms/downloads/report/index.html 
91. Ermisch, J, Pevalin, D.J. Early childbearing and housing choices.  Journal of 
Housing Economics (2004); 13: 170–194. doi: 10.1016/j.jhe.2004.07.001. 
92. Fagerström, K, Hughes, J. Varenicline in the treatment of tobacco dependence. 
Neuropsychiatric Disease and Treatment (2008); 4: 353- 363. 
93. Feenstra,T,.L, Hamberg-van Reenen, H,H, Hoogenveen, R.T, Mölken,R. Cost-
Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic 
Modeling Study. Value in Health (2005); 8: 178- 190. doi: 10.1111/j.1524-
4733.2005.04008.x 
94. Ferguson, A, Bauld, L, Chesterman, J, Judge, K. The English smoking 
treatment services: one-year outcomes. Addiction (2005); 100: 59- 69. doi: 
10.1111/j.1360-0443.2005.01028.x 
95. Finchman, J.E. Response Rates and Responsiveness for Surveys, Standards, 
and the Journal. American Journal of Pharmaceutical Education (2008); 72 (2) 
Article 43. 
96. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an 
adjunct to physicians’ smoking cessation counselling. JAMA (1996); 275 :1247– 
1251. doi:10.1001/jama.1996.03530400035035. 
97. Fitzgerald, N, Watson, H, McCaig, D, Stewart, D. Developing and evaluating 
training for community pharmacists to deliver interventions on alcohol issues. 
Pharm World Sci (2009); 31:149–153. doi: 10.1007/s11096-009-9284-1. 
98. Folkes, L, Graham, A, Weiss, M. A qualitative study of the views of women 
aged 18-29 on over-the counter availability of hormonal emergency contraception. 
The Journal of Family Planning and Reproductive Health Care (2001); 27(4):189- 
192. doi: 10.1783/147118901101195731. 
99. Food and Drug Administration. [Published March 2012, cited 18th September 
2013]. Available from: 
http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/u
cm297786.htm 
158 
 
100. Fraser, L. K, Edwards, K. L. The association between the geography of fast 
food outlets and childhood obesity rates in Leeds, UK. Health & Place (2010); 16: 
1124–1128. doi:10.1016/j.healthplace.2010.07.003. 
101. Fu, S, Burgess, D, Ryn, M, V, Hatsukami, D, K, Solomon, J, Joseph, A, M. 
Views on smoking cessation methods in ethnic minority communities: A qualitative 
investigation. Preventive Medicine (2007); 44: 235- 240. doi: 
10.1016/j.ypmed.2006.11.002. 
102. Fukuda, Y, Nakamura, K, Takano, T. Socioeconomic Pattern of Smoking in 
Japan: Income Inequality and Gender and Age Differences. AEP (2005);15: 365- 
372. doi: 10.1016/j.annepidem.2004.09.003. 
103. Gale, A. Watson, M. C. The provision of current and future sexual health 
services from community pharmacies in Grampian, Scotland. Int J Clin Pharm 
(2011); 33: 183– 190. doi: 10.1007/s11096-010-9458-x. 
104. Gidman, w. Increasing community pharmacy workloads in England: causes 
and consequences. Int J Clin Pharm (2011);33: 512- 520. doi: 10.1007/s11096-011-
9498-x. 
105. Gilman, S, E, Martin, L, T, Abrams, D, B. Smoking educational attainment and 
cigarette smoking: a causal association? International Journal of Epidemiology 
(2008); 37: 615–624. doi: 10.1093/ije/dym250. 
106. Giskes, K. Lenthe, F,J. Turrell, G, Mackenbach, J, P. Smokers living in 
deprived areas are less likely to quit: a longitudinal follow-up. Tobacco Control 
(2006); 15: 485- 488. doi: 10.1136/tc.2006.015750. 
107. Glasier A, Baird DT. The effects of self-administering emergency 
contraception. New Eng J Med (1998); 339: 1–4. doi: 
10.1056/NEJM199807023390101 
108. Glasier A. Emergency contraception. Is it worth all the fuss? BMJ (2006);333: 
560– 1. doi 10.1136/bmj.38960.672998.80. 
109. Glasier, A. Emergency contraception: clinical outcomes. Contraception (2013); 
87:  309– 313. doi: 10.1016/j.contraception.2012.08.027 
110. Glasier, A, Manners, R, Loudon, J. C, Muir, A. Community pharmacists 
providing emergency contraception give little advice about future contraceptive use: 
a mystery shopper study. Contraception (2010a); 82(6): 538- 542. doi: 
10.1016/j.contraception.2010.05.008 
111. Glasier, A.F, Cameron, S.T, Fine, P.M, Logan, S.J. Ulipristal acetate versus 
levonorgestrel for emergency contraception: a randomised non-inferiority trial and 
meta-analysis. The Lancet (2010b); 375: 555–562. doi: 10.1016/S0140-
6736(10)60101-8. 
 
159 
 
112. Gliem, J.A, Gliem, R.R. Calculating, interpreting, and reporting Cronbach's 
Alpha reliability coefficient for likert-type scales. Midwest Research to Practice 
Conference in Adult, Continuing, and Community Education, Ohio, USA (2003): 82–
88. 
113. Goodman A., Kaplan G. and Walker I. Understanding the effects of early 
motherhood in Britain: the effects on mothers. IFS Working Papers (2004); W04/20. 
114. Grimes, D, Hertzen, H. V, Piaggio, G, Van Look, P. F. A. Randomised 
controlled trial of levonrgesterl versus the Yuzpe regimen of combined oral 
contraceptives for emergency contraception. The Lancet (1998); 352: 428- 432. doi: 
10.1016/S0140-6736(98)05145-9  
115. Gross, T, Lafortune, J, Low, C. (2012). What happens the morning after? The 
costs and benefits of expanding access to emergency contraception. Unpublished 
Working Paper available at 
http://eco3147.facea.puc.cl/economia_puc/docs/dt_425.pdf 
116. Gudka, S, Bourdin, A, Watkins, K, Eshghabadi, A. Self-reported risk factors for 
chlamydia: a survey of pharmacy-based emergency contraception consumers. 
International Journal of Pharmacy Practice (2014);22: 13–19. doi: 
10.1111/ijpp.12042. 
117. Gudka, S, Marshall , L, Creagh, A, Clifford, R. M. To develop and measure the 
effectiveness and acceptability of a pharmacy-based chlamydia screening 
intervention in Australia. BMJ (2013) ; 3. doi:10.1136/bmjopen-2013-003338 
118. Gupta, N, Kuran, U, Bhal, K. Teenage pregnancies: Obstetric characteristics 
and outcome. European Journal of Obstetrics & Gynecology and Reproductive 
Biology (2008); 137: 165–171. doi: 10.1016/j.ejogrb.2007.06.013. 
119. Harden, A, Brunton, G, Fletcher, A. Teenage pregnancy and social 
disadvantage: systematic review integrating controlled trials and qualitative studies. 
BMJ (2009); 339: 254. doi: http://dx.doi.org/10.1136/bmj.b4254. 
120. Harrison-Woolrych M, Duncan, A,  Howe J, Smith, C. Improving access to 
emergency contraception. BMJ (2001); 322: 186– 187. doi: 
http://dx.doi.org/10.1136/bmj.322.7280.186/a. 
121. Hasan, S, Sulieman, H, Chapman, C. B, Stewart, K. Community pharmacy 
services in the United Arab Emirates. International Journal of Pharmacy Practice 
(2012); 20:  218– 225. doi: 10.1111/j.2042-7174.2011.00182.x. 
122. Hassel, K. Office of Fair Trading. The control of entry regulations and retail 
pharmacy services in the UK. [Published January 2003, cited 24th April 2011].  
Available from: http://www.kernowlmc.org.uk/OFT_Control_of_Entry_Regs.pdf 
 
 
160 
 
123. Hassell, K, Seston, E.M, Shafheutle, E.I, Wagner, A. Workload in community 
pharmacies in the UK and its impact on patient safety and pharmacists’ well-being: 
a review of the evidence. Health and Social Care in the Community (2011); 19(6): 
561– 575. doi: 10.1111/j.1365-2524.2011.00997.x. 
124. Health and Social Care Information Centre. General Pharmaceutical Services 
in England- 2002-2003 to 2011- 2012. [Published November 2012a, cited  24th 
January 2013]. Available from: 
http://www.hscic.gov.uk/searchcatalogue?productid=9731&q=general+pharmaceuti
cal+services&topics=1%2fPrimary+care+services%2fCommunity+pharmacy+servic
es&sort=Most+recent&size=10&page=1#top 
125. Health and Social Care Information Centre. General Pharmaceutical Services 
in England- 2003-2004 to 2012- 2013. [Published November 2013, cited  6th April 
2014]. Available from: http://www.hscic.gov.uk/article/2021/Website-
Search?productid=13373&q=general+pharmaceutical+service&sort=Relevance&siz
e=10&page=1&area=both#top 
126. Health and Social Care Information Centre. Statistics on Alcohol: England 
2011. [Published May 2011a, cited 3rd April 2014]. Available from: 
http://www.hscic.gov.uk/catalogue/PUB00144/alco-eng-2011-rep.pdf. 
127. Health and Social Care Information Centre. Statistics on Smoking- England 
2006. [Published August 2006 , cited 9th July 2013]. Available from: 
http://www.hscic.gov.uk/catalogue/PUB00662/smok-eng-2006-rep.pdf. 
128. Health and Social Care Information Centre. Statistics on NHS Stop Smoking 
Services- England, April 2010 to March 2011, Annual report. [Published August 
2011b, cited  8th September 2013]. Available from: 
http://www.hscic.gov.uk/catalogue/PUB00417/nhs-stop-smok-serv-eng-2010-2011-
rep.pdf. 
129. Health and Social Care Information Centre. Statistics on Smoking- England 
2012. [Published August 2012b, cited July 2013]. Available from: 
http://www.hscic.gov.uk/catalogue/PUB07019. 
130. Health and Social Care Information Centre. Statistics on NHS Stop Smoking 
Services- England, April 2009 to March 2010, Annual report. [Published August 
2010, cited  September 2013]. Available from: 
http://www.hscic.gov.uk/searchcatalogue?productid=1220&q=title%3a%22Statistics
+on+NHS+Stop+Smoking+Services%22&sort=Relevance&size=10&page=2#top 
131. Health & Social Care Information Centre. Statistics on Smoking: England, 
2007. [Published September 2007, cited 2nd July 2013]. Available from: 
http://www.hscic.gov.uk/article/2021/Website-
Search?productid=1275&q=title%3a%22Statistics+on+Smoking%22&sort=Relevan
ce&size=10&page=2&area=both#top 
161 
 
132. Heikkinen, H, Patja, K,  Jallinoja, P. Smokers’ accounts on the health risks of 
smoking: Why is smoking not dangerous for me? Social Science & Medicine 
(2010); 71:  877- 883. doi: 10.1016/j.socscimed.2010.05.036.  
133. Hendricks, P. S, Ditre, J. W, Drobes, D. J. The early time course of smoking 
withdrawal effects. Psychopharmacology (2006); 187: 385– 396.doi: 
10.1007/s00213-006-0429-9 
134. Henkler, F, Luch, A. E‑cigarettes in Europe: does regulation swing from 
overcautious to careless? Arch Toxicol (2014); 88: 1291–1294. doi: 
10.1007/s00204-014-1293-8. 
135. Hertzen, H. V, Piaggio, G, Peregoudov, A, Ding, J. Low dose mifepristone and 
two regimens of levonorgestrel for emergency contraception: a WHO multicentre 
randomised trial. The Lancet (2002); 360- 1803- 1810. doi: doi:10.1016/S0140-
6736(02)11767-3. 
136. Hertzog, M. A. Considerations in Determining Sample Size for Pilot Studies. 
Research in Nursing & Health (2008); 31: 180– 191. doi: 10.1002/nur.20247. 
137. Hinchliffe, A. Literature review: emergency hormonal contraception and other 
interventions to reduce teenage pregnancy. Public Health Wales NHS Trust (2010). 
[Published July 2019; cited 12th January 2013]. Available from: 
https://www2.nphs.wales.nhs.uk/PharmaceuticalPHTDocs.nsf/($All)/C3D14C48910
CF6378025723500377DF6/$File/Microsoft%20Word%20-%20Literature%20review-
%20emergency%20hormonal%20contraception%20_update%202010_.pdf?OpenEl
ement. 
138. Hiscock, R, Bauld, L, Amos, A, Fidler, Plarr, S. Smoking and socioeconomic 
status in England: the rise of the never smoker and the disadvantaged smoker. 
Journal of Public Health (2012a); 34: 390- 396. doi: 10.1093/pubmed/fds012. 
139. Hiscock, R, Bauld, L, Amos, A, Fidler, J, A, Munaf, M. Socioeconomic status 
and smoking: a review. Ann. N. Y. Acad. Sci (2012b); 1248, 107- 123. doi: 
10.1111/j.1749-6632.2011.06202.x. 
140. Horgan, J. M. P, Blenkinsopp, A, McManus, R. J. Evaluation of a 
cardiovascular disease opportunistic risk assessment pilot (‘Heart MOT’ service) in 
community pharmacies. Journal of Public Health (2010); 32(1): 110-116. doi: 
10.1093/pubmed/fdp092. 
141. Horsfield, E, Kelly, F, Sheridan, J, Stewart, J. Could community pharmacies 
help to improve youth health? Service availability and views of pharmacy personnel 
in New Zealand. Int J Public Health (2014). doi:10.1007/s00038-014-0593 
142. Hudson, B, Boylan, M. The School of Pharmacy, University of London: 
Medicines Science and Society, 1842-2012; (2013). Available from: 
http://www.sciencedirect.com/science/book/9780124076655  
162 
 
143. Huisman, M, Kunst, A.E, Mackenbach, J.P. Inequalities in the prevalence of 
smoking in the European Union: comparing education and income. Preventive 
Medicine (2005); 40: 756– 764. doi:10.1016/j.ypmed.2004.09.022.  
144. Hukkanen, J, Jacob, P, Benowitz, N, L. Metabolism and Disposition Kinetics of 
Nicotine. Pharmacological Reviews (2005); 57: 79- 115. doi: 10.1124/pr.57.1.3.   
145. Hutzler, C, Paschke, M, Kruschinski, S, Henkler, F, Hahn, J, Luch, A. 
Chemical hazards present in liquids and vapors of electronic cigarettes. Arch 
Toxicol (2014); 88: 1295– 1308. doi: 10.1007/s00204-014-1294-7. 
146. Jacobs, S, Hassell, K, Ashcroft, D, Johnson, S. Workplace stress in 
community pharmacies in England: associations with individual, organizational and 
job characteristics. Journal of Health Services Research & Policy (2014); 19(1): 27–
33. doi: 10.1177/1355819613500043. 
147. Jackson, R, A, Schwarz, E. B, Freedman, L, Darney, P. Advance Supply of 
Emergency Contraception: Effect on Use and Usual Contraception—A Randomized 
Trial. The American College of Obstetricians and Gynecologists (2003); 102: 8- 16.  
148. Jarvis, M.J. ABC of smoking cessation- Why people smoke. BMJ (2004); 328: 
227- 279. 
149. Jha, P, Peto, Zatonski, W, Boreham, J, Jarvis, M, J, Lopez, A, D. Social 
inequalities in male mortality, and in male mortality from smoking: indirect 
estimation from national death rates in England and Wales, Poland, and North 
America. The Lancet (2006); 368: 367- 370. doi: 10.1016/S0140-6736(06)68975-7. 
150. Jha, P, Ramasundarahettige, C, Landsman, V. 21st-Century Hazards of 
Smoking and Benefits of Cessation in the United States. The new England Journal 
of Medicine (2013); 368: 341- 350. doi:10.1056/NEJMsa1211128. 
151. Jolly, K, Lewis, A, Beach, J, Denley, J. Comparison of range of commercial or 
primary care led weight reduction programmes with minimal intervention control for 
weight loss in obesity: Lighten Up randomised controlled trial. BMJ (2011); 343: 1- 
16.  doi: http://dx.doi.org/10.1136/bmj.d7243. 
152. Kaplan G, Goodman A, Walker I (2004), Understanding the Effects of Early 
Motherhood in Britain: the Effects on Mothers. Economic Research Papers (2004); 
706. Coventry: University of Warwick. 
153. Karlsen, S, Millward, D, Sandford, A. Investigating ethnic differences in current 
cigarette smoking over time using the health surveys for England. European 
Journal of Public Health (2011); 22: 254- 256. doi: 10.1093/eurpub/ckr097. 
154. Khan, N. S, Norman, I. J, Dhital, R, McCrone, P. Alcohol brief intervention in 
community pharmacies: a feasibility study of outcomes and customer experiences. 
Int J Clin Pharm (2013) ; 35: 1178– 1187.  doi:10.1007/s11096-013-9845-1. 
155. Killick, S. R, Irving, G. A national study examining the effect of making 
emergency hormonal contraception available without prescription. Human 
Reproduction (2004); 19: 553- 557. doi: 10.1093/humrep/deh128. 
163 
 
156. Kissiwaa, S, Simpson, M.D, Burton, D.L. Smoking cessation and the 
pharmacy: what are the issues that need to be addressed before the 
implementation of an intensive pharmacy based smoking cessation programme? 
Pharmacists and pharmacy assistant perspective. Innovative Journal of Medical 
and Health Science (2012); 2: 112 – 117. 
157. Kotz D, West, R. Explaining the social gradient in smoking cessation: it's not in 
the trying, but in the succeeding. Tob Control (2009), 18: 43- 46. doi: 
10.1136/tc.2008.025981 
158. Krska, J, Lovelady, C, Connolly, D, Parmer, S. Community pharmacy 
contribution to weight management: identifying opportunities. International Journal 
of Pharmacy practice (2010); 18: 7- 12. doi: 10.1211/ijpp/18.01.0003. 
159. Krska,J, Mackridge, A. J. Involving the public and other stakeholders in 
development and evaluation of a community pharmacy alcohol screening and brief 
advice service. Drug and Alcohol Review (2013); 32:  147– 156. doi: 
10.1111/j.1465-3362.2012.00513.x. 
160. Lader, D. (2007). Smoking-related Behaviour and Attitudes, 2006. London: 
The Office for National Statistics. Available from: 
http://www.ons.gov.uk/ons/rel/lifestyles/smoking-related-behaviour-and-
attitudes/2006/index.html 
161. Laliberté, M, Perreault, S, Damestoy, N, Lalonde, L. Ideal and actual 
involvement of community pharmacists in health promotion and prevention: a cross-
sectional study in Quebec, Canada. BMC Public Health (2012);12: 192- 201. doi: 
10.1186/1471-2458-12-192. 
162. Lancaster, G. A, Dodd, S, Williamson, P. R. Design and analysis of pilot 
studies: recommendations for good practice. Journal of Evaluation in Clinical 
Practice (2004); 10: 307– 312. doi: 10.1111/j..2002.384.doc.x 
163. Lea VM, Corlett, SA, Rodgers, RM. Workload and its impact on community 
pharmacists' job satisfaction and stress: a review of the literature. Int J Pharm Pract 
(2012);20: 259-71. doi: 10.1111/j.2042-7174.2012.00192.x. 
164. Legislation.gov.uk. Health Act 2009. [Published 2009; cited 22th October 
2013]. Available from: http://www.legislation.gov.uk/ukpga/2009/21/contents 
165. Lewington, G, Marshall, K. Access to emergency hormonal contraception from 
community pharmacies and family planning clinics. British Journal of Pharmacology 
(2006); 61(5): 605- 608. doi:10.1111/j.1365-2125.2006.02623.x. 
166. Lloyd, K, Gale, E. Provision of emergency hormonal contraception through 
community pharmacies in a rural area. J Fam Plann Reprod Health Care (2005); 
31(4): 297- 300. doi: 10.1783/jfp.31.2.297. 
167. Low. A, Unsworth. L, Miller. I. Avoiding the danger that stop smoking services 
may exacerbate health inequalities: building equity into performance assessment. 
BMC Public Health  (2007); 7: 198. doi:10.1186/1471-2458-7-198. 
164 
 
168. Low, N,  McCarthy, A, Macleod, J, Salisbury, C. Epidemiological, social, 
diagnostic and economic evaluation of population screening for genital chlamydial 
infection. Health Technology Assessment (2007); 11: 1-148. doi: 10.3310/hta11080. 
169. Lowey H, Tocque K, Bellis MA et al. Smoking cessation services are reducing 
inequalities. J Epidemiol Community Health. (2003); 57(8): 579– 580. 
doi:10.1136/jech.57.8.579 
170. Maguire, T.A, Mcelnay, J.C, Drummonda, A. Randomized controlled trial of a 
smoking cessation intervention based in community pharmacies. Addiction (2001); 
96: 325- 331. doi: 10.1046/j.1360-0443.2001.96232516.x 
171. Mandelblatt, J. S, Fryback, D.G, Weinstein, M. C, Russell, L. B. Assessing the 
effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-
Effectiveness in Health and Medicine. J Gen Inern Med  (1997); 12: 551– 558 
172. Marciante, K.D, Gardner, J.S, Veenstra, D.L, Sullivan, S.D. Modeling the Cost 
and Outcomes of Pharmacist-Prescribed Emergency Contraception. American 
Journal of Public Health (2001); 91: 1443- 1445. 
173. Marston, C, Meltzer, H, Majeed, A. Impact on contraceptive practice of making 
emergency hormonal contraception available over the counter in Great Britain: 
repeated cross sectional surveys. BMJ (2005); 331: 271- 276. doi: 
http://dx.doi.org/10.1136/bmj.38519.440266.8F. 
174. McAllister, K. F, Elliott, L, Thomson, D. A, Bigrigg, A.  Evaluation of a young 
person’s sexual health service in a commercial setting.  The Journal of Family 
Planning and Reproductive Health Care (2002); 28(4): 203–206. doi: 
10.1783/147118902101196586. 
175. McCabe, C. What is cost–utility analysis?. Hayward Group Ltd, February 2009. 
Available from: 
http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/What_is_cost-
util.pdf  
176. McCaig, D, Fitzgerald, N, Stewart, D. Provision of advice on alcohol use in 
community pharmacy: a cross-sectional survey of pharmacists’ practice, 
knowledge, views and confidence. International Journal of Pharmacy practice 
(2011); 19 (3): 171- 178. doi: 10.1111/j.2042-7174.2011.00111.x. 
177. McEwen, A, West, R, McRobbie, H. Effectiveness of specialist group treatment 
for smoking cessation vs. one-to-one treatment in primary care. Addictive 
Behaviours (2006); 31: 1650-1660. doi: 10.1016/j.addbeh.2005.12.014. 
178. McNaughton, R. J, Oswald, N. T. A, Shucksmith, J. S, Heywood, P.J. Making 
a success of providing NHS Health Checks in community pharmacies across the 
Tees Valley: a qualitative study. BMC Health Services Research (2011); 11: 222- 
228. doi:10.1186/1472-6963-11-222. 
179. McNeill, A, Raw, M, Whybrow, J, Bailey, P. A national strategy for smoking 
cessation treatment in England. Addiction (2005); 100: 1-11. doi: 10.1111/j.1360-
0443.2005.01022.x. 
165 
 
180. Medicines and Healthcare Products Regulatory Agency. Azithromycin 
reclassification: pharmacy availability to treat chlamydia. [Published September 
2008, cited 17th May 2014]. Available from: 
http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON094193. 
181. Medicines and Healthcare Products Regulatory Agency. Change in dose of 
emergency contraceptive (Levonelle). [Published December 2003; cited 5th 
January 2013]. Available from: 
http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywa
rningsandmessagesformedicines/CON2015690. 
182. Medicines and Healthcare Products Regulatory Agency. Legal status and 
reclassification. [Updated  May 2013a, cited 24th February 2014]. Available from: 
http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Legalstat
usandreclassification/. 
183. Medicines and Healthcare Products Regulatory Agency. Patient Group 
Directions in the NHS. [Updated December 2013b, cited 22th March 2014]. 
Available from: 
http://www.mhra.gov.uk/Howweregulate/Medicines/Availabilityprescribingsellingand
supplyingofmedicines/ExemptionsfromMedicinesActrestrictions/PatientGroupDirecti
onsintheNHS/index.htm. 
184. Medicines and Healthcare Products Regulatory Agency. Stop smoking 
treatments. [Updated February 2014, cited 24th March 2014]. Available from: 
http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Prod
uct-specificinformationandadvice/Product-
specificinformationandadvice%E2%80%93M%E2%80%93T/Stopsmokingtreatment
s/index.htm 
185. Merks,P, Kaźmierczak,J, Olszewska, A.E, Kołtowska-Häggström, M. 
Comparison of factors influencing patient choice of community pharmacy in Poland 
and in the UK, and identification of components of pharmaceutical care. Patient 
Preference and Adherence (2014); 8: 715– 726. doi: 10.2147/PPA.S53829. 
186. Meshack, A, Moultry, A.M, Hu, S, McAlister, A.L. Smoking Cessation 
Counseling Practices of Texas Pharmacists. J Community Health (2009); 34: 231– 
238. doi: 10.1007/s10900-008-9146-0. 
187. Molyneux, A. ABC of smoking cessation Nicotine Replacement Therapy. BMJ 
(2004); 328: 454- 456. 
188. Momin, B, Neri, A, McCausland, K, Duke, J, Hansen, H. Traditional and 
Innovative Promotional Strategies of Tobacco Cessation Services: A Review of the 
Literature. J Community Health (2014); 39: 800– 809. doi: 10.1007/s10900-014-
9825-y. 
189. Montouchet, C, Trussell, J. Unintended pregnancies in England IN 2010: costs 
to the National Health Service (NHS). Contraception (2013); 87(2): 149– 153. doi: 
10.1016/j.contraception.2012.06.008 
166 
 
190. Morrison, D, McLoone, P, Brosnahan, N, McCombie, L. A community 
pharmacy weight management programme: an evaluation of effectiveness. BMC 
Public Health (2013); 13: 382- 389. doi: 10.1186/1471-2458-13-282. 
191. Murray, R. L, Bauld, L, Hackshaw, L.E, McNeill, A. Improving access to 
smoking cessation service for disadvantaged groups: a systematic review. Journal 
of Public Health (2009); 31: 258- 277. doi: 10.1093/pubmed/fdp008. 
192. National Chlamydia Screening Programme. Guidance for the development of 
specifications for the commissioning of chlamydia screening in General Practice 
and Community Pharmacy. [Published  March 2010a, cited 25th June 2014]. 
Available from: 
http://www.chlamydiascreening.nhs.uk/ps/resources/guidelines/guidance_developm
ent_of_specifications.pdf 
193. National Chlamydia Screening Programme. Home page on the internet. 
[Published 2013, cited 24th April 2014]. Available from: 
http://www.chlamydiascreening.nhs.uk/. 
194. National Chlamydia Screening Programme. NHS Vital Signs 2009/10. 
[Published 2010b, cited 11th June 2011]. Available from: 
http://www.chlamydiascreening.nhs.uk/ps/resources/data-
tables/VSI_by_PCT_Apr09_Mar10.pdf 
195. NHS Ashton, Leigh and Wigan. Pharmaceutical Needs Assessment. 
[Published February 2011, cited 24th March 2011]. Available from: 
http://www.wigan.gov.uk/Docs/PDF/Council/Strategies-Plans-and-
Policies/HealthAndSocialCare/JSNA/NHSALWPharmaceuticalNeedsAssessment-
Finalversion.pdf 
196. National Health Services Choices. Emergency contraception (morning after 
pill, IUD). [Updated January 2013, cited 24th May 2014]. Available from: 
http://www.nhs.uk/Conditions/contraception-guide/Pages/emergency-
contraception.aspx. 
197. NHS Portsmouth. Healthy Living Pharmacy Prospectus. [Published December 
2009; cited 16th September 2014]. Available from: http://www.networks.nhs.uk/nhs-
networks/hlp-pathfinder-sites/documents/hlp-
prospectus/072HealthyLivingPharmacyFINAL.pdf 
198. National Institute for Health and Care Excellence. The guidelines manual. 
[Published November 2012; cited 15th August 2013]. Available from: 
http://publications.nice.org.uk/the-guidelines-manual-pmg6/about-this-manual. 
199. National Pharmacy association. Healthy Living Champion course and Applied 
Award. [Updated 2014; cited 16th September 2014]. Available from: 
http://www.npa.co.uk/Developing-Teams-Careers/NPA-Learning/Healthy-Living-
Champion-course-and-Applied-Award/    
167 
 
200. Newlands, R. S, Watson, M. C, Lee, A. J. The provision of current and future 
Healthy Weight Management (HWM) services from community pharmacies: a 
survey of community pharmacists’ attitudes, practice and future possibilities. 
International Journal of Pharmacy practice (2011); 19(2): 106- 114. doi: 
10.1111/j.2042-7174.2010.00080.x. 
201. Nowak, D, Jörres, R.A, Rüther, T. E-Cigarettes—Prevention, Pulmonary 
Health, and Addiction. Dtsch Arztebl Int (2014); 111: 349-355. doi: 
10.3238/arztebl.2014.0349. 
202. Noyce, P.R. Providing Patient Care Through Community Pharmacies in the 
UK: Policy, Practice, and Research. The Annals of Pharmacotherapy (2007); 41: 
861-868. 
203. O'Donnell, S. C, Brown, C. M, Dastani, H. B.Barriers to Counseling Patients 
With Obesity: A Study of Texas Community Pharmacists. J Am Pharm 
Assoc (2006); 46(4): 465- 471.  
204. Office of Fair Trading. Evaluating the impact of the 2003 OFT study on the 
Control of Entry regulations in the retail pharmacies market. [Published  March 
2010, cited 11th January 2014]. Available from: 
http://www.dotecon.com/assets/images/oft1219.pdf. 
205. Office for National Statistics. Population estimates by ethnic group 
(experimental), mid-2009. [Published May 2011, Accessed 15th September 2012]. 
Available from: http://www.ons.gov.uk/ons/rel/peeg/population-estimates-by-ethnic-
group--experimental-/current-estimates/population-estimates-by-ethnic-group-mid-
2009-for-primary-care-organisations--experimental-.xls. 
206. Oza, A.. Plan b as insurance: The effect of over-the-counter emergency 
contraception on pregnancy terminations and STIs. Unpublished Working Paper. 
Retrieved from Indiana University-Purdue University Indianapolis Department of 
Economics website. [Published  October 2009; cited 25th January 2013] Available 
from:  http://liberalarts.iupui.edu/economics/uploads/docs/oza.pdf. 
207. Oza, S, Thun, M, J, Henley, S, J, Lopez, A, D, Ezzati, M. How many deaths 
are attributable to smoking in the United States? Comparison of methods for 
estimating smoking-attributable mortality when smoking prevalence changes. 
Preventive Medicine (2011); 52: 428–433. doi: 10.1016/j.ypmed.2011.04.007. 
208. Park, E.R, Chang, Y, Quinn, V, Regan, S, Cohen, L. The association of 
depressive, anxiety, and stress symptoms and postpartum relapse to smoking: A 
longitudinal study. Nicotine & Tobacco Research (2009); 11: 707– 714. doi: 
10.1093/ntr/ntp053. 
209. Parson, J, Adams, C, Aziz, N, Holmes, J. Evaluation of a community pharmacy 
delivered oral contraception service. Journal of Family Planning and Reproductive 
Health Care (2013); 39: 97– 101. doi:10.1136/jfprhc-2012-100304 
210. Peipert J.F. Genital Chlamydial Infections. New England Journal of 
Medicine (2003); 349: 2424-2430. doi: 10.1056/NEJMcp030542 
168 
 
211. Peipert, J.F, Madden, T, Allsworth, J.E, Secura, M. Preventing Unintended 
Pregnancies by Providing No-Cost Contraception. Obstet Gynecol (2012); 120(6): 
1291–1297. doi: http://10.1097/AOG.0b013e318273eb56. 
212. Pfleger D, McHattie L, Diack H, McCaig D, Stewart D. Views, attitudes and self 
assessed training needs of Scottish community pharmacists to public health 
practice and competence. Pharmacy World and Science (2008); 30: 801-809. doi: 
10.1007/s11096-008-9228-1 
213. Pharmaceutical Services Negotiating Committee. Services specifications and 
resources. [Updated 2014, Accessed 11th June 2014]. Available from: 
http://psnc.org.uk/services-commissioning/locally-commissioned-services/service-
specifications-and-resources/ 
214. Phillips, C.  What is cost effectiveness? Hayward Group Ltd, February 2009. 
Available from: 
http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/Cost-effect.pdf 
215. Phillips, C, Thompson, G. What is QALY? Hayward Group Ltd, April 2009. 
Available from: 
http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/QALY.pdf 
216. Pirie, K, Peto, R, Reeves,G, K, Green,J, Beral, V. The 21st century hazards of 
smoking and benefits of stopping: a prospective study of one million women in the 
UK. The Lancet (2013); 381: 133–141. doi: http://dx.doi.org/10.1016/S0140-
6736(12)61720-6. 
217. Pisinger, C, Aadahl, M, Toft, U, Jørgensen, T. Motives to quit smoking and 
reasons to relapse differ by socioeconomic status. Preventive Medicine (2011); 52: 
48–52. doi: 10.1016/j.ypmed.2010.10.007. 
218. Primary Care Commissioning. Pharmacy enhanced services from 1 April 2013. 
[Published April 2013, cited 5th August 2014]. Available from: http://www.pcc-
cic.org.uk/article/pharmacy-enhanced-services-1-april-2013. 
219. Public Health England. Consolidating and developing the evidence base and 
research for community pharmacy’s contribution to public health: a progress report 
from Task Group 3 of the Pharmacy and Public Health Forum. [Published January 
2014, cited 4th  September 2014]. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/2716
82/20140110-Community_pharmacy_contribution_to_public_health.pdf 
220. Public Health England. Welcome to Health Profiles. [Published July 2010, 
cited 25th July 2010]. Available from: 
http://www.apho.org.uk/default.aspx?QN=HP_FINDSEARCH2012 
221. Richardson, E, Pollock, A. M. Community pharmacy: moving from dispensing 
to diagnosis and treatment. BMJ (2010); 340: 1066- 1068. doi: 
http://dx.doi.org/10.1136/bmj.c2298.  
169 
 
222. Roddy, E, Antoniak, M, Britton, J. Barriers and motivators to gaining access to 
smoking cessation services amongst deprived smokers – a qualitative study. BMC 
Health Services Research (2006); 6: 147- 153. doi:10.1186/1472-6963-6-147 
223. Royal Pharmaceutical Society. History of pharmacy. [Published 2014, cited 
11th May 2014]. Available from: http://www.rpharms.com/about-pharmacy/history-of-
pharmacy.asp 
224. Saba, M, Diep, J, Bittoun, R, Saini, B. Provision of smoking cessation services 
in Australian community pharmacies: a simulated patient study. Int J Clin Pharm 
(2014); 36: 604– 614. doi: 10.1007/s11096-014-9944-7. 
225. Santos, J. R. Cronbach's Alpha: A tool for assessing the reliability of 
scales. Journal of Extension  (1999), 37(2). Available 
from: http://www.joe.org/joe/1999april/tt3.html 
226. Sarayani, A, Rashidian, A, Gholami, K.Efficacy of Continuing Education in 
Improving Pharmacists’ Competencies for Providing Weight Management Service: 
Three-Arm Randomized Controlled Trial. Journal of Continuing Education in Health 
Professions (2012); 32: 165- 173. doi: 10.1002/chp.  
227. Saunders, J.M, Mercer, C.H, Sutcliffe, L.J, Hart, G.J. Where do young men 
want to access STI screening? A stratified random probability sample survey of 
young men in Great Britain. Sex Transm Infect (2012); 88; 427–  432. 
doi:10.1136/sextrans-2011-050406 
228. Schunck, R. Rogge, B.G. No causal effect of unemployment on smoking? A 
German panel study. International Journal of Public Health (2012); 57: 867- 874. 
doi: 10.1007/s00038-012-0406-5. 
229. Schillo, B.A, Mowery, A, Greenseid, L.O, Luxenberg, M. G, Zieffler, A. The 
relation between media promotions and service volume for a statewide tobacco 
quitline and a web-based cessation program. BMC Public Health (2011); 11: 939- 
948. doi:10.1186/1471-2458-11-939 
230. Seston, E. M, Elliott, R. A, Noyce, P. R, Payne, K. Women’s preferences for 
the provision of emergency hormonal contraception services. Pharmacy world & 
Science (2007); 29(3): 183- 189. doi: 10.1007/s11096-006-9068-9. 
231. Seston, E.M, Holden, K, Cantrill, J. Emergency hormonal contraception: The 
community pharmacy perspective. The Journal of Family Planning and 
Reproductive Health Care (2001); 27(4): 203-208. doi: 
10.1783/147118901101195768. 
232. Seston L, Hassel K. Royal Pharmaceutical Society of Great Britain. Pharmacy 
Workforce Census 2008. [Published July 2009, cited 12th August 2013]. Available 
from: http://www.rpharms.com/about-pharmacy-pdfs/census08.pdf 
233. Sinclair, HK, Bond, CM, Stead, LF. Community pharmacy personnel 
interventions for smoking cessation (Review). Cochrane Database Systematic 
Review (2004); 4. 
170 
 
234. Sinclair, HK, Silcock, J, Bond, CM, Lennox, AS. The cost effectiveness of 
intensive pharmaceutical intervention in assisting people to stop smoking. Int J 
Pharm Pract (1999); 7: 107- 112. doi:10.1111/j.2042-7174.1999.tb00957.x 
235. Sindelar, J.L, O'Malley, S.S. Financial versus health motivation to quit 
smoking: A randomized field study. Preventive Medicine (2014); 59: 1– 4. doi: 
10.1016/j.ypmed.2013.10.008. 
236. Smith, F. Private local pharmacies in low- and middle-income countries: a 
review of interventions to enhance their role in public health. Tropical Medicine and 
International Health (2009); 14(3): 362- 372.  doi:10.1111/j.1365-
3156.2009.02232.x. 
237. Social Exclusion Unit (SEU) (1999) Teenage Pregnancy. London: Stationery 
Office. [Published  June 1999; cited 5th January 2013]. Available from:  
http://dera.ioe.ac.uk/15086/1/teenage-pregnancy.pdf. 
238. Sonnenberg, F. A, Burkman, R. T, Hagerty, C. G, Speroff, L. Theodore. Costs 
and net health effects of contraceptive methods. Contraception (2004); 69:  447– 
459. doi: 10.1016/j.contraception.2004.03.008. 
239. Sonnenberg, P, Cliffton, S, Beddows, S, Field, N. Prevalence, risk factors, and 
uptake of interventions for sexually transmitted infections in Britain: findings from 
the National Surveys of Sexual Attitudes and Lifestyles (Natsal). The Lancet( 2013); 
382: 1795–806. doi: 10.1016/S0140-6736(13)61947-9. 
240. Stafford, M., Brunner, E. J., Head, J. & Ross, N. A. Deprivation and the 
development of obesity a multilevel, longitudinal study in England. American 
Journal of Preventative Medicine (2010); 39: 130-139. doi: 
10.1016/j.amepre.2010.03.021. 
241. Stapleton, J. Cigarette smoking prevalence, cessation and relapse. Statistical 
Methods in Medical Research (1998); 7: 187- 203. 
doi: 10.1177/096228029800700206 
242. Stead, LF, Perera, R, Bullen, C, Mant, D, Hartmann-Boyce, J, Cahill, K, 
Lancaster, T. Nicotine replacement therapy for smoking cessation. Cochrane 
Database of Systematic Reviews (2012); 1: CD000146. 
doi:10.1002/14651858.CD000146.pub4. 
243. Taylor, M.  What is sensitivity analysis. Consortium YHE: University of York. 
(2009):1-8. Available from: 
http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/What_is_sens_an
aly.pdf. 
244. Taylor, J, Krska, J, Mackridge, A. A community pharmacy-based 
cardiovascular screening service: views of service users and the public. 
International Journal of Pharmacy Practice  (2012); 20:  277– 284. doi: 
10.1111/j.2042-7174.2012.00190.x. 
171 
 
245. Taylor, K. M. G., Harding, G. Pharmacy Practice [e- book]. Hoboken: Taylor 
and Francis; 2003. p. 5- 27 [cited 26 August  2013]. Available from: Ebook Library: 
http://www.kingston.eblib.com/patron/FullRecord.aspx?p=198366. 
246. Thabane, L, Mbuagbwa, L, Zhang, S, Samaan, Z. A tutorial on sensitivity 
analyses in clinical trials: the what, why, when and how.  BMC Medical Research 
Methodology (2013); 13: 92- 103. 
247. The Scottish Government. Review of the Community Pharmacy Public Health 
Service for Smoking Cessation and Emergency Hormonal Contraception. 
[Published 2011, cited 24th August  2013]. Available from: 
http://www.scotland.gov.uk/Resource/Doc/363654/0123440.pdf  
248. Thomas, C. M, Schmid, R, Cameron, S. Is it worth paying more for emergency 
hormonal contraception? The cost-effectiveness of ulipristal acetate versus 
levonorgestrel 1.5 mg. J Fam Plann Reprod Health Care (2010a); 36: 197-  201. 
doi: 10.1783/147118910793048656.  
249. Thomas, G, Humphris, G, Ozakinci, G,  O'Brien, K.  A qualitative study of 
pharmacists’ views on offering chlamydia screening to women requesting 
emergency hormonal contraception. An International Journal of Obstetrics & 
Gynaecology (2010b); 117(1): 109- 113. doi: 10.1111/j.1471-0528.2009.02362.x. 
250. Todd, A, Copeland, A, Husband, A, Kasim, A. The positive pharmacy care law: 
an area-level analysis of the relationship between community pharmacy distribution, 
urbanity and social deprivation in England. BMJ Open (2014); 4: 1- 8. doi: 
10.1136/bmjopen-2014-005764. 
251. Trojesen, I. E-cigarretes are to be regulated as medicines from 2016. BMJ 
(2013); 346: f3859. 
252. Tinelli, M, Blenkinsopp, A, Latter, S, Smith, A, Chapman, S.R. Survey of 
patients’ experiences and perceptions of care provided by nurse and pharmacist 
independent prescribers in primary care Health Expectations (2013); 16: 113– 224. 
doi: 10.1111/hex.12099. 
253. Tremblay, M, Cournoyer, D, O'Loughlin, J. Do the correlates of smoking 
cessation counseling differ across health professional groups? Nicotine & Tobacco 
Research (2009); 11(11): 1330- 1338. doi: 10.1093/ntr/ntp142. 
254. Trussell, J, Lallac, A.M, Donac, Q.V, Reyes, E. Cost Effectiveness of 
Contraceptives in the United States. Contraception (2009); 79(1): 5– 14. doi: 
10.1016/j.contraception.2008.08.003. 
255. Um, I. S, Armour, C. Krass, I, Gill, T, Chaar, B. B. Consumer perspectives 
about weight management services in a community pharmacy setting in NSW, 
Australia. Health Expectations (2012); 17: 579- 592. doi: 10.1111/j.1369-
7625.2012.00788.x 
172 
 
256. Um, I. S, Armour, C. Krass, I, Gill, T, Chaar, B. B. Managing obesity in 
pharmacy: the Australian experience. Pharm World Sci (2010) ;  32: 711– 720. doi:  
10.1007/s11096-010-9426-5. 
257. Verma, A, Harrison, A, Torun, P, Vestbo, J. Edwards, R. Are pharmacists 
reducing COPD’S impact through smoking cessation and assessing inhaled steroid 
use? Respiratory Medicine (2012);106: 230- 234. doi: 10.1016/j.rmed.2011.08.011. 
258. Warner, C, Shoain, M. How does bupropion work as a smoking cessation aid? 
Addiction Biology (2005); 10: 219 – 231. doi: 10.1080/13556210500222670 
259. Weidmann, A.E, Cunningham, S, Gray, G, Hansford, D, Bermano, G, Stewart, 
D. Views of the Scottish general public on community pharmacy weight 
management services: international implications. Int J Clin Pharm (2012); 34: 389– 
397. doi: 10.1007/s11096-012-9624-4. 
260. Weiss, M. C, Booth, A, Jones, B, Ramjeet, S. Use of simulated patients to 
assess the clinical and communication skills of community pharmacists. Pharmacy 
world & Science (2010); 32(3): 353- 361. doi: 10.1007/s11096-010-9375-z. 
261. West R. ‘Payment by results’ and smoking cessation support. Addiction 
(2011);106: 1730–1731. 
262. West, R, McNeill, A, Raw, M. Smoking cessation guidelines for health 
professionals: an update. Thorax (2000);55: 987- 999. 
263. West, R, May, S, West, M, Croghan, E. Performance of English stop smoking 
services in first 10 years: analysis of service monitoring data. BMJ (2013); 347: 1-9. 
doi: http://dx.doi.org/10.1136/bmj.f4921. 
264. Whalley, B.J, Fletcher, K, Weston, S, Howard, R. Foundation in Pharmacy 
Practice [e- book]. Royal Pharmaceutical Society; 2008. p. 9- 22. [cited 26 August  
2013]. Available from: https://www.dawsonera.com/abstract/9780853699408.    
265. White, M, Bush, J, Kai, J, Bhopal, R, Rankin, J. Quitting smoking and 
experience of smoking cessation interventions among UK Bangladeshi and 
Pakistani adults: the views of community members and health professionals. J 
Epidemiol Community Health (2006); 60:405–411. doi: 10.1136/jech.2005.040345. 
266. Wibowo, Y, Berbatis, C, Joyce, J, Sunderland, V. B. Analysis of enhanced 
pharmacy services in rural community pharmacies in Western Australia. Rural and 
Remote Health (2010); 10: 1400- 1408. 
267. Wilcox, A.J, Dunson, D.B, Weinberg, C.R, Trussell, J. Likelihood of conception 
with a single act of intercourse: providing benchmark rates for assessment of post-
coital contraceptives. Contraception (2001); 63: 211– 215. doi: 10.1016/S0010-
7824(01)00191-3. 
 
 
173 
 
268. Wilkins, N., A. Yurekli, and T. Hu.  Economic Analysis of Tobacco Demand. 
Tool 3: Demand Analysis. World Bank Economics of Tobacco Control Tool Kit. 
[Published 2007, cited January 2014]. Available from: 
http://siteresources.worldbank.org/INTPH/Resources/3Demand.pdf. 
269. Wilson, N, Grigg, M, Graham, L, Cameron, G. The effectiveness of television 
advertising campaigns on generating calls to a national Quitline by Ma¯ori. Tobacco 
Control (2005); 14: 284– 286. doi:10.1136/tc.2004.010009 
270. Wiltshire, S, Bancroft, A, Amos, A, Parry, O. They're doing people a service -
qualitative study of smoking, smuggling, and social deprivation. BMJ (2001); 323: 
203- 207.  
271. Wise, J. UK survey confirms link between deprivation and smoking. BMJ 
(2014): 348. doi: http://dx.doi.org/10.1136/bmj.g2184. 
272. Woodhall, S. C, Sile, B, Talebi, A, Baraitser, P. Internet testing for Chlamydia 
trachomatis in England, 2006 to 2010. BMC Public Health (2012); 12: 1095- 2003. 
doi: 10.1186/1471-2458-12-1095. 
273. Woolacott, NF, Jones, L, Forbes, CA, Mther, LC. The clinical effectiveness and 
cost-effectiveness of bupropion and nicotine replacement therapy for smoking 
cessation: a systematic review and economic evaluation. Health Technology 
Assessment (2002); 6: 1- 245.  
274. World Health Organisation. Global status report on alcohol and health 2014. 
[Published 2014, cited 26 July  2014]. Available from: 
http://apps.who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf?ua=1   
275. Wyatt S. Payment by results can increase the availability of Smoking 
Cessation Services while improving quality and equity. Addiction (2012); 107: 226–
7. 
276. Zhou, X, Nonnemaker, J, Sherrill, B, Gilsenan, A.W. Attempts to quit smoking 
and relapse: Factors associated with success or failure from the ATTEMPT cohort 
study. Addictive Behaviors (2009); 34: 365– 373. doi: 10.1016/j.addbeh.2008.11.01 
 
 
 
 
 
 
 
174 
 
Appendices 
Appendix 1: Examples of different models used by different PCTs to pay CPs 
to provide SSS 
Appendix 1.1: Kent PCT 
 
175 
 
 
 
 
 
 
176 
 
 
 
 
 
 
177 
 
 
 
 
 
 
178 
 
 
 
 
 
 
179 
 
 
 
 
 
 
180 
 
 
 
 
 
 
181 
 
 
 
 
 
 
182 
 
Appendix 1.2: Mid Essex PCT 
 
 
 
 
183 
 
 
 
 
 
 
184 
 
 
 
 
 
 
185 
 
 
 
 
 
 
186 
 
 
 
 
 
 
187 
 
 
 
 
 
 
188 
 
 
 
 
 
 
189 
 
 
 
 
 
 
190 
 
 
 
 
 
 
191 
 
Appendix 1.3: Devon PCT 
 
 
 
 
192 
 
 
 
 
 
 
193 
 
 
 
 
 
 
194 
 
 
 
 
 
 
195 
 
 
 
 
 
 
196 
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Safety. 
 
 I confirm that the research study is compliant with the requirements of the Criminal Records 
Bureau where applicable. 
 
 I am satisfied that the research study is compliant with the Data Protection Act 1998, and that 
necessary arrangements have been, or will be made with regard to the storage and processing of 
participants’ personal information and generally, to ensure confidentiality of such data supplied 
and generated in the course of the research.  
(Note: Where relevant, further advice should be sought from the Data Protection Officer, 
University Secretary’s Office) 
 
 I shall ensure that the research is undertaken in accordance with the University’s Diversity and 
Equality Policy Statement 
 
 I will ensure that all adverse or unforeseen problems arising from the research project are 
reported immediately to the Chair of the relevant Faculty Research Ethics Committee.  
 
 I will undertake to provide notification when the study is complete and if it fails to start or is 
abandoned; 
 
 (For supervisors, if the applicant is a student) I have met and advised the student on the ethical 
aspects of the study design, and am satisfied that it complies with the current professional (where 
relevant), departmental and University guidelines. I accept responsibility for the conduct of this 
research and the maintenance of any consent documents as required by this Committee. 
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 I understand that failure to provide accurate information can invalidate ethical approval. 
 
 
 
Signature of lead applicant: Mr. Wail Chalati Date: 15/06/2012 
 
Signature of co-applicant:                                 Date: 
 
Signature of co-applicant:                                        Date: 
 
Signature of co-applicant:                                      Date: 
 
Signature of supervisor: Dr. Reem Kayyali      Date: 15/06/2012 
 
Signature of supervisor: Dr. John Fletcher      Date: 15/06/2012 
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CHECKLIST 
 
Please complete the checklist and attach it to your application: 
 
Project title:  Cost-effectiveness analysis of vascular and sexual enhanced pharmacy services 
 
Lead Applicant:  Mr. Wail Chalati 
 
Date of application:  
 
 
 
Before submitting this application, please check 
that you have done the following:  (N/A = not applicable) 
Applicant Committee use 
only 
 
 
Yes No N/A Yes No N/A 
 
All questions have been answered  
 
 
 
 
 
 
 
 
 
 
 
 
 
All applicants have signed the application form 
      
 
The research proposal is attached 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correspondence from other ethics committees is attached 
      
 
Informed Consent Form is attached 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant Information Sheets are attached 
 
 
 
 
 
 
 
 
 
 
 
 
All letters, advertisements, posters or other recruitment 
material to be used are attached 
 
 
 
 
 
 
 
 
 
 
 
 
All surveys, questionnaires, interview/focus group schedules, 
data sheets, etc, to be used in collecting data are attached 
 
 
 
 
 
 
 
 
 
 
 
 
Reference list attached, where applicable  
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Appendix 2.2: SSS survey cover letter 
       
Dr Reem Kayyali 
Dr. John Fletcher 
Kingston University London 
Pharmacy Department 
School of Pharmacy and Chemistry 
Penrhyn Road 
Kingston Upon Thames 
KT1 2EE 
15/09/2012 
Dear Sir/Madam 
 
I am writing to kindly request your participation in my pharmacy research project. I am a PhD student studying at Kingston, 
aiming to determine the cost-effectiveness of enhanced vascular pharmacy services. 
 
As community pharmacies provide easy access to many services, it seems that they could be the correct place to bridge the 
gaps in health inequalities between different areas with different deprivation statuses. As commissioning of pharmacy 
enhanced services will change in the future, it is useful to identify the cost effectiveness of enhanced vascular pharmacy 
services. My project aims to identify the relationship between needs for sexual health pharmacy services and the provision of 
these services through community pharmacies and the uptake of these services. By identifying the needs, provisions and 
uptakes together with the costs of running these services; I will be able to create a cost-effective analysis for these services. 
 
I would be grateful if you could complete the enclosed questionnaire regarding the costs and uptake of sexual health 
enhanced pharmacy services that you are currently providing at your PCT. All data provided will be dealt with confidentially 
and anonymously. 
 
This study has been approved by the Science, Engineering and Computing Faculty Research Ethics Committee at Kingston 
University. If you need any further information, do not hesitate to contact me or one of my supervisors at the e-mails below. 
Please return the questionnaires in the stamped envelopes by 15/10/2012. 
 
Mr Wail Chalati: K0800011@kingston.ac.uk 
Dr.Reem Kayyali: R.Kayyali@kingston.ac.uk 
Dr.John Fletcher: J.Fletcher@kingston.ac.uk 
 
 
I look forward to hearing from you. Thank you for your time. 
 
 
 
Yours sincerely 
 
Wail Chalati 
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Appendix 2.3: SSS survey questionnaire 
This questionnaires is aimed to determine the costs and uptakes of smoking cessation enhanced pharmacy 
services based on information provided by PCTs. I would be very grateful if you could spare some of your 
precious time in filling my questionnaires. All questionnaires will be dealt with anonymously and 
confidentially.  
 
Please complete all questions related to smoking cessation enhanced services that are offered now or were offered 
previously within your PCT.  
For all questions, I would be grateful if you could provide approximate values if the exact figures are unknown.  
 
 
 
There are two parts under this section:  
- Part A, which aims to complete the information provided in the Pharmaceutical Needs Assessment (PNA) 
reports released in 2011, by asking questions related to the provision of the enhanced stop smoking 
pharmacy service in 2010 within your PCT.  
- Part B, which intends to determine how the provision, costs and uptake of the enhanced stop smoking 
pharmacy service have changed since 2010 within your PCT. 
 
 Part A- Service provision in financial year 2009/2010 
 
1) What year did your PCT start providing the enhanced stop smoking pharmacy service? 
___________________ 
          
2) In financial year 2009/2010, how was each community pharmacy being paid for providing the 
enhanced stop smoking service? 
(Please specify the payment rate in your answer) 
        A- As a fixed fee 
        £ ______________________ per (month/year)                                                               (Delete as appropriate) 
          
        B- Per each service provided 
        £______________________ for returning individual client data 
        £______________________ for successful quit at 4 week follow up 
 
3) Beyond the fees specified in the question above (question 2), what was the average spend per 
pharmacy to provide (training, advertising, equipment, etc) related to stop smoking pharmacy service? 
£_______________________ 
4) In financial year 2009/2010, how many individuals have set a quit date for smoking at community 
pharmacies within your PCT? 
        _______________________ Individuals 
 
5) In financial year 2009/2010, and after 4-week follow up, how many individuals who set a quit date at a 
community pharmacy within your PCT were still not smoking? 
_______________________ Individuals 
 
6) What method was used to determine whether an individual had successfully quit smoking after 4 
weeks follow up? 
          Self- reported method 
          Carbon-monoxide testing 
          Others, please specify:_____________________________________________________________________ 
    
Part B- Service current provision 
   
1) How many community pharmacies within your PCT provide a stop smoking service currently? 
(Fill as appropriate) 
______________________ Community pharmacies 
Stop Smoking Enhanced Pharmacy Service 
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______________________ % of all community pharmacies within your PCT. 
 
2) How was the uptake of stop smoking services changed since 2010? 
          Increased 
          Decreased 
          Did not change 
 
3) Has the fee for providing an enhanced stop smoking service changed since 2010? 
          Yes                             
          NO 
        If the answer is yes, how much is the rate now? 
        (Please specify the payment rate in your answer) 
        A- As a fixed fee 
        £ ______________________ per (month/year)                                                               (Delete as appropriate) 
 
        B- Per each service provided 
        £______________________ for returning individual client data 
        £______________________ for successful quit at 4 week follow up 
 
4) If you have any comments or any extra information related to the stop smoking pharmacy service you 
like to share please write them in the following box.  
(Use an extra paper if the space is not enough) 
 
                                                              
 
 
 
 
 
 
 
 
Thank you for taking your time to complete this questionnaire. 
Please return any completed questionnaire in the enclosed stamped envelope  
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Appendix 3: Sexual health PCT Survey 
Appendix 3.1: Sexual health survey cover letter 
                                                         
       
Dr Reem Kayyali 
Dr. John Fletcher 
Kingston University London 
Pharmacy Department 
School of Pharmacy and Chemistry 
Penrhyn Road 
Kingston Upon Thames 
KT1 2EE 
20/11/2012 
Dear Sir/Madam 
 
I am writing to kindly request your participation in my pharmacy research project. I am a PhD student studying 
at Kingston, aiming to determine the cost-effectiveness of enhanced sexual health pharmacy services. 
 
As community pharmacies provide easy access to many services, it seems that they could be the correct place 
to bridge the gaps in health inequalities between different areas with different deprivation statuses. As 
commissioning of pharmacy enhanced services will change in the future, it is useful to identify the cost 
effectiveness of enhanced sexual health pharmacy services. My project aims to identify the relationship 
between needs for sexual health pharmacy services and the provision of these services through community 
pharmacies and the uptake of these services. By identifying the needs, provisions and uptakes together with 
the costs of running these services; I will be able to create a cost-effective analysis for these services. 
 
I would be grateful if you could complete the enclosed questionnaire regarding the costs and uptake of sexual 
health enhanced pharmacy services that you are currently providing at your PCT. All data provided will be dealt 
with confidentially and anonymously. 
 
This study has been approved by the Science, Engineering and Computing Faculty Research Ethics Committee 
at Kingston University. If you need any further information, do not hesitate to contact me or one of my 
supervisors at the e-mails below. Please return the questionnaires in the stamped envelopes by 10/12/2012. 
 
Mr Wail Chalati: K0800011@kingston.ac.uk 
Dr.Reem Kayyali: R.Kayyali@kingston.ac.uk 
Dr.John Fletcher: J.Fletcher@kingston.ac.uk 
 
 
I look forward to hearing from you. Thank you for your time. 
 
 
 
Yours sincerely 
 
Wail Chalati 
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Appendix 3.2: Sexual Health survey questionnaire 
This questionnaire is aimed to determine the costs and uptakes of sexual health enhanced 
pharmacy services based on information provided by PCTs. I would be very grateful if you could 
spare some of your precious time in filling my questionnaires. All questionnaires will be dealt with 
anonymously and confidentially.  
 
The questionnaire is divided into two sections: 
Section Three: Emergency Hormonal Contraception enhanced pharmacy service                         (Pages 1, 2) 
Section Four: Chlamydia screening and treatment enhanced pharmacy service                             (Pages 3- 5) 
 
Please complete the two sections which are related to the sexual health enhanced services that are offered 
now or were offered previously within your PCT.  
For all questions, I would be grateful if you could provide approximate values if the exact figures are 
unknown.  
 
 
 
 
There are two parts under this section:  
- Part A, which intends to complete the information provided in the Pharmaceutical Needs 
Assessment (PNA) reports released in 2011, by asking questions related to the provision of an 
enhanced Emergency Hormonal Contraception service at community pharmacies in 2010 within 
your PCT.  
- Part B, which intends to look at how the provision, costs and uptake of Emergency Hormonal 
Contraception service have changed since 2010 within your PCT. 
 
Part A- Service provision in 2009/2010 
 
1) What year did your PCT start providing Emergency Hormonal Contraception (EHC) service as 
an enhanced service through community pharmacies? 
___________________________ 
 
2) In financial year 2009/2010, how was each community pharmacy being paid for providing an 
enhanced Emergency Hormonal Contraception service? 
        (Please specify the payment rate in your answer) 
        A- As a fixed fee 
        £_____________ per (month/year)                                                                                 (Delete as appropriate) 
        B- Per each service provided 
        £_____________ for each consultation 
        £_____________ for prescribed medication provided 
 
3) Beyond the fees specified in the question above, what was the average spend per to provide 
(training, advertising, equipments, etc) related to Emergency Hormonal Contraception 
service? 
£______________ 
4) In financial year 2009/2010, how many individuals did use the Emergency Hormonal 
Contraception service at community    pharmacies within your PCT?  
______________ individuals 
 
Section One: Emergency Hormonal Contraception Service 
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5) In financial year 2009/2010, how many individuals who used the Emergency Hormonal 
Contraception service at community pharmacies within your PCT were provided with the 
prescribed medication? 
______________ individuals 
 
Part B- Service current provision 
 
1) Approximately, how many community pharmacies are currently providing an enhanced 
Emergency Hormonal Contraception service within your PCT? 
(Fill as appropriate) 
___________________ community pharmacies 
___________________% of all community pharmacies in your PCT 
 
2) How did the uptake of Emergency Hormonal Contraception service changed since 2010? 
          Increased     
          Decreased 
          Did not change 
 
3) Has the fee for providing Emergency Hormonal Contraception service changed since 2010? 
          Yes                             
          No 
       If the answer is yes, how much is the rate now? 
        (Please specify the payment rate in your answer) 
        A- As a fixed fee 
        £_____________ per (month/year)                                                                                 (Delete as appropriate) 
         
        B- Per each service provided 
        £_____________ for each consultation 
        £_____________ for prescribed medication provided 
 
4) If you have any comments or any extra information related to the Emergency Hormonal 
Contraception pharmacy service you like to share please write them in the following box.  
(Use an extra paper if the space is not enough) 
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There are two parts under Chlamydia screening and treatment services:  
- Part A, which intends to complete the information provided in the Pharmaceutical Needs Assessment (PNA) 
reports released in 2011, by asking questions related to the provision of an enhanced Chlamydia screening 
and treatment services at community pharmacies in 2010 within your PCT.  
- Part B, which intends to look at how the provision, costs and uptake of Chlamydia screening and treatment 
services at community pharmacies within your PCT have changed since 2010. 
 
1- Chlamydia Screening Service 
 
Part A- Service provision in 2010 
 
1) What year did your PCT start providing an enhanced Chlamydia screening service at 
community pharmacies? 
________________ 
                       
2) In financial year 2009/2010, how is each community pharmacist being paid for providing 
Chlamydia screening service?  
        (Please specify the payment rate in your answer) 
       A- As a fixed fee 
        £_____________ per (month/year)                                                                         (Delete as appropriate) 
       
        B- Per each service provided 
        £_____________  for each consultation 
        £_____________ for test kit provided 
        £_____________ for validated test returned 
 
3) Beyond the fees specified in the question above, what is the average spend per pharmacy to 
provide (training, advertising, equipment, etc) related to Chlamydia screening service? 
£______________ 
 
4) In financial year 2009/2010, how many individuals were screened for Chlamydia infection at 
community pharmacies within your PCT? 
______________ individuals 
 
5) In financial year 2009/2010, how many of those who screened for Chlamydia infection at 
community pharmacies were tested positive within your PCT? 
______________ individuals 
 
Part B-Service current provision 
 
1)  Approximately, how many community pharmacies currently provide the enhanced 
Chlamydia screening service within your PCT?  
(Fill as appropriate)  
________________ Community pharmacies 
________________% of all community pharmacies within your PCT 
Section Two: Chlamydia Screening and Treatment Pharmacy 
Services 
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2) How is the uptake of an enhanced Chlamydia screening service through community 
pharmacies changed since 2010? 
          Increased     
          Decreased 
          Did not change 
3) Has the fee for providing an enhanced Chlamydia screening service changed since 2010? 
          Yes                             
          No 
      If the answer is yes, how much is the rate now? 
       A- As a fixed fee 
        £_____________ per (month/year)                                                                         (Delete as appropriate) 
 
        B- Per each service provided 
        £_____________ for each consultation 
        £_____________ for test kit provided 
        £_____________ for validated test returned 
 
2- Chlamydia Treatment Service: 
 
Part A- Service provision in 2010 
 
1) What year did your PCT start providing an enhanced Chlamydia treatment service at 
community pharmacies? 
________________ 
                       
2) In financial year 2009/2010, how is each community pharmacist being paid for providing 
Chlamydia treatment service?  
        (Please specify the payment rate in your answer) 
       A- As a fixed fee 
        £_____________ per (month/year)                                                                         (Delete as appropriate) 
        B- Per each service provided 
        £_____________ for each consultation 
        £_____________ for treatment provided 
        £_____________ for screening and treatment provided 
 
3) Beyond the fees specified in the question above, what is the average spend per pharmacy to 
provide (training, advertising, equipment, etc) related to Chlamydia treatment service? 
£______________ 
4) In financial year 2009/2010, how many individuals were treated for Chlamydia infection at 
community pharmacies within your PCT? 
______________ individuals 
 
Part B-Service current provision 
 
1) Does your PCT provide chlamydia treatment service as an enhanced service through 
community pharmacist? 
          Yes 
          NO                                                                                                            (If the answer is NO, please go to question 5) 
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2) Approximately, how many community pharmacies currently within your PCT provide 
Chlamydia treatment service? 
        (Fill as appropriate) 
________________ Community pharmacies 
________________% of all community pharmacies within your PCT 
 
3) How is each community pharmacist being paid for providing Chlamydia treatment service? 
        (Please specify the payment rate in your answer) 
        A- As a fixed fee 
£____________ per (month/year)                                                (delete as appropriate) 
 
B- Per each service provided 
£____________ for treatment provided 
£____________ for screening and treatment provided 
 
4) Beyond the fees specified in the question above, what is the average spend per pharmacy to 
provide (training, advertising, equipment, etc) related to Chlamydia treatment service? 
£______________ 
 
5) If you have any comments or any extra information related to the Chlamydia screening and 
treatment pharmacy services you like to share please write them in the following box.  
(Use an extra paper if the space is not enough) 
 
 
 
 
 
 
 
 
 
 
Thank you for taking your time to complete this questionnaire. 
Please return any completed questionnaire in the enclosed stamped envelope  
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Appendix 4: Examples of pharmacy questionnaire from PNA reports 
Appendix 4.1: Milton Keynes PCT 
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Appendix 4.2: Wolverhampton PCT 
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Appendix 4.3: Barking and Dagenham PCT 
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Appendix 5: CP survey 
Appendix 5.1: RE4 (APPLICATION FORM For Ethical Review) 
 
SECTION A 
 
Project title: 
 
 
 
Name of the lead applicant: 
Name (Title / first name / 
surname): 
Wail Chalati 
Position held: PhD student 
School/Faculty:  Faculty of Science, Engineering and 
Computing 
Telephone:  
Email address: K0800011@kingston.ac.uk 
 
Name of co-applicants: 
Name (Title / first name / 
surname): 
 
Position held:  
Department/School/Faculty:   
Telephone:  
Email address:  
 
Name (Title / first name / 
surname): 
 
Position held:  
Cost-effectiveness analysis of vascular and sexual health pharmacy services 
 
Ref no (for admin use):   
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Department/School/Faculty:   
Telephone:  
Email address:  
 
Name (Title / first name / 
surname): 
 
Position held:  
Department/School/Faculty:   
Telephone:  
Email address:  
 
Is the project 
Student research     
KU Staff research     
Research on KU premises     
 
If it is STUDENT research: Course: PhD in Pharmacy Practice 
 
Supervisor/DoS: Dr. Reem Kayyali – Dr. John Fletcher 
SECTION B 
 
Has approval for the project already been granted by another ethics 
committee?  
 
 If NO, proceed to Section C;  
If YES, please complete the rest of this section before going to the declaration in 
Section D: 
 
Name of the committee:  __________________________________ Date of 
approval:  _________ 
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Please attach the submission made to that committee, together with the approval 
letter. The Faculty Research Ethics Committee (FREC) may require further 
information or clarification from you and you should not embark on the project until 
you receive notification from the FREC that recognition of the approval has been 
granted. 
SECTION C 
 
Briefly describe the procedures to be used in this research involving human 
participants  
 
 
  
 
Summarise the data sources to be used in the project: 
 
1- The needs of these services were obtained from the health profiles (Public 
Health Authorities website) and chlamydia screening programme website. 
2- The provisions of services were imported from the Pharmaceutical Needs 
Assessment (PNA) reports released in February 2011 for all PCTs in 
England. 
3- Uptake and costs of the services will be obtained through surveying certain 
PCTs ( Application for this survey was submitted to the Faculty of Science, 
Engineering and Computing Ethics Committee on 21/06/2012 with a 
reference number 1112/53). 
4- The provision, uptake and perceptions of community pharmacists regarding 
vascular and sexual health enhanced pharmacy services will be identified 
through surveying community pharmacist in certain PCTs (The questionnaires 
for this survey are the ones attached with this form). 
  
 
 
 
 
The research at this point will survey community pharmacists within certain PCTs 
chosen based on identifying the needs for vascular and sexual health enhanced 
pharmacy services.  
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Estimate duration of the project (months):  6 months 
 
State the source of funding:  
 
Is it collaborative research?  No 
 
If YES, name of the collaborator institutions:  
Provide a brief project description (max. 150 words). This should be written for a 
lay audience 
 
 The project aimed to determine the cost-effectiveness analysis of vascular 
and sexual health enhanced pharmacy services. Through identifying the 
needs, provisions and uptake of these services. Needs and provisions of the 
services were identified earlier. Uptake and costs attributed with the services 
will be identified through surveying certain PCTs (chosen to represent all 
PCTs in England based on demographic characteristics). Community 
pharmacies will be surveyed for assessing their views regarding the services 
and the uptake of the services. 
 
 
Risk Assessment:  Does the proposed research involve any of the following?   
  
Children or young people under 18 years of age? 
 
Yes 
 
 No 
 
 
If YES, have you complied with the requirements of the CRB? Yes 
 
 No 
 
 
 
People with an intellectual or mental impairment, temporary or 
permanent?  
Yes 
 
 No 
 
 
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People highly dependent on medical care, e.g., emergency 
care, intensive care, neonatal intensive care, terminally ill, or 
unconscious?   
Yes 
 
 No 
 
 
 
Prisoners, illegal immigrants or financially destitute? 
 
Yes 
 
 No 
 
 
 
Women who are known to be pregnant? 
 
Yes 
 
 No 
 
 
 
Will people from a specific ethnic, cultural or indigenous group be 
targeted in the proposed research? 
Yes 
 
 No 
 
 
 
Assisted reproductive technology? Yes 
 
 No 
 
 
 
Human genetic research? 
 
Yes 
 
 No 
 
 
 
Epidemiology research? 
 
Yes 
 
 No 
 
 
 
Stem cell research? 
 
Yes 
 
 No 
 
 
 
 Use of environmentally toxic chemicals? 
 
Yes 
 
 No 
 
 
 
Use of ionizing radiation? 
 
Yes 
 
 No 
 
 
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Ingestion of potentially harmful or harmful dose of foods, fluids or 
drugs? 
Yes 
 
 No 
 
 
 
Contravention of social/cultural boundaries? 
 
Yes 
 
 No 
 
 
 
Involves use of data without prior consent? 
 
Yes 
 
 No 
 
 
 
Involves bodily contact? 
 
Yes 
 
 No 
 
 
 
Compromising professional boundaries between participants and 
researchers? 
Yes 
 
 No 
 
 
 
Deception of participants, concealment or covert observation? 
 
Yes 
 
 No 
 
 
 
 
Will this research significantly affect the health* outcomes or 
health services of subjects or communities? 
Yes 
 
 No  
Note* health is defined as not just the physical well-being of the individual but also 
the social, emotional and cultural well-being of the whole community. 
 
Is there a significant risk for enduring physical and/or 
psychological harm/ distress to participants? 
Yes 
 
 No 
 
 
 
Does your research raise any issues of personal safety for you 
or other researchers involved in the project? (especially if taking 
place outside working hours or off University premises) 
Yes 
 
 No 
 
 
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Will the research be conducted without written informed consent 
being obtained from the participants? 
 
Yes 
 
 No 
 
 
 
Will financial/in kind payments (other than reasonable expenses 
and compensation for time) be offered to participants? (Indicate 
in the proposal how much and on what basis this has been 
decided) 
Yes 
 
 No 
 
 
 
Is there a potential danger to participants in case of accidental 
unauthorised access to data? 
Yes 
 
 No 
 
 
 
 
N.B. If you have answered YES to any of these questions, you should address 
them fully in your project proposal and show that there are adequate controls 
in place. 
 
 
Storage, access and disposal of data 
Describe what research data will be stored, where, for what period of time, the 
measures that will be put in place to ensure security of the data, who will have 
access to the data, and the method and timing of disposal of the data.  
 
All data will be anonymised whereby each PCT will be given a code, and the 
later will be used in all electronic processing of responses. The spreadsheet 
identifying the codes will be stored electronically on a password protected 
saved file on Dr. Reem Kayyali and Dr. John Fletcher D-drives and on my H-
drive and the hard copies of it will be kept under lock in Dr.Reem Kayyali and 
Dr.John Fletcher office for a period of 5 years. All electronic files will be 
encrypted using Microsoft office rather than normal saving. After the period of 
five years all documents will be disposed of using confidential waste service 
available at Kingston University. 
All other data will be maintained anonymous in the thesis write-up and any 
other form of presentation findings (including publications and presentations at 
conferences) and the identities of community pharmacies will not be revealed in 
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reports or presentations. 
 
 
SECTION D 
 
To be signed by all applicants 
 
Declaration to be signed by the applicant(s) and the supervisor (in the case of 
a student): 
 
 I confirm that the research will be undertaken in accordance with the Kingston 
University Guidance and procedures for undertaking research involving human 
participants 
 
 I will undertake to report formally to the relevant Faculty Research Ethics 
Committee for continuing review approval. 
 
 I shall ensure that any changes in approved research protocols or membership 
of the research team are reported promptly for approval by the relevant Faculty 
Research Ethics Committee. 
 
 I shall ensure that the research study complies with the law and University 
policy on Health and Safety. 
 
 I confirm that the research study is compliant with the requirements of the 
Criminal Records Bureau where applicable. 
 
 I am satisfied that the research study is compliant with the Data Protection Act 
1998, and that necessary arrangements have been, or will be made with regard 
to the storage and processing of participants’ personal information and 
generally, to ensure confidentiality of such data supplied and generated in the 
course of the research.  
(Note: Where relevant, further advice should be sought from the Data 
Protection Officer, University Secretary’s Office) 
 
 I shall ensure that the research is undertaken in accordance with the 
University’s Single Equality Scheme. 
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 I will ensure that all adverse or unforeseen problems arising from the research 
project are reported immediately to the Chair of the relevant Faculty Research 
Ethics Committee.  
 
 I will undertake to provide notification when the study is complete and if it fails to 
start or is abandoned; 
 
 (For supervisors, if the applicant is a student) I have met and advised the 
student on the ethical aspects of the study design, and am satisfied that it 
complies with the current professional (where relevant), departmental and 
University guidelines. I accept responsibility for the conduct of this research and 
the maintenance of any consent documents as required by this Committee. 
 
 I understand that failure to provide accurate information can invalidate ethical 
approval. 
 
 
Signature of lead applicant:  Wail Chalati                          Date: 
04/07/2012 
 
Signature of supervisor: Dr. Reem Kayyali                         Date: 
04/07/2012 
Signature of supervisor: Dr. John Fletcher                         Date: 
04/07/2012 
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CHECKLIST 
 
Please complete the checklist and attach it to your application: 
 
Project title:   Cost-effectiveness analysis of vascular and sexual health pharmacy 
services   
 
Lead Applicant:   Mr. Wail Chalati  
 
Date of application: 04/07/2012  
 
 
Before submitting this application, please 
check 
that you have done the following:  (N/A = not 
applicable) 
Applicant Committee use 
only 
 
 
Yes No N/A Yes No N/A 
 
All questions have been answered  
 
 
 
 
 
 
 
 
 
 
 
 
 
All applicants have signed the application form 
      
 
The research proposal is attached 
  
 
 
 
 
 
 
 
 
 
 
Correspondence from other ethics committees is 
attached 
 
 
     
 
Informed Consent Form is attached 
  
 
 
 
 
 
 
 
 
 
 
Participant Information Sheets are attached 
  
 
 
 
 
 
 
 
 
 
All letters, advertisements, posters or other 
recruitment material to be used are attached 
  
 
 
 
 
 
 
 
 
 
All surveys, questionnaires, interview/focus 
group schedules, data sheets, etc, to be used in 
collecting data are attached 
  
 
 
 
 
 
 
 
 
 
Reference list attached, where applicable   
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Appendix 5.2: CP survey cover letter 
 
                                                                   
 
Mr. Wail Chalati 
Dr Reem Kayyali 
Kingston University London 
Pharmacy Department 
School of Pharmacy and Chemistry 
Penrhyn Road 
Kingston Upon Thames 
KT1 2EE 
 
15/05/2013 
Dear Sir/Madam 
 
I am writing to kindly request your participation in my pharmacy research project. I am a PhD student studying 
at Kingston University, aiming to determine the cost-effectiveness of enhanced vascular and sexual health 
pharmacy services (Currently called as locally commissioned services). 
 
As community pharmacies provide easy access for many services, it seems that they could be the correct place 
for bridging the gaps in health inequalities between different areas with different deprivation statuses. My 
project aims to identify the relationship between needs for vascular and sexual health pharmacy services and 
the provision of services through community pharmacies and the uptake. Findings, so far, showed that 
provision of those services through community pharmacies did not match the needs. Healthy Living Pharmacies 
(HLPs) were introduced in order to reduce health inequalities. Evaluation report of HLPs showed that uptake 
has increased in terms of smoking cessation and sexual health services. 
 
 
I would be grateful if you could complete the enclosed questionnaire to provide me with information about 
vascular and sexual health pharmacy services that you provide at your pharmacy, with identification whether 
you are HLP or not, and your perception towards the future of pharmacy services. All data provided will be 
dealt with confidentially and anonymously. 
 
This study has been approved by the Faculty of Science, Engineering and Computing Ethics Committee at 
Kingston University. Please return the completed questionnaire in the enclosed stamped, addressed envelope 
by 5
th
 June 2013. If you need any further information, do not hesitate to contact me or one of my supervisors 
at the emails below. 
 
Mr Wail Chalati: K0800011@kingston.ac.uk 
Dr.Reem Kayyali: R.Kayyali@kingston.ac.uk 
Dr.John Fletcher: J.Fletcher@kingston.ac.uk 
 
I look forward to hearing from you. Thank you for your time.  
Yours sincerely 
Wail Chalati 
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Appendix 5.3: CP survey questionnaire 
Dear Pharmacist, 
I would be grateful if you could please spare ten minutes of your time to complete 
the questionnaire. Answers provided will be confidential and will be used only for 
the purpose of this study. When answering the questions please tick the relevant 
box and follow the instructions provided. Your participation is highly valued. 
 
 
 
Q1. Which of the following Enhanced services do you provide? Please tick as 
appropriate. 
Chlamydia Screening     NHS Health Checks 
Emergency Hormonal Contraception   Smoking Cessation   
Q2. Please rank the following enhanced services in order of importance, (1 = 
Most Important to 4 = Least Important)  
Chlamydia Screening     NHS Health Checks 
Emergency Hormonal Contraception   Smoking Cessation   
Q3. What is your motivational driver for providing the above Enhanced 
services? Please tick the TWO most important options based on your 
opinion. 
To play a more active role in health promotion 
To overcome health inequalities 
To obtain better training 
To meet the needs of the local population in accordance to the PCT 
To provide the pharmacy with equipment  
To earn more remuneration 
Other, please specify:………………………………………………………………… 
 
 
Section 1: Enhanced Services 
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Q4. Please complete the following table, tick as appropriate 
 
 
Q5. In general, what are the barriers limiting the provision of the enhanced 
services listed in Q1? Please choose the TWO most important barriers. 
The service was not a priority in the local population 
Inadequate facilities 
Limited training for the staff to provide the services 
Lack of time 
Lack of public awareness e.g lack of advertising  
Provided elsewhere or through other Health services e.g by GPs 
Others, please specify:………………………………………………………………….. 
Types of Enhanced 
services 
Provision status 
 
Please specify the 
approximate number of 
times the service has 
been provided in the 
last month 
 
Chlamydia screening 
service 
 
 
 
Current provider 
 
Willing to provide 
 
Unwilling to provide 
 
 
 
Emergency Hormonal 
Contraception service 
 
 
 
Current provider 
 
Willing to provide 
 
Unwilling to provide 
 
 
 
Smoking Cessation 
 
 
 
Current provider 
 
Willing to provide 
 
Unwilling to provide 
 
 
 
NHS Health Checks 
 
 
Current provider 
 
Willing to provide 
 
Unwilling to provide 
 
 
 
Section 2: Barriers and facilitators related to the provision of sexual and vascular services 
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Q6. For each of enhanced services listed below, Please indicate the TWO 
main barriers specifically limiting the provision of that service  
Type of  sexual 
health service 
Barriers limiting the provision of services 
 
Chlamydia 
screening service 
 
 
 
The service was not a PCT priority  
 
Financial constraints 
 
Lack of public need 
 
Lack of demand 
 
Inadequate facilities 
 
Lack of public trust in pharmacy 
 
Limited training for the staff to provide the service 
 
Lack of time 
 
Lack of public awareness e.g lack of advertising 
 
Provide elsewhere or through other Health services 
 
Other, please specify:………………………………………….. 
 
 
Emergency 
Hormonal 
Contraception 
service 
 
 
 
The service was not a PCT priority  
 
Financial constraints 
 
Lack of public need 
 
Lack of demand 
 
Inadequate facilities 
 
Lack of public trust in pharmacy 
 
Limited training for the staff to provide the service 
 
Lack of time 
 
Lack of public awareness e.g lack of advertising 
 
Provide elsewhere or through other Health services 
 
Other, please specify:………………………………………….. 
 
Smoking 
Cessation 
 
 
The service was not a PCT priority  
 
Financial constraints 
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Lack of public need 
 
Lack of demand 
 
Inadequate facilities 
 
Lack of public trust in pharmacy 
 
Limited training for the staff to provide the service 
 
Lack of time 
 
Lack of public awareness e.g lack of advertising 
 
Provide elsewhere or through other Health services 
 
Other, please specify:………………………………………….. 
 
 
NHS Health 
Checks 
 
 
 
The service was not a PCT priority  
 
Financial constraints 
 
Lack of public need 
 
Lack of public demand 
 
Inadequate facilities 
 
Lack of public trust in pharmacy 
 
Limited training for the staff to provide the service 
 
Lack of time 
 
Lack of public awareness e.g lack of advertising 
 
Provide elsewhere or through other Health services 
 
Other, please specify:………………………………………….. 
 
 
 
Q7. Are you a Healthy Living Pharmacy, with an identifiable Healthy Living 
Champion (HLC)? Please tick the most applicable to you. 
Yes (please go to Q9)              No (Please go to Q8)         In the process of 
accreditation       
Not currently but willing to provide the scheme in the future  
Section 3: Healthy Living Pharmacies 
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Q8. What are the barriers for not providing the Healthy Living Pharmacy 
scheme? Please tick the TWO most important barriers based on your opinion. 
Low engagement within the community 
Pharmacy team not working proactively together  
Limited training for the staff to provide the service 
Inadequate facilities and resources 
Not enough public awareness e.g. reduced signposting  
Lack of interest to act as a HLC 
Lack of identifiable HLC  
Lack of time 
Others, please specify:………………………………………………………………… 
Q9. What other services do you provide in your pharmacy? Please tick as 
appropriate. 
Alcohol Screening 
Weight management 
Medicine Use Review 
Minor ailment service 
Cholesterol testing 
Blood pressure monitoring 
Others, please specify:…………………………………………………………… 
Please only fill the remainder of this section if you are currently a Healthy Living 
Pharmacy. Otherwise please go to Q12 and thank you for completing the 
questionnaire. 
Q10. What is your motivational driver in becoming a Healthy Living Pharmacy? Please tick the 
most important TWO options that apply to you. 
To play more active role in health promotion 
To overcome health inequalities 
To obtain better training 
To improve the uptake of pharmacy services 
To meet the needs of the local population in accordance to the PCT 
Other, please specify:……………………………………………………………… 
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Q11. Please complete the following table to indicate the status of Enhanced 
services that your pharmacy provides after becoming a Healthy Living 
Pharmacy (please tick as appropriate) 
 
 
 
 
 
 
Types of 
Enhanced 
services 
Public 
awareness of 
each enhanced 
service 
Provision 
status 
Please specify the 
approximate number of 
times the service has 
been provided PRE 
and POST becoming a 
HLP. 
 
Chlamydia 
screening service 
 
Increased 
 
Decreased 
 
No change 
 
Increased 
 
Decreased 
 
No Change 
 
PRE 
 
 
POST 
 
Emergency 
Hormonal 
Contraception 
service 
 
 
 
Increased 
 
Decreased 
 
No Change 
 
Increased 
 
Decreased 
 
No Change 
 
PRE 
 
 
POST 
 
Smoking 
Cessation 
 
Increased 
 
Decreased 
 
No Change 
 
 Increased 
 
Decreased 
 
No Change 
 
 
PRE 
 
 
POST 
 
NHS Health 
Checks 
 
 
 
Increased 
 
Decreased 
 
No Change 
 
Increased 
 
Decreased 
 
No change 
 
 
PRE 
 
 
POST 
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Q12. Please indicate your level of agreements of each of the following 
statements regarding the current and future of enhanced pharmacy services 
following the introduction of HLP scheme. 
Statement Strongly 
Disagree 
    Strongly 
Agree 
HLP scheme will be the future 
for all enhanced pharmacy 
services 
1 2 3 4 5 6 
HLP has enhanced the role of 
the pharmacist in the 
community 
1 2 3 4 5 6 
The marketing and promotion 
of HLP scheme was effective 
1 2 3 4 5 6 
Training for HLP scheme 
should be provided at 
undergraduate level of study 
1 2 3 4 5 6 
If HLP scheme fails to achieve 
the desired results, enhanced 
pharmacy services will be 
decommissioned 
1 2 3 4 5 6 
HLP is a way to improve public 
awareness of the public 
regarding enhanced services. 
1 2 3 4 5 6 
 
 
Q13. In your opinion, how do you think the public became aware of the availability of 
enhanced services within the pharmacy? 
Please tick the TWO most important and useful methods based on your opinion. 
Through posters displayed in pharmacies 
Through leaflets distributed in pharmacies 
Recommended by pharmacists 
Through a friend or family 
Advertisements on television, radio, magazines and newspaper. 
Others,  specify: 
………………………………………………………………………………… 
Section 4: Public awareness and methods to improve success of SSS 
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Q14. How we can improve the public awareness of the availability of 
enhanced services within the pharmacy? Please tick the TWO most important 
and useful methods based on your opinion. 
Organise health campaigns in schools  
Use social websites (e.g. Facebook, Twitter) 
Use posters within public transports (e.g. buses and tubes) 
Benefit from digital gadgets (e.g. SMS and emails) 
Others, please specify:………………………………………………………………… 
 
Q15. Based on your experience, what are the main factors that make smokers 
who set a quit date relapse? Please tick the TWO most important barriers 
Enjoy smoking 
Lack of follow up 
Loss of stress relief 
Craving 
Fear of weight gain 
Withdrawal symptoms 
Other, please specify:……………………………………………………………… 
 
Q16. Based on your opinion, how we can help smoker who decide to quit smoking in 
achieving quit smoking at the end of the follow up? Please tick as appropriate. 
Improve the motivational and consultation skills for pharmacists and their teams 
Increase the frequency of follow up meetings 
Introduce smokers who decide to quit smoking to each other to share their experiences                                            
Use the latest technology (e.g. mobile applications, SMS) to support the smoker who decided to quit 
smoking                                                                                                    
Involve a close friend or part of smoker’s family to support them during quitting                  
Other, please specify:………………………………………………………………………….. 
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 Finally, could you please fill in the questions below providing information about yourself and 
your pharmacy. I assure you again that all information will be dealt with in anonymously and 
confidently.  
  
Q1. Please indicate your gender. 
 Male 
 Female 
 
 Q2.  What type of pharmacist do you consider yourself are? 
 Employee pharmacist 
 Locum pharmacist 
 Manger pharmacist 
 Owner  
 Q3. Please indicate your years of experience as a pharmacist 
 < 1year 
 1-2 years 
 3-4 years 
 5-6 years 
 7-8 years 
 9-10 years 
 > 10 years 
 
 Q4.  What type of pharmacy is your pharmacy? 
 Independent (5 outlets or less) 
 Small chain ( >5-20 outlets) 
 Large chain ( >20- <200 outlets) 
 Multiple ( 200 or more outlets)  
 
 
 
 
 
Section 5:  General information 
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If you have any extra information regarding the vascular services that you like 
to share, or if you have any comments about the questionnaires please write 
them in the following box (use an extra paper if necessary) 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you are willing to participate in a future follow up regarding vascular or 
sexual health pharmacy services, or you are willing to be contacted regarding 
the service, please provide your contact details in the box below. 
 
 
 
 
Thank you for taking your time to complete this questionnaire. 
Please return any completed questionnaire in the enclosed stamped envelope  
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Appendix 6: Examples of the used calculations 
Appendix 6.1: Descriptive analysis of all PCTs using SPSS 17 output 
 
  Prevalence of 
smoking adults 
(%) 
Total reach out 
of needs (%) 
Total success 
out of needs 
(%) 
Self reported 
quit rate (%) 
N Valid 138 138 138 138 
Missing 0 0 0 0 
 Mean 22.940194 8.767947 4.302071 49.894723 
Median 22.440677 7.874028 3.939604 49.258559 
Range 23.2000 31.4328 15.9607 38.6961 
Percentiles 25 19.266795 6.654696 3.322088 44.088656 
50 22.440677 7.874028 3.939604 49.258559 
75 26.658270 9.712818 4.757390 56.827244 
 
  CO-validated 
quit rate (%) 
Deprivation 
score (IMD) 
Ethnicity 
minority 
proportion (%) 
Male proportion 
(%) 
N Valid 138 138 138 138 
Missing 0 0 0 0 
 Mean 34.161978 23.326091 12.965 52.472 
Median 35.503221 22.967205 9.104 52.506 
Range 55.5991 34.6378 50.2 4.1 
Percentiles 25 28.145008 16.425153 5.396 52.061 
50 35.503221 22.967205 9.104 52.506 
75 40.756076 29.270540 19.195 53.013 
 
  Weighted provision of SSS 
(%) 
Weighted provision of SSS 
(N) 
N Valid 138 138 
Missing 0 0 
 Mean 58.534512 3.21 
Median 62.882653 3.15 
Range 92.0000 6 
Percentiles 25 39.070048 2.09 
50 62.882653 3.15 
75 76.762295 4.34 
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Appendix 6.2: Correlations between  needs, demographic characteristics and 
CP SSS provision SPSS 17 output 
Correlations 
   Prevalence of 
smoking 
adults (%) 
Deprivation 
score (IMD) 
Spearman's rho Prevalence of smoking 
adults (%) 
Correlation 
Coefficient 
1.000 .760
**
 
Sig. (2-tailed) . .000 
N 138 138 
Deprivation score (IMD) Correlation 
Coefficient 
.760
**
 1.000 
Sig. (2-tailed) .000 . 
N 138 138 
Ethnicity minority 
proportion (%) 
Correlation 
Coefficient 
-.022 .197
*
 
Sig. (2-tailed) .800 .021 
N 138 138 
Male proportion (%) Correlation 
Coefficient 
-.065 -.204
*
 
Sig. (2-tailed) .449 .017 
N 138 138 
Weighted provision of 
SSS (%) 
Correlation 
Coefficient 
-.037 .089 
Sig. (2-tailed) .668 .300 
N 138 138 
Weighted provision of 
SSS (N) 
Correlation 
Coefficient 
.062 .269
**
 
Sig. (2-tailed) .470 .001 
N 138 138 
CPs per 25000 
population 
Correlation 
Coefficient 
.340
**
 .634
**
 
Sig. (2-tailed) .000 .000 
N 138 138 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Correlations 
 
 
  Ethnicity 
minority 
proportion 
(%) 
Male 
proportion 
(%) 
Spearman's rho Prevalence of smoking 
adults (%) 
Correlation 
Coefficient 
-.022 -.065 
Sig. (2-tailed) .800 .449 
N 138 138 
Deprivation score (IMD) Correlation 
Coefficient 
.197
*
 -.204
*
 
Sig. (2-tailed) .021 .017 
N 138 138 
Ethnicity minority 
proportion (%) 
Correlation 
Coefficient 
1.000 -.147 
Sig. (2-tailed) . .085 
N 138 138 
Male proportion (%) Correlation 
Coefficient 
-.147 1.000 
Sig. (2-tailed) .085 . 
N 138 138 
Weighted provision of 
SSS (%) 
Correlation 
Coefficient 
.330
**
 -.067 
Sig. (2-tailed) .000 .435 
N 138 138 
Weighted provision of 
SSS (N) 
Correlation 
Coefficient 
.363
**
 -.124 
Sig. (2-tailed) .000 .147 
N 138 138 
CPs per 25000 
population 
Correlation 
Coefficient 
.181
*
 -.234
**
 
Sig. (2-tailed) .034 .006 
N 138 138 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Correlations 
   Weighted 
provision of 
SSS (%) 
Weighted 
provision of 
SSS (N) 
Spearman's rho Prevalence of smoking 
adults (%) 
Correlation 
Coefficient 
-.037 .062 
Sig. (2-tailed) .668 .470 
N 138 138 
Deprivation score (IMD) Correlation 
Coefficient 
.089 .269
**
 
Sig. (2-tailed) .300 .001 
N 138 138 
Ethnicity minority 
proportion (%) 
Correlation 
Coefficient 
.330
**
 .363
**
 
Sig. (2-tailed) .000 .000 
N 138 138 
Male proportion (%) Correlation 
Coefficient 
-.067 -.124 
Sig. (2-tailed) .435 .147 
N 138 138 
Weighted provision of 
SSS (%) 
Correlation 
Coefficient 
1.000 .921
**
 
Sig. (2-tailed) . .000 
N 138 138 
Weighted provision of 
SSS (N) 
Correlation 
Coefficient 
.921
**
 1.000 
Sig. (2-tailed) .000 . 
N 138 138 
CPs per 25000 
population 
Correlation 
Coefficient 
.120 .444
**
 
Sig. (2-tailed) .160 .000 
N 138 138 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Correlations 
   CPs per 25000 
population 
Spearman's rho Prevalence of smoking 
adults (%) 
Correlation Coefficient .340
**
 
Sig. (2-tailed) .000 
N 138 
Deprivation score (IMD) Correlation Coefficient .634
**
 
Sig. (2-tailed) .000 
N 138 
Ethnicity minority proportion 
(%) 
Correlation Coefficient .181
*
 
Sig. (2-tailed) .034 
N 138 
Male proportion (%) Correlation Coefficient -.234
**
 
Sig. (2-tailed) .006 
N 138 
Weighted provision of SSS 
(%) 
Correlation Coefficient .120 
Sig. (2-tailed) .160 
N 138 
Weighted provision of SSS 
(N) 
Correlation Coefficient .444
**
 
Sig. (2-tailed) .000 
N 138 
CPs per 25000 population Correlation Coefficient 1.000 
Sig. (2-tailed) . 
N 138 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Appendix 6.3: Cost-effective analysis of SSS excel sheets 
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Appendix 6.4: Responses from CP's survey 
PCT Number of surveyed CPs RESPONSES RESPONE RATE 
Bedfordshire 53 6 11.32 
Bexley 36 2 5.56 
Blackburn 35 12 34.29 
Blackpool 34 6 17.65 
Brighton and Hove city 47 6 12.77 
Bristol 68 4 5.88 
Croydon 57 10 17.54 
Doncaster 57 8 14.04 
Dudley 52 4 7.69 
Greenwich 43 4 9.30 
Haringey 46 6 13.04 
Hasting and Rother 30 9 30.00 
Isle of Wight 24 8 33.33 
Kingston 24 8 33.33 
Knowesly 27 5 18.52 
Lambeth 21 6 28.57 
Leeds 106 21 19.81 
Lewisham 43 3 6.98 
Medway 40 12 30.00 
Middleborough 22 7 31.82 
North Somerset 32 10 31.25 
Portsmouth 30 10 33.33 
Richmond 37 6 16.22 
Southwark 49 5 10.20 
Stockport 51 5 9.80 
Sutton and Merton 61 13 21.31 
Wandsworth 50 19 38.00 
Warwickshire 74 26 35.14 
Total 1249 241 19.30 
 
